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1. Abstract 
Cystatin C is an important inhibitor of lysosomal and extracellular cysteine 
proteases. It is synthesized as a precursor containing a signal sequence that targets 
the protein to the secretory pathway. In retinal pigment epithelial (RPE) cells, 
cystatin C is abundantly expressed and secreted, suggesting a critical role in the 
regulation of the proteolytic activity in the extracellular space, which, if altered, 
may contribute to diseases such as Age-related Macular Degeneration (AMD). An 
amino acid substitution in the signal sequence of the precursor cystatin C generates 
the variant B, which has been linked to an increased risk of developing AMD and 
Alzheimer’s disease (AD). This mutation has been reported to affect protein 
trafficking, resulting in decreased secretion and mitochondrial mislocalization. 
Recently, however, both its disease association as well as the effect on the protein 
trafficking have been questioned. The main aim of my study was to further 
investigate the trafficking and secretion of the mutated cystatin C. Recombinant 
wild-type and variant B cystatin C constructs, untagged or linked to different tags 
(EGFP, FLAG, HA), were transfected into RPE cell lines. Intracellular localization was 
investigated by imaging and subcellular fractionation. Protein trafficking and 
secretion were examined by analysing protein release into the culture media and 
the use of inhibitors of the secretory pathway. In addition, glycosylation sites were 
engineered to monitor transition through the Endoplasmic Reticulum (ER) and 
Golgi apparatus. Constructs encoding the signal sequence linked to EGFP were also 
used to evaluate the targeting properties of the variant B signal sequence. In the 
second part of my study, the efficiency of signal sequence cleavage was 
investigated by analysing the levels and localization of the precursor fraction by 
immunoprecipitation and imaging. The presence of alternatively cleaved forms and 
glycosylation modifications was also analysed, using immunodetection, mass 
spectrometry and deglycosylation treatments. In the last part, mechanisms of 
protein regulation, including degradation, internalization, dimerization were 
investigated to identify possible differences between the wild-type and variant B 
proteins. Interacting proteins were identified by mass spectrometry. My results 
showed no major differences in trafficking and regulation between wild-type and 
variant B proteins.  Only the EGFP-tagged constructs resulted in mistrafficking to 
mitochondria, and this was the case for both cystatin C forms, suggesting that EGFP 
is not a suitable tag to study cystatin C and excluding mitochondrial mislocalization 
as a factor contributing to disease association. There were also no differences in 
secretion, regulation and interaction partners between wild-type and variant B. 
However, precursor processing for the variant B was slightly less efficient, resulting 
in a slightly higher fraction of non-processed precursor protein and an alternatively 
cleaved, possibly O-glycosylated form. The mutation in the signal sequence 
therefore appears to affect the precursor processing rather than targeting. These 
forms may accumulate over-time generating proteolytic imbalance and protein 
aggregates, which ultimately may lead to cellular dysfunction and degeneration 
associated with AMD and AD. Interestingly, inhibition of the ubiquitin-proteasome 
system or the autophagy-lysosome pathway, which become functionally impaired 
during aging and disease, led to a decrease or increase of cystatin C protein levels, 
respectively, suggesting a possible involvement in the altered levels of cystatin C in 
the structural and functional changes seen in age-related conditions.  
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1.1. Cystatin superfamily 
Cystatins represent a superfamily of reversible competitive inhibitors of cysteine 
proteases, which are enzymes responsible for the degradation of proteins as part 
of many biological mechanisms. Regulation of protease activity is fundamental for 
the maintenance of cellular homeostasis and impairment of the actions of cystatins 
contribute to many pathological conditions primarily characterised by 
accumulation of misfolded proteins and generation of insoluble aggregates such as 
neurodegeneration (Turk, Stoka & Turk 2008). Roles in cardiovascular diseases, 
osteoporosis, arthritis, and tumorigenesis, among others, have also been reported 
(Ochieng, Chaudhuri 2010, Turk, Stoka & Turk 2008). 
Cystatins can be subdivided into three major families: stefins, cystatins and the 
kininogens. The type 1 family includes the intracellular inhibitors stefin A and B 
(also named cystatin A and B) that are non-glycosylated proteins lacking a signal 
sequence and disulphide bridge. On the contrary, members of the type 2 family are 
characterised by the presence of a signal peptide, which targets the proteins for 
secretion, two disulphide bonds in their structure and, in some of the members, 
glycosylation. Cystatin C, D, E/M, F, G, S, SA and SN belong to the type 2 family and, 
due to the signal sequence, are mainly localised extracellularly. Finally, the 
members of the type 3 family are large glycosylated intravascular proteins with two 
protease inhibitor domains (Ochieng, Chaudhuri 2010, Turk, Stoka & Turk 2008). 
 
1.2. Cystatin C 
Cystatin C, also originally known as γ-trace and post-γ-globulin and main member 
of cystatin type 2 family, is the most potent inhibitor of major lysosomal and 
extracellular cysteine-proteases such as the plant derived papain and the 
mammalian lysosomal cathepsins B, H, L and S as well as some lysosomal caspases, 
such as legumain (Barrett, Davies & Grubb 1984, Turk, Bode 1991). It interacts 
reversibly with its target proteases to prevent the binding of substrate to the 
enzyme by competitively binding to the enzyme active site (Nycander et al. 1998). 
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Human Cystatin C is encoded by the CST3 gene located on chromosome 20p11.21 
(Abrahamson et al. 1989). Three KspI single nucleotide polymorphisms (SNPs) have 
been identified within the gene, the first two occurring in the 5’ untranslated 
sequence at positions -157 and -72 and the third at position +73 consisting of a G to 
A nucleotide substitution in the coding region of the transcript, which leads to an 
alanine to threonine amino acid substitution in the penultimate position of the 
signal peptide. Due to strong linkage disequilibrium between the three SNPs, 
cystatin C is present only as two haplotypes called variant A (wild-type) and variant 
B, whose allele frequencies have been shown in a Caucasian population to be 0.71 
and 0.29 respectively, and frequency of the homozygote B/B genotype of 7.5% 
(Balbín, Abrahamson 1991, Balbín, Grubb & Abrahamson 1993).  
Another variant form of cystatin C generated by a point mutation which results in a 
leucine to glutamine amino acid substitution at position 68 of the mature protein 
sequence, has been also identified. This variant is highly amyloidogenic and the 
cause of a pathological condition known as hereditary amyloid angiopathy (Wei et 
al. 1998). 
 
1.2.1. Cystatin C Structure and mode of actions 
Human cystatin C protein is a non-glycosylated, basic, low molecular weight 
protein, synthetized as a precursor of 146 amino acids containing a hydrophobic N-
terminal signal sequence of 26 amino acids (MW 2.5 kDa) that targets the protein 
to the Endoplasmic Reticulum (ER). Here the signal sequence undergoes cleavage 
by a specific peptidase and the resulting mature form of cystatin C is directed from 
the ER to the Golgi apparatus and the secretory pathway (Paraoan et al. 2001, 
Paraoan, Grierson 2007). The mature active cystatin C is a monomeric protein thus 
consisting of 120 amino acid residues with a molecular mass of approximately 13.3 
kDa, folding into five-stranded antiparallel β-sheets partially twisted around an α-
helix, with two disulphide bridges at the C-terminus, typical of the type 2 cystatins 
(Bode et al. 1988, Kozak et al. 1999) (figure 1.1).  
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The peptidase-binding site is composed of three main regions essential for the 
cystatin C inhibitory action, which consists of two β-hairpin loops and the N-
terminus of the mature protein (Figure 1.1). In the N-terminal segment a conserved 
amino acid sequence, consisting of Arg-Leu-Val-Gly at position 8-11, guarantees the 
optimal interaction with the target protease by increasing the binding affinity. One 
of the β -hairpin loops, consisting of five amino acid residues at position 55-59 (Gln-
Val-Ile-Ala-Gly), is crucial for binding cysteine proteases and the second one, 
consisting of the Pro105-Trp106 region, is involved in tightly anchoring cystatin C to 
its target enzyme once the complex is assembled (Paraoan et al. 2010, Cimerman 
et al. 1999). The inhibitory mechanism of cystatin C consists of two steps: an initial 
weak interaction that involves the binding of the N-terminal region of cystatin C to 
its target, which results in a conformational change that leads to a tighter 
association with the inhibitor and renders the active site of the enzyme partially 
blocked (Nycander et al. 1998), therefore preventing access of substrates. 
 
 
Figure 1.1 - Structure of cystatin C. It consists of five antiparallel β-sheets around a α-helix. 
The N-terminal region and the two hairpin loops L1 and L2 are critical for the inhibitory 
activity of cystatin C (Figure reproduced from (Szymańska et al. 2009)). 
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1.2.2. Cystatin C Regulation 
Because of the presence of a signal sequence, active monomeric cystatin C is 
secreted into the extracellular environment where it acts as a protease inhibitor. In 
order to control its concentration and activity there are several mechanisms of 
regulation. 
One mechanism that has been suggested to regulate cystatin C activity consists in 
its dimerization, which causes a complete loss of its protease inhibitory activity 
(Janowski et al. 2001). During intracellular trafficking, cystatin C has been 
demonstrated to form dimers through a process called three-dimensional domain 
swapping, which requires partial unfolding of the monomer followed by separation 
into two domains and subsequent exchange between two similarly unfolded 
molecules (Janowski et al. 2001, Janowski et al. 2005). In this conformation the 
inhibitory region of cystatin C is buried within the dimer interface, thus resulting in 
a loss of activity (Ekiel, Abrahamson 1996). This mechanism of dimerization has 
been hypothesized to regulate the level of active cystatin C in the cell. A study 
conducted in Chinese hamster ovary cells has reported that cystatin C can adopt 
this non-active dimeric conformation in the early part of its intracellular trafficking 
and then monomerizes shortly before secretion (Merz et al. 1997). Regulation of its 
dimer state has also been shown to play a role in the maturation of hematopoietic 
cells (Xu et al. 2014). Impairment of this mechanism can lead to an unbalanced 
proteolytic activity in the cell as well as an improper protein oligomerization 
leading to aggregation-related conditions. For instance, under condition of 
intracellular oxidative stress, an increase in the process of protein dimerization and 
oligomerization has been observed (Xu et al. 2014).  
 
Regulation of cystatin C levels and activity also occurs through digestion by 
proteases. Its proteolytic digestion results in an N-terminal truncation of the 
protein, removing its inhibitory capacity. This can occur by the action of a number 
of different proteases, including the intracellular aspartic-cathepsin D, the serine-
protease elastase and the extracellular matrix metalloproteinase 2 (MMP2) 
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(Abrahamson et al. 1991, Lenarčič et al. 1991, Dean et al. 2007, Laurent-Matha et 
al. 2012). Inactivation of cystatin C has also been shown to occur by one of its 
target enzymes through a non-inhibitory interaction with the extracellular cysteine-
Cathepsin L, which cleaves 11 residues at the N-terminus of the protease inhibitor 
(Popovič et al. 1999).  
 
Cystatin C is found predominately in the extracellular environment, consistent with 
the presence of the leader peptide responsible for targeting the protein to the 
secretory pathway. However, its target proteases belonging to the cysteine-
cathepsin family mainly localize intracellularly in the lysosomes. Cystatin C is 
therefore also required inside the cell in order to regulate the intracellular 
proteolytic activity. For this reason its involvement in additional trafficking 
pathways has been investigated and it has been demonstrated that cystatin C can 
be subjected to internalization from the extracellular space via clathrin-dependent 
endocytosis (Kaseda et al. 2007, Ekström et al. 2008). Accordingly, cystatin C has 
been found also in endosomal-lysosomal cellular compartments, where it can 
inhibit cathepsin activities. For instance, exogenous cystatin C was shown to 
colocalize with cathepsin B and legumain in lysosomes after its uptake, causing a 
down regulation of their activities (Wallin, Abrahamson & Ekstrom 2013). 
Interestingly, cystatin C uptake can also occur in cells other than the ones that 
produced it, suggesting a paracrine role. This process has been shown to be 
particularly exploited by tumour cells (Wallin, Abrahamson & Ekstrom 2013, Wallin 
et al. 2010) as a protective mechanism to inhibit the degradation activity of 
cathepsins, which are involved in extracellular matrix degradation during cancer 
cell invasion and metastasis. Therefore, it was suggested that impairment of this 
cystatin C uptake might be crucial for the regulation of the proteolytic activity in 
both intracellular and extracellular environments (Wallin, Abrahamson & Ekstrom 
2013, Wallin et al. 2010). 
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Cystatin C can also be alternatively secreted by a mechanism of exocytosis that 
involves the release of exosomes (Ghidoni et al. 2011b). Exosomes are 30-150 nm 
lipid-membrane vesicles generated in the endocytic pathway from late 
endosomes/multivesicular bodies (MVBs) (Raposo, Stoorvogel 2013). Exosomes 
transport a variety of molecules such as proteins, miRNA and lipids, and they are 
known to have roles in cell-cell communication, immune response/antigen 
presentation, removal of intracellular unwanted proteins or overload of damaged 
molecules, cell death, angiogenesis and inflammation (Raposo, Stoorvogel 2013). 
Once released into the extracellular environment, exosomes can be internalized by 
the same cell or by a secondary cell, or their content can be directly released into 
the extracellular space (Raposo, Stoorvogel 2013). Transport of cystatin C by 
exosomes may therefore represents an additional pathway of proteolysis 
regulation to maintain both intracellular and extracellular proteolytic balance. 
Interestingly exosomes have been found to be involved in different neurologic and 
degenerative conditions, such as Alzheimer disease and Age-related macular 
degeneration (AMD) (Ghidoni et al. 2011b, Wang et al. 2009, Joshi et al. 2015). 
 
1.2.3. Functions of cystatin C 
Cystatin C, initially identified in urine and cerebrospinal fluid (CSF), was later found 
to be ubiquitously expressed in a wide variety of human tissues and cell types, 
including kidney, brain, liver, placenta, pituitary glands, thyroid and alveolar 
macrophages (Turk, Stoka & Turk 2008). As a secreted protein it was particularly 
identified at significant concentrations in extracellular body fluids such as CSF, 
urine, blood serum, semen, saliva and tears, indicating that it performs a crucial 
role in the regulation of extracellular proteolytic activity. It was found to be highly 
expressed by the choroid plexus in the brain tissue and consequently secreted in 
the CSF, where it represents more than 90% of the total concentration of cysteine 
protease inhibitors (Cimerman 2007). Because of its presence in the blood plasma 
it is currently used in the clinic as a biomarker for kidney function, where it is a 
good indicator of glomerular filtration rate (GFR) due to its small molecular weight 
and easy detection (Shlipak et al. 2013).  
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Given its ubiquitous expression throughout the body, cystatin C may therefore play 
a general and crucial role in the regulation of protein degradation in the human 
body. 
 
1.2.3.1. Protein degradation 
Protein degradation is an essential cellular function that guarantees the turnover 
and removal of damaged or unnecessary proteins. The main cellular protein 
degradation systems are the ubiquitin-proteasome system (UPS) and the 
autophagy-lysosome pathway (ALP). Defects in either of these mechanisms of 
proteolysis can lead to several pathological conditions (Nedelsky, Todd & Taylor 
2008). 
The UPS system is the major mechanism for protein catabolism, responsible for the 
regulation of intracellular protein concentration and degradation of misfolded and 
damaged proteins. It therefore represents a quality control mechanism essential 
for cell survival (Amm, Sommer & Wolf 2014). The UPS mechanism of degradation 
consists of two steps: conjugation of a substrate protein with multiple ubiquitin 
molecules through a covalent bond, thus targeting the tagged protein to the 
proteasome, and the subsequent degradation in the catalytic core of the 26S 
proteasome (Hipp, Park & Hartl 2014, Vilchez, Saez & Dillin 2014). Additional roles 
identified for the proteasome system include regulation of gene transcription and 
antigen presentation (Lecker, Goldberg & Mitch 2006). The ALP is a mechanism 
that delivers cellular components to the lysosome for degradation and is mainly 
responsible for removal of damaged cell organelles, large protein aggregates, 
membrane proteins and extracellular endocytosed proteins. Different mechanisms 
are therefore involved in this pathway such as autophagy for cytoplasmic material, 
and endocytosis for exogenous and membrane components (Hipp, Park & Hartl 
2014, Vilchez, Saez & Dillin 2014). In addition, autophagy has been shown to be 
involved in several crucial cellular mechanisms including apoptosis, protection 
against metabolic stress, DNA damage, defense against intracellular pathogens and 
antigen presentation (Eskelinen, Saftig 2009). 
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Autophagy can be classified into three types. Microautophagy involves the 
engulfment of cytoplasm into the lysosome. Chaperone-mediated autophagy 
(CMA) for proteins containing specific recognition sites that translocate across the 
lysosomal membrane with the help of chaperone molecules and specific lysosomal 
receptors. Macroautophagy is the main and more widely investigated mechanism 
and involves the formation of an isolated membrane called the phagophore that 
expands and engulfs the target substrate forming a double membrane structure, 
the autophagosome, which then fuses with the lysosome (autopagolysosome), 
where contents are degraded by the lysosomal enzymes (Nedelsky, Todd & Taylor 
2008, García-Arencibia et al. 2010) (Figure 1.2). 
 
 
Figure 1.2 - Autophagy pathway. It begins with the formation of an isolation membrane 
(phagophore) that expands and engulfs the target substrates (e.g. proteins, aggregates, 
organelles). The resulting autophagosome fuses with the lysosome forming the 
autophagolysosome or autolysosome, where contents are degraded by the lysosomal 
hydrolases (figure from (Meléndez, Levine 2005)).   
 
The other major route to the lysosome is the endocytic pathway, where 
extracellular material, cell membrane proteins and soluble molecules such as 
ligands bound to the cell surface are internalized in endocytic vesicles and directed 
to the lysosome for degradation (Doherty, McMahon 2009). Based on the size of 
the material engulfed into the vesicles, endocytosis can be divided in pinocytosis, 
for uptake of fluids and small solutes, and phagocytosis for engulfment of larger 
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particles, including cell debris, microorganisms and apoptotic cells. Different 
mechanisms have been described, depending on the composition and size of the 
vesicles: clathrin-mediated endocytosis, caveolae-mediated endocytosis, 
macropinocytosis and clathrin/claveolae independent endocytosis (Doherty, 
McMahon 2009). Briefly, the mechanism of endocytosis consists in the 
internalization of components from the plasma membrane into early endosomes 
where proteins can be sorted and either be sent back to the plasma membrane by 
the recycling endosomes or targeted to the lysosomes for degradation through the 
late endosomes. Late endosomes also contain proteases and lysosomal proteins 
and they have been reported to transport and exchange components with other 
organelles such as the trans-Golgi network (TGN), which provides newly 
synthesized lysosomal components and enzymes to the endosome-lysosomal 
system (Huotari, Helenius 2011). 
The different mechanisms of autophagy and endocytosis described above 
eventually merge at the lysosome, where degradation of all kinds of 
macromolecules occurs thanks to the presence of a variety of hydrolases that 
include nucleases, lipases and proteases. Among the proteases involved in this 
process, cathepsins play a key role in protein degradation. 
 
1.2.3.2. Cathepsins 
Cathepsins represent the major family of proteases involved in protein 
degradation. They are subdivided in different groups known as cysteine-cathepsins 
(B, C, F, H, K, L, O, S, V, W, X), aspartic-cathepsins (D and E) and serine-proteases (A 
and G), depending on the amino acid residue found at the active site of the enzyme 
(Brix 2005). They are mostly endopeptidases, but some of them also show 
exopeptidase or dual endo/exopeptidase activity. The cysteine cathepsins 
represent the largest group and play the main role in the protein degradation in the 
lysosomes (Turk et al. 2012). Regulation of cathepsin activity is essential for 
lysosomal function as accumulation of undegraded material could lead to severe 
pathological conditions. Cystatin C represents their main endogenous inhibitor. 
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Cathepsins are synthesised as precursor pro-enzymes containing an N-terminal 
signal peptide responsible for targeting to the endoplasmic reticulum. After 
removal of the leader peptide by a signal peptidase, the partially folded pro-
cathepsins undergo N-linked glycosylation in the ER and are then transported to 
the Golgi apparatus, where a further events of glycosylation occurs, including the 
addition of a mannose-6-phospate (M6P) that directs the protein to the trans Golgi 
network (TGN) upon binding to M6P-receptors. The enzyme-receptor complex exits 
from the TGN and fuses with late endosomes. Here the acidic pH causes 
dissociation of the pro-enzyme from the M6P-receptor and the resulting active 
protease is sent to lysosomes (Brix 2005, Turk et al. 2012). Active cathepsins are 
therefore found mainly in the lysosomes, where they are required for homeostatic 
protein turnover, but they have also been found in other intracellular vesicular 
compartments of the endosomal-lysosome system, such as trans-Golgi derived 
vesicles, transport vesicles, secretory vesicles, clathrin-coated vesicles and 
endosomes (Guha, Padh 2008, Repnik, Cesen & Turk 2013). 
Functions within the endosomal-lysosome system include protein degradation and 
turnover, antigen processing during immune response, and processing/activation 
of pro-proteins and pro-hormones (Brix 2005). 
In addition to their key function in the lysosomal system, cathepsins were also 
identified to play a role in different compartments such as cytoplasm and 
extracellular space, where they have been implicated in essential processes 
including apoptosis, inflammation, extracellular matrix (ECM) remodelling and 
angiogenesis. To fulfil these functions, cathepsins are required to exit from the 
lysosomal compartment (Turk et al. 2012, Repnik, Cesen & Turk 2013). Studies 
revealed that lysosomes are indeed also involved in the secretion of molecules by a 
mechanism known as lysosomal exocytosis (Jaiswal, Andrews & Simon 2002, 
Rodriguez et al. 1997). This secretory pathway consists in the fusion of the 
lysosome with the plasma membrane and the consequent release of lysosomal 
content extracellularly. In the extracellular environment cathepsins have been 
shown to be involved in ECM degradation and remodelling. Several components 
such as collagens, proteoglycans, fibronectin and laminins have been shown to be 
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targets for cathepsin cleavage (Turk et al. 2012). Furthermore, cathepsins have also 
been implicated in the process of angiogenesis, regulating levels of angiogenic 
factors and components of the vascular and epithelial membrane (Turk et al. 2012).  
In addition, cathepsins have been shown to exert important roles within the cytosol 
such as involvement in apoptosis and inflammasome activation (Conus, Simon 
2008). A prerequisite for cathepsin release into the cytosol is lysosomal membrane 
permeabilization (LMP), for example by stimuli such as reactive oxygen species 
(ROS), which are increased in oxidative stress conditions (Zdolsek, Svensson 1993). 
Active cathepsins released into the cytosol can then process other molecules. LMP 
has also been described as an early event of apoptosis and involvement of 
cathepsins in programmed cell death has been widely established. The pro-
apoptotic Bcl-2 family member Bid was shown to be activated by cathepsins whilst, 
on the contrary, anti-apoptotic proteins Bcl-2 and Bcl-XL were shown to be 
inhibited (Droga-Mazovec et al. 2008, Repnik, Cesen & Turk 2013, Marques et al. 
2013). Lysosome permeabilization and cathepsin activity has also been implicated 
in activation of the inflammasome, a multiprotein complex that initiates the 
inflammation process (Conus, Simon 2008, Tseng et al. 2013). Interestingly, in 
degenerating neurons, cathepsin release into the cytoplasm has been described 
after disruption of lysosomes, with deleterious consequences for the cells, thus 
indicating a role of these proteases in the cell degenerative process, possibly by 
activation of an abnormal inflammatory response and apoptosis. 
 
1.2.3.3. Roles of cystatin C 
Given its ubiquitous expression throughout the body and the several crucial roles 
played by its target enzymes, cystatin C is implicated in different key physiological 
functions and disease conditions.  
As main inhibitor of cysteine-cathepsins, cystatin C plays an essential role in 
regulating the proteolytic activity within the endosomal-lysosomal system to 
ensure a proper protein turnover and maintenance of cellular homeostasis (Xu et 
al. 2015, Cimerman 2007). As previously described, uptake of cystatin C from the 
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extracellular environment occurs in different cell types in order to modulate 
intracellular cathepsin activity (Ekström et al. 2008, Wallin et al. 2010, Wallin, 
Abrahamson & Ekstrom 2013).  
An important biological process involving cystatin C within the endosomal-
lysosome system is antigen presentation occurring during the immune response in 
antigen-presenting cells such as the peripheral dendritic cells (Cimerman 2007, Xu 
et al. 2015). Cysteine-cathepsins have been widely reported to play a role in 
antigen presentation, being responsible of proteolytic degradation of pathogen 
proteins within the endosomal-lysosomal system to generate the immunogenic 
peptides that subsequently associate to MHC II to induce the immune response. 
However, conflicting results about the involvement of cystatin C in modulating 
cathepsin activities in MHC II antigen presentation have been reported (Cimerman 
2007, Xu et al. 2015). 
Cathepsins can be released from lysosomes upon membrane permeabilization and 
are implicated in the process of apoptosis. Consistently, upregulation of cystatin C 
expression was found to correlate with oxidative stress-induced apoptosis in 
cultured rat neurons, indicating a role in regulation of programmed cell death 
(Nishio et al. 2000). Cystatin C has also been reported to lead to neuronal cell death 
in vivo by up-regulation of caspase-3, which can be conversely inhibited by 
cathepsin B (Nagai et al. 2005). Furthermore, Liang et al. have shown that cystatin 
C induction of apoptosis in neuronal cells involves the decrease of anti-apoptotic 
Bcl-2 and increase of pro-apototic Bax and active caspase-9 protein levels via JNK-
dependent pathway (Liang et al. 2011). In another study cystatin C was shown to 
trigger neurodegeneration through up-regulation and accumulation of the 
insoluble α-synuclein in neurons, which leads to apoptosis (Suzuki, Jin & Yazawa 
2014). Conversely, protective and anti-apoptotic effects on neuronal cells have 
been also described, thus preventing cell death in vivo through inhibition of the 
activity of cathepsins (Nishiyama et al. 2005, Mori et al. 2016) and promoting 
neuronal regeneration (Kaur et al. 2010, Xu et al. 2005, Pirttilä et al. 2005). 
Furthermore, modulation of cell proliferation in normal and cancer cells by 
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antagonizing transforming growth factor-beta (TGF-β) signalling was also reported 
for cystatin C thereby promoting cell survival (Sokol, Schiemann 2004).  
Several roles of cystatin C in the inflammatory process have been also described, 
including modulation of chemotactic activity and phagocytosis in neutrophils, 
activation of the complement cascade, involvement in the IFNγ signal transduction 
pathway, leading to nitric oxide production and release from macrophages and 
down-regulation of IL-10 (Xu et al. 2015, Cimerman 2007, Schulte et al. 2010).  
 
Being primarily a secreted protein and given its high concentration in most body 
fluids, cystatin C is likely to play an essential role, along with its target cathepsins, 
in the maintenance of homeostasis and balance of proteins in the extracellular fluid 
and in the remodelling of extracellular membranes and structures. Regulation of 
proteolytic activity has been described to be involved in the 
preservation/remodelling of ECM in various human tissues and its impairment may 
result in disease conditions such as atherosclerosis, where arterial wall remodelling 
is dysregulated, and cancer, where ECM degradation facilitates tumour cell 
invasion and metastasis (Xu et al. 2015). Indeed, low levels of cystatin C were found 
to be associated with atheroma plaque formation, and cancer cell invasion was 
shown to be reduced by inhibition of the cystatin C targets cathepsin B and 
legumain (Keppler 2006, Wallin, Abrahamson & Ekstrom 2013). 
Cystatin C in body fluids has been reported to vary under influence of many factors 
and in pathological conditions. Several stimuli such as cytokines, pathogens, growth 
factors, hormones, physicochemical damages and oxidative stress have been 
identified to affect cystatin C synthesis and secretion (Xu et al. 2015). For instance, 
reduction of the level of expression and secretion of cystatin C is caused by the 
presence of bacterial LPS as well as of inflammatory cytokines IFNγ and IL-6 (Xu et 
al. 2015). On the contrary, an up-regulation of its expression has been observed 
upon TGF-β stimulation, with exposure to oxidative stress and after induction of 
inflammatory IL-10 induced-IRF8 transcription factor (Xu et al. 2015). Alterations in 
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balance of cystatin C and its target cathepsins have been also associated with 
several disease conditions. 
In conclusion, cystatin C is found in many compartments inside and outside the cell 
where it regulates cathepsin activity within the lysosomes as well as in other 
compartments including the extracellular space. Because cathepsins are involved in 
several physiological processes such as protein turnover, protein processing, tissue 
remodelling, antigen presentation, apoptosis as well as pathological conditions 
such as cardiovascular disease, cancer, inflammation and cell degeneration (Turk et 
al. 2012), it is essential that their activity is tightly regulated by their inhibitor. 
 
1.3. Disease involvement of cystatin C 
Cystatin C has been associated with several pathological conditions. Its involvement 
in neurodegenerative diseases has been particularly investigated given its high 
expression in brain tissue by neurons, astrocytes, endothelial and microglial cells, 
its presence at high level in the CSF and its involvement in brain development 
(Paraoan et al. 2010). Its involvement in Alzheimer’s disease (AD) has been 
extensively described and it has been found to co-localise with β-amyloid 
precursors in the fibrils plaques generated in the brain of patients affected by AD 
(Levy et al. 2001, Mi et al. 2009). Other conditions where it has been implicated to 
play a role, as a consequence of its altered expression, are Parkinson’s disease, 
multiple sclerosis, tissue-degenerative diseases such as osteoporosis and 
periodontisis as well as vascular diseases, like atherosclerosis and aneurysms, and 
cancer (Bengtsson, Nilsson & Jovinge 2008, Chen et al. 2015, Suzuki, Jin & Yazawa 
2014, Xu et al. 2015, Schulte et al. 2010, Wilson et al. 2010).  
In particular, changes in the level of cystatin C in CSF and plasma have been 
associated with various disease conditions. Increase of cystatin C level has been 
shown in several neurodegenerative diseases, brain injuries such as ischemia and 
epilepsy and cardiac injury, suggesting a protective role of the protease inhibitor 
(Zhong et al. 2013, Chen et al. 2015, Xie et al. 2010, Žerovnik 2009). Overall, it 
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indicates that preservation of the secretion level of cystatin C plays an important 
role in health and disease. 
In addition, due to its propensity to self-assemble and form insoluble fibrils 
(Janowski et al. 2001, Tsiolaki et al. 2015), it has been implicated in aggregation-
related degenerative conditions such as hereditary amyloidosis characterised by 
generation of amyloid deposits in the vascular walls causing severe angiopathy. 
 
1.3.1. Amyloydogenic properties 
As mentioned previously, cystatin C has been demonstrated to form inactive 
dimers and oligomers by a process known as three-dimensional domain swapping 
(Janowski et al. 2001). This tendency to form dimers can lead to protein 
aggregation causing the formation of amyloid deposits, which has been observed 
both in vitro under pre-denaturing conditions and in vivo where this process is 
particularly enhanced in the presence of an N-truncated form of cystatin C, as 
described in various neuropathologies (Nilsson et al. 2004, Janowski et al. 2004).  
Amyloidogenic properties of cystatin C have been particularly observed in the case 
of the L68Q mutant cystatin C, a variant form responsible for a rare autosomal 
dominant form of amyloidosis called hereditary amyloid angiopathy, also known as 
Icelandic type that causes fatal cerebral haemorrhage (Wei et al. 1998, Calero et al. 
2001, Rodziewicz-Motowidlo et al. 2006). Substitution of leucine by glutamine in 
position 68 seems to retain the inhibitory function of cystatin C but causes a 
decreased stability by disrupting the hydrophobic interaction network, thus leading 
to increased tendency for dimerization and aggregation in vitro and in vivo where 
generation of fibril deposits occurs in the brain vasculature (Wei et al. 1998, 
Rodziewicz-Motowidlo et al. 2006). In addition, these patients have shown a 
reduced level of cystatin C in the CSF, thus indicating an impaired trafficking of this 
variant form. However, Wei et al. (1998) have suggested that the reduced level in 
the CSF is due to an increased susceptibility of the variant to degradation by serine 
proteases in the extracellular space rather than a difference in level of secretion 
(Wei et al. 1998). 
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1.3.2. Neuroprotective roles 
Despite its involvement in amyloidogenic and neurodegenerative diseases, cystatin 
C has also been described to have multiple neuroprotective roles (reviewed in 
(Gauthier et al. 2011, Mathews, Levy 2016)), through inhibition of its target 
enzymes, induction of cell proliferation and inhibition of apoptosis.  
An important cellular protective mechanism is represented by the autophagy-
lysosome pathway. Interestingly, cystatin C has been described to induce cellular 
autophagy via mTOR pathway inhibition, a mechanism that could be essential to 
increase lysosomal proteolytic clearance and remove accumulating detrimental 
substances or damaged organelles in pathological conditions. Through this 
mechanism, cystatin C protects neuronal cells against various stress conditions such 
as oxidative stress and starvation (Tizon et al. 2010b, Watanabe et al. 2014, Liu et 
al. 2013). Recently, reduced levels of cystatin C have been associated with 
autophagy dysfunction in atheroma plaques resulting in an increased 
atherosclerosis in mice (Li et al. 2016), thus further indicating an important role of 
cystatin C in the regulation of autophagy in pathological processes. 
Furthermore, wild-type cystatin C was found to exhibit a protective role in 
Alzheimer’s disease by binding soluble β-amyloid protein, thus preventing its 
aggregation and fibril formation in vitro and reducing cerebral β-amyloid plaque 
deposition in vivo (Mi et al. 2007, Sastre et al. 2004, Kaeser et al. 2007). It was also 
described to protect neuronal cells from amyloid toxicity by promoting neuronal 
cell survival (Tizon et al. 2010a). Another study has also reported a role of cystatin C 
in regulating β-amyloid levels, this time through its action on cathepsin B. However, 
in contrast to the above-mentioned works, it was the removal of cystatin C that 
played the protective role by increasing the cathepsin B-induced degradation of β-
amyloid, thus indicating a neuroprotective role of cathepsin B rather than its 
inhibitor (Sun et al. 2008, Wang et al. 2012, Mueller-Steiner et al. 2006). 
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1.3.3. Cystatin C involvement in AD and AMD 
Cystatin C’s involvement in AD and other aggregation-related disease such as age-
related macular degeneration (AMD) has been well investigated.  
AD and AMD in particular are both age-related degenerative diseases that present 
many similarities, suggesting the involvement of common mechanisms in their 
pathogenesis. They are both characterized by aggregation and accumulation of 
extracellular deposits, i.e. amyloid plaques and drusen in AD and AMD, 
respectively, as a consequence of a dysregulation of the cellular proteolytic activity 
(Kaarniranta et al. 2011). Furthermore, these insoluble deposits show similarities in 
their composition and have been reported to trigger inflammation and impair 
essential cellular functions, leading eventually to cell degeneration (Kaarniranta et 
al. 2011). Some studies have suggested they share several genetic determinants 
(Logue et al. 2014) and pathogenic mechanisms (Ohno-Matsui 2011). Noteworthy, 
β-amyloid protein deposition was found in both senile plaque in the brain and 
drusen in AMD (Zhao et al. 2015, Feng, Wang 2016).  
As mentioned before, Cystatin C has been implicated in AD. Low levels of serum 
cystatin C have been associated with AD and its levels in CSF correlate with 
amyloid-β peptide levels (Ghidoni et al. 2010, Sundelof et al. 2008, Sundelöf et al. 
2010, Zhong et al. 2013, Ghidoni et al. 2011a). Cystatin C localizes and interacts 
with β-amyloid proteins in AD and has been reported to play a role in physiological 
conditions in promoting the proliferation of Neural Stem/Progenitor cells through 
stimulation of amyloid precursor protein expression (Hu et al. 2013). This therefore 
strongly indicates that there is an interaction between cystatin C and β-amyloid 
proteins. Cystatin C involvement in aging and AMD development has also been 
suggested (Kay et al. 2014, Klein et al. 2009) further indicating a protective role of 
cystatin C against age-related conditions (discussed in next sections). In addition, 
the CST3 polymorphism that generates the variant B cystatin C has been found to 
be associated with both AD and AMD diseases (Crawford et al. 2000, Finckh et al. 
2000, Zurdel et al. 2002). Recent studies have further confirmed the variant B 
implication as a risk factor for late onset AD and exudative AMD (Hua et al. 2012, 
Butler et al. 2015). 
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In this study we focused on the role of cystatin C, and particularly of its variant B, in 
retinal pigment epithelial (RPE) cells and therefore in relation to AMD 
pathogenesis. However, given the similarities between these two conditions and 
the association of the CST3 polymorphism with both diseases, the biological effects 
of the mutated form are expected to be likely similar in both pathologies. 
 
1.3.3.1. Cystatin C in AMD 
Age-related macular degeneration (AMD) is a condition that affects a part of the 
retina called the macula, causing irreversible loss of the central vision and 
representing the leading cause of blindness in the elderly (Liu, Xie 2012). The 
macula is a specialized area of the neurosensitive layer of the retina that contains 
specific photoreceptors responsible for central vision (Jager, Mieler & Miller 2008). 
The retinal pigment epithelium (RPE) plays an important role in the AMD 
pathogenesis (Kinnunen et al. 2012). This highly specialized epithelial tissue, 
consisting of a monolayer of polarized cells, is the outermost layer of the retina, in 
contact apically with the photoreceptor layer of the neuroretina and basally with a 
basement acellular membrane called Bruch’s membrane (BrM), which separates 
the retina from the vascularised choroid that consists of a network of blood vessels 
called choriocapillaries (Strauss 2005). 
The RPE has many functions essential to the nourishment and maintenance of the 
functional integrity of the neuroretina. Functions include formation, along with the 
extracellular matrix BrM, of a protective blood-retinal barrier, that controls 
transport of nutrients and ions between the choroid and photoreceptors as well as 
removal of waste products. Other roles include the visual retinoid cycle, 
phagocytosis of spent photoreceptor outer segments (POS), absorption of light and 
anti-oxidant properties. Finally, RPE is involved in the secretion of several growth 
factors and proteins into both the apical and basal environments, including cystatin 
C, proteinases and angiogenic factors such as VEGF, thus playing a role in the 
regulation of the ECM composition of the BrM and of the choroidal vascularization, 
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as well as in the maintenance of the structural integrity of photoreceptors (Strauss 
2005, Thumann, Hoffmann & Hinton 2006, Kay, Yang & Paraoan 2013). Given its 
roles, dysfunction of the RPE can lead to a severe visual impairment. AMD is 
characterized by pathological changes that involve primarily RPE dysfunction and 
degeneration, leading to subsequent dysfunction of photoreceptor cells in the 
macula region as well as affecting BrM composition and the underlying 
choriocapillaries (Kaarniranta et al. 2010, Klettner et al. 2013).  
The early stage of AMD is characterised by the presence of drusen, yellow 
extracellular protein-lipid deposits, which accumulate between the RPE and the 
BrM and mainly consist of lipids such as unesterified and esterified cholesterol, 
phosphatidylcholine and fatty acids, and several other molecules such as 
apolipoproteins, advanced glycation end products (AGEs) and amyloid proteins 
(Gehrs et al. 2006, Jager, Mieler & Miller 2008). An increased formation and 
accumulation of lipofuscin also occurs within the lysosomes. Lipofuscin consists of 
undegradable polymeric granules composed of cross-linked protein and lipid-
residues derived from inefficient lysosomal digestion. These granules are formed by 
oxidative stress and normally accumulate with age. Their presence decreases 
lysosomal enzyme activity and impairs autophagic clearance of damaged proteins, 
further contributing to proteolytic dysfunction (Gehrs et al. 2006, Jager, Mieler & 
Miller 2008). Advanced stages of AMD can be subdivided into two categories: 
geographic atrophy, also known as dry form, which is characterized by progressive 
atrophy of RPE, thickening of BrM and degeneration of photoreceptor cells; and 
exudative or wet AMD, characterised by an abnormal choroidal neovascularization 
(CNV) where the new forming leaky blood vessels penetrate through the BrM and 
the neuroretina causing serious damages of these layers, thus leading to rapid loss 
of central vision (Gehrs et al. 2006, Jager, Mieler & Miller 2008). 
Impairment of proteolytic activity in RPE, resulting in drusen generation and 
increased accumulation of lipofuscin, is a hallmark of AMD pathogenesis. These 
events lead to activation of complement cascade, chronic inflammation and 
oxidative stress that contribute to RPE degeneration and subsequent 
photoreceptor loss (Gehrs et al. 2006, Jager, Mieler & Miller 2008).  
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Cystatin C is abundantly expressed in RPE and has been implicated in several of the 
processes that also characterize AMD. Alteration in the activity of its target 
cathepsins has been reported to affect ECM structure, the process of 
vascularization and to induce inflammatory and apoptotic processes, thus 
suggesting a role of the cystatin C-cathepsin axis in the pathogenesis of this 
degenerative disease (Turk et al. 2012, Repnik, Cesen & Turk 2013). Moreover, 
impaired autophagy and secretion of exosomes have been also implicated in 
drusen formation and AMD development (Wang et al. 2009). Dysregulation of 
autophagy has been particularly investigated for its involvement in RPE dysfunction 
suggesting a key role of this process in AMD pathogenesis (Wang et al. 2009, 
Kaarniranta et al. 2013, Mitter et al. 2014). Many of the pathological events that 
characterise AMD can therefore be associated with cystatin C. In agreement with 
the hypothesis of a key role played by cystatin C in the maintenance of retina 
integrity and functionality, Ahuja et al. have shown an imbalance in the activity of 
cystatin C and its target proteases in the retina of mice affected by retinitis 
pigmentosa, a condition characterized by retinal degeneration (Ahuja et al. 2008). 
In addition, the level of serum cystatin C has been found to associate with severe 
retinopathy in type 2 diabetes (He et al. 2013) and with the incidence of early AMD 
(Klein et al. 2009). To better understand cyatatin C association with AMD it is 
necessary to further explore its function in the RPE. 
 
1.3.3.2. Cystatin C in RPE 
In the eye cystatin C is present in a variety of tissues and detected at particularly 
high levels in the ciliary epithelium and in the retina (Wassélius et al. 2001, 
Wasselius et al. 2004). Within the retina, RPE cells have been described to 
predominantly express cystatin C transcripts (Paraoan, Grierson & Maden 2000) 
and constitutively secrete the protein into the extracellular environment (Paraoan 
et al. 2001). The role of the leader peptide in targeting the protease inhibitor to the 
secretory pathway in RPE cells was further confirmed by using a construct encoding 
the mature cystatin C lacking the signal sequence, which was no longer targeted to 
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the ER/Golgi pathway, thus presenting a diffuse distribution throughout the 
cytoplasm and nucleus of the cell (Paraoan, Grierson & Maden 2003).  
In vitro analysis of Cystatin C secretion by RPE has shown it to occur on the 
basolateral side of the cell layer, suggesting a main role of this inhibitor in 
maintaining the proteolytic balance in the RPE underlying Bruch’s membrane and 
vascularized choroid (Kay, Yang & Paraoan 2013). However, because cystatin C has 
also been shown to inactivate its target enzymes intracellularly, following re-
uptake, it has been suggested that cystatin C in the intracellular compartment may 
be involved in the regulation of photoreceptor phagocytosis and degradation, an 
essential function of the RPE (Wassélius et al. 2001, Wassélius et al. 2005). 
Secretion of cystatin C has also been described to occur in RPE via exosomes (Locke 
et al. 2014). Both mechanisms of internalization and release by exosomes may play 
an important role in RPE cells to regulate the extracellular levels of cystatin C in 
order to maintain the correct balance between cystatin C and cathepsins in the 
ECM.   
Given its abundance and functions, cystatin C has been suggested to play a role in 
the age-related changes that occur in RPE and BrM (Kay et al. 2014). A progressive 
decline of proteostasis has been widely established to occur with age, involving 
both UPS and ALP systems (Hipp, Park & Hartl 2014, Vilchez, Saez & Dillin 2014), 
thus reducing the capacity to prevent the accumulation of misfolded/damaged 
proteins and cytotoxic protein aggregates. In particular, in RPE cells phagocytosis 
and lysosomal degradative mechanisms can be impaired, resulting in decreased 
POS degradation and renewal with consequent photoreceptor dysfunction (Guha 
et al. 2014). Moreover, accumulation of intra-lysosomal debris such as lipofuscin 
and deposition of extracellular debris has been observed in senescent RPE cells, 
along with generation of reactive oxygen species (ROS), structural changes in BrM 
composition and altered vascularization (Guha et al. 2014). As a consequence, 
vision ability is impaired in the elderly. These age-related effects also characterize 
the onset of age-related maculopathy and AMD (Rakoczy et al. 2002). Interestingly, 
alterations in the expression of cathepsins and impairment in the lysosomal 
function were observed in RPE with aging (Glenn et al. 2009) as well as a decreased 
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expression and secretion of cystatin C (Kay et al. 2014), further indicating a crucial 
role of cystain C concentration in maintaining the proteolytic balance in the RPE 
and in contributing to RPE dysfunction in ageing and AMD. 
 
1.4. Variant B 
A variant form of cystatin C, homozygote for haplotype B, has been reported to be 
a risk factor for both AMD and AD development. The CST3 polymorphism 
implicated in such association consists in a G73A base change that results in an 
alanine (A) to threonine (T) substitution of the 25th amino acid residue (A25T) of 
the precursor cystatin C. This substitution resides within the signal sequence at the 
-2 position from the cleavage site (Figure 1.3) (Balbín, Abrahamson 1991, Balbín, 
Grubb & Abrahamson 1993). This CST3 polymorphism has been investigated for its 
association with exudative AMD in a case-control study in a Caucasian population 
and is significantly higher in patients (6.6%) compared to controls (2.3%) (Zurdel et 
al. 2002). The odds ratio for disease association with the homozygous CST3 
genotype B/B is 2.97, nearly three-fold higher than the wild-type. In this study, 
A25T has been also suggested to be a recessive risk allele, since the heterozygote 
A/B did not correlate with the disease.  
A genetic association for the variant B polymorphism has also been identified with 
late-onset Alzheimer’s disease (Finckh et al. 2000, Crawford et al. 2000), suggesting 
a role of this protein in contributing to cell degenerative processes. Variant B 
association with AD has been more extensively investigated (Bertram et al. 2007, 
Hua et al. 2012) and, recently, these findings have been further supported by 
Butler et al., who have confirmed in a meta-analysis study the significant recessive 
effect of variant B genotype on both AMD and AD (Butler et al. 2015). The 
haplotype frequencies estimated are 76% for variant A and 23% for variant B, with 
a frequency of homozygote B/B genotype in AMD patients of 4.6%. 
Interestingly, CST3 haplotype B has been also associated with other degenerative 
and aggregation-related neurological disorders such as the frontotemporal lobar 
degeneration, dementia in Lewy Body disease and parkinsonian form of multiple 
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system atrophy (Benussi et al. 2010, Maetzler et al. 2010, Urbizu et al. 2015), which 
further supports the role of variant B in proteolytic dysfunction and cell 
degeneration. 
However, in conflict with the above-mentioned studies, there are many other 
works that have reported no association between the CST3 polymorphism and AD 
(Roks et al. 2001, Maruyama et al. 2001, Monastero et al. 2005, Nacmias et al. 
2006, Wang et al. 2008). Further investigations are also required to confirm the 
association with AMD, since so far only two works have reported cystatin C 
association with exudative AMD (Zurdel et al. 2002, Butler et al. 2015), one of 
which is a meta-analysis that used data from the initial clinical study. Many 
genome-wide association studies have been also carried out and all of them have 
failed to identify CST3 among the loci associated with either AD or AMD (Butler et 
al. 2015). Therefore, the role of variant B cystatin C in disease pathogenesis still 
needs to be clarified. 
 
 
Figure 1.3 - Signal sequence of cystatin C. Amino acid sequence of cystatin C signal peptide 
(residues 1 to 26). Variant B is generated by Alanine to Threonine substitution on the 25th 
residue. 
 
It is still not well understood how the variant B could cause an increased risk of 
developing AMD and AD pathologies. Several studies have investigated the 
mechanisms behind such association but so far inconclusive results were obtained. 
Since the A25T mutation occurs in the signal sequence of the precursor protein, it 
has been suggested that it does not affect any of the cystatin C domains involved in 
its inhibitory functions (Paraoan et al. 2004). However, an impairment in the 
intracellular trafficking of cystatin C variant B has been observed to occur in RPE 
cells in vitro by using EGFP-linked cystatin C constructs (Paraoan et al. 2004).  
Compared to the wild-type protein that was shown to localize in the ER/Golgi 
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apparatus and be normally processed for secretion in RPE cells, the variant B was 
mainly retained intracellularly, showing a diffuse intracellular distribution 
throughout the cytosol and nucleus and, in particular, an association with the 
mitochondria. As a consequence, a reduction in variant B cystatin C secretion into 
conditioned media by approximately 50% was also observed compared to the wild-
type, thus indicating that variant B proteins are still partially processed in the ER 
and secreted from the cells, but due to the mutation likely a reduction in the 
efficiency of targeting and/or processing through the secretory pathway occurs for 
the variant protein (Paraoan et al. 2004). In another work by the same group, using 
a mutated variant of cystatin C linked to EGFP, it has been reported that the 
substitution of the amino acid alanine at the 25th position of the signal sequence 
with a serine, which has intermediate hydrophobic properties between alanine and 
threonine, results in an intermediate level of secretion between the wild-type and 
the A25T variant, as well as a localization to the ER/Golgi and mitochondria 
(Ratnayaka et al. 2007). This suggests that the change in the hydrophobicity is 
sufficient to interfere with the protein trafficking. 
Therefore, regarding the variant B, it has been suggested that the substitution of 
the nonpolar alanine amino acid to a polar threonine residue, which significantly 
reduces the signal sequence hydrophobicity, is sufficient to interfere with the 
functionality of the leader peptide, preventing the proper targeting and/or 
processing of cystatin C through the secretory pathway, thus causing protein 
mistrafficking and decreased secretion (Ratnayaka et al. 2007). Given that a 
fraction of the protein is still secreted, Paraoan et al. have hypothesised that the 
signal sequence did not lose its targeting properties, but it may act as a weaker 
signal. The decreased hydrophobicity profile of the signal sequence could affect 
different steps (described in section 1.5.1), such as the signal-recognition process, 
thus partially blocking the protein targeting to the endoplasmic reticulum, or the 
interactions with the ER translocation channel, therefore preventing the 
translocation into the ER lumen, or the cleavage process by the signal peptidase 
(Paraoan et al. 2004). However, considering that the cleavage of the signal peptide 
would generate the same mature protein as that of the wild-type it has been 
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suggested that the variant B precursor protein is not entirely processed and as a 
consequence the whole precursor cystatin C with the signal peptide uncleaved may 
adopt an altered intracellular conformation that may incorrectly target the protein 
to the mitochondria (Paraoan et al. 2004). 
 
Impaired secretion of variant B has been also described in B/B homozygous skin 
fibroblasts taken from AD donors, likely as a result of less efficient cleavage of the 
leader peptide in the case of the variant B (Benussi et al. 2003), thus supporting the 
hypothesis of a defective processing of cystatin C. Given the neuroprotective role 
of cystatin C in promoting cell survival and inhibition of β-amyloid deposition, they 
have suggested that the impaired production and secretion of cystatin C observed 
for the haplotype B might be responsible for the increased susceptibility to 
neurodegeneration (Benussi et al. 2003). In support of this hypothesis it has been 
observed that there is a reduction of cystatin C secretion in mice carrying a 
mutation in presenilin 2 gene, which is associated with familial AD (Ghidoni et al. 
2007). The mutation seems to directly impair the trafficking of cystatin C causing 
intracellular accumulation and consequent reduction in secretion (Ghidoni et al. 
2007), supporting a key role of cystatin C level in AD pathogenesis. 
Interestingly, several studies in vivo have also reported association of the variant B 
haplotype with decreased levels of cystatin C in plasma and CSF in various 
pathologies, including neurological disorders and vascular diseases (Noto et al. 
2005, Maetzler et al. 2010, Yamamoto-Watanabe et al. 2010, Åkerblom et al. 
2014). 
The CST3 polymorphism seems therefore to be associated with increased risk of 
developing both AMD and Alzheimer’s disease through a reduction in the levels of 
cystatin C secretion in the extracellular fluids, as a consequence of a decreased 
efficiency or partial failure of signal cleavage.  
 
In addition to these studies, Nilsson et al. (2009) have suggested that the 
intracellular cleavage of cystatin C variant B may occur at an alternative site, 
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between the 20th and 21st residue (Nilsson et al. 2009). In this study a O-linked 
glycan has been identified to be present in the variant B protein, likely residing on 
Ser27, Ser28 or on the mutated Thr25, therefore suggesting that the cleavage in 
the different position makes the six residues-longer mature protein able to 
undergo a O-linked glycosylation event, which may affect cystatin C functionality or 
stability. As described previously for the L68Q variant, this alternatively processed 
protein could be more susceptible to degradation and therefore the reduced levels 
in the extracellular compartment may result from a combination of a defect in 
cystatin C trafficking and an increased degradation of the secreted protein.  
In contrast, a more recent study has shown no difference in secretion between the 
wild-type and variant B cystatin C in two different cell lines, ARPE19 and HEK-293T, 
and using different cystatin C constructs either untagged or tagged with GFP or 
FLAG tag (Nguyen, Hulleman 2016). Moreover, in this study they have shown that 
wild-type cystatin C can alternatively undergo signal sequence cleavage in two 
different sites, between the amino acids Gly26-Ser27, which represents the 
canonical cleavage site, and the second one between residues Ala20-Val21 that 
occurs at lower frequency. Interestingly, this alternative cleavage site was 
predicted to occur in the variant B by Nilsson et al. (2009) and, consistently, 
Nguyen and Hulleman have suggested that A25T protein has an increased 
probability to be alternatively cleaved at the 20th amino acid residue compared to 
the wild-type and the resulting processed protein consequently may be more likely 
to undergo O-glycosylation in the Golgi apparatus (Nguyen, Hulleman 2016). 
Furthermore, an additional study has also found association of haplotype B with 
increased risk of developing AD but no significant difference in the plasma level of 
variant B cystatin C compared to the wild-type was observed in AD patients (Chuo 
et al. 2007). 
 
Based on the studies here described, the increased risk of developing AMD can 
therefore be due to the reduced level of cystatin C in the extracellular 
environment, which may affect the proteolytic balance in the extracellular space of 
the RPE (Paraoan et al. 2004). As described previously cystatin C is abundantly 
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present in this area where it may play an important role in the modulation of the 
proteolytic activity of cathepsin (Paraoan, Grierson & Maden 2000, (Paraoan et al. 
2001). Its impaired secretion could therefore affect the ECM remodelling of the 
BrM and the angiogenesis balance in the underlying choroid. As mentioned before 
a decrease in cystatin C secretion from RPE has been also observed to occur with 
age (Kay et al. 2014) where it may contribute to the RPE dysfunction observed in 
aging. Therefore, the reduction in secretion observed for the variant B could 
accelerate the dysregulation of the proteolytic balance in the extracellular 
environment contributing even more to RPE dysfunction and AMD development 
(Kay et al. 2014).   
In addition to the reduction in secretion, the intracellular accumulation of variant B 
and in particular its unusual association with mitochondria observed by Paraoan et 
al. may further contribute to RPE cell dysfunction, especially given that RPE cells 
are consistently rich in mitochondria, aligned with their high metabolic activity 
(Thumann, Hoffmann & Hinton 2006). Moreover, there is a large body of evidence 
that mitochondria alterations may play a role in AMD and other retinal pathologies 
(Feher et al. 2006, Nordgaard et al. 2008, Karunadharma et al. 2010, Jarrett et al. 
2008) as well as in other degenerative diseases such AD and Parkinson (Eckmann et 
al. 2013, Moreira et al. 2010, Hirai et al. 2001) where proteins involved in such 
pathologies (i.e. β-amyloid precursor and α-synuclein) can be abnormally 
associated with mitochondria (Grant et al. 1999, Anandatheerthavarada et al. 2003, 
Anandatheerthavarada, Devi 2007, Liu et al. 2009, Devi et al. 2008, Devi, 
Anandatheerthavarada 2010). 
Moreover, besides the impairment in secretion and intracellular mislocalization, an 
alternative mechanism through which the CST3 polymorphism increases the risk for 
the development of AD and AMD can be due to the alternative signal cleavage that 
generates a mature protein with six additional amino acids with increased 
propensity to undergo O-glycosylation. These additional residues at the N-terminus 
and/or the presence of O-glycosylation may affect cystatin C function, stability and 
regulation. 
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In conclusion, given the role of cystatin C and its target enzymes in processes such 
as inflammation, lysosomal function, autophagy, apoptosis, ECM remodelling, 
angiogenesis, all of which have been shown to be altered in AMD, there is a strong 
suggestion that there is a role for cystatin C in AMD pathogenesis. However, if and 
how the variant B of cystatin C alters the regulation of proteolytic balance is not 
well understood and controversial. 
Therefore, further clarifying the molecular mechanisms underlying the trafficking, 
function and regulation of variant B will help us understand whether and how it 
contributes to the impairment of RPE function and to AMD development, and 
similarly to other degenerative diseases. 
 
 
 
1.5. Protein Targeting and Trafficking 
In all eukaryotic cells, proteins are synthesised on ribosomes and then can be 
targeted to cellular compartments, dependent upon specific signals present in the 
amino acid sequence of the protein. Generally, proteins targeted to the cytosol, 
nucleus, mitochondria, chloroplasts and peroxisomes are translated on “free” 
ribosomes in the cytosol and then transported to their target organelle (Kim, 
Hwang 2013, Barlowe, Miller 2013). Alternatively, proteins directed to the 
endoplasmic reticulum (ER), Golgi apparatus, lysosomes, plasma membrane and 
extracellular matrix or space are usually translated on ER-attached ribosomes and 
translocated into the ER before being directed to their specific cellular organelle. 
From the ER, proteins are transported to and across the Golgi apparatus and 
subsequently to the target intracellular compartment or extracellular space by 
vesicular transport (Figure 1.4). This ER-Golgi-vesicles route is generally known as 
the secretory pathway (Kim, Hwang 2013, Barlowe, Miller 2013). 
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Figure 1.4 - Protein trafficking in the secretory pathway. Nascent proteins are targeted 
and translocated into the ER for their processing and folding. Proteins are subsequently 
delivered to Golgi apparatus, through the different Golgi compartments, where they can 
undergo post-translational modifications. Finally, proteins are sorted to the appropriate 
intracellular or extracellular destination. Endocytic pathway is also shown (Figure adapted 
from (Alberts et al. 2008)). 
 
1.5.1. Secretory pathway 
The secretory pathway consists of the transportation of both soluble and integral 
membrane proteins. Soluble proteins destined for secretion are mainly considered 
in this study, although some can also be delivered to intracellular organelles such 
as lysosomes by binding to mannose-6-phosphate receptors (e.g. cathepsins) 
(Braulke, Bonifacino 2009, Coutinho, Prata & Alves 2012). As mentioned above, the 
canonical pathway that leads to protein secretion comprises the ER, where proteins 
undergo process of co- or post-translational insertion, folding and modification, the 
Golgi apparatus, where further post-translational modification can occur, and the 
secretory vesicles, which ultimately will fuse with the plasma membrane thus 
releasing proteins outside the cell (Barlowe, Miller 2013). The trans compartment 
of the Golgi is, in addition, a major sorting compartment for delivery to intracellular 
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compartments such as lysosomes and different secretory compartments (e.g. 
luminal and serosal or dendritic and axonal in epithelial or neuronal cells, 
respectively, (Gu, Crump & Thomas 2001, Nejsum, Nelson 2009, Bradke, Dotti 
1998)). 
The main aspect investigated in this study is the role of signal sequences in ER 
targeting, translocation and processing of secretory proteins, which represent the 
first step of the canonical secretory pathway. Quality control and protein 
modifications, occurring along this pathway, will be also briefly discussed. 
 
1.5.1.1. Translocation of nascent polypeptide chains across the ER 
membrane 
Targeting and translocation of nascent polypeptide chains into the ER is a 
mechanism based on an amino-terminal signal sequence, also termed the leader 
peptide, within the nascent precursor polypeptide. This, together with transport 
components present in both cytosol and ER called molecular chaperones, permits 
targeting and translocation of proteins to the ER, where the signal sequence is 
cleaved from the protein. In the lumen of the ER, mature proteins are then 
subjected to folding and modifications, such as glycosylation, before being 
delivered to the Golgi apparatus (Barlowe, Miller 2013). 
 
Translocation across the ER membrane can occur either co-translationally or post-
translationally. The co-translational process begins when a hydrophobic signal 
sequence is translated during the protein synthesis, started on a free ribosome in 
the cytosol, and recognized by the signal-recognition particle (SRP). The ribosome-
associated protein is thus targeted to the SRP receptor (SR) on the ER membrane in 
proximity of the ER translocation machinery (Walter, Blobel 1981, Görlich, 
Rapoport 1993) (Figure 1.5). Post-translational transport involves specific cytosolic 
chaperones necessary to maintain the fully synthetized polypeptide in an unfolded 
state, an essential condition for the protein to be able to cross the ER membrane. 
These chaperones belong to the heat shock proteins Hsp 70 and Hsp 40 families 
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(Chirico, Waters & Blobel 1988, Deshaies et al. 1988, Ast, Cohen & Schuldiner 
2013). 
Even though the mechanisms are not completely understood, in yeast it seems that 
generally the level of hydrophobicity of the signal sequence represents the main 
factor that determines which translocation pathway the protein will follow (Ng, 
Brown & Walter 1996, Hatsuzawa, Tagaya & Mizushima 1997). Secretory proteins 
with high hydrophobic signal sequences and integral membrane proteins typically 
make use of the SRP-dependent pathway, whereas a post-translational transport is 
preferred by proteins with soluble, less hydrophobic signal sequences (Ng, Brown & 
Walter 1996, Hatsuzawa, Tagaya & Mizushima 1997). In mammals one main 
feature that seems to characterize precursor proteins targeted for post-
translational translocation is the length of the nascent polypeptide; if it contains 
less than 75-100 amino acid residues it seems not to be able to establish the proper 
interactions with SRP. Other characteristics are also suggested to play a role in 
signal sequence recognition, such as its orientation at the ribosomal surface, helical 
propensity and presence of N-terminal basic residues (Shao, Hegde 2011, Lakkaraju 
et al. 2012, Johnson et al. 2012, Peterson, Woolhead & Bernstein 2003).  
Both of these mechanisms merge at the central component of the ER-membrane 
translocation machinery, the heterotrimeric Sec61 complex, or translocon, 
consisting of Sec61p associated with Sss1p and Sbh1p proteins in yeast, and named 
as Sec61α, Sec61β, and Sec61γ in mammalian cells. This complex forms an aqueous 
channel consisting of 10 transmembrane segments, which allow the passage of 
hydrophilic polypeptides across the ER membrane, and a lateral gate toward the 
lipid bilayer for integration of hydrophobic segments (Panzner et al. 1995, Görlich 
et al. 1992, Görlich, Rapoport 1993, Stirling et al. 1992). Various ligands interact 
with the Sec61 channel to promote protein translocation and to regulate its 
dynamics between the open and closed conformations. The major roles in this 
process are played by the precursor polypeptide itself, the ribosome and, at the ER 
lumen side, by the molecular chaperone Kar2 in yeast, a member of the heat shock 
protein 70 (Hsp70) family, or its equivalent in mammals BiP (immunoglobulin-
heavy-chain binding protein) (Chirico, Waters & Blobel 1988, Craven, Egerton & 
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Stirling 1996, Panzner et al. 1995, Görlich et al. 1992). Binding of the chaperone to 
the nascent precursor protein at the luminal side guarantees an efficient and 
unidirectional transport across the ER membrane (Alder et al. 2005, Tyedmers et al. 
2003). 
 
 
Figure 1.5 - Co-translational translocation of proteins to the Endoplasmic Reticulum (ER). 
It consists of SRP-mediated targeting of a nascent polypeptide chain-ribosome complex to 
the SRP receptor at the ER membrane, followed by translocation through the Sec61 
complex into the ER lumen, with the assistance of Kar2 (or BiP) chaperone. The signal 
sequence is subsequently cleaved by the Signal Peptidase Complex, as soon as the cleavage 
site is exposed in the ER lumen (Figure adapted from (Barlowe, Miller 2013)) 
 
The prevalent mechanism reported in mammalian cells appears to be co-
translational (Figure 1.5), involving most of the secretory proteins and many 
organellar and membrane proteins, whose biosynthesis occurs on rough ER-
associated ribosomes simultaneously with their translocation into the membrane 
or lumen of the ER. Membrane proteins are inserted into the ER membrane unlike 
soluble, secretory polypeptides that are transported to the ER lumen (Barlowe, 
Miller 2013). 
Once translation of mRNAs has started, the signal sequence of the nascent protein 
is bound by the cytosolic SRP as it is synthetized and emerges from the ribosome. 
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This usually occurs when the protein is about 70 amino acids long as 30 residues 
remain buried in the ribosome (Walter, Blobel 1981, Halic et al. 2004).  
Signal sequences differ in length among the secretory proteins as well as in shape 
and amino acid composition. However, they usually consist of 16-30 amino acid 
residues, which present a similar tripartite structure consisting of a positively 
charged N-terminus, a main central hydrophobic region and C-terminal polar region 
containing the cleavage site (described in details in the next section) (Heijne 1983, 
von Heijne 1984, von Heijne 1985). 
The SRP is a ribonucleoprotein composed of a 7S RNA component of 300 
nucleotides and various protein subunits: Srp7p, Srp14p, Sec65p, Srp21p, Srp54p, 
Srp68p and Srp72p in yeast, or the equivalent SRP9, SRP14, SRP19, SRP54, SRP68, 
and SRP72 in mammalian cells (Brown et al. 1994, Halic et al. 2004, Nyathi, 
Wilkinson & Pool 2013). A major role is performed by the SRP54 subunit, which 
interacts with the ribosome, the signal sequence and with its receptor (SR) at the 
ER membrane, a heterodimer formed by α and β subunits (High, Dobberstein 1991, 
Zopf, Bernstein & Walter 1993, Nyathi, Wilkinson & Pool 2013). SRP normally binds 
to non-translating ribosomes with low affinity and the presence of the signal 
sequence at the exit site of the ribosome has been shown to increase its affinity for 
the ribosome (Flanagan et al. 2003, Halic et al. 2004). 
After binding the signal peptide, the SRP binds its ER-membrane localized receptor, 
based on a GTP-dependent interaction between the SRP54 protein of the SRP and 
the α subunit of the SR (Nyathi, Wilkinson & Pool 2013). As a result, the ribosome-
nascent chain-SRP complex is targeted to the Sec61 complex in the ER membrane 
so that the signal sequence can bind to the translocon, stimulating the initiation of 
the protein translocation across the ER membrane. The Sec61 complex undergoes a 
conformational change, thus opening the internal channel (Görlich et al. 1992, 
Rutkowski et al. 2003). The signal sequence seems also to mediate the ribosome 
association with the translocon, which facilitates stabilization and opening of the 
translocation complex (Nyathi, Wilkinson & Pool 2013, Rutkowski et al. 2003). 
Subsequently, the SRP-SR complex dissociates from the ribosome and the SRP is 
released in the cytosol, upon GTP hydrolysis, so that it can be used for a new 
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nascent precursor protein. The nascent chain inserts into the conducting channel of 
the translocon with the leader peptide ultimately assuming a loop conformation, 
with the N-terminus usually facing the cytosolic face and the C-terminus with the 
cleavage site facing the ER lumen (Shaw, Peter & Rose 1988, Goder, Spiess 2003). 
The polypeptide chain is now translated and simultaneously translocated into the 
translocation pore, a process driven by the hydrolysis of ATP. In yeast it has been 
widely reported that the ER chaperone Hsp70-type Kar2 binds to the growing chain 
on the luminal surface and then, again powered by the hydrolysis of ATP, releases 
the nascent chain (Craven, Egerton & Stirling 1996, Dierks et al. 1996). This cycle of 
binding and release of the nascent chain by Kar2 is essential for translocation to 
continue. The ATP needed for the luminal chaperones to fulfil their function is 
imported from the cytosol by an ATP/ADP translocase, called nucleotide exchange 
factor (NEF), located in the ER membrane (Craven, Egerton & Stirling 1996, Dierks 
et al. 1996). As mentioned earlier, the binding of Kar2/BiP to the incoming 
polypeptide ensures correct and unidirectional translocation, as movement 
through the translocation channel would otherwise be reversible (Tyedmers et al. 
2003, Alder et al. 2005). 
As soon as the cleavage site is exposed within the lumen, it is recognized and 
cleaved by the signal peptidase complex (SPC) located at the luminal side of the ER 
membrane. The SPC is an endoprotease consisting of four subunits: Spc1, Spc2, 
Spc3 and Sec11 (Evans, Gilmore & Blobel 1986). The latter contains the protease 
active site and is suggested to be located close to the translocation channel exit at 
the lumenal surface; Spc3 seems to be also essential for peptidase activity whereas 
Spc2 was reported to bind the Sec61 complex (Evans, Gilmore & Blobel 1986, 
Meyer, Hartmann 1997, Antonin, Meyer & Hartmann 2000).  
The cleaved signal peptide is subsequently digested by the signal peptide peptidase 
(SPP), located within the ER membrane, and the resulting fragments are eventually 
released from the membrane into the cytosol, where they can be further processed 
or rapidly degraded in the proteasome (Lyko et al. 1995). The nascent protein 
continues its co-translational translocation and its process of maturation into the 
ER lumen, which includes events of modification. Specific enzymes present on the 
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luminal surface can add carbohydrates to the chain at specific residues of 
asparagine as soon as they emerge from the translocon (described in section 
1.5.1.4). This represents a predominant protein modification known as N-linked 
glycosylation and operated by the oligosaccharyl transferase (OST) complex 
(Chavan, Yan & Lennarz 2005). Once translation is completed, the ribosomes are 
released, the C-terminus portion of the protein is also transferred into the ER 
lumen, the conducting channel of the translocon shuts, and the protein is subjected 
to a process of folding by the assistance of lumenal chaperones, such as BiP 
(Barlowe, Miller 2013). Lectins, such as calnexin and calreticulin, are crucial for the 
folding of glycoproteins through their interactions with sugars (Barlowe, Miller 
2013). Further glycosylation events can occur within the ER after the protein is fully 
translated, consisting of subsequent modifications of the N-glycan attached 
previously as well as O-glycosylation (described below). Other modifications that 
can occur in the ER include the formation of disulphide bonds by the protein-
disulfide isomerase (PDI) and the addition of a glycophosphatidylinositol (GPI) 
anchor (Barlowe, Miller 2013). 
 
Post-translational translocation also occurs through the translocon complex but in 
a ribosome- and SRP-independent manner. In yeast and mammalian cells, 
precursor polypeptides entirely synthetized on unattached ribosomes in the cytosol 
are then targeted to the ER translocation machinery thanks to the interaction with 
cytosolic molecular chaperones, such as members of the Hsp70 and Hsp40 
chaperone families, which maintain precursor proteins in an unfolded state and 
promote their binding with transport components in the ER membrane (Chirico, 
Waters & Blobel 1988, Deshaies et al. 1988, Ast, Cohen & Schuldiner 2013). 
In this post-translation process, the Sec61 machinery is associated to another 
heterotrimeric complex at the ER membrane, the Sec63 complex, consisting of 
Sec63, Sec62 components (and additional Sec71, and Sec72 in yeast) (Deshaies et 
al. 1991, Panzner et al. 1995, Meyer et al. 2000). This Sec63 complex seems to act 
as a signal peptide receptor, binding the N-terminal signal sequence of the 
polypeptide and subsequently inducing a conformational change of the Sec61 
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channel in an open state to allow insertion of the protein into the ER membrane. As 
a result, the signal sequence can interact with cytosolic components of the Sec61 
complex and be inserted in the translocation pore (Plath et al. 1998). Involvement 
of Sec62 and Sec63 has been actually reported also in the co-translational 
mechanism of certain precursor polypeptides in yeast and mammalian cells. For 
instance, in yeast, Sec62 and Sec63 were shown to interact with ribosomes and BiP 
to take part in the regulation of Sec61 channel conformation by binding to the ER 
luminal side of Sec61α and providing binding energy to the system (Brodsky, 
Schekman & Goeckeler 1995, Young et al. 2001). As mentioned above, the lumenal 
Hsp70-type chaperone Kar2 in yeast, or BiP in mammalian cells, is the other 
fundamental component that promotes the efficient protein import through the ER 
membrane. Once a hydrophilic region of the protein is inserted into the channel, 
the Kar2 chaperone is able to bind the polypeptide in an ATP-dependent manner, 
thus regulating and directing the protein import across the membrane (Craven, 
Egerton & Stirling 1996, Dierks et al. 1996). Kar2 chaperone has been also reported 
to interact with the luminal DnaJ domain of the Sec63 component and together 
they seem to tightly regulate the protein transport until it is completed (Brodsky, 
Schekman 1993, Panzner et al. 1995, Misselwitz et al. 1999, Matlack et al. 1999). As 
for the co-translational process, the N-terminal signal sequence, that initially 
remains inserted into the ER membrane facing the cytosol, is eventually removed 
by the ER membrane-associated SPC by endoproteolytic cleavage, thus permitting 
the protein release into the lumen. 
 
Other components of the translocation machinery have also been described 
although their role is not fully understood. Examples are the translocating chain-
associating membrane (TRAM), the translocon-associated protein (TRAP) complex, 
the ribosome-associated membrane protein RAMP4, and additional molecular 
chaperones (Voigt et al. 1996, Fons, Bogert & Hegde 2003, Shao, Hegde 2011, 
Johnson et al. 2012, Pool 2009). 
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1.5.1.2. Roles of the signal sequence 
Signal sequences play several roles to ensure the efficient targeting, translocation 
and processing of nascent proteins (Hegde, Bernstein 2006). They usually consist of 
16-30 amino acid residues located at the N-terminus of the respective protein. 
Although they do not display extensive homology in their amino acid sequence, 
they share similar features in the structure, which typically consists of three 
conserved domains, a positively charged N-terminus, a predominant hydrophobic 
core, and a C-terminal polar domain which contains the cleavage site for the signal 
peptidase (Heijne 1983, von Heijne 1984, von Heijne 1985). They are termed 
respectively n-, h- and c-region. These structural features are crucial to permit the 
efficient SRP recognition, translocation into the ER and cleavage of the precursor 
proteins (Nilsson et al. 2015). 
The h-region is a 6-15 residue long domain fundamental for co-translational 
processing. As mentioned above, the hydrophobicity of the signal peptide is the 
main criterion that determines the translocation pathway of a nascent polypeptide, 
whether co-translational or post-translational (Ng, Brown & Walter 1996, 
Hatsuzawa, Tagaya & Mizushima 1997). High hydrophobic signal peptides usually 
characterize proteins that are directed to the SRP-dependent pathway. The h-
region has been shown to be essential and sufficient for signal peptide 
recognition/binding by SRP. Moreover, mutations in this region have been also 
shown to affect protein translocation across the membrane. Indeed, the 
hydrophobicity has been described as having an effect on the orientation of the 
signal sequence within the translocon, influencing the N-terminus positioning 
towards the lumenal or cytosolic side and consequently affecting the protein 
orientation (Nilsson et al. 2015, Rosch et al. 2000). 
The n-region is a short 1-5 residue hydrophilic domain that contains up to three 
positively charged basic residues, which have been described to facilitate the 
binding to SRP and the translocation across the membrane (Nilsson et al. 2015, 
Peterson, Woolhead & Bernstein 2003). Mutations in this region have shown to 
decrease the efficiency but not completely abolish the signal sequence recognition 
by SRP and the subsequent translocation, thus suggesting that the positive charged 
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amino acids mainly promote and guarantee the efficient interaction of the signal 
sequence with SRP and with the translocon components. Studies have reported 
that the positive charged residues contribute to the correct orientation of the 
signal sequence across the ER membrane, through a dynamic process that 
ultimately leads the positive N-terminus toward the cytosol (Nilsson et al. 2015, 
Kocik, Junne & Spiess 2012). 
The c-region is a polar domain consisting of 4-7 residues, which include crucial 
amino acids required for the signal peptide cleavage. Residues at -1 and -3 
positions, preceding the cleavage site, are particularly critical in regards to this. 
These positions are usually occupied by small and neutral residues, such as Ala, Gly, 
Cys, and Ser, leading to the formulation of the so-called (-1,-3) rule (Nothwehr, 
Gordon 1990, Auclair, Bhanu & Kendall 2012). Moreover, this region was also 
termed Ala-X-Ala motif due to the prevalence of Ala in such positions (Auclair, 
Bhanu & Kendall 2012). Other studies have also reported that the physical-chemical 
properties of the -1 residue and the length of the c-region are particularly 
important in defining the site of cleavage (Nothwehr, Gordon 1990, Auclair, Bhanu 
& Kendall 2012). Typically, the c-region also contains Pro or Gly residues, which are 
suggested to be important to impede the formation of a secondary structure 
(Nothwehr, Gordon 1990, Auclair, Bhanu & Kendall 2012). Structural features of 
this region are therefore critical for the efficient interaction with the active site of 
the signal peptidase. 
The signal sequence has been described to influence the timing and efficiency of 
the protein translocation and cleavage. Consequently this affects the timing of 
post-translational modification, folding and ER exit of the proteins (Rutkowski et al. 
2003, Hegde, Bernstein 2006). The signal sequence, through its hydrophobic 
domain, can reorient itself within the translocation channel, through its interaction 
with the translocon components Sec61α and Sec61β. This regulates its 
presentation to the processing machinery, providing access to the active site of the 
SPC and allowing subsequent N-linked glycosylation by the OST (Rutkowski et al. 
2003, Hegde, Bernstein 2006). In the case of glycoproteins with N-glycosylation 
acceptor sites located close to the signal peptide, it has been shown that signal 
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sequence cleavage is a prerequisite for the efficient glycosylation modification 
(Chen et al. 2001). 
 
1.5.1.3. Quality control of protein folding 
In order to ensure the correct protein folding and assembly within the ER, proteins 
undergo a process of quality control (Hegde, Ploegh 2010). This is monitored by a 
system mainly consisting of ER chaperones, which associate with unfolded proteins 
to assist their maturation. Proteins that fail to assume the correct conformation are 
prevented from continuing along the secretory pathway. If this is the case, the 
quality control system acts to repair or remove these incorrect proteins (Tsai, Ye & 
Rapoport 2002, Hegde, Ploegh 2010, Buchberger, Bukau & Sommer 2010) (Figure 
1.6).  
The presence of misfolded proteins has been described to disrupt ER homeostasis, 
a condition called ER stress, which activates a signalling network known as the 
unfolded protein response (UPR) (Hegde, Ploegh 2010). Through activation of 
different signalling pathways, UPR leads to an increase in the chaperone 
concentration within the ER as well as of the cellular proteolytic system 
components, by up-regulation of their gene expression. The higher presence of 
chaperones is needed to restore the correct folding process. A simultaneous down-
regulation of the global protein translation is also usually induced to facilitate the 
folding process machinery (Tsai, Ye & Rapoport 2002, Hegde, Ploegh 2010, 
Buchberger, Bukau & Sommer 2010). 
In the case the chaperone-mediated folding continues to fail, proteins are recruited 
for proteasomal degradation in the cystosol, through a process called ER-associated 
degradation (ERAD). This mechanism consists of selective recognition of the 
misfolded substrate by the action of several factors. They typically include 
components of the ER processing machinery, including the chaperone BiP, calnexin, 
calreticulin, protein disulfide isomerase (PDI) and GRP94 (Tsai, Ye & Rapoport 2002, 
Hegde, Ploegh 2010, Buchberger, Bukau & Sommer 2010). Usually the substrate is 
recognised because of the exposure of structural elements not normally present in 
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the native protein, such as hydrophobic regions, erroneous post-translational 
modification and disulphide bonds formation. In the case of glycoproteins, for 
example, they can be targeted for degradation depending on the glycan 
composition, specifically modified by glycosidase/glycosyltransferase enzymes and 
recognised by the calnexin/calreticulin system. Glycans can act as signals to inform 
about the status of the proteins and either direct them to the target cellular 
compartment, if they are properly folded, or trigger the quality control system to 
assist their folding process, or delivering to ERAD (Tsai, Ye & Rapoport 2002, Hegde, 
Ploegh 2010, Buchberger, Bukau & Sommer 2010). 
 
Figure 1.6 - Quality control of protein folding. It ensures that only proper folded proteins 
proceed along the secretory pathway. Otherwise, the presence of misfolfed proteins 
determines ER stress and induces the Unfolded Protein Response (UPR), which in turn 
activates ER chaperones (e.g. BiP) to facilitate the folding or the ERAD/ubiquitin 
proteasome system (UPS) pathway to degrade the protein (Figure adapted from (Nielsen 
2013)). 
 
Recognised substrates, in association with the ER chaperones, are subsequently 
delivered, through an ER transmembrane complex, to the cytosolic face of the ER 
membrane where an ubiquitin-ligase complex targets them for proteasomal 
degradation (Tsai, Ye & Rapoport 2002). A process of retro-translocation from the 
ER back to the cystosol is therefore required. The export machinery has not been 
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fully characterised but different complexes have been suggested to be involved in 
this process. These include the same complex involved in protein translocation to 
the ER (Sec61), the ubiquitin-ligase complex and members of the Derlin family 
(Tsai, Ye & Rapoport 2002, Hegde, Ploegh 2010, Buchberger, Bukau & Sommer 
2010). As soon as proteins emerge at the cytosolic face of the ER membrane, they 
are subjected to polyubiquitination by the action of the catalytic subunit E3 
ubiquitin-ligase. Proteins can then be released into the cytosol, via an ATP-driven 
mechanism, and recognized by proteasomal components for their degradation 
(Tsai, Ye & Rapoport 2002, Hegde, Ploegh 2010, Buchberger, Bukau & Sommer 
2010) (Figure 1.6). 
In addition to the ERAD system, misfolded proteins can sometimes proceed 
through the secretory pathway and be sent to lysosomes for degradation (Hegde, 
Ploegh 2010). Furthermore, in the case of an excessive accumulation of misfolded 
proteins, overwhelming the ERAD system or causing formation of protein 
aggregates in the ER, their degradation can occur through the autophagic pathway 
(Buchberger, Bukau & Sommer 2010). It is unlikely that large protein aggregates 
can be transported through the ER membrane export channel. The ERAD system is 
also involved in the “quantity” control to remove proper folded proteins when 
over-produced and unnecessary (Hegde, Ploegh 2010).  
Finally, in case the degradative system is unable to remove the misfolded or 
aggregated protein, the UPR can induce the apoptotic pathway in order to remove 
the damaged cell (Kim et al. 2006). This, for example, occurs in degenerative 
diseases, characterised by accumulation of misfolded proteins, protein aggregates 
and a saturated/non-functional proteolytic system, where UPR ultimately leads to 
cell death (Rutishauser, Spiess 2002). 
 
1.5.1.4. Protein maturation in the ER and Golgi apparatus  
Once proteins have been folded and appropriately modified, vesicular transport 
allows them to be directed from ER to Golgi apparatus and subsequently to the cell 
surface for secretion (Barlowe, Miller 2013). Vesicles formation from donor 
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membranes requires the recruitment of cytosolic coat proteins, which differ based 
on the cellular route. Transport vesicles that bud off from the ER directed to the 
Golgi apparatus are COPII-coated. There is also a retrograde transport from Golgi 
back to ER, essential to retrieve escaped proteins that are misfolded or not fully 
processed, or proteins that are destined to reside in the ER. This transport is 
mediated by COPI-coated vesicles (Barlowe, Miller 2013, Nickel, Wieland 1998). 
ER-originated COPII-coated vesicles merge together to form the ER-Golgi 
intermediate compartment (ERGIC). Subsequently, the cargo proteins are 
transported through the various cisternae of the Golgi stack, consisting of cis-Golgi, 
medial compartment, trans-Golgi and ultimately to the trans-Golgi network (TGN), 
where proteins are sorted and delivered to the appropriate destination i.e. the 
endosomal-lysosome system, the plasma membrane or the secretory granules 
(Barlowe, Miller 2013). In absence of other signals present within the protein 
sequence or acquired by post-translational modifications, proteins are usually 
directed for secretion through secretory vesicles that fuse with the plasma 
membrane, thus releasing their content in the extracellular space (Barlowe, Miller 
2013).  
Within the Golgi apparatus, cargo proteins can undergo extensive glycan 
processing as well as additional modifications including phosphorylation, sulfation, 
and proteolytic processing, which are usually necessary for the bioactivity, 
targeting or stability of the protein (Barlowe, Miller 2013). Among the different 
post-translational modifications, glycosylation represents one of the most 
important processes, which modulates both structural and regulatory functions of 
proteins by monitoring protein folding and targeting for degradation (Stanley 
2011). Glycosylation is also often essential for protein targeted to specific cellular 
compartments, as occurs for lysosomal hydrolases such as cathepsins (described in 
section 1.2.3.2).  
Main forms of glycosylation include N-linked and O-linked glycosylation, which 
consist, respectively, in the covalent addition of a glycan to the side-chain amino 
group of an asparagine (N) residue within the conserved Asn-X-Thr/Ser sequence 
(where X can be any amino acid expect Proline), and to the hydroxyl group (O) of a 
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serine or threonine amino acid (Stanley 2011). The O-linked glycans usually consist 
of simple oligosaccharide structures compared to the N-linked glycans, whose 
complexity varies among different glycopeptides. In both forms of glycosylation, 
sugar nucleotides are used as monosaccharide donors (Stanley 2011). 
As described earlier, N-glycosylation typically occurs co-translationally. It begins in 
the ER with the addition of a precursor oligosaccharide to a nascent growing 
protein during its translocation into the ER lumen (Chavan, Yan & Lennarz 2005). 
The precursor oligosaccharide is synthesised and activated in the cytosol from 
sugar nucleotides and then transferred and linked to dolichol, which is a lipid 
carrier in the ER membrane (Stanley 2011). High energy is required for synthesis 
and transfer of an oligosaccharide. Its transfer to the protein is mediated by the 
transmembrane enzyme OST, as soon as the Asn-X-Ser/Thr acceptor site emerges 
into the ER lumen. The N-glycan is then further processed in the ER and then, once 
in the Golgi apparatus, can remain unmodified or undergo further changes. Specific 
modifications occur in the different Golgi compartments consisting in both removal 
and addition of specific sugar residues ultimately leading to formation of complex 
or hybrid N-glycans (Schedin‐Weiss, Winblad & Tjernberg 2014, Stanley 2011).   
O-glycosylation only occurs post-translationally by addition of a sugar molecule to 
Ser or Thr residues of a fully translated and folded protein (Stanley 2011). It can 
begin in the ER or alternatively in the cis-Golgi compartment. Transfer of the 
cytosolic precursor oligosaccharide is catalysed by an O-galactosaminyl-transferase 
(OGT), localised in both ER and cis-Golgi (Schedin‐Weiss, Winblad & Tjernberg 
2014, Stanley 2011, Steen et al. 1998). Subsequently, O-glycans are extended and 
modified in the other Golgi compartments by sequential removal and addition of 
different types of sugar residue, by the action of glycosidase and glycosyl-
transferase enzymes. In the different Golgi compartments the glycan can be also 
modified by epimerases and sulfotransferases, thus adding different modifications. 
Furthermore, in some cases, the event of O-glycosylation can occur also in the 
cytosol and nucleus, where it has been reported to be involved in gene expression 
regulation or signal transduction (Schedin‐Weiss, Winblad & Tjernberg 2014, 
Stanley 2011, Steen et al. 1998). 
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1.5.2. Alternative secretory pathways 
A large number of soluble proteins are secreted from secretory vesicles fusing with 
the plasma membrane via the classical secretory pathway. However, many proteins 
are also released in the extracellular space via alternative mechanisms, which do 
not require ER and Golgi involvement. These so-called unconventional secretory 
pathways have been shown to be unaffected by the inhibitor of the classical ER-
Golgi pathway, brefeldin A (BFA) (Nickel 2005). Mechanisms and functions of these 
alternative pathways are not entirely understood. In general, these proteins do not 
contain signal sequences, usually localize in the cytoplasm and can be secreted 
under physiological and pathological conditions (Nickel 2005). 
Several unconventional pathways have been reported (Figure 1.7), including the 
lysosomal exocytosis and the secretion by exosomes. These two pathways consist 
of fusion to the plasma membrane of intracellular vesicles derived from the 
endosomal system, followed by release of the protein cargo into the extracellular 
space (Nickel 2005). In addition, cytosolic proteins can also be directly translocated, 
through a non-vesicular mechanism, from the cytoplasm across the plasma 
membrane into the extracellular space. This can occur by means of protein 
conducting channel (e.g. ATP-binding cassette (ABC) transporters) or through 
plasma membrane blebbing that consists in the shedding of membrane-derived 
vesicles (Nickel 2005). 
Another alternative Golgi-independent pathway has been described particularly for 
membrane proteins, which consists in the direct protein transportation from the ER 
to the plasma membrane (Nickel, Rabouille 2009).  
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Figure 1.7 - Unconventional secretory pathways. As an alternative to the conventional 
secretory pathway (1, 2 in blue), a number of proteins is released in the extracellular space 
by several other ER-Golgi independent mechanisms, such as lysosomal exocytosis (1, in 
red), exosomes (2, in red), membrane blebbing (3), or transporter-mediated pathway (4) 
(Figure from (Bhattacharya, Prakash & Eissa 2014)). 
 
1.5.3. Targeting to mitochondria 
Protein transportation to mitochondria always occurs post-translationally, after the 
protein has been fully synthesised as precursor on cytosolic ribosomes (Kim, Hwang 
2013). Subsequently, molecular chaperones are responsible for delivering the 
protein to the mitochondrial membrane for its subsequent translocation (Kim, 
Hwang 2013).  
Mitochondria are complex organelles, consisting of two membranes, called outer 
and inner membrane, an intermembrane space and, more internally, the matrix. 
For this reason, mitochondrial import is a highly complex mechanisms consisting of 
multiple import machineries and targeting signals, depending on the compartment 
where the protein is destined to reside (Chacinska et al. 2009, Schmidt, Pfanner & 
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Meisinger 2010, Becker, Böttinger & Pfanner 2012). In general, the precursor 
protein contains a targeting signal, which leads the protein to the mitochondrial 
outer membrane. From here, additional signals can direct the protein to its specific 
intra-mitochondrial compartment (Chacinska et al. 2009, Schmidt, Pfanner & 
Meisinger 2010, Becker, Böttinger & Pfanner 2012). A variety of targeting and 
sorting signals is present to specifically target the protein to one of the several 
translocation machineries present in the mitochondria, in both the outer and inner 
membranes. Several cytosolic (e.g. Hsp70, Hsp90, MSF) and mitochondrial 
chaperones (e.g. small TIM chaperones) are also essential for the correct protein 
transportation. 
The different import pathways characteristic for each mitochondrial compartment 
are extensively reviewed elsewhere (Chacinska et al. 2009, Schmidt, Pfanner & 
Meisinger 2010, Becker, Böttinger & Pfanner 2012) (Figure 1.8). The variety of 
targeting signals is briefly described below. 
 
 
Figure 1.8 - Mitochondrial import pathways. They include several mechanisms depending 
on the protein properties and the submitochondrial compartment where the protein is 
destined to reside (i.e. outer membrane, intermembrane space, inner membrane, matrix). 
Further details are described in the section 1.5.3 (Figure adapted from (Schmidt, Pfanner & 
Meisinger 2010)). 
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Precursor proteins synthesised in the cytosolic ribosome contain targeting signals 
recognised by specific cytosolic chaperones and/or by receptors present in the 
mitochondrial outer membrane. These signals can be generally subdivided in 
cleavable N-terminal pre-sequences and non-cleavable internal signals. The first 
group is usually recognised by the specific receptors Tom20 and Tom22, which are 
part of the translocase of the outer membrane (TOM) complex. The second group 
is usually recognised by the receptor Tom70, also part of the TOM complex, with 
the assistance of cytosolic chaperones (Hsp70 and Hsp90) (Chacinska et al. 2009, 
Schmidt, Pfanner & Meisinger 2010, Becker, Böttinger & Pfanner 2012). However, 
both groups merge to the hydrophilic channel Tom40 for their translocation across 
the outer membrane, which therefore represents the common gate entry for the 
majority of the mitochondrial precursors. Subsequently, the different precursors 
engage specific pathways for each mitochondrial sub-compartment, depending on 
additional sorting signals present in the protein sequence (Schmidt, Pfanner & 
Meisinger 2010, Chacinska et al. 2009, Becker, Böttinger & Pfanner 2012). 
The N-terminal pre-sequence usually consists of 10 to 60 amino acids forming an 
amphipathic, positively charged α-helix. Both its hydrophobic and charged surfaces 
are essential for recognition and binding by Tom receptors. In absence of any other 
signals, these precursors are subsequently targeted to TIM23 complex in the inner 
membrane. Then, with the cooperation of the import motor PAM, they are 
released in the matrix where the pre-sequence is proteolytically cleaved by the 
mitochondrial processing peptidase (MPP) and the mature protein subjected to 
folding with the help of mitochondrial chaperones (Schmidt, Pfanner & Meisinger 
2010, Chacinska et al. 2009). Next to the pre-sequence, precursor proteins can 
possess an additional uncleaveable or cleavable hydrophobic sorting signal. In the 
first case it operates as a stop transfer signal to hold the protein in the 
mitochondrial inner membrane. In the second case, this signal is subsequently 
cleaved by the inner membrane peptidase (IMP), thus releasing the protein in the 
intermembrane space (Schmidt, Pfanner & Meisinger 2010, Chacinska et al. 2009).   
The second group of mitochondrial targeted proteins contains non-cleavable 
internal signals, which therefore remain in the mature proteins. They can be 
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destined to the inner membrane, intermembrane space and outer membrane. 
Proteins directed to the inner membrane usually possess multiple internal signals 
which permit protein transfer from the TOM complex to the inner membrane 
TIM22 complex, with the help of small TIM chaperones in the intermembrane 
space. These signals usually consist of six transmembrane segments distributed 
along the protein sequence (Schmidt, Pfanner & Meisinger 2010, Chacinska et al. 
2009, Becker, Böttinger & Pfanner 2012). 
Internal signals for intermembrane space proteins are instead characterised by 
cysteine motifs, which allow formation of disulphide bonds between the precursor 
emerging from the TOM complex and the receptor Mia40, located in the inner 
membrane facing the intermembrane space (Schmidt, Pfanner & Meisinger 2010, 
Chacinska et al. 2009, Becker, Böttinger & Pfanner 2012). 
Proteins targeted to the outer membrane can be subdivided in α-helical and β-
barrel proteins, and they are always characterised by a non-cleavable anchor-
targeting signal. For α-helical proteins, the targeting signal can be located at the N-
terminus, C-terminus or in the middle of the protein sequence. This signal generally 
contains positively charged residues at the side of a hydrophobic α-helical 
transmembrane segment. Depending on its position within the sequence, different 
pathways are engaged. For example, these include the protein transfer through the 
intermembrane space, via small TIM chaperones, from the Tom40 to the sorting 
and assembly machinery (SAM) in the outer membrane. Alternatively, the protein 
insertion can occur through the mitochondrial import 1 (Mim1), which then also 
interacts with the SAM complex. This pathway therefore does not involve the main 
Tom40 channel. Differently, β-barrel proteins possess a β-strand at the C-terminus 
(β-signal), which is also recognized by SAM thus permitting protein insertion in the 
mitochondrial outer membrane (Schmidt, Pfanner & Meisinger 2010, Chacinska et 
al. 2009, Becker, Böttinger & Pfanner 2012).  
Mitochondrial protein import is therefore a highly elaborated mechanism, 
necessary to guarantee the correct protein localization in the various sub-
mitochondrial compartments and consequently the correct mitochondrial 
functionality.  
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2. Chapter 2 - Materials and Methods  
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2.1. Cell culture 
2.1.1. Cell lines used 
Several human immortalised RPE cell lines were used in this study, including 
ARPE19, D4O7 and hTERT-RPE1. In addition, HeLa cell line was used as additional 
control. 
The ARPE19 cell line is an immortal, non-transformed line derived from a primary 
culture of human RPE cells that maintains RPE-specific structural and functional 
characteristics (Dunn et al. 1996). It possesses classic epithelial cobblestone 
morphology with intercellular junction forming stable polarized epithelial 
monolayers. These cells are therefore valuable tools for in vitro studies of retinal 
pigment epithelium (Dunn et al. 1996). For this reason, this cell line was mainly 
utilised in this work. Origin: American Type Culture Collection (ATCC). 
D407 cells are a spontaneously transformed human RPE cell line that also retains 
many morphologic and metabolic characteristics of RPE cells (Davis et al. 1995). 
However, it has been reported the loss of some enzymatic activity, involved for 
example in the retinol cycle, and cytoskeletal polarization (Davis et al. 1995). This 
cell line was used for some of the studies due to the advantage of higher 
transfection rate and faster growth. Origin: Departmental stocks. 
hTERT-RPE1 cell line is a human telomerase-immortalized RPE cell line derived from 
a 1-year-old person, obtained transfecting the RPE-340 cell line with the pGRN145 
hTERT-expressing plasmid (Gong et al. 2014). This line has been reported to achieve 
a high degree of RPE functional maturation (Gong et al. 2014). This cell line was 
used as control in some imaging experiments. Origin: ATCC. 
HeLa cell line is a widely used immortalised epithelial cell line derived from cervical 
cancer cells (Scherer, Syverton & Gey 1953). It was used as additional control for 
some imaging experiments. Origin: ATCC. 
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2.1.2. Maintenance of cells in culture 
ARPE19, D4O7 and hTERT-RPE1 cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM):Ham’s F12 Nutrient Mixture (1:1) (GIBCO, 11330), supplemented 
with 10% fetal bovine serum (FBS) (Sigma, 2442) and maintained at 37°C in 5% CO2.  
HeLa cells were cultured in DMEM (Biopolis Shared Facilities, IMCB, A*STAR, 
Singapore) supplemented with 10% FBS, 2mM L-Glutamine (Gibco, 25030081), 1 
mM sodium-pyruvate (Gibco, 11360070) and 1% (0.1 mM) non-essential amino 
acids (Gibco, 11140050). 
All cells were grown in 75cm3 culture flasks and routinely subcultured by 
trypsinization using the following procedure. The cell monolayer was washed with 
phosphate buffered saline (PBS) (Biopolis Shared Facilities, IMCB, A*STAR, 
Singapore), then incubated with Trypsin-EDTA (Biopolis Shared Facilities, IMCB, 
A*STAR, Singapore) at 37°C for 2-3 minutes to allow cells to detach from the 
surface. Pre-warmed complete media was then added to neutralise the trypsin, and 
the cell suspension centrifuged at 200 g for 3 minutes. The cell pellet was then 
resuspended in complete media and seeded into new flasks at 1:3-1:5 ratio 
depending on the cell line. Cell counting by haemocytometer was carried out if 
seeding a precise number of cells was required for experimental purposes.  
All cells lines were tested for the presence of mycoplasma contamination using the 
LookOut PCR Mycoplasma Detection Kit (Sigma), following manufacture’s 
guidelines. 
Cell stocks were stored and cryopreserved in liquid nitrogen using freezing media 
(50% FBS, 40% complete media, 10% DMSO).  
 
2.1.3. Transfection 
Cell lines were transiently transfected with cDNA plasmids encoding the protein of 
interest (described in section 2.2), using the lipid-based reagent Lipofectamine LTX 
with Plus reagent (Thermo Fisher Scientific, 15338). This transfection reagent was 
mainly used in this study. However, TurboFect (Thermo Fisher Scientific, R0531), a 
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cationic polymer-based transfection reagent, was also occasionally used. Higher 
transfection efficiency was achieved using Lipofectamine. 
Transfection methods were used following manufacturer’s guidelines. Most of the 
experiments were carried out on cells seeded in 6-well plates. Cells in 24-well 
plates and 100 mm dishes were also used in some experiments. 
 
Cells were seeded in 6-well plates the day before transfection at a density between 
2.5x105 to 5.0 x105 cells per well (depending on the cells line) in order to have cells 
70-80% confluent at the time of transfection. The next day the media of cells was 
removed and replaced with Opti-MEM reduced serum media (Thermo Fisher, 
31985). The transfection mixture used for each well consisted of 2 µg of DNA and 9 
µl of Lipofectamine (6 µl in the case of Turbofect). The media was then replaced 5 
hours after transfection with fresh complete media. Analysis was typically 
performed after 24 hours for all the different experiments.  
For transfections in different sized culture plates or dishes, the amount of DNA and 
reagent was scaled appropriately based on manufacturer’s guidelines. In general, 
0.5 µg of DNA was used for cells in 24 well plates and 10 µg for cells in 100 mm 
dishes with 3 and 30 µL of Lipofectamine, respectively.  
 
2.1.4. Cell treatments 
In this study cells were treated with a number of different reagents. These 
treatments were usually carried out on ARPE19 cells seeded onto 6-well plates, 
transfected or non-transfected with cDNA constructs. In the case of transfected 
cells, reagents were added to the culture the day after transfection.  
a) Inhibition of the secretory pathway was performed by using different 
reagents which block protein trafficking at different steps of the pathway. 
Brefeldin A (BFA), which blocks protein transport from ER to Golgi (Klausner, 
Donaldson & Lippincott-Schwartz 1992), Monensin, which inhibits transport 
of proteins through the Golgi stack (Mollenhauer, Morré & Rowe 1990) and 
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Nocodazole, a microtubule-depolymerizing agent that affects the Golgi 
structure and the transport of secretory vesicles (Trucco et al. 2004, 
Thyberg, Moskalewski 1999). Cells were treated with BFA (Epicentre, 
B901MG), at a final concentration of 5 µg/mL, Monensin (BioLegend, 
420701) at 5µM, Nocodazole (Merk Millipore, 487928) at 10 µg/mL. Cell 
lysates and conditioned media were collected 3 and 7 hours post-
treatment. 
b) Inhibition of protein synthesis was carried out using cycloheximide (Sigma, 
C7698 and C1988), an antibiotic that blocks the mRNA translation on 
ribosomes (Obrig et al. 1971). It was used at a final concentration of 200 µM 
and cell lysates and conditioned media collected at 2, 7, and 24 hours after 
treatment. 
c) Inhibition of proteolytic systems was performed by using Chloroquine (CQ) 
and MG132 to suppress ALP and UPS, respectively (described in chapter 
6.2). CQ (Sigma, C6628) and MG132 (Merk Millipore, 474790) were used at 
final concentrations of 25 µM and 5 µM, respectively. Cell lysates and 
conditioned media were collected 24-hours post-treatment. mRNA was also 
extracted from cells treated with MG132 (described below).  
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2.2. Cloning 
2.2.1. Plasmid DNA constructs used 
2.2.1.1. Existing constructs 
The pCys-EGFP construct was used to express the wild-type full-length precursor 
cystatin C. The plasmid was developed cloning cDNA of cystatin C into a pEGFP-N3 
backbone, as described previously in Paraoan et al. (2001) (Figure 1.1). The 
Ala25Thr_pCys-EGFP plasmid was used to express the variant B full-length protein. 
This construct was produced by site-directed mutagenesis as described in Paraoan 
et al. (2004). 
Wild-type and variant B cystatin C are therefore expressed as fluorescently labelled 
fusion proteins easily detected in live cells by fluorescence microscopy. They will be 
called WT-EGFP and VB-EGFP. 
 
 
Figure 2.1 - Diagram of pCys-EGFP and Ala25Thr_pCys-EGFP constructs. Sequence 
encoding the wild-type or variant precursor cystatin C (449bp) was inserted into the 
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multiple cloning site (MCS, restriction sites HindIII/BamHI) of the pEGFP-N3 vector (4729 
bp) (BD Biosciences Clontech). EGFP-linked cystatin C fusion proteins, separated by a 9 bp 
linker, are expressed in eukaryotic cells from a CMV promoter. Black arrows represent 
primers used for sequencing whereas red arrows represent the primers designed to 
develop the new constructs (see Table 1).  
 
2.2.1.2. New constructs 
Using the existing constructs as template (Figure 2.1 and Figure 2.2), new 
recombinant plasmids were generated (table 2) by designing specific primers (Table 
1) in order to amplify and modify the sequence of interest. Restriction site 
sequences were included in all the primers: HindIII sequence in all the forward 
primers and BamHI in all the reverse primers (sequences shown in bold in Table 1). 
Start or stop codons were added when needed. 
a) pEGFP-N3 based constructs 
New EGFP-based constructs were engineered to express EGFP proteins fused to the 
leader sequence of the wild-type or variant B precursor cystatin C only. These 
constructs were named LPWT-EGFP and LPVB-EGFP respectively (Figure 2.3) and 
are used to further characterise the role of the signal peptide in the protein 
trafficking. Primers used for this purpose were designed in order to amplify only 
the signal sequence of cystatin C protein and are described in table 1 (Forward 
CysC and Reverse Signal Seq. primers). 
 
b) pcDNA3-based constructs 
Other constructs were obtained by subcloning the sequence of interest into the 
plasmid pcDNA3 that does not encode fluorescent proteins (Figure 2.4). In such 
constructs cystatin C is untagged or linked to small, non-fluorescent tags or N-
linked glycosylation sites. 
 
All the new constructs are shown in Table 2. 
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AAACCGCTAGCGCTACCGGACTCAGATCTCGAGCTCAAGCTTCCTAGCCGACCATGGCCGGGCCCCTG 
CGCGCCCCGCTGCTCCTGCTGGCCATCCTGGCCGTGGCCCTGGCCGTGAGCCCCGCGG/ACCGGCTC 
CAGTCCCGGCAAGCCGCCGCGCCTGGTGGGAGGCCCCATGGACGCCAGCGTGGAGGAGGAGGGTGTGC
GGCGTGCACTGGACTTTGCCGTCGGCGAGTACAACAAAGCCAGCAACGACATGTACCACAGCCGCGCG
CTGCAGGTGGTGCGCGCCCGCAAGCAGATCGTAGCTGGGGTGAACTACTTCTTGGACGTGGAGCTGGG
CCGAACCACGTGTACCAAGACCCAGCCCAACTTGGACAACTGCCCCTTCCATGACCAGCCACATCTGA 
AAAGGAAAGCATTCTGCTCTTTCCAGATCTACGCTGTGCCTTGGCAGGGCACAATGACCTTGTCGAAA 
TCCACCTGTCAGGACGCCGGATCCATCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGT 
GGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCG 
AGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCC
TGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAA
GCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGG
ACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAG
CTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAG
CCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACA
ACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCC
GTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCG
CGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACA
AGTAA 
 
 
.  
 
 
 
 
 
 
 
 
 
HindIII 
BamHI Linker EGFP 
Precursor cystatin C pEGFP-N3 backbone 
 
Forward CysC 
FLAG or HA Forward + FLAG  or HA sequence 
Reverse signal seq. 
Reverse CysC 
FLAG or HA Reverse or N-glyco Reverse + FLAG  or HA sequence or 
glycosylation sites 
Figure 2.2 Sequence of the wild-type or variant cystatin C linked to EGFP in pCys-EGFP and 
Ala25Thr_pCys EGFP constructs respectively. The existing constructs expressing wild-type or 
variant B cystatin C linked to EGFP were used as template to generate the new recombinant 
plasmids. The arrows represent the sequences used for the forward and reverse primers, with 
the additional nucleotides to linking cystatin C sequence to a specific tag. 
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PRIMERS SEQUENCE (5’-3’) Description T annealing 
Forward 
CysC 
TCAAGCTTCCTAGCCGACCA
TGGCC   
Forward primer used to 
amplify insert from the 
N-terminus of full-length 
precursor cystatin C or 
leader sequence 
61°C-65°C 
Reverse 
CysC  
AAGGATCCTTAGGCGTCCT
GACAGGTGGA 
Reverse primer to 
amplify from the C-
terminus of cystatin C 
61°C 
Reverse 
signal seq. 
WT: 
GGGGATCCGCCGGCCGCG 
VB:  
GGGGATCCGCCGGTCGCG   
Reverse primers to 
amplify from the wild-
type or variant B leader 
sequence of cystatin C 
65°C 
N-glyco 
reverse 
AAGGATCCTTACTTGTCATC
GTCGTCCTTGTAGTCCATGG
TGCTGTTACTGGTGCTGTTA
CCGGCGTCCTGACAGGTGG
A 
Reverse primer to 
amplify from the C-
terminus of cystatin C 
linked to two N-
glycosylation sites and a 
FLAG tag 
65°C 
FLAG 
reverse 
AAGGATCCTTACTTGTCTCG
TCGTCCTTGTAGTCGGCGTC
CTGACAGGTGGA 
Reverse primer to 
amplify from the C-
terminus of cystatin C 
linked to a FLAG tag 
61°C 
HA reverse AAGGATCCTTAAGCGTAAT
CTGGAACATCGTATGGGTA
GGCGTCCTGACAGGTGGA 
Reverse primer to 
amplify from the C-
terminus of cystatin C 
linked to HA tag 
61°C 
FLAG 
forward 
AAAAGCTTGATTGCCGACC
ATGGACTACAAGGACGACG
ATGACAAGGCCGGGCCCCT
GCGCGCCC 
Forward primer to 
amplify from the N-
terminus of cystatin C 
linked to a FLAG tag 
61°C 
HA forward AAAAGCTTGATTGCCGACC
ATGTACCCATACGATGTTCC
AGATTACGCTGCCGGGCCC
CTGCGGCCC 
Forward primer to 
amplify from the N-
terminus of cystatin C 
linked to a HA tag 
61°C 
E1-pEGFP TATAAGCAGAGCTGGTTTA
G 
Forward primer for 
pEGFP-N3-based 
constructs sequencing 
- 
E2-pEGFP CGTCGCCGTCCAGCTCGACC
AG 
Reverse primer for 
pEGFP-N3-based 
constructs sequencing 
- 
Table 1 - Sequences of forward and reverse primers used to generate the new constructs 
and for sequencing purposes. Primers included restriction site sequences for HindIII or BamHI 
in forward and reverse primers, respectively (in bold, black). Some primers contained a 
sequence encoding a tag, FLAG or HA (in bold, red) or for N-glycosylation sites (in blue). All 
primers are produced by Integrated DNA Technologies (IDT). 
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Figure 2.3 - Representation of LPWT-EGFP and LPVB-EGFP constructs. Sequence encoding 
the leader peptide of wild-type or variant cystatin C (89 bp including the Kozak sequence) 
was inserted into the multiple cloning site (MCS, restriction sites HindIII/BamHI) of a 
pEGFP-N3 vector (4729 bp). Leader Peptide-EGFP fusion proteins, including a 9 bp linker 
between their sequences, are expressed from a CMV promoter. 
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Figure 2.4 - Diagram of new pcDNA3-based constructs. Sequence encoding wild-type or 
variant cystatin C (449 bp) was inserted into the multiple cloning site (MCS) of a pcDNA3 
vector (5.4kb) (Invitrogen) at HindIII/BamHI restrictions sites. Depending on the constructs, 
the sequence inserted into the vector includes also additional nucleotides to link cystatin C 
at either C- or N-terminal or both to small tags (FLAG or HA) or N-linked glycosylation sites. 
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Table 2 - Summary table of new constructs developed in this study. Names assigned to 
the new constructs, vectors used and size of the plasmid are reported in the table below. 
In the description, amino acid sequences of the tags used are also shown: N-glycosylation 
site in orange, FLAG in red and HA in blue. 
CONSTRUCT NAME Description Vector Size 
Leader peptide 
constructs 
LPWT-EGFP 
and LPVB-
EGFP 
WT or VB Leader 
sequence of 
cystatin C linked to 
EGFP 
pEGFP-N3 4729 + 89 = 
4818 bp 
Untagged cystatin C 
constructs  
WT-Cystc and 
VB-CystC 
WT or VB 
precursor cystatin 
C untagged 
pcDNA3 5446 + 452 = 
5898 bp 
Cystatin C linked to 
N-glycosylation sites 
WT Glyco and 
VB-Glyco 
WT or VB 
precursor cystatin 
C linked at the C-
terminal to two N-
linked 
glycosylation sites 
and a FLAG tag: G-
[NST]-S-[NST]-M-
DYKDDDDK) 
pcDNA3 5446 + 503 = 
5949 bp 
C-terminal FLAG-
tagged cystatin C 
WT-FLAG and 
VB-FLAg 
FLAG tag 
(DYKDDDDK) at the 
C-terminal of 
precursor WT or 
VB cystatin C 
pcDNA3 5446 + 476 = 
5922 bp 
C-terminal HA-
tagged cystatin C 
WT-HA and 
VB-HA 
HA tag 
(YPYDVPDYA) at 
the C-terminal of 
precursor WT or 
VB cystatin C 
pcDNA3 5446 + 479 = 
5925 bp 
N-terminal FLAG-
tagged cystatin C 
FLAG-WT and 
FLAG-VB 
FLAG tag 
(DYKDDDDK) at the 
N-terminal of 
precursor WT or 
VB cystatin C 
pcDNA3 5446 + 476 = 
5922 bp 
N-terminal HA-
tagged cystatin C 
HA-WT and 
HA-VB 
HA tag 
(YPYDVPDYA) at 
the N-terminal of 
precursor WT or 
VB cystatin C 
pcDNA3 5446 + 479 = 
5925 bp 
FLAG- and HA-
tagged cystatin C 
constructs at both 
N- and C-terminus 
HA-WT-FLAG, 
HA-VB-FLAG 
and  
FLAG-WT-HA, 
FLAG-VB-HA 
FLAG and HA  at 
either the N-
terminal or C-
terminal of 
precursor WT or 
VB cystatin C 
pcDNA3 5446 + 503 = 
5949 bp 
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2.2.2. Generation of new constructs 
All the steps were performed according to manufacturer’s guidelines. 
Sequences of interest were generated by PCR using the existing EGFP-linked full-
length cystatin C constructs as template and a thermostable proofreading DNA 
polymerase (Expand High Fidelity PCR Systems, Roche, 11 732 650 001). 100 ng of 
template DNA was mixed with 1µL of polymerase (3.5 U), 500 nM of primers and 
200 µM of dNTPS and 5µL of Expand High Fidelity buffer in 50 µL of total volume. 
The PCR parameters (shown in figure 2.5) used in a Peltier Thermal Cycler were 
optimised with annealing temperature as per Table 1.  
 
 
Figure 2.5 - PCR cycling conditions used for generation and amplification of new 
sequences of interest. After an initial denaturation step at 94°C for 3 min, 35 cycles of 
denaturation, annealing and extension were performed followed by a final extending step 
at 72°C for 5 min. Temperature of annealing differs for the different constructs depending 
on the primers used as described in Table 1. 
 
 
PCR products were isolated by 1.5% agarose gel electrophoresis in the presence of 
ethidium bromide at 90V. DNA bands were visualised by use of a UV 
transilluminator and were then cut from the gel and purified using gel extraction kit 
(Qiagen). All the amplified sequences and the vectors (pEGFP-N3 or pcDNA3) were 
digested with BamHI and HindIII restriction endonucleases (FastDigest, Thermo 
Fisher Scientific, FD0054 and FD0504) by incubation at 37°C for 30 min. DNA was 
then purified using a QIAquick PCR purification kit (Qiagen).  
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Ligation was performed to insert PCR products into vectors, using Quick Ligation Kit 
(New England BioLabs, M2200S) followed by transformation using Subcloning 
Efficiency™ DH5α™ Competent Cells (Thermo Fisher, 18265-017), in order to either 
amplify the new constructs or for routine amplification of existing ones. Briefly, 
around 10 ng of DNA plasmids was used for each construct; cells were subject to 
heat-shock at 42°C and then grown in 1mL LB medium for 1 hour at 37°C. Different 
volumes of the initial 1mL culture were plated on either Kanamicyn (50 μg/mL) or 
Ampicillin (100 μg/mL) agar plates, depending on the vector used, in order to 
obtain well-defined colonies. 
Transformed colonies were picked and cultured over/night in 5 ml LB broth with 
Kanamicyn or Ampicillin antibiotic in a shaking incubator at 250 rpm. Plasmid DNA 
was then purified using QIAprep Mini-Prep DNA isolation kit (Qiagen) following 
manufacturer’s protocol. Plasmid DNA was resuspended in 50 μL of nuclease-free 
water and analysed by restriction digestion, using HindIII and BamHI enzymes, and 
gel electrophoresis as previously described. Positive clones were then further 
grown overnight in 100 mL LB broth with Kanamicyn or Ampicillin antibiotic and the 
final DNA plasmids purified using large scale QIAGEN Endo Free Plasmid DNA 
Purification Maxi-Prep kit (Qiagen) and checked by restriction analysis and DNA 
sequencing using primers shown in Table 1 (DNA Sequencing Facility, IMCB, 
A*STAR, Singapore). Quantification and quality control of DNA preparations were 
carried out by measuring absorbance using a Nanodrop spectrophotometer. 
 
2.3. Gene expression analysis 
2.3.1. RNA isolation 
Total RNA was extracted from cells using TRIzol Reagent (Thermo fisher, 15596) 
following the standard protocol (as described in the manufacturer’s guidelines).  
Briefly, ARPE19 cells seeded in 6-well plates were homogenised using 1mL of 
TRIzol, which extracts RNA, DNA and proteins. Subsequent phase separation was 
performed following addition of 0.2 mL of chloroform (Sigma) and the clear 
aqueous phase taken. RNA was precipitated by adding an equal volume of 100% 
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isopropanol (Sigma). RNA was pelleted by centrifugation at 14,000g and then 
washed with 1mL of 70% Ethanol. The RNA pellet was air dried and then dissolved 
in 50 µL of nuclease free water. RNA concentration and purity was measured using 
a Nanodrop spectrophotometer. 
 
2.3.2. cDNA synthesis 
RNA was reverse-transcripted into cDNA using M-MLV Reverse Transcriptase (RT) 
(Promega, M170), following the protocol described in the manufacturer’s 
guidelines. Briefly, 1µg of RNA was incubated with 1µL of random primers 
(Promega, C1181) at 70 °C for 5 minutes to ensure proper denaturation of GC-rich 
RNA. Subsequently M-MLV 5X Reaction buffer, 2mM of dNTPs (Bioline, BIO-3944) 
and 200 U of M-MLVRT polymerase were added and the reaction mixture 
incubated at 37°C for 1 hour, to allow cDNA synthesis, and 95°C for 10 minutes to 
terminate the reaction.  
 
2.3.3. Quantitative RT-PCR 
qPCR was used in this study to quantify the mRNA level of cystatin C in response to 
treatment with proteasome-inhibitor MG132. This was performed by using 
GoTaq@qPCR Master Mix (Promega, A6002), which utilizes a proprietary double 
stranded DNA-binding dye, which works similarly to the widely used SYBR Green to 
allow quantification of PCR product (Zipper et al. 2004, Ponchel et al. 2003). 
Analysis was carried out using an Applied Biosystems 7300 instrument. The 
reaction mixture consi_sted of cystatin C or GAPDH primers at a final concentration 
of 300nM, 2X PCR Master Mix and cDNA generated as described in 2.3.2. Primers 
for both cystatin C and GAPDH (Eurogentec) are shown in table 3. Cystatin C 
primers were designed by using Primer Express Software. 
 
65 
 
Table 3 - Sequence information of cystatin C and GAPH primers used in qPCR 
experiments. 
Gene Strand Sequence 
Cystatin C Forward 5’-CGT AGC TGG GGT GAA CTA CT-3’ 
Reverse 5’-ATC TGG AAA GAG CAG AAT GC-3’ 
GAPDH Forward 5’-ATG GGG AAG GTG AAG GTC G-3’ 
Reverse 5’-TAA AAG CAG CCC TGG TGA CC-3’ 
 
Three independent experiments were performed. For each of them, three non-
treated and three treated samples were analysed. Each of them was run in 
triplicate and analysed for both cystatin C and GAPDH. The relative mRNA levels 
were quantified using the ΔCt method (Rao et al. 2013), by using the Ct values 
generated by the qPCR software, using the formula:  
2^ (-ΔCt) = 2-(Ct CysC - Ct GAPDH) 
Values of relative mRNA abundance were obtained for both treated and not 
treated cells for comparison. 
 
2.4. Protein analysis 
2.4.1. Sample preparation 
In many of the experiments performed in this study cell lysates and conditioned 
media were analysed. Cells used for protein analysis were usually seeded in 6 well-
plates, grown in 2-3 mL of complete media. Conditioned media was collected from 
each well and subjected to centrifugation at 3000 g for 10 minutes at 4°C to 
remove cell debris. Cells were washed with PBS and collected in 200 µL of RIPA lysis 
buffer (appendix 1). Cells were then homogenised by sonication. 1X Laemmli buffer 
(appendix 1) was added to both cell lysate and media samples and heated to 95°C 
for 5 minutes to denature the proteins. Total protein concentration was calculated 
for the cell lysates using the Bradford assay (Bio-Rad Protein Assay Dye Reagent 
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Concentrate, 500-0006). This was performed to ensure equal loading on western 
blots. 
Depending on the experiment, cell lysates samples were either normalised to their 
protein content (10-20 µg) or loaded at the same volumes (8-20 µL), which also 
correspond approximately to the same protein concentration. Conditioned media 
samples were loaded at the same volumes (20-40 µL). 
 
2.4.2. Polyacrylamide gel electrophoresis (SDS-PAGE)  
Cell lysates and conditioned media were loaded on polyacrylamide gels, using a 
Bio-Rad Electrophoresis System, to allow proteins to be separated based on size. 
Resolving gel (appendix 1) was typically prepared at concentration of 12 or 15%. 
The higher concentration was used to allow separation of proteins with similar 
molecular weight. The stacking gel (appendix 1) was always at 4% concentration. 
Gels were then assembled in the electrode module and tank, adequately filled with 
running buffer (Appendix 1).  
Samples were loaded on the gels, together with a Prestained Protein Ladder 
(Thermo Fisher) used to indicate molecular weight. Gels were typically run at 110V 
for approximately 2 hours, until bands were adequately separated. 
 
2.4.3. Western blotting  
Proteins separated by SDS-PAGE were transfer onto a nitrocellulose membrane 
using electric current, and subsequently detected by specific antibodies. The 
transfer was typically conducted at 100V for 2 hours at 4°C. After the transfer was 
completed, the membrane was washed and stained with Ponceau S solution 
(Sigma) to verify that the transfer was successful. Subsequently, membranes were 
washed 0.1% Tween-20 in PBS, blocked for 1.5 hours in blocking buffer (0.1% 
Tween-20 in PBS, 5% dry milk or BSA) and incubated with primary antibodies 
diluted in blocking buffer over-night at 4°C. Membranes were then washed in 0.1% 
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Tween-20 in PBS and incubated with HRP-conjugated secondary antibodies diluted 
in blocking buffer for 1.5 hours at room temperature. 
Primary and secondary antibodies used are described in Table 4 and 5. 
Bands corresponding to the proteins of interest were visualised using the 
appropriate chemiluminescent substrate reagent (Pierce ECL Substrate, SuperSignal 
West Pico Chemiluminescent Substrate or SuperSignal West Femto Maximum 
Sensitivity Substrate (Thermo Fisher)) and imaged through either exposure to X-ray 
films or by using a Bio-Rad ChemiDoc imaging system. Densitometry analysis, when 
needed, was performed using either Image J analysis software (NIH) or Image Lab 
5.0 (Bio-Rad) software. 
Membranes were usually incubated with Restore™ Western Blot Stripping Buffer, 
(Thermo Fisher, 21059) to re-probe the membrane with a different antibody (e.g. 
anti-GAPDH). 
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Table 4 - Primary antibodies used for Western Blot and immunofluorescence 
Antibody Supplier  
catalogue number 
Description Concentration 
WB IF 
EGFP Clontech, 632381 Mouse monoclonal 1:1000 - 
Cystatin C Merk Millipore, 
ABC20 
Rabbit polyclonal 1:2000 1:500 
Cystatin C Abcam, ab109508 Rabbit monoclonal 
 
1:10000 - 
GAPDH Merk Millipore, 
MAB374 
Mouse 1:40000 - 
GAPDH Abcam ab8245 Mouse monoclonal 1:30000 - 
TOM20 Santa Cruz sc-11415 Rabbit polyclonal 1:2000 1:200 
Mannosidase II Abcam ab77353 Goat polyclonal 1:1000 - 
FLAG (M2) Sigma F3165 Mouse monoclonal 1:2000 1:300 
FLAG Abcam ab1162 Rabbit polyclonal 1:10000 - 
HA Roche 11867423001 Rat monoclonal 1:1000 1:200 
Calreticulin Thermo Fisher PA3-
900 
Rabbit polyclonal - 1:500 
GM130 BD Biosciences 
610822 
Mouse monoclonal - 1:100 
 
Table 5 - Secondary antibodies used in this study for Western Blot 
Antibody Supplier 
catalogue number 
Description Concentration 
Anti-
mouse 
Bio-Rad 170-6516 Goat IgG, HRP-linked 1:5000 
Anti-rabbit Bio-Rad 170-6515 Goat IgG, HRP-linked 1:5000 
Anti-goat Santa Cruz SC-2350 Bovine IgG, HRP-linked 1:5000 
Anti-rat Jackson ImmunoResearch 
Laboratories 712-035-153 
Donkey IgG, HRP-
linked 
1:5000 
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2.4.4. Deglycosylation 
Cell lysates and conditioned media samples, collected as previously described, 
were subjected in some experiments to deglycosylation treatments, prior to SDS-
PAGE.  
Endo H, PNGase F and protein Deglycosylation Mix (New England BioLabs, P0702S, 
P0704S, P6039S) were used for this purpose, following manufacturer’s guidelines. 
Endo H removes N-glycans attached to proteins in the ER compartment, whereas 
PNGase F can also remove complex N-glycans that were further modified in the 
Golgi apparatus (Maley et al. 1989). Resistance or sensitivity to Endo H can 
therefore be used to monitor whether a glycosylated protein traffics through the 
Golgi. 
Protein Deglycosylation Mix is composed of five different glycosidases: PNGase F, 
O-Glycosidase, Neuraminidase, β1-4 Galactosidase, β-N-Acetylglucosaminidase (as 
described in the manifacturer’s datasheet). This mix therefore allows removal of all 
N-linked oligosaccharides and most of the common O-linked glycans from 
glycoproteins.  
To perform deglycosylation, 10X denaturing buffer was added to 9 µL of cell lysate 
or 18 µL of conditioned media and heated at 100°C for 10 minutes. Subsequently, 
reaction buffer and H2O were added to the sample together with the specific 
enzyme, EndoH (2 µL) or PNGaseF (1 µL) (in a total volume of 20 and 30 µL of 
reaction for cells and media respectively), and incubated for 1 hour at 37°C. 
Alternatively, samples were treated with Protein Deglycosylation Mix (3 µL) (in a 
total volume of 40 µL) and incubated for 5 hours at 37°C.  
 
2.5. Protein pull-down 
In this study, pull-down of cystatin C constructs was carried out for different 
experiments: to analysis the signal cleavage (chapter 4), the species secreted 
(chapter 5), the dimerization (chapter 6.3) and the interacting partners of cystatin C 
(chapter 6.5).  
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Depending on the experiment, immunoprecipitation (IP) was performed for CysC-
FLAG or HA-Cys-FLAG constructs, by using the ANTI-FLAG M2 Affinity Gel (Sigma, 
A2220), following manufacturer’s guidelines. This resin consists of Anti-FLAG M2 
monoclonal antibodies attached to agarose beads, which permit pull-down of 
FLAG-tagged cystatin C constructs. 
In general, RPE cells seeded in 6-well-plates were transfected and subjected to IP 
24-hour post-transfection. Cell lysates were collected in RIPA buffer and 
homogenised, as described previously. Cells from three wells (2-4 mg) were 
combined and diluted to a final volume of 1mL in RIPA buffer. 40 µL of anti-FLAG 
beads, after being adequately washed in RIPA buffer, were added to the sample ( 2̴-
4 mg) followed by incubation over-night at 4°C with gentle shaking. The resin was 
then washed three times and collected by spinning at 8000g for 5 minutes at 4°C. 
Elution of the FLAG-constructs was performed using the 3X FLAG Peptide (Sigma, 
F4799), following manufacture’s protocols.  50-100 µL of 3X FLAG solution at a 
concentration of 250 ng/µL was added to each sample and incubated for 1 hour at 
4°C with gentle shaking. Resin was then pelleted by centrifugation and the 
supernatant transferred to a fresh tube. Prior to Western Blotting analysis Laemmli 
buffer was added to the samples followed by denaturation, as described 
previously.  
Also media samples were subjected to IP. Anti-FLAG beads were added to 1mL of 
conditioned media collected from cells in 6-well plates and immunoprecipitation 
and elution were performed, as described before.  
Regarding samples subjected to IP, prior to mass spectrometry analysis, cells were 
seeded in 100mm dishes. Cell lysates and conditioned media derived from two 
dishes were combined and subjected to IP as described before. Conditioned media 
was first concentrated by spinning using Amicon Ultra-4 3K Centrifugal Filter 
Devices (Merk Millipore) to a final volume of approximately 1.5 mL. Both media 
samples and cell lysates ( ̴10 mg) were subjected to IP using 50 µL of anti-FLAG 
beads and eluted in 30 µL of 3X FLAG peptide (2.5 µg/mL). 
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2.6. Mass spectrometry 
Samples for mass spectrometry analysis were obtained after pull-down, as 
described above. 5µL of the 30 µL eluted sample (either from cell lysates or 
conditioned media), were subjected to Western blotting analysis and the other 25 
µL sent to the Proteomics facility for analysis (IMCB, A*STAR, Singapore). Here the 
samples were processed through mass spectrometry and analysed. Essentially, 
samples were first separated by SDS-PAGE and proteins visualised by coomassie 
blue staining. For each sample, the bands of interest or the entire lanes of the gel, 
depending on the experiment (as shown in results chapter), were cut and subjected 
to in-gel digestion by trypsinization. The extracted peptides were then analysed 
using an Orbitrap mass spectrometer. 
The proteins within each sample were identified using the Mascot search engine 
and analysed using the proteasome software Scaffold (Searle 2010). Each protein 
reports the UniProt code, the spectra counts and the percentage of coverage, as 
described in chapter 4. This peptide mapping analysis permits only a qualitative 
characterization of the proteins. 
 
2.7. Mitochondria isolation 
Mitochondria were isolated for subsequent protein localization analysis by 
immunoblotting. Two methods were used for this purpose: magnetic separation 
and differential centrifugation. 
2.7.1. Magnetic separation (MACS) 
Mitochondria were isolated by using the Human Mitochondrial Isolation Kit 
(Miltenyi Biotec, 130-094-532), according to manufacturer’s guidelines. This 
method is based on MACS technology, consisting of magnetic separation of 
mitochondria. In general, cells collected from two 100mm dishes were 
resuspended in 1 mL of Lysis Buffer (provided in the kit) and homogenised by 
syringing with 26 G needle. Subsequently, the lysate was subjected to magnetic 
labelling by incubation with 50 µL of anti-TOM22 MicroBeads for 1 hour at 4°C with 
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gentle shaking. Antibody anti-TOM22 specifically binds mitochondrial outer 
membrane proteins (Pfanner, Craig & Hönlinger 1997). By using MACS separation 
columns, placed in the magnetic field of a QuadroMACS separator, the labelled 
mitochondrial are retained inside the column. Elution was carried out by removing 
the magnetic field after which the mitochondria were pelleted by centrifugation 
and resuspended in storage buffer. 
2.7.2. Differential Centrifugation (DC)  
This method allows cellular sub-fractionation in order to isolate the different 
cellular compartments.  
Cells collected from two 100 mm dishes were resuspended in 2 mL of ice-cold 
Mitochondrial Isolation Buffer (MIB) (Appendix 1), described by Takeyama et. al 
(Takeyama et al. 2002). Cells were then lysed by syringing with 26 G needle and 
subjected to several step of centrifugation at different speed.  
The first spin was carried out at 750g for 10 minutes at 4°C to pellet nuclei. This 
fraction contains also cell debris and whole cells escaped from homogenization. 
The pellet obtained was resuspended in 0.5 mL of MIB, further homogenised and 
spun again to improve the purity of the nuclear pellet (P1). The supernatants were 
combined and centrifuged at 13000g for 20 minutes at 4°C to pellet the 
mitochondria. The pellet was washed and spun again. The final mitochondria 
enriched pellet (P2) also contains lysosomes and peroxisomes. Golgi apparatus are 
also mainly present in this fraction. The supernatant (SF) contains the soluble 
fraction (cytosolic proteins) as well as ER and microsomes.  The pellets P1 and P2 
were finally resuspended in 0.5 mL of MIB. 
 
Fractions obtained with both MACS and DC methods were analysed by Western 
blotting. Regarding the MACS fractions, 50 µg of each mitochondria fraction and 80 
µg of each entire cell lysate were loaded on a polyacrylamide gel. For the DC 
fractions, 40 µg for each mitochondria fraction (P2) and 100 µg of each entire cell 
lysate were loaded on gel. Fraction P1 and SF were loaded at the same volume 
used for the P2. 
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2.8. Cell imaging 
2.8.1. Live cell imaging 
Cells were seeded on glass-bottom dishes 35 mm (Greiner Bio-One, 627861) at a 
density of 3-5 X 105 cells and transfected with EGFP-linked constructs as described 
previously. 
Cells were imaged 24-hours post-transfection using a Zeiss Axio Observer-Apotome 
fluorescence microscope or Zeiss LSM700 Confocal microscope. 
Prior to imaging, the cells were incubated for 30 minutes with either 250 nM 
Mitotracker Red FM (Thermo Fisher, M22425) or 5 µM BODIPY TR Ceramide 
complexed to BSA (Thermo Fisher, B-34400) diluted in media, as described in the 
manufacturer’s guidelines. These dyes accumulate within the mitochondria and 
Golgi complex respectively (Chazotte 2011, Pagano et al. 1991), emitting red 
fluorescence at 644 and 617 nm. NucBlue Live ReadyProbes Reagent (Thermo 
Fisher, R37605), containing Hoechst 33342 dye, was used to stain nuclei, and emits 
blue fluorescence at 460 nm. 
Fluorescence images were taken for green, red and blue channels. Co-localisation 
of the EGFP-tagged protein (in green) with mitochondria and Golgi (in red) was 
carried out based on overlap of the two different fluorescence patterns. 
For EGFP-tagged cystatin C, twelve independent experiments were carried out in 
ARPE19 cells and representative results from one experiment are shown in the 
respective section. Two independent experiments were carried out in D4O7 and 
Hela and one in hTertRPE-1. For the Leader Peptide constructs, seven independent 
experiments were carried out in ARPE19 cells and representative results from one 
experiment are shown in the respective section.  
2.8.2. Immunofluorescence 
Cells were grown on sterile glass coverslips in 24-well plates (5 X104 - 1X105 
cells/well). They were transfected with cystatin C constructs and fixed 24-hours 
post-transfection for subsequent immunostaining and analysis using an Olympus 
Fluoview upright confocal microscope. 
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Cells were washed with PBS and fixed for 30 minutes at room temperature (RT) 
with 4% paraformaldehyde (PFA) in PBS. The reaction was then quenched with 
50mM NH4Cl in PBS for 10 minutes at RT and cells were permeabilized with 0.2% 
Triton X-100 in PBS for 10 minutes at RT. Before immunostaining, cells were 
blocked for 1 hour at RT in blocking buffer (0.1% Triton X-100 in PBS, 1% BSA), 
followed by incubation with primary antibody diluted in blocking solution for 1.5 
hour. The cells were washed with PBS and incubated for 1h with appropriate 
secondary antibodies conjugated to AlexaFluor 488 (green) and AlexaFluor 594 
(red). Cells were stained with 10 mM DAPI (Thermo Fisher, D3571) in PBS for 10 
minutes, washed and finally mounted onto glass slides using mounting solution 
(Clear Mount with Tris Buffer, Electron Microscopy Sciences 17985-15). 
The primary and secondary antibodies used are shown in table 5 and 6. In some 
experiments mitochondria were stained by using Mitotracker Red CMXRos (Thermo 
Fisher, M7512), which emits red fluorescence at 599nm. As for Mitotracker Red FM 
used for live imaging, cells were incubated for 30 minutes at 37°C with 250nM of 
the dye, prior to cell fixation. 
 
Table 6 - Secondary antibodies used for immunofluorescence. 
Antibody Supplier 
(catalogue number) 
Description Concentration 
Anti-rabbit Thermo Fisher (A11008) Goat IgG, Alexa Fluor 
488 
1:1000 
Anti-rabbit Thermo Fisher (A21207) Donkey IgG, Alexa 
Fluor 594 
1:1000 
Anti-mouse Thermo Fisher (A21202) Donkey IgG, Alexa 
Fluor 488 
1:1000 
Anti-mouse Thermo Fisher (A21203) Donkey IgG, Alexa 
Fluor 594 
1:1000 
Anti-rat Thermo Fisher (A11006) Goat IgG, Alexa Fluor 
488 
1:1000 
Anti-rat Thermo Fisher (A11007) Goat IgG, Alexa Fluor 
594 
1:1000 
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For the EGFP-tagged cystatin C, three independent experiments were carried out in 
ARPE19 and D4O7 cells and representative results from one experiment are shown 
in the respective section. For the untagged and C-terminal FLAG- and HA-tagged 
cystatin C constructs, three independent experiments were carried out in ARPE19 
cells and two independent experiments were carried out in D4O7 cells. 
For the N-terminal constructs, two independent experiments were carried out in 
ARPE19 and D4O7 cells and representative results from one experiment are shown 
in the respective section. 
 
2.9. Statistical analysis 
Unpaired, paired, or one-sample t-test were used as statistical tests depending on 
the experiment, as specified in the respective results sections. The unpaired t-test 
is suitable for analysis of two independent samples, whereas the paired t-test is 
applied to a sample of matched pairs of data samples, and the one-sample t-test 
for comparing a data set against a single hypothetical value. The analyses were 
calculated using GraphPad Prism version 5.0 (GraphPad Software Inc.). P-values are 
reported for each experiment to quantify the statistical significance. In this study, 
analyses were typically carried out to compare wild-type versus variant B cystatin C 
proteins, or treated versus non-treated samples. 
Pearson’s chi-square (χ2) test was also used for comparison of discreet categorical 
data (e.g. cell counts in the analysis of cystatin C distribution in section 3.2). 
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3. Chapter 3 - Analysis of intracellular 
localization, trafficking and secretion 
of cystatin C variant B 
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3.1. Introduction 
Cystatin C is a secretory protein synthesised as a precursor containing a N-terminal 
signal peptide that leads the nascent protein to the ER. Here the mature form is 
generated by cleavage of the leader peptide, subsequently delivered to the Golgi 
apparatus and finally, through secretory vesicles, released into the extracellular 
matrix (Paraoan et al. 2001). 
The Ala25Thr mutation in the leader peptide of cystatin C, which generates the 
haplotype B, has been reported to affect the intracellular trafficking of the protein 
both in vitro and in vivo. In particular a reduction in the level of secretion of the 
variant B has been described, possibly as a result of a decreased efficiency of the 
signal sequence in targeting or processing the precursor protein through the 
secretory pathway (Benussi et al. 2003, Paraoan et al. 2004). One of these studies 
has also reported that the variant B accumulates intracellularly, where it 
mislocalizes in the cytoplasm, nucleus and particularly in the mitochondria 
(Paraoan et al. 2004). The impairment in cystatin C secretion can be therefore a 
consequence of such intracellular mistrafficking. Both these events have been 
hypothesised to contribute to cellular dysfunction associated with AMD and AD 
pathologies, as a consequence of a proteolytic activity imbalance both inside and 
outside the cell as well as a disruption of mitochondria functionality (Benussi et al. 
2003, Paraoan et al. 2004). 
However, other studies found no difference in secretion between the wild-type and 
variant form of cystatin C (Nguyen, Hulleman 2016, Chuo et al. 2007) and, so far, no 
additional studies have reported the mitochondrial association detected for the 
variant B. Furthermore a number of groups have also debated about the 
involvement of the Cystatin C haplotype B in both AD and AMD development, as no 
association was identified in their studies (Roks et al. 2001, Maruyama et al. 2001, 
Monastero et al. 2005, Nacmias et al. 2006, Wang et al. 2008, Butler et al. 2015). 
 
The aim of the first part of this study was therefore to further investigate the effect 
of the A25T mutation on the trafficking of the variant B cystatin C, in order to 
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identify whether there is any impairment in this process that helps us to 
understand how the protein is linked to disease development. For this purpose we 
analysed the intracellular localization of cystatin C, investigated whether the 
variant B protein accumulates intracellularly or follows the canonical ER-Golgi 
secretory pathway, evaluated the level of protein secretion in the conditioned 
media and finally we assessed the targeting properties of the signal sequence. 
For these analyses different RPE cell lines were used. Most of the experiments 
were carried out in ARPE19 cells, which are the most representative cells to study 
RPE given their high morphological and functional similarities (Dunn et al. 1996). In 
addition, D4O7 cells were used in some experiments due to their higher 
transfectability and yield of protein expression, which was necessary for some of 
the experiments (Davis et al. 1995). Finally, hTert-RPE1 and the widely used cervical 
adenocarcinoma cell line HeLa were used as additional controls for imaging analysis 
to study the protein localization (Gong et al. 2014).  
Different constructs were made in this study as described in materials and 
methods. The ones used for the analyses described in this chapter include C-
terminal tagged cystatin C proteins with either an EGFP, FLAG or HA tag, untagged 
constructs, constructs with N-glycosylation sites. In addition, leader peptide 
constructs linked to the EGFP tag were used. 
 
3.2. Analysis of protein localization 
Analysis of intracellular localization of cystatin C was investigated by imaging and 
fractionation studies to determine whether the variant B deviates from the 
secretory pathway, thus mislocalizing in a different cellular compartment. As a 
foundation for the subsequent work and given the discrepancies in the literature 
(Nguyen, Hulleman 2016, Paraoan et al. 2004), it was important to confirm the 
reported localization of the variant B in mitochondria.  
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3.2.1. Both wild-type and variant B EGFP-tagged constructs show 
partial mitochondrial mislocalization 
Via their fluorescent EGFP tag, cells transfected with full-length cystatin C-EGFP 
constructs were first analysed for their protein distribution by live cell imaging. 
Figure 3.1 and 3.2 show representative images obtained by fluorescence 
microscopy of ARPE19 cells transfected with WT-EGFP and VB-EGFP constructs 
respectively. To assess their intracellular localization, mitochondria and Golgi 
apparatus were stained. An ER/Golgi localization of cystatin C, as indicated by its 
colocalization with BODIPY, and therefore consistent with the distribution of 
secretory proteins, was found for both wild-type and variant constructs. However, 
a significant fraction of cells also showed mitochondrial colocalization for both the 
wild-type and variant B proteins. A dual Golgi-mitochondria distribution was also 
sometimes observed. Percentages of cells showing mitochondrial and secretory 
pathway distributions were quantified as shown in figure 3.3. Twelve independent 
experiments were performed and a chi-square test was used to assess whether 
there was a significant difference between wild-type and variant B protein 
distribution. 56% and 46% of ARPE19 cells were found to display the unusual 
mitochondrial association for the WT-EGFP and VB-EGFP proteins respectively, and 
this difference was statistically significant. Percentages were calculated by 
considering the total number of cells, obtained combining all the individual 
experiments (Figure 3.3.). Analysis of mitochondrial distribution at the level of each 
individual replicate resulted in 51%±16 and 40%±15 (Mean±SD, N=12) for wild-type 
and variant B, respectively. 
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Figure 3.1 - Localization of EGFP-tagged wild-type cystatin C constructs (WT-EGFP). A) 
Living cultured human ARPE19 cells expressing wild-type cystatin C linked to eGFP were 
imaged 24 h post-transfection. The emission specific for eGFP constructs is shown in green. 
Mitotracker and Bodipy, which fluoresce red, were used to visualize mitochondria and 
Golgi complex, respectively. The blue fluorescent Hoechst 33342 probe was used to stain 
nuclei. For each field of cells imaged, green and red fluorescence were recorded as 
separate images and then merged, along with the blue signal and bright field, for assessing 
the overlap of the respective signals. Cells showing ER/Golgi or mitochondrial distribution 
are indicated by orange and white arrows, respectively. B) and C) show higher 
magnification of images of cells expressing wild-type constructs with Mitotracker (B) and 
Bodipy (C). Scale bars are 20 µM. 
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Figure 3.2 - Localization of EGFP-tagged variant B cystatin C constructs (VB-EGFP). Living 
cultured human ARPE19 cells expressing variant B cystatin C linked to eGFP were imaged 
24 h post-transfection. The emission specific for eGFP constructs is shown in green. 
Mitotracker and Bodipy, which fluoresce red, were used to visualize mitochondria and 
Golgi complex respectively. The blue fluorescent Hoechst 33342 probe was used to stain 
nuclei. For each field of cells imaged, green and red fluorescence were recorded as 
separate images and then merged, along with the blue signal and bright field, for assessing 
the overlap of the respective signals. Cells showing ER/Golgi or mitochondrial distribution 
are indicated by orange and white arrows, respectively. B) and C) show higher 
magnification of images of cells expressing variant B constructs with Mitotracker (B) and 
Bodipy (C). Scale bars are 20 µM. 
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Figure 3.3 - Quantification of EGFP-tagged cystatin C distribution in live transfected 
ARPE19 cells. ARPE19 cells transfected with either WT or VB-EGFP constructs were 
quantified to compare secretory pathway distribution and mitochondrial localization of 
cystatin C. The fraction of cells showing mitochondrial association results 56% and 46% for 
the WT and VB-EGFP proteins respectively. Percentages are calculated by considering the 
total number of cells obtained combining all the individual experiments. Chi-square test (χ2 
=25.63), p-value <0.00001.  
 
 
Analysis of intracellular localization in live cells for the EGFP-tagged cystatin C 
constructs was also performed in D4O7, hTert-RPE1 and HeLa cell lines as shown in 
Figure 3.4 a, b and c, respectively.  
Mitochondrial association for both wild-type and variant B constructs was again 
observed in a significant number of cells, thus excluding an ARPE19 cell-related 
effect. In particular, for all cell lines analysed, cells with an ER/Golgi distribution, a 
mitochondrial association or a dual Golgi-mitochondria distribution were observed 
for both wild-type and mutant cystatin C.  
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a)   D4O7 
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b)  
Figure 3.4 - Localization of EGFP-tagged 
cystatin C constructs. Living cultured 
human D4O7 (a), hTert-RPE1 (b) and 
HeLa (c) cells expressing wild-type  or 
variant B cystatin C linked to eGFP were 
imaged 24 h post-transfection. The 
emission specific for eGFP constructs is 
shown in green. Mitotracker was used to 
visualize mitochondria and it fluoresces 
red. Hoechst 33342 probe that emits 
blue fluorescence was used to stain 
nuclei. For each field of cells imaged, 
green and red fluorescence were 
recorded as separate images and then 
merged, along with the blue signal, for 
assessing the overlap of the respective 
signals. Cells showing ER/Golgi or 
mitochondrial distribution are indicated 
by orange and white arrows, 
respectively. Scale bars are 10 µM. 
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3.2.2. EGFP-tagged constructs mislocalise unlike untagged, FLAG- 
and HA-tagged constructs which localise in the ER/Golgi 
compartments 
To confirm the results obtained by life cell imaging, analysis of intracellular 
localization was also performed by immunofluorescence (IF) on PFA-fixed cells. In 
addition to the EGFP-tagged constructs, untagged, FLAG- or HA-tagged constructs 
were analysed. Since the latter do not emit fluorescence, immunostaining was 
needed for protein visualization. Figure 3.5 shows ARPE19, D4O7, hTert-RPE1 and 
HeLa cells (a, b, c and d, respectively) transfected with WT-EGFP or VB-EGFP cDNAs. 
Mitotracker was used to stain mitochondria. As observed for live cell imaging, cells 
displayed either a secretory distribution or a mitochondrial association for both 
wild-type and variant B constructs. Percentages were calculated by considering the 
total number of cells, obtained combining all the individual experiments 
Quantification shown in figure 3.6 for the ARPE19 cells resulted in 32% and 30% of 
the cells expressing  wild-type and variant B, respectively, showing mitochondrial 
localization, with no significant difference observed between them. Analysis of 
mitochondrial distribution at the level of each individual replicate resulted in 
32%±10 and 31%±6 (Mean±SD, N=3) of the cells expressing wild-type and variant B, 
respectively, showing mitochondrial localization. 
 
 
 
 
 
 
 
 
 
 
90 
 
  
 
  
Figure 3.5 - Localization of EGFP-tagged cystatin C constructs. Cultured human ARPE19 (a) 
D4O7 (b), hTert-RPE1 (c) and HeLa (d) cells expressing wild-type or variant B cystatin C 
a) ARPE19 
 
b) D4O7 
 
7 
d) HeLa c) hTert-RPE1 
EGFP-tagged cystatin C constructs 
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linked to EGFP were PFA-fixed 24 h post-transfection and subsequently imaged. The 
emission specific for EGFP constructs is shown in green. Mitotracker, which fluoresces red, 
was used to visualize mitochondria. The blue fluorescent DAPI was used to stain nuclei. For 
each field of cells imaged, green and red fluorescence were recorded as separate images 
and then merged, along with the blue signal, for assessing the overlap of the respective 
signals. Cells showing ER/Golgi or mitochondrial distribution are indicated by orange and 
white arrows, respectively. Scale bars are 20 µM. 
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Figure 3.6 - Quantification of EGFP-tagged cystatin C distribution in fixed transfected 
ARPE19 cells. ARPE19 cells transfected with either WT or VB-EGFP constructs were 
quantified to compare secretory pathway distribution and mitochondrial localization of 
cystatin C. Percentages are calculated by considering the total number of cells obtained 
combining all the individual experiments. The fraction of cells showing mitochondrial 
association results 32% and 30% for the WT and VB-EGFP proteins respectively. Chi-square 
test (χ2 =0.19), p-value =0.66.  
 
Subsequently, IF was performed on cells transfected with the untagged constructs 
or constructs tagged with the small FLAG or HA tags to further investigate the 
protein distribution. Antibodies against cystatin C, or FLAG or HA tag were used to 
detect the untagged or the fusion proteins. DAPI, mitotracker and anti-calreticulin 
and anti-GM130 antibodies were used to stain nuclei, mitochondria, ER and Golgi, 
respectively.  
Figure 3.7 shows ARPE19 cells transfected with the untagged cystatin C cDNAs and 
immunostained with anti-cystatin C, mitotracker and anti-GM130. Surprisingly, and 
in contrast to the results obtained for the EGFP-tagged constructs, neither the 
variant or wild-type proteins showed mitochondrial localisation. Colocalisation with 
92 
 
the Golgi apparatus was instead observed, suggesting that both WT-CysC and VB-
CysC localise in the secretory pathway. Figure 3.8 shows the same analysis 
performed on D4O7 cells. Again, no colocalization with mitotracker was found for 
either the untagged wild-type or variant B cystatin C. Also in D407 cells, although 
no other organelles were stained, anti-cystatin C antibody gave us a typical 
reticular and perinuclear staining, consistent with the ER/Golgi. 
The same results were obtained by using wild-type and variant B cystatin C 
constructs tagged with FLAG- or HA-tags in both ARPE19 and D4O7 cells (ARPE19 in 
figure 3.9 and 3.10 and D4O7 in figure 3.11 and 3.12), where cystatin C was again 
found to be distributed in the ER/Golgi with no mitochondria localization detected. 
Untagged cystatin C constructs 
 
  
Figure 3.7 - Localization of untagged cystatin C constructs. Human ARPE19 cells expressing 
wild-type or variant B cystatin C were PFA-fixed 24 h post-transfection, immunostained 
with anti-cystatin C antibody and subsequently imaged. The emission specific for cystatin C 
constructs is shown in green. Mitotracker and anti-GM130 antibody, which fluoresce red, 
were used to visualize mitochondria and Golgi complex, respectively. The blue fluorescent 
DAPI was used to stain nuclei. For each field of cells imaged, green and red fluorescence 
ARPE19 
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were recorded as separate images and then merged, along with the blue signal, for 
assessing the overlap of the respective signals. Scale bars are 20 µM. 
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Figure 3.8 - Localization of untagged 
cystatin C constructs. Human D4O7 cells 
expressing wild-type or variant B cystatin C 
were PFA-fixed 24 h post-transfection, 
immunostained with anti-cystatin C 
antibody and subsequently imaged. The 
emission specific for cystatin C constructs is 
shown in green. Mitotracker, which 
fluoresces red, was used to visualize 
mitochondria. The blue fluorescent DAPI 
was used to stain nuclei. For each field of 
cells imaged, green and red fluorescence 
were recorded as separate images and 
then merged, along with the blue signal, for 
assessing the overlap of the respective 
signals. Scale bars are 20 µM. 
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FLAG-tagged cystatin C constructs 
Figure 3.9 - Localization of FLAG-tagged 
cystatin C constructs. Human ARPE19 cells 
expressing wild-type or variant B cystatin 
C linked to a FLAG tag were PFA-fixed and 
immunostained 24h post-transfection. 
Cystatin constructs were detected using 
either anti-FLAG or anti-cystatin C 
antibodies and shown in green. 
Mitotracker and the antibodies anti-
calreticulin and anti-GM130, which 
fluoresce red, were used to visualize 
mitochondria, Endoplasmic Reticulum and 
Golgi apparatus, respectively. The blue 
fluorescent DAPI was used to stain nuclei. 
For each field of cells imaged, green and 
red fluorescence were recorded as 
separate images and then merged, along 
with the blue signal, for assessing the 
overlap of the respective signals. Scale 
bars are 20 µM. 
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HA tagged cystatin C constructs 
 
Figure 3.10 - Localization of HA-tagged 
cystatin C constructs. Human ARPE19 
cells expressing wild-type or variant B 
cystatin C linked to a HA tag were PFA-
fixed and immunostained 24h post-
transfection. Cystatin constructs were 
detected using either anti-HA or anti-
cystatin C antibodies and shown in green. 
Mitotracker and the antibodies anti-
calreticulin and anti-GM130, which 
fluoresce red, were used to visualize 
mitochondria, Endoplasmic Reticulum 
and Golgi apparatus, respectively. The 
blue fluorescent DAPI was used to stain 
nuclei.  For each field of cells imaged, 
green and red fluorescence were 
recorded as separate images and then 
merged, along with the blue signal, for 
assessing the overlap of the respective 
signals. Scale bars are 20 µM. 
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Figure 3.11 - Localization of FLAG-tagged cystatin C constructs. Human D4O7 cells 
expressing wild-type (a) or variant B (b) cystatin C linked to a FLAG tag were PFA-fixed and 
immunostained 24h post-transfection. Cystatin constructs were detected using either anti-
FLAG or anti-cystatin C antibodies and shown in green. Mitotracker and the antibodies 
anti-calreticulin and anti-GM130, which fluoresce red, were used to visualize mitochondria, 
Endoplasmic Reticulum and Golgi apparatus, respectively. The blue fluorescent DAPI was 
used to stain nuclei.  For each field of cells imaged, green and red fluorescence were 
recorded as separate images and then merged, along with the blue signal, for assessing the 
overlap of the respective signals. Scale bars are 20 µM. 
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Figure 3.12 - Localization of HA-tagged cystatin C constructs. Human D4O7 cells 
expressing wild-type (a) or variant B (b) cystatin C linked to a HA tag were PFA-fixed and 
immunostained 24h post-transfection. Cystatin constructs were detected using either anti-
HA or anti-cystatin C antibodies and shown in green. Mitotracker and the antibodies anti-
calreticulin and anti-GM130, which fluoresce red, were used to visualize mitochondria, 
Endoplasmic Reticulum and Golgi apparatus, respectively. The blue fluorescent DAPI was 
used to stain nuclei.  For each field of cells imaged, green and red fluorescence were 
recorded as separate images and then merged, along with the blue signal, for assessing the 
overlap of the respective signals. Scale bars are 20 µM. 
 
 
 
  
Anti-HA Anti-CysC Anti-HA Anti-CysC 
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3.2.3. Wild-type and variant B EGFP-tagged constructs are similarly 
present in the mitochondria fraction and both differ from 
the endogenous cystatin C distribution 
Analysis of intracellular localization of cystatin C was also performed by cell 
fractionation and subsequent immunoblotting of cellular organelle fractions, in 
particular to determine whether the variant B cystatin C is present in the 
mitochondrial fraction.  
For this purpose, mitochondria were enriched from D4O7 cells transfected with the 
EGFP-linked wild-type or variant B cystatin C constructs by using an antibody-based 
magnetic separation (MACS) protocol or, alternatively, they were enriched along 
with nuclear and ER/cytosolic fractions by a differential centrifugation method 
(DC). 
Data from 4 independent transfection experiments were analysed for each method 
(MACS and DC). The entire cell lysate and the different cellular fractions were 
analysed by probing with either anti-cystatin C or anti-EGFP antibodies to detect 
the level of fusion protein in each fraction. Golgi and Mitochondria markers (anti-
Mannosidase II and anti-TOM20 antibodies, respectively (Pfanner, Craig & 
Hönlinger 1997, Shah, Kuntz & Rose 2008)) were used to assess organelles cross-
contamination and evaluate the purity of each fraction. 
Representative immunoblots of cellular fractions obtained by DC or MACS are 
shown in figure 3.13 and 3.14, respectively. Neither of these separation techniques 
allowed me to get pure mitochondria fractions, as shown by the presence of Golgi 
marker (Mannosidase II) as well as endogenous cystatin C in such cellular fraction. 
In the same way the mitochondrial marker Tom20 was also found in the nuclei and 
ER/Cytosol fractions. For this reason, the presence of both wild-type and variant 
proteins in the enriched mitochondrial samples may be due to such organelles 
cross-contamination and this limitation did not allow a proper unequivocal analysis. 
Nevertheless, the levels of the two constructs in the mitochondrial fraction were 
compared to identify whether there was a significant difference between them that 
may be attributed to the actual presence of cystatin C in the mitochondria. To 
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compare their levels in the mitochondria fractions, the expression level of the two 
constructs in the respective cell lysates was taken into account as well as the 
amount of mitochondria and Golgi organelles present in the isolated mitochondrial 
fractions. Considering similar levels of mitochondria and Golgi contamination, 
results seem to indicate no difference in the level of EGFP wild-type or variant 
cystatin C fusion protein found in the mitochondrial fractions obtained from either 
MACS or DC techniques. However, regarding the analysis of the DC fractions a 
remarkable difference in the distribution of the endogenous cystatin C compared 
to the transfected EGFP fusion proteins was observed (figure 3.13 a). While the 
former was mainly present in the soluble fraction (SF) that includes ER and cytosol, 
the EGFP-linked proteins were predominantly in the Golgi/Mitochondria fraction 
(P2). As a control, the distribution of EGFP on its own was also analysed, and was 
found to be mainly in the cytosolic fraction as expected (figure 3.13 b). 
 
     
Figure 3.13 - Subcellular fractionation by differential centrifugation. P1, P2 and SF are 
respectively the nuclear fraction, mitochondria/Golgi fraction and the ER/cytosolic 
fraction. The entire cell lysate prior to fractionation was also loaded. In figure a) samples 1 
to 4 are from D4O7 cells transfected with EGFP-tagged wild-type cystatin c and samples 5 
to 8 are from cells transfected with EGFP-tagged Variant B cystatin C.  Protein of interest 
was detected using either anti-EGFP or anti-cystatin C antibodies. Anti-Mannosidase II and 
anti-Tom20 are used as Golgi and mitochondria marker respectively. In figure b) subcellular 
fractions from cells transfected with EGFP alone we analysed. 
a) b) 
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Figure 3.14 - Mitochondria isolation by magnetic separation (MACS). Lanes 1, 2, 3 are 
mitochondrial fractions isolated from cell transfected respectively with EGFP-tagged 
cystatin C wild-type, variant B and only EGFP. Lanes 4, 5, 6 are the respective entire cell 
lysates transfected with wild-type, variant B and only EGFP. 
 
Overall, a partial localization of the EGFP tagged wild-type and variant cystatin C 
constructs into the mitochondria was observed by both imaging and fractionation 
analyses. In contrast, mitochondrial localization was not apparent for the cystatin 
C-constructs carrying FLAG or HA tags, or for endogenous or overexpressed 
untagged cystatin C. These data suggest that the EGFP tag mediates mitochondrial 
mislocalization of both the wild-type and variant B cystatin C constructs, whereas 
the other constructs a delivered to the ER-Golgi secretory pathway.  
 
3.3. Analysis of intracellular accumulation 
Variant B cystatin C has been previously reported to accumulate intracellularly 
(Paraoan et al. 2004). As a consequence a reduction of its secretion in the cultured 
media was also observed (Paraoan et al. 2004). This situation has been suggested 
to generate an unbalance in the proteolytic activity both inside and outside the cell, 
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thus affecting RPE functionality (Paraoan et al. 2004). Moreover, given the 
amyloidogenic properties of cystatin C, intracellular accumulation of the protein 
may lead to formation of intracellular aggregates (Tsiolaki et al. 2015). Previously, a 
mitochondrial association of the variant B using the EGFP-linked constructs was 
reported (Paraoan et al. 2004). As we observed that this occurs for both wild-type 
and variant B, and only when cystatin C is linked to the EGFP tag, we further 
investigated and compared the intracellular amounts of wild-type and variant B for 
the EGFP- as well as the FLAG- or HA-tagged cystatin C constructs. 
 
For this purpose, inhibition of protein synthesis by cycloheximide was carried out in 
transfected ARPE19 cells and levels of intracellular and secreted cystatin C were 
analysed at different time points. After inhibition of protein synthesis a progressive 
reduction in the levels of intracellular cystatin C is expected, as the protein is 
gradually secreted into the extracellular environment. 
 
3.3.1. EGFP-tagged constructs are partially retained intracellularly 
compared to the HA- or FLAG-constructs which are entirely 
secreted 
Immunoblotting in figure 3.15 shows cell lysates and media of treated and non-
treated ARPE19 cells transfected with Cys-HA (a) Cys-FLAG (b), Cys-EGFP (c) or only 
EGFP (d) after 2h (a) and 7h (b, c, and d). 
After 2h of cycloheximide treatment (a) a difference in the intracellular level of 
cystatin C can be already observed compared to the untreated samples. No 
difference occured between WT and VB constructs where levels of protein 
expression decrease at similar rate if compared to the respective levels in non-
treated cells. GAPDH immunodetection was also used as a loading control. After 7h 
of treatment the reduction of the intracellular levels increases for both EGFP- (c) 
and FLAG-tagged (b) constructs, unlike EGFP alone (d) that only slightly decreases, 
consistent with it not undergoing secretion but remaining intracellularly (Tsien 
1998). This indicates that all the cystatin C constructs are progressively released 
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extracellularly and again no difference between wild-type and variant B is 
observed. However, at equal levels of expression in the non-treated samples can be 
observed that the reduction of the cysC-FLAG constructs in the intracellular fraction 
(Fig. 3.15 b) is notably higher than the one of the cysC-EGFP constructs (c). To be 
able to detect Cys-FLAG proteins intracellularly after 7h of cycloheximide treatment 
a higher exposure needed to be carried out. This suggests that the EGFP constructs, 
either wild-type or variant B, may be partially retained intracellularly or be secreted 
with significantly slower kinetics. 
To investigate this aspect further, an overnight treatment with cycloheximide was 
performed to give sufficient time to let all the proteins be secreted into the 
conditioned media. Figure 3.16 (a) shows ARPE19 transfected with Cys-FLAG 
constructs and treated overnight with cycloheximide. No bands were detected for 
either wild-type or variant B in the cell lysates, even at higher exposure. Only in the 
conditioned media was it possible to detect cystatin C proteins. This indicated that 
all the proteins were eventually secreted and no accumulation had occurred. On 
the contrary, cells transfected with CysC-EGFP constructs, shown in figure 3.16 (b) 
still revealed the presence of cystatin C constructs inside the cells even after 
overnight cycloheximide treatment, suggesting that CysC-EGFP constructs are 
partially retained intracellularly. 
Furthermore, live imaging of ARPE19 cells transfected with EGFP-linked cystatin C 
constructs were performed prior to the immunoblotting analysis to confirm the 
intracellular presence of the EGFP-tagged proteins through emission of green 
fluorescence. As can be observed in Figure 3.17 Cys-EGFP proteins were still 
detected in a fraction of cells after overnight treatment, therefore confirming 
immunoblotting results and indicating a tendency of EGFP-linked constructs to 
accumulate intracellularly. Furthermore, in these cells, the fluorescence was 
emitted from what appeared to be mitochondria and diffused in the cytosol. This is 
consistent with proteins being entirely secreted from those cells where proteins 
localised in the ER/Golgi, therefore not fluorescing after cycloheximide treatment. 
 
104 
 
 
 
 
       
Figure 3.15 - Immunodetection of cystatin C upon inhibition of protein synthesis. ARPE19 
cells transfected with Cys-HA (a), Cys-FLAG (b), Cys-EGFP (c) or only EGFP (d) were treated 
with cycloheximide 200 uM for 2h (a) or 7h (b, c and d) in order to inhibit synthesis of new 
proteins. Cells treated or non-treated were then immunoblotted with anti-cystatin C to 
assess whether the protein is secreted or tends to accumulate intracellularly. GAPDH 
immunoblotting detection was used as a loading control. In figure b) and c) also media 
samples from treated or non-treated cells were loaded together with the respective cell 
lysates. The amount of cell lysate loaded was 7X more than the media (cell lysate 20µL/250 
µL, media 30µL/2.5mL). 
 
a) CysC-HA 
c) CysC-EGFP 
b) CysC-FLAG 
d) EGFP 
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Figure 3.16 - Immunodetection of cystatin C upon inhibition of protein synthesis. ARPE19 
cells transfected with Cys-FLAG (a) or Cys-EGFP (b) were treated o/n with cycloheximide 
200 µM in order to inhibit synthesis of new proteins. Cells treated or not treated were then 
a) CysC-FLAG 
b) CysC-EGFP 
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immunoblotted with anti-cystatin C to assess whether the protein is secreted or tend to 
accumulate intracellularly. GAPDH immunoblotting detection was used as a loading 
control. In figure b) and c) also media samples were loaded together with the cell lysates. 
Samples were also collected before the treatment with cycloheximide, indicated with (pre) 
in the blots, to evaluate level of protein inside and outside the cells at the time of the 
treatment. The amount of cell lysate loaded was 7X more than the media (cell lysate 
20µL/250 µL, media 30µL/2.5mL). 
 
Wild-type CysC-EGFP + Cycloheximide (200uM) overnight 
 
Figure 3.17 - Live cell imaging of ARPE19 cells transfected with WT-EGFP and treated o/n 
with cycloheximide. Cells treated with cycloheximide 200 µM were imaged before being 
analysed by immunoblotting in figure 3.2.2 (b) to evaluate cell viability and double check 
the intracellular presence of proteins thanks to the presence of EGFP linked to cystatin C. 
Scale bars are 50 µm. 
 
Overall, these results show again a different behaviour between the cysC-EGFP 
constructs, which seem to be partially retained intracellularly, and the FLAG-tagged 
cystatin C, which completes its passage along the secretory pathway and is 
consequently released from the cells, equally for wild-type and variant B. 
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3.4.  Analysis of secretion 
Cystatin C variant B has been reported to show impaired secretion, likely due to a 
reduced efficiency in the cleavage of the signal sequence or in the translocation 
through the ER membrane as a consequence of the change in hydrophobicity 
caused by the Ala to Thr substitution in the leader peptide (Benussi et al. 2003, 
Paraoan et al. 2004). Paraoan et al. (2004) also attributed the reduced secretion of 
the variant cystatin C to a mistargeting that leads to the unusual mitochondrial 
association. However, another study failed to report such difference in secretion 
between wild-type and variant B (Nguyen, Hulleman 2016). 
As described in the previous sections, neither mitochondrial localization nor 
intracellular accumulation was observed for the variant B, which followed the 
secretory pathway similarly to the wild-type form of cystatin C, eventually being 
secreted into the culture media. On the contrary, intracellular retention and 
mistrafficking of cystatin C was observed to occur only in the presence of EGFP, 
affecting similarly wild-type and variant B proteins. 
Even though cystatin C variant B seems to normally undertake the secretory 
pathway, a difference in the extent of secretion might occur due to reduced 
efficiency of targeting/processing of the precursor protein for secretion, as 
suggested by different groups (Benussi et al. 2003, Paraoan et al. 2004). As 
contrasting data on this aspect have been reported in literature, I decided to 
further investigate whether the level of secreted cystatin C differs between wild-
type and variant proteins by using EGFP-, FLAG-, HA-tagged or untagged cystatin C 
constructs in ARPE19 and D4O7 cells. 
 
3.4.1. Wild-type and variant B EGFP-, FLAG- and  HA-tagged and 
untagged cystatin C are similarly secreted by RPE  
Culture media from cells transfected with the different constructs were subjected 
to SDS-PAGE electrophoresis, together with the respective cell lysates, and 
immunodetected by using anti-cystatin C and the specific anti-tag antibodies (EGFP, 
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FLAG or HA) depending on the construct used. Cell lysate and culture medium from 
untransfected cells were sometimes used as controls. 
For each construct, the level of secretion was analysed 24h after transfection. Same 
volume of cell lysates, also corresponding to same protein content, was loaded 
onto the gel, as well as the same volume of media samples. The fraction of 
secreted cystatin C was assessed by calculating the total protein secreted and 
normalising this value to the total cystatin C protein, combining the total secreted 
and the total intracellular cystatin C levels. This method of normalization removes 
variability due to difference in number of cells or transfection efficiency, as it just 
calculates the percentage of protein secreted out of the total after a certain period 
of time. 
Immunoblots and analysis of secreted fractions in ARPE 19 cells are shown in figure 
3.18, 3.19, 3.20 and 3.21 for Cys-EGFP, untagged Cys, Cys-FLAG and Cys-HA, 
respectively. The wild-type and variant B proteins were secreted with similar 
efficiencies, irrespective of whether an anti-EGFP, an anti-cystatin C, an anti-FLAG 
or anti-HA antibody, depending on the construct used, was used for detection. 
 
 
 
 
a) CysC-EGFP 
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Figure 3.18 - Analysis of secretion of cystatin C wild-type or variant B linked to EGFP in 
ARPE19. (a) Immunoblot of cell lysates and conditioned media collected from cells 
expressing respectively wild-type Cys-EGFP, variant B Cys-EGFP, only EGFP and 
untransfected cells not expressing any of these proteins. Western blots were probed with 
anti-cystatin C antibody, which detected the cystatin C-EGFP fusion protein, consisting of a 
band of approximately 40KDa, and the endogenous cystatin C of 13KDa, and with anti-
EGFP antibody, which also identified the fusion proteins and EGFP on its own (27KDa). 
Anti-GAPDH antibody was also used as loading control for cell lysates, whereas 
endogenous cystatin C in the media can be used as loading control for the media samples. 
The amount of cell lysate loaded was 4X more than the media (cell lysate 8µL/250 µL, 
media 20µL/2.5mL). Level of secreted cysC-EGFP fusion proteins in the conditioned 
medium of cells transfected with wild-type or mutant constructs were evaluated by 
densitometry of western blots probed with anti-EGFP (b) or anti-cystatin C (c) and the total 
cystatin C secreted was calculated and normalized to total cystatin C protein (total 
intracellular + total secreted). Using anti-EGFP antibody the fractions of secreted proteins 
result to be 0.62 ± 0.09 (SD) for wild-type and 0.55 ± 0.12 (SD) for variant B. Unpaired t test 
(N=4) two-tailed, p=0.39. Using anti-cystatin C antibody the fractions of secreted proteins 
result to be 0.56 ± 0.05 (SD) for wild-type and 0.53 ± 0.03 (SD) for variant B. Unpaired t test 
(N=4) two-tailed, p=0.26. Results are presented as percentages. ns=non-significant. 
 
 
 
 
b) Anti-EGFP c) Anti-cystatin C 
ns ns 
110 
 
 
 
 
        
w
t c
ys
C
 u
nt
ag
ge
d
vb
 c
ys
C
 u
nt
ag
ge
d
0
20
40
60
80
100
F
ra
c
ti
o
n
 o
f 
s
e
c
re
te
d
 C
y
s
C
 (
%
)
(n
o
rm
a
li
z
e
d
 t
o
 t
o
ta
l 
p
ro
te
in
)
 
Figure 3.19 - Analysis of secretion of untagged cystatin C wild-type or variant B in 
ARPE19. (a) Immunoblot of cell lysates and conditioned media collected from cells 
expressing respectively wild-type CysC, variant B CysC and untransfected cells. Western 
blots were probed with anti-cystatin C antibody, which detected the transfected untagged 
cystatin C protein, consisting of a band of approximately 13KDa, and the endogenous 
cystatin C that can be also detected at higher exposure. Anti-GAPDH antibody was also 
used as loading control for cell lysates. The amount of cell lysate loaded was 5X more than 
the media (cell lysate 10µL/250 µL, media 30µL/3.75mL). Level of secreted cysC proteins in 
the conditioned medium of cells transfected with wild-type or mutant constructs were 
evaluated by densitometry of western blots probed with anti-cystatin C (b) and the total 
cystatin secreted was calculated and normalized to total cystatin C protein (total 
intracellular + total secreted). The fractions of secreted proteins result to be 0.79 ±0.01 
(SD) for wild-type and 0.81 ±0.04 (SD) for variant B. Unpaired t test (N=3) two-tailed, 
p=0.36. Results are presented as percentages. ns=non-significant. 
 
a) CysC untagged 
b) Anti-cystatin C 
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Figure 3.20 - Analysis of secretion of cystatin C wild-type or variant B linked to FLAG in 
ARPE19. (a) Immunoblot of cell lysates and conditioned media collected from cell 
expressing respectively wild-type Cys-FLAG and variant B Cys-FLAG. Western blots were 
probed with anti-cystatin C antibody, which detected the cystatin C-FLAG fusion protein, 
consisting of a band of approximately 14KDa, and the endogenous cystatin C of 13KDa that 
can be detected at higher exposure, and with anti-FLAG antibody, which also identified the 
cystatin C fusion proteins. Anti-GAPDH antibody was used as loading control for cell 
lysates. The amount of cell lysate loaded was 5X more than the media (cell lysate 10µL/250 
µL, media 30µL/3.75mL). Level of secreted cysC-FLAG fusion proteins in the conditioned 
medium of cells transfected with wild-type or mutant constructs were evaluated by 
a) CysC-FLAG b) Anti-FLAG 
c) Anti-cystatin C 
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densitometry of western blots probed with anti-FLAG (b) or anti-cystatin C (c) and the total 
cystatin secreted was calculated and normalized to total cystatin C protein (total 
intracellular + total secreted). Using anti-FLAG antibody the fractions of secreted proteins 
result to be 0.86 ± 0.02 (SD) for wild-type and 0.88 ± 0.06 (SD) for variant B. Unpaired t test 
(N=3) two-tailed, p=0.66. Using anti-cystatin C antibody the fractions of secreted proteins 
result to be 0.83 ± 0.04 (SD) for wild-type and 0.83 ± 0.03 (SD) for variant B. Unpaired t test 
(N=3) two-tailed, p=0.90. Results are presented as percentages. ns=non-significant. 
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Figure 3.21 - Analysis of secretion of cystatin C wild-type or variant B linked to HA in 
ARPE19. (a) Immunoblot of cell lysates and conditioned media collected from cell 
expressing respectively wild-type Cys-HA and variant B Cys-HA. Western blots were probed 
a) CysC-HA b) Anti-HA 
c) Anti-cystatin C 
ns 
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with anti-cystatin C antibody, which detected the cystatin C-HA fusion protein, consisting 
of a band of approximately 14.1KDa, and the endogenous cystatin C of 13KDa that can be 
detected at higher exposure, and with anti-HA antibody, which also identified the cystatin 
C fusion proteins. Anti-GAPDH antibody was used as loading control for cell lysates. The 
amount of cell lysate loaded was 5X more than the media (cell lysate 10µL/250 µL, media 
30µL/3.75mL). Level of secreted cysC-HA fusion proteins in the conditioned medium of 
cells transfected with wild-type or mutant constructs were evaluated by densitometry of 
western blots probed with anti-HA (b) or anti-cystatin C (c) and the total cystatin secreted 
was calculated and normalized to total cystatin C protein (total intracellular + total 
secreted). Using anti-HA antibody the fractions of secreted proteins result to be 0.66 ± 0.07 
(SD) for wild-type and 0.63 ± 0.07 (SD) for variant B. Unpaired t test (N=3) two-tailed, 
p=0.63. Using anti-cystatin C antibody the fractions of secreted proteins result to be 
0.87±0.02 (SD) for wild-type and 0.84±0.02 (SD) for variant B. Unpaired t test (N=3) two-
tailed, p=0.14. Results are presented as percentages. ns=non-significant. 
 
The same analysis was also performed in D4O7 cells to control for cell line 
specificity. Immunoblots and analyses of secretion are shown in figure 3.22, 3.23 
and 3.24 for untagged CysC, Cys-FLAG and Cys-HA constructs, respectively. Again, 
wild-type and variant B proteins are secreted similarly apart from a subtle, 
statistically significant decrease for variant B found for the untagged constructs. 
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Figure 3.22 - Analysis of secretion of untagged cystatin C wild-type or variant B in D4O7. 
(a) Immunoblot of cell lysates and conditioned media collected from cell expressing 
respectively wild-type CysC, variant B CysC and untransfected cells. Western blots were 
probed with anti-cystatin C antibody, which detected the transfected untagged cystatin C 
protein, consisting of a band of approximately 13KDa. Anti-GAPDH antibody was used as 
loading control for cell lysates. The amount of cell lysate loaded was 6X more than the 
* 
a) CysC untagged b) Anti-cystatin C 
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media (cell lysate 8µL/250 µL, media 20µL/3.75mL). Level of secreted cysC proteins in the 
conditioned medium of cells transfected with wild-type or mutant constructs were 
evaluated by densitometry of western blots probed with anti-cystatin C (b) and the total 
cystatin secreted was calculated and normalized to total cystatin C protein (total 
intracellular + total secreted). The fractions of secreted proteins result to be 0.70±0.01 (SD) 
for wild-type and 0.66±0.02 (SD) for variant B. Unpaired t test (N=4) two-tailed, p=0.02 (*). 
Results are presented as percentages.  
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Figure 3.23 - Analysis of secretion of cystatin C wild-type or variant B linked to FLAG in 
D4O7. (a) Immunoblot of cell lysates and conditioned media collected from cell expressing 
respectively wild-type Cys-FLAG and variant B Cys-FLAG. Western blots were probed with 
anti-cystatin C antibody, which detected the cystatin C-FLAG fusion protein, consisting of a 
band of approximately 14KDa, and with anti-FLAG antibody, which also identified the 
cystatin C fusion proteins. Anti-GAPDH antibody was used as loading control for cell 
a) CysC-FLAG b) Anti-FLAG 
c) Anti-cystatin C 
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lysates. The amount of cell lysate loaded was 6X more than the media (cell lysate 8µL/250 
µL, media 20µL/3.75mL). Level of secreted cysC-FLAG fusion proteins in the conditioned 
medium of cells transfected with wild-type or mutant constructs were evaluated by 
densitometry of western blots probed with anti-FLAG (b) or anti-cystatin C (c) and the total 
cystatin secreted was calculated and normalized to total cystatin C protein (total 
intracellular + total secreted). Using anti-FLAG antibody the fractions of secreted proteins 
result to be 0.78±0.01 (SD) for wild-type and 0.76±0.03 (SD) for variant B. Unpaired t test 
(N=4) two-tailed, p=0.43. Using anti-cystatin C antibody the fractions of secreted proteins 
result to be 0.84±0.01 (SD) for wild-type and 0.77±0.05 (SD) for variant B. Unpaired t test 
(N=4) two-tailed, p=0.06. Results are presented as percentages. ns=non-significant. 
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Figure 3.24 - Analysis of secretion of cystatin C wild-type or variant B linked to HA in 
D4O7. (a) Immunoblot of cell lysates and conditioned media collected from cell expressing 
respectively wild-type Cys-HA and variant B Cys-HA. Western blots were probed with anti-
cystatin C antibody, which detected the cystatin C-HA fusion protein, consisting of a band 
a) CysC-HA b) Anti-HA 
c) Anti-cystatin C 
ns 
ns 
116 
 
of approximately 14.1KDa, and with anti-HA antibody, which also identified the cystatin C 
fusion proteins. Anti-GAPDH antibody was used as loading control for cell lysates. The 
amount of cell lysate loaded was 6X more than the media (cell lysate 8µL/250 µL, media 
20µL/3.75mL). Level of secreted cysC-HA fusion proteins in the conditioned medium of 
cells transfected with wild-type or mutant constructs were evaluated by densitometry of 
western blots probed with anti-HA (b) or anti-cystatin C (c) and the total cystatin secreted 
was calculated and normalized to total cystatin C protein (total intracellular + total 
secreted). Using anti-HA antibody the fractions of secreted proteins result to be 0.73±0.10 
(SD) for wild-type and 0.66±0.16 (SD) for variant B. Unpaired t test (N=4) two-tailed, 
p=0.96. Using anti-cystatin C antibody the fractions of secreted proteins result to be 
0.79±0.08 (SD) for wild-type and 0.80±0.07 (SD) for variant B. Unpaired t test (N=4) two-
tailed, p=0.46. Results are presented as percentages. ns=non-significant. 
 
3.4.2. Secreted levels of EGFP constructs are significantly lower 
compared to the untagged, FLAG- or HA-tagged constructs and to 
the endogenous cystatin C  
Looking at the analyses of secretion described in the previous section for the 
different constructs, a difference in the fraction of cystatin C secreted can be 
observed between EGFP-linked constructs and the other three constructs 
(untagged, FLAG- and HA-tagged). To exclude a possible variability due to the use 
of different antibodies, I considered the values obtained using the anti-cystatin C 
antibody, which can detect all the four different constructs, for the comparison. In 
table 7 all of the fractions of secreted proteins calculated previously are reported 
for each construct. It is clear that the fraction of secreted protein is lower for the 
EGFP-constructs in comparision to the FLAG or HA tagged constructs, being around 
50% of the total, compared to the about 80% for the other constructs or untagged 
cystatin C.  
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FRACTION OF SECRETED CYSTATIN C 
CONSTRUCT: Wild-type Variant B 
Cys-EGFP 0.56 ± 0.05 0.53 ± 0.03 
Cys-FLAG 0.83 ± 0.04 0.83 ± 0.03 
Cys-HA 0.87 ± 0.02 0.84 ± 0.02 
CysC untagged 0.79 ± 0.01 0.81 ± 0.04 
 
Moreover, ARPE19 cells cultured in the same conditions and transfected with the 
different constructs were analysed by western blotting, loading same volume of 
cell lysate and medium for all the constructs. Blots were probed with anti-cystatin C 
antibody so that all the different constructs could be detected at the same time, 
minimizing the variability caused by using different antibodies and allowing 
comparison among the different constructs (figure 3.25). The level of secreted 
cystatin C was significantly lower in the case of the Cys-EGFP constructs when 
compared to the other three constructs. Indeed, an increase in exposure time was 
needed to be able to detect cystatin C in the conditioned media samples for the 
Cys-EGFP construct. At higher exposure it was also possible to detect the 
endogenous cystatin C in the cell and media samples from both transfected and 
untransfected ARPE19 cells. Interestingly, the proportion of endogenous cystatin C 
inside and outside the cells differed from the EGFP constructs but was similar to 
that observed for the Cys-FLAG, Cys-HA and untagged CysC constructs. These 
results suggest that these three constructs are properly secreted from the cells 
with similar rates as the endogenous protein. In contrast, the EGFP-constructs 
show a reduced level of secretion and higher intracellular levels, consistent with 
their tendency to accumulate intracellularly and mislocalize. This can be easily 
Table 7 - Fraction of secreted cystatin C from ARPE19 cells transfected with Cys-EGFP, 
Cys-FLAG, Cys-HA or untagged CysC constructs. Values obtained by densitometry of 
western blots probed with anti-cystatin C were normalized as described in section 3.3.1. 
and the resulting fractions of secreted Cystatin C calculated for each construct. 
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assessed by comparing the level of secreted and cell associated protein in figure 
3.25. 
 
Figure 3.25 - Immunodetection of cystatin C in cell lysate and culture media samples 
from ARPE19 cells transfected with Cys-FLAG, Cys-HA, Cys untagged and Cys-EGFP 
constructs. Same volumes of cell lysates and same volumes of media samples were loaded 
on gels for all the constructs in order to directly compare the level of proteins inside and 
outside the cells. The amount of cell lysate loaded was 5X more than the media (cell lysate 
10µL/250 µL, media 30µL/3.75mL). Anti-cystatin C antibody was used to detect bands of 
interest and anti-GAPDH as additional control. Cys-FLAG, Cys-HA, untagged CysC and Cys-
EGFP are detected at approximately 14KDa, 14.1KDa, 13KDa and 40KDa, respectively. At 
higher exposure endogenous cystatin C is also detected for all the constructs except the 
untagged ones being of the same size.  
 
Overall, these results indicate that there is no major difference in secretion 
between wild-type and variant B. Furthermore, they are consistent with the 
hypothesis that EGFP likely affects the trafficking of cystatin C, causing intracellular 
accumulation with mitochondrial association of the protein and consequently a 
reduction in its level of secretion.  
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3.5. Analysis of secretory trafficking 
In addition to the canonical ER/Golgi secretory pathway, other unconventional 
pathways have been described to target proteins for secretion. For instance, ER- 
and/or Golgi-independent secretion, lysosomal exocytosis and exosomes pathway 
have been reported, as described in section 1.5.2. Moreover, cystatin C itself has 
been also shown to be secreted by exosomes under certain circumstances 
(described in section 1.2.2) (Ghidoni et al. 2011b). 
For this reason, even though the rate of secretion was similar between wild-type 
and variant B in our analysis, I investigated whether the variant B is secreted by 
pathways other than the conventional one, which may shed light onto its 
postulated link to disease. Inhibition of the classical pathway was therefore carried 
out to assess whether the protein was still secreted. 
 
3.5.1. Variant B cystatin C is targeted to the conventional 
secretory pathway 
ARPE19 cells transfected with wild-type or variant Cys-FLAG constructs were 
treated with either Brefeldin A (BFA) or Monensin for 7h. BFA inhibits transport of 
proteins from ER to Golgi (Klausner, Donaldson & Lippincott-Schwartz 1992), thus 
causing protein accumulation in the ER. Monensin blocks protein transport through 
the Golgi stack (Mollenhauer, Morré & Rowe 1990), resulting in retention of 
proteins in the Golgi apparatus. In both cases, protein secretion is prevented. By 
inhibiting the conventional secretory pathway by two different means and 
analysing the secretion of cystatin C, it is possible to exclude the involvement of 
other ER/Golgi-independent secretory pathways. 
Immunoblot in figure 3.26 shows the levels of FLAG-tagged cystatin C fusion 
proteins after treatment with either BFA or Monensin in both the cell and media 
samples. Untreated samples were used as control. Higher levels of cystatin C 
proteins in the cell lysates were observed for both the wild-type and variant B 
proteins after treatment with either BFA or Monensin, consistent with the 
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accumulation of proteins in the ER and Golgi, respectively. Concurrently, a 
significant decrease in the levels of secreted proteins in the culture media is 
observed in both cases. Only at higher exposures it is possible to detect cystatin C 
in the media after Monensin treatment, probably reflecting that Monensin does 
not completely block the secretory pathway at the concentration used. 
Interestingly, no difference between wild-type and variant B was observed, as their 
levels equally increased intracellularly and decreased in the media. This is 
consistent with the notion that cystatin C followed the same canonical ER-Golgi 
secretory pathway and no alternative pathways are involved. 
 
 
Figure 3.26 - Immunodetection of cystatin C in cell lysates and conditioned media of 
ARPE19 cells transfected with wild-type and variant B cys-FLAG constructs after 
treatment with BFA or Monensin. Samples collected from RPE cells transfected with either 
wild-type or variant B constructs and subjected to inhibition of secretory pathway by using 
BFA 5 µg/mL or Monensin 5µM for 7h were analysed by immunoblotting with anti-cystatin 
C antibody, shown at different time exposure to allow detection of proteins present in 
small amounts. Anti-GAPDH antibody was used as loading control for cell lysates. The 
amount of cell lysate loaded was 10X more than the media (cell lysate 20µL/250µL, media 
20µL/2.5mL). 
 
ARPE19 cells transfected with Cys-FLAG constructs and treated with either BFA or 
Monensin were also imaged by IF/ICC. Figure 3.27 shows images of PFA-fixed cells 
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immunostained with anti-FLAG or anti-cystatin C antibodies to detect the fusion 
protein and with anti-calreticulin or anti-GM130 to detect ER and Golgi, 
respectively. After 7-hour treatment with BFA (Figure 3.2 a), cystatin C is localized 
within the ER but not within the Golgi apparatus. The Golgi apparatus appeared to 
be disrupted as GM130 shows a diffuse distribution. This is consistent with the 
block of the transport of all the proteins from the ER to Golgi. In contrast, after 7-
hour treatment with Monensin (Figure 3.27 b), the structure of the Golgi apparatus 
was maintained, with GM130 staining concentrated to a specific perinuclear region, 
characteristic of the Golgi. Cystatin C was distributed to both the ER and Golgi, 
colocalizing with both organelles markers. No difference between wild-type and 
variant B proteins was observed.  
These results strongly indicate that both cystatin C proteins follow the classical ER-
Golgi secretory pathway, further excluding mislocalization of the variant B.  
 
   
a) Treatment with BFA 
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Figure 3.27 - Localization of FLAG-tagged cystatin C constructs in ARPE19 cells after 
treatment with BFA or Monensin. Living cultured human ARPE19 cells expressing wild-
type or variant B cystatin C linked to a FLAG tag were PFA-fixed and immunostained after 
treatment with BFA (a) or Monensin (b) for 7h. Cystatin C constructs were detected using 
either anti-FLAG or anti-cystatin C antibodies and shown in green. Anti-calreticulin and 
anti-GM130 antibodies, which fluoresces red, were used to visualize Endoplasmic 
Reticulum and Golgi apparatus, respectively.  The blue fluorescent DAPI was used to stain 
nuclei. For each field of cells imaged, green and red fluorescence were recorded as 
separate images and then merged, along with the blue signal, for assessing the overlap of 
the respective signals. Scale bars are 20 µM. 
 
 
3.5.2. Wild-type and variant B are processed through the secretory 
pathway with the same efficiency 
Analysis of secretory trafficking undertaken by variant B cystatin C was further 
investigated by using the Glyco-Cys constructs, encoding for cystatin C encoding 
two N-linked glycosylation sites and a FLAG tag at the C-terminus, as described in 
materials and methods. 
b) Treatment with Monensin 
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N-linked glycosylation site, consisting in the consensus amino acid sequence Asn-X-
Ser/Thr, is a specific site that undergoes glycosylation in the lumen of the ER by the 
action of an oligosaccharyltransferase (OST), as described in section 1.5.1. The 
glycan attached to the protein can subsequently be modified in the Golgi apparatus 
through removal or addition of sugar residues (Stanley 2011). This post-
translational modification is important for the correct folding and function of 
several eukaryotic proteins (Stanley 2011). 
Addition of glycans on cystatin C, which normally does not undergo such 
modification in humans (Paraoan, Grierson 2007), may therefore affect its 
structure and activity. However, for the purpose of this study, it is only important 
that the trafficking is not affected. If so, then the addition of glycosylation sites 
allows the analysis of cystatin C trafficking because glycoslylation of the 
recombinant protein can be monitored. If the protein is translocated into the ER, it 
will be modified by addition of a sugar molecule. Should it then proceed to the 
Golgi apparatus, it is likely that the glycan structure will undergo further 
modification. Analysis of this glycosylation will therefore provide further evidence 
to determine whether wild-type and variant B are secreted through the ER-Golgi 
pathway. 
a) Western blot analysis: 
Protein expression of the Glyco-constructs was analysed by immunoblotting. Both 
cell lysate and media samples of D407 RPE cells were analysed 24h post-
transfection. Analysis of the conditioned media was carried out to evaluate 
whether cystatin C proteins are still normally processed for secretion.  
Immunoblots in figure 3.28 shows cell lysates (a) and media samples (b) from RPE 
transfected with wild-type or variant B Glyco-Cys constructs. Anti-cystatin C 
revealed two main bands at approximately 18KDa and 15KDa in both cell and 
media samples, likely corresponding to a glycosylated form and a non-glycosylated 
form, respectively, the latter suggesting incomplete glycosylation. The size of the 
fusion protein without glycosylation is indeed expected to be about 15KDa. This 
form is present in lower amount compared to the glycosylated one. At higher 
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exposures the endogenous cystatin C (13KDa) is also detected in both cell lysates 
and conditioned media.  
These results indicate that the presence of two glycosylation sites and a FLAG tag at 
the C-terminal of cystatin C does not prevent the protein to be secreted. Moreover, 
the event of N-linked glycosylation seems to occur similarly for both wild-type and 
variant B, consistent with both entering the secretory pathway.  
 
 
Figure 3.28 - Immunodetection of cystatin C in cell lysates and conditioned media of 
D4O7 cells transfected with Glyco-cysC constructs. Cell lysate (a) and conditioned media 
(b) samples collected from RPE cells transfected with either wild-type or variant B 
constructs were analysed by immunoblotting with anti-cystatin C antibody, shown at two 
different exposure times. Three bands were detected at approximately 18, 15 and 13KDa 
and corresponding to glycosylated cystatin C, non-glycosylated cystatin C and endogenous 
cystatin C, respectively. Anti-GAPDH antibody was used as loading control for cell lysates. 
Two independent samples were loaded for each construct. 
 
b) Immunofluorescence analysis 
RPE cells transfected with Glyco-constructs were also imaged by IF/ICC using anti-
FLAG antibodies to analyse the distribution of recombinant cystatin C, which 
appears not to be affected by its linkage, as shown in Figure 3.29.  
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a) WT-GLYCO    b) VB-GLYCO 
     
Figure 3.29 - Localization of Glyco-cystatin C constructs in D4O7 cell. Cultured human 
D4O7 cells expressing wild-type (a) or variant B (b) cystatin C linked to two N-linked 
glycosylation sites and a FLAG were PFA-fixed and immunostained 24h post-transfection. 
Cystatin C fusion proteins were detected using anti-FLAG antibody, shown in green. The 
blue fluorescent DAPI was used to stain nuclei. Scale bars are 10 µM. 
  
c) Deglycosylation experiments 
To investigate whether the bands detected actually correspond to the glycosylated 
and non-glycosylated forms of the protein, cell lysates and media samples were 
subjected to deglycosylation with either Endoglycosydase H or PNGaseF enzymes. 
EndoH is able to remove the glycan added in the ER lumen prior to any further 
modification in the Golgi. PNGase F can remove any sugar molecules prior or after 
modification in the Golgi apparatus (Maley et al. 1989). 
As shown in figure 3.30 (a), treatment of cell lysates with EndoH resulted in a 
decrease of the 18KDa band and a simultaneous increase of the 15KDa band, thus 
indicating, as hypothesized, that the larger band represents the glycosylated form 
and the smaller one the non-glycosylated. At higher exposures it was still possible 
to detect a fraction of glycosylated cystatin C. 
PNGaseF treatment also determines the removal of the glycosylated band and 
increase of the 15KDa protein. In this case the 18KDa band disappeared completely 
after treatment. This likely indicates that EndoH removes only the glycan added in 
the ER and not yet modified in the Golgi, unlike the PNGase F, which removes any 
sugar molecules from cystatin C. This is therefore consistent with the protein 
Anti-FLAG 
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moving through both the ER and Golgi apparatus, confirming cystatin C trafficking 
along the canonical secretory pathway. 
Analysis in the conditioned media (figure 3.30. b) confirms this, as EndoH was no 
longer able to act on the glycosylated form, unlike PNGaseF, which completely 
converted the 18KDa band into the 15kDA species. This is consistent with the 
secreted protein, after going through the Golgi apparatus, having acquired a 
mature glycan structure which is no longer a substrate for the EndoH enzyme. 
 
 
 
Figure 3.30 - Immunodetection of cystatin C in cell lysates and conditioned media of 
D4O7 cells transfected with Glyco-cysC constructs and subjected to deglycosylation 
treatment. Cell lysate (a) and conditioned media (b) samples collected from RPE cells 
transfected with either wild-type or variant B constructs were subjected to deglycosylation 
with either EndoH or PNGaseF and subsequently analysed by immunoblotting with anti-
cystatin C antibody. Two bands were detected at approximately 18 and 15KDa and 
corresponding to glycosylated and non-glycosylated form of cystatin C. 
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d) Inhibition of secretion 
Since the 15kDa form that is not glycosylated is still secreted into the culture 
media, inhibition of secretion with either BFA, Monensin or Nocodazole was 
performed to verify whether it also goes through the ER-Golgi secretory pathway. 
After treatment for 3h with any of these compounds, conditioned media from WT- 
or VB-Glyco transfected cells were analysed (figure 3.31). A reduction of both 
glycosylated and non-glycosylated forms occurs, thus indicating that both forms 
follow the ER-Golgi secretory pathway and involvement of a non-classical secretory 
pathway for the 15kDa fraction can be excluded. 
 
Figure 3.31 - Immunodetection of cystatin C in conditioned media of D4O7 cells 
transfected with Glyco-cysC constructs and subjected to inhibition of secretion. 
Conditioned media collected from RPE cells transfected with either wild-type or variant B 
constructs and treated with either BFA (5 µg/mL), Monensin (5 µM) or Nocodazole (10 
µg/mL) for 3h, was probed with anti-cystatin C antibody. Two bands were detected at 
approximately 18 and 15KDa and corresponding to glycosylated and non-glycosylated form 
of cystatin C. 
 
Overall, the results obtained in this section further support the notion that both 
wild-type and variant proteins pass similarly through the conventional ER/Golgi 
secretory pathway.  
 
3.6. Analysis of targeting properties of the cystatin C signal 
sequence 
Since the A25T mutation occurs in the leader sequence, it has been proposed that 
the mutation affects the targeting of cystatin C into the secretory pathway. 
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However, our results so far indicate that the variant B is still properly targeted for 
secretion; no differences in localization, trafficking and secretion were observed. To 
further investigate whether the mutation affects the ER targeting properties of the 
signal sequence, constructs encoding the leader peptide from wild-type or variant 
B cystatin C linked to EGFP were made and expressed in RPE cells and the 
distribution and secretion conferred to EGFP was then analysed. 
 
3.6.1. Both wild-type and variant B leader sequences are 
functional in targeting the EGFP to the secretory pathway  
Protein distribution of the leader peptide constructs was analysed in living ARPE19 
cells. Figure 3.32 shows representative images obtained by fluorescence 
microscopy of ARPE19 cells transfected with wild-type or variant Leader constructs 
or EGFP alone (a, b and c, respectively). In order to evaluate whether EGFP is 
targeted to the ER/Golgi pathway, the Golgi complex was also stained with the 
specific dye BODIPY.  
As shown in figure 3.32 (a) and (b), an ER/Golgi localization of EGFP, indicated by 
colocalization with BODIPY, was found in ARPE19 cells for both wild-type and 
variant leader peptide constructs. However, a significant fraction of cells also 
showed a diffuse distribution in cytosol and nuclei for both wild-type and variant B 
leader constructs, similar to the distribution of the EGFP on its own (c). 
The presence of EGFP in the ER/Golgi secretory pathway suggests that the wild-
type and mutated leader peptides are still able to target the proteins linked to it for 
secretion. On the other hand the diffuse distribution observed for both constructs 
indicates that in a fraction of cells EGFP is not properly targeted. Quantification of 
cells showing either an ER/Golgi distribution or a diffuse distribution for both wild-
type or mutated leader peptide constructs is shown in figure 3.33. Results show 
that 45% and 46% of ARPE19 cells were found to display the diffuse distribution for 
the LPWT-EGFP and LPVB-EGFP proteins respectively, with no significant difference 
between the two constructs. Percentages were calculated by considering the total 
number of cells obtained combining all the individual experiments (Figure 3.33). 
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Analysis of diffuse distribution at the level of the individual replicates results in 
42%±12 and 44%±13 (Mean±SD, N=7) for wild-type and variant B Leader 
constructs, respectively. 
 
  a                b                                                     c 
  
Figure 3.32 - Localization of cystatin C leader sequence constructs. Living cultured human 
ARPE19 cells expressing the leader peptide from wild-type (LPWT-EGP) or variant B (LPVB-
EGFP) cystatin C linked to EGFP (a and b respectively) and EGFP on its own (c) were imaged 
24 h post-transfection. The emission specific for eGFP constructs is shown in green. Bodipy, 
which fluoresces in red, was used to visualize Golgi complex. The blue fluorescent Hoechst 
33342 probe was used to stain nuclei. For each field of cells imaged, green and red 
fluorescence were recorded as separate images and then merged, along with the blue 
signal and brightfield, for assessing the overlap of the respective signals. 
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Figure 3.33 - Quantification of Leader sequence constructs distribution in live transfected 
ARPE19 cells. ARPE19 cells transfected with either wild-type or variant B leader peptide 
constructs were quantified to compare secretory pathway distribution and diffuse 
distribution of EGFP. Percentages are calculated by considering the total number of cells 
obtained combining all the individual experiments. The fraction of cells showing diffuse 
distribution results 45% and 46% for the WT and VB Leader constructs respectively. 
No difference in distribution was found between LPWT and LPVB. Chi-square test (χ2 
=0.20), p-value=0.65.  
 
3.6.2. Wild-type and variant B leader peptides direct EGFP 
similarly for secretion  
Secretion of EGFP linked to wild-type or variant B leader peptide was also analysed 
to further investigate whether the signal sequence targets proteins for secretion 
and whether there is a difference between the two constructs.  
Culture media and respective cell lysates from ARPE 19 cells transfected with wild-
type or variant B leader construct, EGFP on its own and from non-transfected cells 
were subjected to SDS-PAGE electrophoresis and probed with an anti-EGFP 
antibody (figure 3.34 a). A band of 27KDa corresponding to EGFP protein was 
detected in both cell and media samples for both LPWT and LPVB transfected cells. 
Anti-cystatin C and anti-GAPDH antibodies were used as loading controls. 
The bands detected for both the leader peptide constructs show the same 
electrophoretic mobility as EGFP alone, indicating that the proteins entered the ER, 
where the signal sequence was cleaved. The presence of EGFP fusion proteins in 
the conditioned media further indicates that the proteins are secreted, thus 
confirming the imaging results. In contrast, EGFP on its own was present only in the 
intracellular fraction and, as expected, was not secreted. 
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The fraction of secreted EGFP fusion proteins from both LPWT and LPVB 
transfected cells was assessed by calculating the total protein secreted and 
normalising this value to the total fusion protein, combining the total secreted with 
the total cell associated, as described previously for the full-length cystatin C 
constructs. Results shown as percentages are plotted in figure 3.34 b. No significant 
differences were observed in the level of secretion of EGFP fusion proteins 
between the wild-type and variant B leader constructs. 
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Figure 3.34 - Analysis of secretion of wild-type or variant B Leader Sequence constructs in 
ARPE19. (a) Immunoblot of cell lysates and conditioned media collected from cells 
expressing respectively wild-type and variant B Leader peptide-EGFP constructs, only EGFP 
and untransfected cells not expressing any of these proteins. Western blots were probed 
a) 
b) 
ns 
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with anti-EGFP antibody, which detected the LP-EGFP proteins and EGFP on its own, both 
consisting of a band of approximately 27KDa. Anti-cystatin C and anti-GAPDH antibodies 
were used as loading control for media and cell lysates, respectively. The amount of cell 
lysate loaded was 4X more than the media (cell lysate 8µL/250 µL, media 20µL/2.5mL).  b) 
Level of secreted EGFP in the conditioned medium of cells transfected with wild-type or 
mutant leader constructs were evaluated by densitometry of western blots and the total 
secreted protein was calculated and normalized to the total EGFP protein (total 
intracellular + total secreted). Using anti-EGFP antibody the fractions of secreted proteins 
result to be 0.66 ± 0.08 (SD) for wild-type and 0.59 ± 0.06 (SD) for variant B. Unpaired t test 
(N=8) two-tailed, p=0.06. Results are presented as percentages. ns=non-significant. 
 
 
Overall, imaging and secretion analyses show that both wild-type and variant B 
signal sequences of cystatin C when fused to EGFP direct EGFP similarly to the 
secretory pathway, in contrast to the leaderless EGFP. This indicates that the 
mutated leader peptide has a similar capacity to target proteins to the ER, and 
subsequently for secretion, as the wild-type leader sequence.  
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3.7. Discussion 
Cystatin C targeting and trafficking were previously reported to be impaired in the 
case of the variant B. In particular a mislocalization in the mitochondria (Paraoan et 
al. 2004) and a decreased secretion were found to characterise this mutated form 
of cystatin C (Benussi et al. 2003, Paraoan et al. 2004). However, another study, 
published while my work was in progress, reported no difference in trafficking and 
secretion (Nguyen, Hulleman 2016), and even the association of variant B with 
AMD and AD diseases remains controversial. 
This study therefore aimed to further investigate whether or not the A25T 
mutation in the precursor cystatin C variant B affects its intracellular trafficking, 
which might explain its possible link to disease. 
 
Results obtained in this study revealed no difference in protein localization, 
trafficking and secretion between wild-type and variant B proteins. However, 
contrasting results depending on the construct used were observed. By using 
constructs encoding cystatin C tagged to small FLAG or HA tags, or untagged, both 
wild-type and variant B proteins localize in the ER/Golgi complex and no 
mitochondrial localization was observed for any of these constructs. Accordingly, 
no intracellular accumulation and normal levels of secretion were observed with 
these constructs. 
On the contrary, using EGFP-tagged cystatin C constructs, both wild-type and 
variant B proteins resulted in partial mitochondrial localization in a significant 
fraction of cells. Analysis of subcellular fractions also indicates that this abnormal 
mitochondrial association occurs with both EGFP-tagged proteins, as they appear 
to be present in the mitochondria/Golgi fraction in similar amount. Consistently, 
they were both observed to be partially retained intracellularly and, as a result, a 
smaller fraction of the total synthesised EGFP-linked wild-type and variant B 
proteins is secreted as compared to the FLAG-, HA- tagged or untagged proteins as 
well as the endogenous cystatin C. Taken together, these results indicates an 
impairment in the trafficking of the EGFP-tagged constructs, resulting in 
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intracellular mislocalization and consequent reduction in the levels of secreted 
cystatin C, for both wild-type and variant B proteins. In living cells, the Chi-square 
test also reported a significant difference between them, i.e. the unusual 
localization occurs with a higher frequency for the wild-type cystatin C. However, 
looking at the individual experiments, this frequency seems to vary considerably, 
suggesting that the extent of mitochondrial association is subject to considerable 
experimental variation and hence, likely not biologically significant. Moreover, this 
difference was not found to be significant when analyzed by IF analysis. 
Furthermore, since untagged cystatin C and constructs with a small tag were never 
found in mitochondria, the main conclusion from these results is that EGFP appears 
to mediate the mitochondrial mislocalization of cystatin C, either wild-type or 
mutated, in a significant fraction of cells.  
In the analysis of subcellular fractionation, it was not possible to obtain pure 
mitochondria fraction because of both technical and biological limitations. 
Mitochondria are indeed in contact with other organelles, such as ER (Kornmann et 
al. 2009, Phillips, Voeltz 2015), hindering their isolation from these other cellular 
compartments and meaning that both DC and MACS methods only permitted an 
enrichment of mitochondria. Therefore, because of these limitations and the 
consequent significant organelle cross-contamination, it was not possible to 
properly quantify the protein levels in each fraction. However, to further minimize 
the possibility that the presence of either wild-type and variant B proteins in the 
mitochondrial fraction was not simply due to organelles cross-contamination, their 
distribution was compared to that of endogenous cystatin C, which was mainly 
present in the ER/cytosolic fraction, thus indicating the EGFP-linked cystatin C 
constructs behave differently from the endogenous protein. This difference 
suggests that the cystatin C fusion proteins either accumulate in the Golgi 
apparatus, or are actually present in the mitochondria. In both cases, however, the 
results indicate that trafficking of both wild-type and variant proteins is influenced 
by the presence of EGFP tag. Taking into account the results obtained by imaging, 
however, it is likely that proteins are present in this fraction as a result of their 
mislocalization in the mitochondria, as opposed to being retained in the Golgi 
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complex. Furthermore, the notable reduction in their level of protein secretion is 
also consistent with the larger intracellular pool of the EGFP-constructs.  
The fact that the protein accumulates intracellularly could consequently determine 
the uncommon mitochondria association. Alternatively, the improper 
mitochondrial targeting itself may be the reason of the intracellular retention and 
impaired secretion observed for both wild-type and variant B proteins linked to 
EGFP (as discussed later in this section). 
Conversely, results obtained using the constructs untagged or carrying a short FLAG 
or HA tag, showed that these cystatin C constructs do not mislocalize intracellularly 
and are efficiently secreted from RPE cells, similarly to the endogenous protein. 
Thus, unlike the EGFP-tagged constructs, neither their overexpression nor the 
presence of the tag seem to affect trafficking of these constructs, showing their 
suitability for these studies. 
 
Specifically regarding the variant B cystatin C, the results obtained with short 
tagged or untagged constructs showed that, in contrast with a previous report 
(Paraoan et al. 2004), the variant B is not retained intracellularly, is still targeted to 
the secretory pathway and does not differ in its level of secretion compared to the 
wild-type protein. An exception to this was the untagged cystatin C constructs in 
D4O7 cells, where a small but statistically significant difference was observed in the 
protein secretion. Whether this reflects the particular cell type is unclear, but 
probably lacks biological significance.  
The correct targeting of the variant B cystatin C to the secretory pathway is further 
confirmed by the results obtained by suppression of the conventional secretory 
pathway and by monitoring the N-glycosylation of the Cys-Glyco proteins. With 
these experiments, the presence of cystatin C in both ER and Golgi apparatus, 
before being secreted, was specifically demonstrated. This also excludes the 
possibility of major contributions of alternative secretory pathways for the release 
of the variant B.  
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Moreover, the N-linked glycosylation event appeared not to differ between wild-
type and variant B proteins, indicating that their maturation occurred similarly in 
acquiring glycosylation in the ER and subsequent modification in the Golgi 
apparatus. Besides confirming the intracellular trafficking, this also suggests that 
wild-type and variant B proteins are targeted to the secretory pathway with similar 
efficiencies. In this analysis an additional 15kDa species was also detected, present 
at lower amount compared to the glycosylated protein, and likely representing the 
non-glycosylated protein. However, this fraction was also observed to pass through 
the ER and Golgi apparatus before being secreted, thus excluding again a major 
involvement of an alternative pathway also for this fraction. The presence of this 
non-glycosylated form in the secreted pool, observed for both wild-type and 
variant, may reflect partial inaccessibility of the glycosylation site during 
biosynthesis, or saturation of the glycosylation machinery due to the 
overexpression of the recombinant proteins (as suggested by a number of groups 
(Massotte 2003, Dalton, Barton 2014, Cottet, Corthésy 1997)), or a combination of 
both. In any case, these results confirm that both the wild-type and variant B 
proteins follow similarly the conventional secretory pathway, excluding the 
possibility that the variant B undertakes a different secretory pathway or 
mislocalizes to a different intracellular compartment. This further supports our 
finding that the variant B is not mistargeted to mitochondria. 
 
Finally, the similar ER/Golgi distribution and secretion of EGFP proteins, 
determined by the wild-type and variant B leader peptides, indicates that the 
mutated signal sequence is still functional in targeting the protein to the secretory 
pathway, with similar efficiency. No mitochondria association was observed for 
these constructs. However, not all the cells displayed the proper targeting of the 
protein, showing a distribution comparable to that of unmodified EGFP, i.e. 
diffused throughout the cytosol and nuclei, in a fraction of the cells. This occurs 
similarly for the wt and variant leader, suggesting that the signal sequence is not 
100% efficient in targeting EGFP for secretion (discussed below). No significant 
difference was also observed in the level of secretion of EGFP between the wild-
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type and variant B leader constructs. Because of the mistrafficking observed in a 
large fraction of cells, these constructs are probably unsuitable for a proper 
quantification of the secreted fractions.  
The main reason why the trafficking of the leader sequence constructs was 
analysed was to characterise the role of the A25T mutation within the signal 
sequence, to determine whether the leader peptide alone is sufficient to affect the 
trafficking/processing of the protein linked to it. Despite the limitations of these 
constructs due to the mislocalization observed, results obtained suggest that the 
variant B leader constructs did not lose its targeting properties and the signal 
sequence alone was not sufficient to determine any significant change that may 
explain cystatin C variant B association with diseases. Therefore, the consequences 
of the A25T mutation, if present, must involve the entire cystatin C protein. 
 
Overall, these results show that the EGFP tag affects the trafficking of cystatin C, 
independently of whether it is fused to the wild-type or variant form of the protein. 
Other constructs with short tags were distributed and secreted in RPE cells in a 
manner similar to untagged overexpressed or the endogenous cystatin C.  
Mislocalization in the mitochondria was previously reported by Paraoan et al. 
(Paraoan et al. 2004). That study used EGFP-linked cystatin C constructs. Because 
the current study does not demonstrate similar findings when cystatin C is 
untagged or linked to a different smaller tag, it seems likely that mitochondria 
association of cysC is actually an artefact caused by the EGFP tag and that variant B 
does not actually show any difference in its intracellular pathway compared to the 
wild-type. 
 
It is noteworthy that a partial mistrafficking occurs for both the EGFP-linked 
constructs, either fused to the full-length cystatin C or only to the signal sequence, 
although being different for each constructs, i.e. mainly associated with 
mitochondria and diffused throughout the cell, respectively. This strongly indicates 
that in both cases, proteins are not properly targeted to the secretory pathway. 
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Protein labelling with a fluorescent tag has been shown to influence folding, 
function and localization of the host protein, especially in case of small proteins 
(Tsien 1998). In particular, other cases of protein mislocalization due to fluorescent 
proteins have also been reported, most commonly in nuclei and cytoplasm (Zhu et 
al. 2013, Seibel et al. 2007). 
The green fluorescent protein (GFP) and other fluorescent tags, such as EGFP or 
YFP, are widely used in real-time imaging to determine the subcellular localization 
of proteins in living cells, thus representing one of the most valuable tools in cell 
biology. However, several disadvantages and limitations need to be considered 
(Tsien 1998, Giepmans et al. 2006, Miyawaki, Sawano & Kogure 2003, Zhang et al. 
2002, Andresen, Schmitz-Salue & Jakobs 2004). 
One main limitation is that all the currently used fluorescent proteins are relatively 
large in size, being all approximately 25-30kDa. Therefore the tag is often similar in 
size or larger than the protein fused to it. This could potentially interfere with the 
folding of the host protein, affect its stability and consequently its abundance 
(Arluison, Taghbalout 2015). An increased protein degradation has been for 
example observed for some fusion proteins (Lisenbee, Karnik & Trelease 2003).  
Furthermore, change in the protein folding can also alter the function of the 
protein as well as its targeting/trafficking (Andresen, Schmitz-Salue & Jakobs 2004). 
It is therefore important to confirm that the recombinant protein maintains the 
normal function and localization of the host protein, in order to avoid 
misinterpretations due to artefactual results. Fusion to a fluorescent protein was 
indeed shown not to be always successful (Tsien 1998), even though only few cases 
are reported in literature, probably due to the fact that the unsuccessful fusions 
are unlikely to be published. 
In certain cases, the use of small tags with less steric bulk is therefore 
recommended as they are less likely to interfere with the localization or function of 
the proteins (Andresen, Schmitz-Salue & Jakobs 2004, Arluison, Taghbalout 2015), 
thus in contrast to the large fluorescent labels. Examples are the FLAG and HA tags, 
which consist of only 8 and 9 amino acids respectively (~1kDa). Their disadvantage 
is the lack of fluorescence and for this reason they cannot be used in live cell 
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imaging. Nevertheless, in our study both tags were found to not affect cystatin C 
trafficking since the respective recombinant proteins, either wild-type or variant, 
followed the ER-Golgi secretory pathway, in the same way as the untagged cysC 
constructs. 
 
Few examples of abnormal cellular localization due to the linkage of proteins with 
fluorescent tags have been reported. A YFP-labelled small protein has been shown 
to mislocalize in Escherichia coli probably due to misfolding or aggregation of the 
fusion proteins (Arluison, Taghbalout 2015). Interestingly, labelling the same 
protein of interest with other large fluorescent tags caused the same aberrant 
localization. In contrast, when the protein was fused to a short tag, such as FLAG or 
HA, it resulted to be normally localised. These results indicate that only large tags 
interfered with the targeting of the host protein, causing artefactual localization. 
This is a similar difference as observed in our study.  
Other cases of mislocalization of the fusion protein have been described. For 
instance, the use of EGFP tags has been reported not to be particularly appropriate 
to study nuclear import of small proteins (Zhu et al. 2013, Seibel et al. 2007). EGFP 
alone normally diffuses throughout the cytosol as well as into the nucleus by 
passive diffusion through the nuclear pores due to its relatively small size. 
However, when in fusion to a protein particularly small in size, the resulting 
recombinant protein might still passively translocate to the nucleus, thus 
generating misleading results (Zhu et al. 2013). This may explain why in our study 
the leader constructs are partially distributed in the nucleus as well as a fraction of 
the EGFP-cystatin C constructs, as reported by Paraoan et al. (Paraoan et al. 2004), 
considering the low molecular weight of cystatin C. 
Distribution of EGFP in form of monomers and tetramers has been also reported. 
Interestingly the monomers were found to be mainly concentrated in the nucleus, 
while the oligomers were located especially in the cytosol (Seibel et al. 2007). This 
results suggest that the size of the protein plays an important role in the protein 
trafficking and might explain in our study why the leader constructs localize in the 
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nucleus while the full-length cystatin C constructs, which have a larger molecular 
weight compared to the leader constructs, tend mainly to localize and accumulate 
in the cytosol. This intra-cytoplasmic accumulation may consequently lead to a 
mitochondria association, as described below. 
Mistargeting to other cellular compartments, including mitochondria, has also been 
reported due to the GFP tag (Lisenbee, Karnik & Trelease 2003, Bejarano, Gonzalez 
1999, González, Bejarano 2000). Several reasons of such mistrafficking have been 
suggested. It might occur because of unspecific interactions with proteins located 
in different organelles, or it may be due to protein aggregation, or to the activation 
of cryptic targeting signals. In particular, the cryptic signals consist of potential 
targeting signal sequences. They are normally inactive because located within the 
folded protein and therefore not accessible, or because a dominant signal 
sequence is present, which leads the protein to a different cellular organelle. 
However, the fusion with a tag protein can cause activation of these signals as a 
consequence of a change in the protein conformation, which will therefore expose 
such signal sequences (González, Bejarano 2000). For example, these silent signals 
have been identified as short open reading frame (ORF), found at very high 
abundance in the genomic DNA of Drosophila by analysing distribution of random 
genomic DNA sequences fused to GFP in transfected human cells. Interestingly, 
15% of the clones generated showed localization of these fusion proteins in the 
mitochondria, even though they were not mitochondrial proteins (Bejarano, 
Gonzalez 1999), thus indicating a frequent presence of cryptic signals for 
mitochondrial targeting. This might explain the mislocalization of cystatin C, whose 
folding is likely affected by the large EGFP tag protein linked to it, and as a 
consequence it may expose a cryptic signal sequence for mitochondrial targeting. 
In addition to the size of the fluorescent proteins, there are other limitations that 
can also interfere with the intrinsic properties of the host protein, causing its 
abnormal localization. One of them consists in the tendency of large fluorescent 
proteins to form dimers/oligomers. Formation of protein aggregates can 
consequently alter the protein function as well as the protein localization 
(Miyawaki, Sawano & Kogure 2003, Lisenbee, Karnik & Trelease 2003). 
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Another main disadvantage is the overexpression of the fusion protein, which can 
determine accumulation of the protein in one of the cellular compartment prior to 
its final target organelle or can completely alter the protein localization (Arluison, 
Taghbalout 2015, Bejarano, Gonzalez 1999). This may also be one of the reasons 
for the improper accumulation in the mitochondria/Golgi fraction observed for the 
cysC-EGFP constructs during the fractionation analysis. In addition, overexpression 
can also lead to accumulation of unfolded proteins, when the protein folding 
machinery is overwhelmed, and to generation of aggregates (Bejarano, Gonzalez 
1999). Indeed, proteins are more inclined to undergo dimerization/oligomerization 
when present at high concentrations. This propensity of overexpressed GFP fusion 
proteins to form dimers might consequently also lead to organelle aggregation, 
thus causing aberrant protein localization (Lisenbee, Karnik & Trelease 2003). This 
situation can be consistent with the high level of fusion proteins that occurs 
intracellularly for the EGFP-cystatin C proteins in our investigation. For instance, 
one study has shown that cells overexpressing a GFP-fusion protein, which is 
normally targeted to peroxisomes, contained aggregated peroxisomes, 
mitochondria and plastids. Interestingly, proteins were normally distributed in 
peroxisomes after 5h post-transfection and somehow were mislocalized to 
mitochondria and plastids only when highly overexpressed for 20-24h (Lisenbee, 
Karnik & Trelease 2003), suggesting that the mitochondrial compartment is a 
common target for overexpressed proteins.  
 
Overall, this suggests that, in the case of cystatin C, EGFP is not a suitable tag for 
studying the intracellular localization and trafficking of the protein. Because of the 
size of EGFP, which is twice bigger than that of cystatin C, it is likely to interfere 
with its folding/targeting. As a consequence the fusion protein is not properly 
directed to the secretory pathway and, conversely, tends to accumulate 
intracellularly. Regarding the unusual mitochondrial localization, the accumulated 
overexpressed fusion proteins in the cytoplasm and/or the presence of cryptic 
signal sequences might consequently determine such artefactual localization. 
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Regarding the leader constructs, in addition to the role of EGFP that can itself 
determine their impaired distribution, another reason could be the fact that the 
signal sequence in study is specific for cystatin C, and is not made to target EGFP or 
any other proteins. Indeed, all the secretory proteins possess unique signal 
sequences, which share similar physical-chemical properties but differ in the amino 
acid sequences (as described in section 1.5.1). Therefore it is likely that the leader 
peptide, which is very efficient to target cystatin C, is simply less efficient for the 
EGFP protein. That may also explain why they partially diffuse throughout the 
cytosol and nuclei as normally occurs for EGFP on its own. These constructs can 
therefore be used to confirm the targeting properties of the signal peptide but, like 
the cysC-EGFP constructs, they are not probably suitable to properly quantify 
protein secretion and analyse its intracellular localization. 
 
On the other hand, results obtained by using the more suitable untagged and FLAG- 
or HA-tagged cystatin C constructs indicate that trafficking and localization of 
cystatin C variant B is not affected by the A25T mutation. Both wild-type and 
variant are normally distributed in the ER/Golgi, they follow the conventional 
secretory pathway and they are efficiently secreted by RPE cells, comparable to 
endogenous cystatin C. Protein mistargeting appears therefore not to be one of the 
consequences caused by the variant B polymorphism, thus excluding a protein 
mislocalization as a possible cause of an increased risk of developing AMD or AD 
diseases.    
Moreover, in our analysis the level of secretion seems not to be affected in the 
case of cystatin C haplotype B. Our findings therefore contrast with earlier reports 
(Paraoan et al. 2004, Benussi et al. 2003), which indicated a decrease in secretion in 
the case of the variant B, but are in agreement with another study (Nguyen, 
Hulleman 2016), where also no difference was observed. In vivo studies have also 
reported decreased levels of cystatin C in CSF or plasma in presence of the variant 
B in several pathological conditions (Noto et al. 2005, Maetzler et al. 2010, 
Yamamoto-Watanabe et al. 2010, Åkerblom et al. 2014). However, Chuo et. al, 
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although reporting association of the variant B specifically with AD, showed no 
difference in its plasma level compared to wild-type cystatin C (Chuo et al. 2007).  
It is important to consider that the experimental conditions used in our study might 
influence the outcome and that the possible effect on secretion may not be 
detectable under certain circumstances. For example, the cellular systems used in 
this study consisted of immortalized cell cultures, which are transiently transfected 
and characterized by overexpression of the protein in study. The experiments 
carried out by Benussi et al (2003) used human primary fibroblasts cultures 
carrying the wild-type or variant B genotype. However, similar to this study, 
transiently transfected primary or immortalized cell lines, characterised by 
overexpression of the protein of interest, were also used in other studies (Paraoan 
et al. 2004, Nguyen, Hulleman 2016). Interestingly, these two groups have reported 
contrasting findings, showing (Paraoan et al. 2004) or not (Nguyen, Hulleman 2016) 
a difference in the secretion between wild-type and variant B. It is noteworthy that 
in the first case only an EGFP-tagged cystatin C construct was used, which has been 
also observed to localize into mitochondria, and, in the second case, like in my 
work, different tagged and untagged constructs were used.  
Moreover, since exogenous proteins are analysed in our system, another factor 
that could influence the results is the time of the analysis that in our investigation 
was performed 24-hours post-transfection. It is possible, for example, that the 
difference in secretion is too small to be detectable after only 24-hours and may 
accumulate over time and become significant only after a longer period. If this is 
the case, such a time-dependent cumulative effect could be consistent with the 
contribution of variant B to age-related diseases, such AMD and AD, where its 
contribution would occur progressively with ageing. 
As suggested in earlier reports, a decreased efficiency in one of the steps of protein 
maturation may occur in the case of the variant B, such as the signal sequence 
interaction with the SRP, the protein translocation across the ER membrane or the 
signal sequence cleavage by the SPC. Therefore, in the case of a subtle reduction in 
the efficiency of protein processing, it might be possible to affect the level of 
secretion only over a long period of time, which may not be detected at 24-hours. 
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Moreover, should this be the case, over-expression of transfected proteins is also 
probably not appropriate to evaluate small differences in protein secretion. 
 
To further investigate whether there is any change in the efficiency of the protein 
maturation, the signal sequence cleavage was analysed in the next chapter. 
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4. Chapter 4 - Analysis of signal 
sequence cleavage and fate of the 
variant B precursor protein  
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4.1. Introduction 
Cystatin C variant B is characterized by a point mutation in its signal peptide, an Ala 
to Thr substitution at the -2 position, which alters the hydrophobic properties of 
the sequence and, in particular, of its C-terminal region. The hydrophobicity profile 
of the signal peptide is known to be essential for its functionality as well as the 
integrity of the C-terminal-region (Nilsson et al. 2015, Auclair, Bhanu & Kendall 
2012), as described in section 1.5.1. This mutation might therefore affect one of 
the steps essential for the precursor protein processing, such as the signal-
recognition process by SRP, the translocation across the ER membrane or the 
cleavage of the signal sequence itself, therefore preventing the correct maturation 
of the precursor protein. Moreover, since the mutation is present in the precursor 
protein, its effect is expected to be exerted at the maturation stage as once the 
signal sequence has been cleaved, the mature protein would not differ from the 
wild-type form of cystatin C. 
Different hypotheses have been suggested in earlier reports. One study suggested 
that the A25T mutation prevents the precursor cystatin C undergoing efficient 
cleavage by the signal peptidase complex (SPC) (Paraoan et al. 2004). As a 
consequence, the resulting unprocessed fraction was proposed to divert from the 
ER pathway and accumulates intracellularly (Paraoan et al. 2004). Benussi et al. 
similarly suggested impairment in the protein maturation due to a reduced 
efficiency in the cleavage of the precursor protein, ultimately causing the lower 
levels of protein secretion reported in their study (Benussi et al. 2003). 
Alternatively, it has been suggested that the cleavage of the precursor protein still 
occurs but at a different location (Nguyen, Hulleman 2016, Nilsson et al. 2009). An 
additional cleavage site for cystatin C has been predicted and suggested to be 
utilized under certain circumstances, particularly in the case of the variant B 
(Nguyen, Hulleman 2016, Nilsson et al. 2009). This differently processed protein 
could possibly assume a different conformation and/or undergo different post-
translational modifications, which in both cases may affect its function and/or 
stability.  
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The aim of the work presented in this chapter was to investigate whether the 
cleavage of the signal sequence is affected in the case of the precursor variant B. 
For this purpose the processing of the precursor was analysed biochemically by 
using N-terminal tagged precursor constructs to determine if the levels of 
precursor/mature proteins differs between wild-type and variant B. 
Immunofluorescence imaging was performed to analyse the fate of the signal 
sequence and, if not cleaved, determine the intracellular localization of the 
precursor proteins. 
 
4.2. Analysis of uncleaved precursor cystatin C  
The level of uncleaved precursor fraction was monitored by using N-terminal 
tagged cystatin C, with either FLAG or HA, and N- and C-terminal tagged constructs, 
described in the materials and methods, section (2.2). The addition of a tag at the 
N-terminal end of the leader peptide should readily allow the identification of the 
precursor form of cystatin C and comparison of wild-type and variant B protein 
levels by Western blotting and immunoprecipitation. 
  
4.2.1. N-terminal tag does not affect cystatin C trafficking and 
levels of precursor fraction appear to be higher in the 
variant B cystatin C 
Labelling cystatin C at the N-terminus of the signal sequence may potentially affect 
the processing/cleavage of the precursor protein. Therefore, correct maturation of 
the protein needed to be confirmed before proceeding with the analysis.  
Cell lysates and cultured media from transfected D4O7 cells expressing the N-
terminal cystatin C constructs were analysed by immunoblotting. Blots were 
probed with an anti-cystatin C antibody, which can detect mature and precursor 
forms, or with anti-FLAG or anti-HA antibodies that, depending on the construct 
used, allowed visualisation specifically of the unprocessed cystatin C. 
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For both the FLAG and HA N-terminal tagged constructs, the expected size of the 
precursor cystatin C is approximately 16.5 kDa (untagged cystatin C precursor of 
15.5 kDa + tag of ~1 kDa), whereas for the mature form should be the same mass 
as wild-type cystatin C (13 kDa) since the tagged leader peptide is removed.  
As expected, bands at 13kDa were detected in both the cell lysate and media 
samples (Figure 4.1.), indicating that the precursor cystatin C was properly 
processed in the ER. Moreover, the presence of the mature form in the conditioned 
media further confirmed that the constructs were normally targeted to the 
secretory pathway. This indicates that the FLAG or HA tags on the signal sequence 
do not affect the ER targeting, translocation and processing of the tagged cystatin 
C, thus establishing their suitability for studying cystatin C processing and 
trafficking.  
Anti-cystatin C antibody also detected a band at around 16.5kDa, which 
corresponds to the precursor form of cystatin C. This band was better visible with 
increased exposure time. This was confirmed by using anti-FLAG or anti-HA 
antibodies, depending on the constructs used, (in figure 4.1. a and b, respectively), 
to detect the N-terminal tag on the signal sequence and which recognized a band 
at the same mass. This 16.5kDa band was not detected in the media, further 
indicating that it corresponds to the unprocessed precursor form of cystatin C. The 
use of N-terminal tagged constructs therefore permitted clear visualisation of the 
uncleaved fraction of cystatin C, allowing their levels to be compared between 
wild-type and variant B proteins. By using either FLAG or HA-tagged constructs, the 
levels of the immature uncleaved cystatin C were found to be noticeably higher for 
the variant B (in figure 4.1 a and b respectively). These levels have been 
qualitatively compared taken in consideration the levels of mature proteins for 
wild-type and variant B. GAPDH was also used as loading control. However, this 
difference observed by using anti-FLAG or anti-HA antibodies was less evident 
when comparing the level of the same precursor fractions visualized with the anti-
cystatin C antibody, especially for the HA-CysC constructs (figure 4.1). 
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The immunoblots in figure 4.2 show the same analysis performed in D4O7 cells 
expressing the constructs tagged at both the N- and C-terminus with each 
combination of FLAG and HA tags. Again, both constructs are efficiently processed 
and secreted in the conditioned media, as previously observed for the other 
constructs. Antibody against the tag located at the C-terminal (HA in fig. 4.2 a, and 
FLAG in 4.2 b) allows detection of both the mature and precursor forms of cystatin 
C, whereas probing with the antibody against the tag at the N-terminus (FLAG in 
fig. 4.2 a, and HA in 4.2 b) permits visualization of only the unprocessed fraction. 
For each construct, the mass expected for mature and precursor proteins are 
approximately 14kDa and 17.5kDa, respectively. Evaluation of the level of non-
mature cystatin C indicates, also with these constructs, a difference between wild-
type and variant B, especially by probing with antibodies against the N-terminal 
tags, with a higher level of unprocessed protein in the case of the variant B. 
In ARPE19 cells, bands representing the precursor proteins were not detected (data 
not shown). This is probably due to the lower protein expression in these cells, 
meaning that the sensitivity of the assay was not high enough to identify the 
precursor fraction, which is present at considerably lower levels than the mature 
one.  
 
150 
 
 
Figure 4.1 - Immunodetection of N-terminal tagged cystatin C constructs in D4O7 cells. 
Immunoblots of cell lysates and conditioned media collected from cell expressing N-
terminal FLAG- (a) or HA- (b) tagged wild-type or variant B cystatin C 24h post-transfection. 
Blots were probed with anti-cystatin C antibody, which detected both precursor and 
mature forms of cystatin C, corresponding to bands of approximately 16.5kDa and 13kDa 
respectively, and with anti-FLAG or anti-HA antibody, depending on the construct used, 
which identified only the uncleaved precursor cystatin C protein (indicated by the arrow). 
Anti-GAPDH antibody was used as loading control for cell lysates. 
 
 
a) b) 
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Figure 4.2 - Immunodetection of N- and C-terminal tagged cystatin C constructs on D4O7 
cells. Immunoblots of cell lysates and conditioned media collected from cell expressing N-
terminal FLAG-tagged and C-terminal HA-tagged (a) or, vice versa,  N-terminal HA-tagged 
and C-terminal FLAG-tagged (b) wild-type or variant B cystatin C. In blot (a) anti-HA 
antibody was used to visualize both the precursor and the mature forms of cystatin C, 
consisting of bands of approximately 17.5kDa and 14kDa respectively, and anti-FLAG 
antibody to detect only the uncleaved precursor cystatin C protein (indicated by the 
arrow). Conversely, in blot (b) anti-FLAG antibody was used to visualize both precursor and 
mature forms of cystatin C protein, consisting of bands of 17.5kDa and 14kDa respectively, 
and anti-HA antibody to detect only the uncleaved precursor cystatin C protein (indicated 
by the arrow). Both blots were probed with anti-GAPDH antibody used as loading control. 
 
4.2.2. Comparison of the level of variant B precursor fraction to 
wild-type cystatin C 
The Western blot analysis described in the previous section revealed that the level 
of unprocessed cystatin C is very low if compared to the mature form. It was 
possible to detect the corresponding band only at very long exposure in the D4O7 
cell line and could not be detected in ARPE19 cells. A pull-down of the transfected 
protein was therefore performed to increase the concentration of the uncleaved 
fraction of cystatin C, so that immunoblotting analysis would be able to more 
accurately evaluate possible differences between the level of unprocessed wild-
type and variant B proteins.   
a) b) 
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For this experiment, constructs encoding cystatin C tagged to HA at the N-terminus 
and to FLAG at the C-terminus were used. Immunoprecipitation of the wild-type 
and variant proteins was performed by using anti-FLAG beads, as described in 
section 2.5 of Materials and Methods, so that both precursor and mature forms 
were isolated. The IP samples obtained were analysed by immunoblotting together 
with the respective cell lysates collected prior to the pull-down. Anti-HA antibody 
was used to detect the unprocessed form of cystatin C and anti-FLAG antibody to 
visualize both the unprocessed and mature proteins. 
Cell lysates were loaded as an additional control to ensure that a similar protein 
expression/transfection efficiency was obtained for both wild-type and variant 
constructs. This showed that the yield of protein obtained after 
immunoprecipitation was similar. The bands obtained in the cell lysates, in figure 
4.4, were also quantified. 
Figure 4.3 shows immunoblots of samples obtained from D4O7 (A) and ARPE19 (B) 
cell lines. Figure 4.3 A shows a representative blot obtained in D4O7 cells. Bands of 
17.5kDa size, corresponding to the uncleaved precursor cystatin C, were detected 
in the IP samples when probing with anti-HA antibody. At longer exposure time, 
bands of the same mass could also be detected in the cell lysates. Considering the 
similar level of mature protein in wild-type and variant B IP samples, detected with 
anti-FLAG antibody, the level of precursor cystatin C for the variant B appeared to 
be noticeably higher than the wild-type. It was not possible to replicate this finding 
using the ARPE19 cell line, where levels of variant precursor were inconsistent and 
either higher 4.3 B (a) or lower 4.3 B (b) compared to the wild-type. This is likely 
due to the extremely small amount of precursor detected in this cell line. Indeed, 
very long exposure times were required to detect bands corresponding to 
unprocessed proteins in the IP samples and no bands for the precursor were 
detected in the cell lysates. 
In this analysis, levels of precursor protein were qualitatively compared between 
wild-type and variant B by taking in consideration the level of mature proteins. 
Quantification of the precursor cystatin C, in D4O7 cells, was also performed by 
densitometry of the bands visualized by using anti-HA antibody (figure 4.3 C). 
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However, normalization of the precursors to the mature proteins was not possible 
for this first set of experiments as the bands corresponding to the mature proteins 
were saturated. Comparison of the precursor levels is therefore performed 
assuming that the levels of mature proteins were approximately the same. Results 
confirm a higher level of precursor in the case of the variant B (figure 4.3 C). 
However, to properly quantify the precursor fraction, a new set of three 
independent experiments was performed again for the D4O7 cells and the 
respective immunoblots are shown in figure 4.4. Levels of precursor proteins 
obtained in either IP or cell lysate samples were evaluated by densitometry and 
normalised to the level of mature proteins. The level of unprocessed protein was 
calculated from the bands obtained with either anti-HA or anti-FLAG antibodies, 
and in both cases they were normalized to the mature form obtained by probing 
with anti-FLAG antibody. Surprisingly, in this experiment the difference observed 
between wild-type and variant precursor was inconsistent. Levels of uncleaved 
precursor in IP samples were higher for the variant B in blots (a) and (c) but not in 
blot (b). Quantification of the blots in figures 4.4 is shown in figure 4.5 and 4.6. 
These show levels of wild-type and variant B precursor in IP samples and cell 
lysates, respectively. Level of wild-type precursor was set to 1.  
Results obtained using either cell lysate or IP samples, analysing the fraction of 
precursor proteins detected with either anti-FLAG or anti-HA, showed no 
statistically significant difference between wild-type and variant B. However, a 
trend corresponding to higher levels of variant B precursor is observed. Taken 
together with the results obtained in the first set of experiments, shown in figure 
4.3 A (plotted in 4.3 C), it may indicate a difference, albeit small in comparison to 
the mature proteins, in the level of precursor proteins between wild-type and 
variant B. 
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Figure 4.3 - Immunodetection of pulled-down N- and C-terminal tagged cystatin C 
constructs from transfected D4O7 and ARPE19 cells. D4O7 (A) and ARPE19 (B) cells 
transfected with wild-type or variant HA-CysC-FLAG constructs were subjected to 
immunopecipitation with anti-FLAG beads in order to pull down the total cystatin C 
protein, including both the precursor and mature forms. IP samples were then analysed by 
western blotting, together with the respective cell lysates, by probing with anti-FLAG and 
with anti-HA antibodies to detect the total cystatin C and only the precursor fraction 
(indicated by the arrow), respectively. Bands of mature and precursor correspond to 14kDa 
and 17.5kDa, respectively. (C) Levels of wild-type and variant B precursor protein obtained 
A) B) 
C) D4O7 
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by immunoprecipitation from transfected D4O7 cells were evaluated by densitometry. The 
level of wild-type precursor was set to 1 and level of variant B precursor resulted to be 
3.28 ± 1.11 (N=3). Standard deviation is indicated in the graph. 
 
 
 
  
Figure 4.4 - Immunodetection of pulled-down N- and C-terminal tagged cystatin C 
constructs from transfected D4O7 cells. D4O7 cells transfected with wild-type or variant 
HA-CysC-FLAG constructs were subjected to immunopecipitation with anti-FLAG beads in 
order to pull down the total cystatin C protein, including both the precursor and mature 
forms. IP samples were then analysed by western blotting, together with the respective 
cell lysates, by probing with anti-FLAG and with anti-HA antibodies to detect the total 
cystatin C and only the precursor fraction, respectively. Bands of mature and precursor 
correspond to 14kDa and 17.5kDa, respectively. 
  
 
 
a) b) c) 
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Figure 4.5 - Quantification of unprocessed precursor cystatin C after pull-down of HA-
CysC-FLAG constructs. Level of precursor wild-type or variant B FLAG-cysC-HA obtained by 
immunoprecipitation from transfected D4O7 cells were evaluated by densitometry of 
western blots and normalized to the level of mature protein. In figure a) level of precursor 
obtained with anti-HA antibody was normalised to level of mature protein obtained with 
anti-FLAG antibody. In figure b) level of precursor was calculated from the band obtained 
with anti-FLAG antibody and normalised to the mature protein obtained with anti-FLAG 
antibody. In both cases, level of wild-type precursor was set to 1 and level of variant B 
precursor resulted to be 1.78 ± 0.61 (a) and 1.51 ± 0.42. One sample t test (N=3) (two-
tailed) p= 0.16 and 0.17, respectively. Standard deviations are indicated in the graph. 
 
 
 
 
 
Figure 4.6 - Quantification of unprocessed precursor FLAG-CysC-HA constructs in D4O7 
cell lysates. Level of precursor wild-type or variant B FLAG-cysC-HA in transfected D4O7 
cells were evaluated by densitometry of western blots and normalized to the level of 
mature protein. In figure a) level of precursor obtained with anti-HA antibody was 
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normalised to level of mature protein obtained with anti-FLAG antibody. In figure b) level 
of precursor was calculated from the band obtained with anti-FLAG antibody and 
normalised to the mature protein obtained with anti-FLAG antibody. In both cases, level of 
wild-type precursor was set to 1 and level of variant B precursor resulted to be 1.64 ± 0.78 
(a) and 1.28 ± 0.31. One sample t test (N=3) (two-tailed) p= 0.29 and 0.26, respectively. 
Standard deviations are indicated in the graph. (ns=non-significant) 
 
4.3. Variant B and wild-type precursor cystatin C both 
localize to the ER 
The precursor cystatin C has been suggested to partially divert from the secretory 
pathway leading the unprocessed protein, with the intact leader peptide, to 
accumulate intracellularly and associate with mitochondria (Paraoan et al. 2004). 
Considering the results obtained in the previous section, the unprocessed 
precursor cystatin C was analysed by IF to further assess whether a difference in its 
level occurs between wild-type and variant B. Although in the previous chapter no 
mislocalization was observed for the variant B, its low abundance might have 
required such a long exposure that it would have been masked by the resulting 
overexposure of the fluorescence from the mature protein. Therefore, the 
localization specifically of the precursor was this time analysed to identify whether 
it partially mislocalizes intracellularly, as hypothesised by Paraoan et al. (2004). For 
this reason, N-terminal tagged cystatin C constructs, with either FLAG or HA tags, 
were used to visualize the precursor protein and determine the fate of the signal 
sequence.  
D4O7 cells were transfected and analysed after fixation by IF using anti-cystatin C 
antibody to detect the mature protein and anti-FLAG or anti-HA antibodies, for the 
N-terminal FLAG- or HA- tagged constructs respectively, to detect the unprocessed 
cystatin C. IF microscopy analysis, shown in figure 4.7, revealed that the precursor 
protein was not easily detected compared to the mature form. This was the case 
for both FLAG- (a) and HA-tagged (b) proteins. It was detected only at very long 
exposure times and did not appear in all the transfected cells. This is consistent 
with the extremely low amount of precursor observed by immunoblotting, 
suggesting that the proteins are rapidly processed to their mature form.  
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The distribution of antibody staining was assessed to determine whether the 
proteins mislocalize, particularly in the mitochondria as hypothesised earlier. D4O7 
cells transfected with FLAG- or HA-tagged constructs were analysed with anti-
cystatin C (figure 4.8) to detect the mature cystatin C, and with anti-FLAG or anti-
HA, depending on the construct (figure 4.9) to detect the unprocessed proteins. 
Mitotracker was used to visualize mitochondria in both figures 4.8 and 4.9 (a). For 
the precursor fraction, the ER compartment was also visualized with anti-
calreticulin antibody in figure 4.9 (b).  
Results showed no mitochondrial distribution for either the mature or precursor 
cystatin C proteins. Mature cystatin C appeared to be present in the ER-Golgi 
complex, thus further indicating a normal localization for variant B protein and 
confirming that a tag at the N-terminal does not affect protein trafficking. The non-
processed precursor was shown to localize in the ER compartment in both wild-
type and variant proteins, thus indicating that it also does not mislocalize. 
The same analysis was performed in ARPE19 for both FLAG- and HA-tagged 
constructs (in figures 4.10 and 4.11, respectively). Again the mature protein 
showed an ER/Golgi distribution, whereas the precursor was found to be 
distributed throughout the ER and no association with mitochondria was observed.  
In some images the precursor appeared to show granule-like structures, which may 
likely represent protein aggregates destined for degradation, but which did not 
colocalize with mitotracker.  
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Figure 4.7 - Comparison between total and precursor fraction of cystatin C by using the 
N-terminal FLAG- or HA-tagged constructs in D4O7 cells. D4O7 cells expressing wild-type 
or variant B cystatin C linked to either FLAG (a) or HA (b) at the N-terminus were PFA-fixed 
and immunostained 24h post-transfection. Anti-cystatin C antibody was used to detect the 
total transfected cystatin C, precursor and mature forms, and anti-FLAG or anti-HA, 
depending on the constructs used, were used to detect only the unprocessed precursor, 
which all fluoresce in green. The blue fluorescent DAPI was used to stain nuclei. Scale bars 
are 50 µM. 
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Figure 4.8 - Localization of mature cystatin C by using N-terminal FLAG- or HA-tagged 
constructs in D4O7 cells. D4O7 cells expressing wild-type or variant B cystatin C linked to 
either FLAG or HA at the N-terminus were PFA-fixed and immunostained 24h post-
transfection. Anti-cystatin C antibody was used to detect the total transfected cystatin C, 
precursor and mature, which fluoresces in green. Mitotracker, which fluoresce red, was 
used to visualize mitochondria. The blue fluorescent DAPI was used to stain nuclei. For 
each field of cells imaged, green and red fluorescence were recorded as separate images 
and then merged, for assessing the overlap of the respective signals. Scale bars are 20 µM. 
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Figure 4.9 - Localization of precursor cystatin C by using N-terminal FLAG- or HA-tagged 
constructs in D4O7 cells. D4O7 cells expressing wild-type or variant B cystatin C linked to 
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either FLAG or HA at the N-terminus were PFA-fixed and immunostained 24h post-
transfection. Anti-FLAG or anti-HA antibodies, depending on the construct used, were used 
to detect the unprocessed precursor cystatin C, which fluoresces in green. Mitotracker (a) 
or the antibody anti-calreticulin (b), which fluoresce red, were used to visualize 
mitochondria and ER, respectively. The blue fluorescent DAPI was used to stain nuclei. For 
each field of cells imaged, green and red fluorescence were recorded as separate images 
and then merged, for assessing the overlap of the respective signals. Scale bars are 20 µM 
 
 
 
  
Figure 4.10 - Localization of N-terminal FLAG- tagged cystatin C constructs in ARPE19 
cells. ARPE19 cells expressing wild-type or variant B cystatin C linked to FLAG at the N-
terminus were PFA-fixed and immunostained 24h post-transfection. Anti-FLAG antibody 
was used to detect the unprocessed precursor cystatin C, which fluoresces in green. Anti-
cystatin C and anti-calreticulin, which fluoresce red, were used to visualize the total 
cystatin C and the ER, respectively. The blue fluorescent DAPI was used to stain nuclei. For 
each field of cells imaged, green and red fluorescence were recorded as separate images 
and then merged, for assessing the overlap of the respective signals. Scale bars are 20 µM. 
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Figure 4.11 - Localization of N-terminal HA-tagged cystatin C constructs in ARPE19 cells. 
ARPE19 cells expressing wild-type or variant B cystatin C linked to HA at the N-terminus 
were PFA-fixed and immunostained 24h post-transfection. Anti-HA antibody was used to 
detect the unprocessed precursor cystatin C, which fluoresces in green. Anti-cystatin C and 
anti-calreticulin, which fluoresce red, were used to visualize the total cystatin C and the ER, 
respectively. The blue fluorescent DAPI was used to stain nuclei. For each field of cells 
imaged, green and red fluorescence were recorded as separate images and then merged, 
for assessing the overlap of the respective signals. Scale bars are 20 µM. 
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4.4. Discussion 
Secretory proteins are synthesized as precursors with an N-terminal signal 
sequence that is usually cleaved during the co-translational translocation of the 
nascent polypeptide chain into the lumen of the ER. As described in section 1.5.1, 
signal sequences are essential to direct proteins to the secretory pathway as they 
mediate their targeting to ER, translocation across the membrane and cleavage by 
signal peptide complex (SPC) (Hegde, Bernstein 2006).  
Targeting of the nascent chain-ribosome complex to the ER occurs by binding of the 
signal peptide to the SRP, which then associates with its receptor at the ER 
membrane (Halic et al. 2004). Subsequently, the signal peptide interacts with the 
Sec61 translocon, promoting the opening of the conducting channel and the 
consequent initiation of translocation (Rutkowski et al. 2003). Properties of the 
signal peptide also determine its orientation across the ER membrane (Kocik, Junne 
& Spiess 2012). Once it emerges into the ER lumen the signal peptide is removed by 
the SPC (Meyer, Hartmann 1997). The cleaved signal peptide is then further 
processed and degraded (Lyko et al. 1995), while the mature protein is released 
into the lumen once its translocation is completed. Therefore, mutations within the 
signal peptide could affect any of these steps, resulting in inefficient/improper 
protein maturation, as reported for several human proteins (Jarjanazi et al. 2008). 
However, in some case mutations have been shown not to have any measurable 
effect (Jarjanazi et al. 2008). 
 
Substitution of the hydrophobic alanine residue in the penultimate position -2 of 
the signal sequence of cystatin C with a more polar threonine amino acid alters the 
hydrophobicity of the signal sequence, thus possibly affecting its functionality. In 
earlier studies, the variant B was processed less efficiently, thus eventually leading 
to a decreased protein secretion (Benussi et al. 2003). Furthermore, the precursor 
was suggested to only be partially cleaved, or cleaved at a different site (Paraoan et 
al. 2004, Nilsson et al. 2009, Nguyen, Hulleman 2016), thus generating a misfolded 
protein that could accumulate and/or mislocalise intracellularly. If the variant B 
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protein is associated with increased risk of disease development, impairment in the 
variant B protein maturation can be expected as, otherwise, the resulting mature 
form would not differ from wild-type cystatin C. The aim of this chapter was 
therefore to investigate whether the variant B polymorphism affects the 
maturation of cystatin C, which could consequently explain its association with 
diseases. 
 
By using constructs encoding precursor cystatin C linked to a tag at the N-terminus 
it was possible to detect the unprocessed precursor fraction individually from the 
mature cystatin C protein. All N-terminal tagged constructs (either wild-type or 
variant B) used in this study resulted to be normally targeted for secretion thus 
confirming their suitability for these studies and also confirming the results on the 
protein trafficking obtained in the previous chapter with the C-terminal tagged and 
untagged constructs. 
The main results obtained in this study revealed a possible difference between the 
levels of wild-type and variant B precursor proteins in D4O7 cells. This fraction 
appears to be higher in the case of the variant B, thus suggesting a less efficient 
processing of the variant precursor. This difference, however, was not obtained in 
ARPE19, likely due to the very low level of precursor present. Indeed, in ARPE19 
cells, where the yield of protein expression is much lower compared to D4O7, it 
was not even possible to detect the precursor fraction in the cell lysates by 
immunoblotting, and it was detected only at very high exposure after selective pull-
down. Consistent with these results, the unprocessed cystatin C could be detected 
in very few ARPE19 cells by IF analysis.  
Regarding the results obtained in D4O7, a trend consisting in an increased level of 
precursor protein in the case of the variant B seems to constantly occur, although 
this difference resulted not to be statistically significant. This non-significance is 
likely due to the very small amount of proteins that are considered in this analysis, 
which is expected to be more susceptible to experimental variation. In addition, the 
analysis was performed 24 hours after transfection, a time that may not allow 
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sufficient accumulation of the precursors to detect a possible significant difference. 
If, as suggested by the results, subtle differences in the efficiency of cleavage of the 
variant B signal peptide indeed exist, over time they may become statistically and 
biologically significant. As a consequence, depending on the turnover of the 
secreted protein it could lead to a long-term reduction in the levels of the secreted 
protein. Therefore, although no difference in the fraction of secreted proteins was 
found between wild-type and variant B (as described in section 3.4), small 
differences in how the variant B precursor is processed could accumulate over 
time. This may explain an association of the variant B with aging related diseases. 
An alternative possibility, however, is that the detection of the precursors in the 
first place was only due to the overexpression of the cystatin C constructs (see 
below). 
 
Cell imaging was then carried out to analyse the destiny of the variant B precursor. 
Results revealed that the mature form is normally distributed in the ER/Golgi, 
whereas the precursor cystatin C appears to localize in the ER, as it is expected for 
a precursor protein. No localization in the Golgi apparatus and no mislocalization in 
other cellular compartment such as mitochondria were observed for the uncleaved 
precursor, suggesting that this fraction, even when increased due to a less efficient 
maturation, is then either removed by degradation or processed, thus generating a 
normal mature protein that will be eventually secreted. If this is the case, the only 
direct consequence would be a gradual decreased in protein secretion. Overall, 
these results further confirm that no mislocalization into the mitochondria occurs 
for the variant B cystatin C, either as mature form or as uncleaved precursor, as the 
latter was instead suggested by Paraoan et al. 2004. It is not clear, though, why the 
precursor fraction was not detected in all the transfected cells. It may probably 
depend on the different efficiency of processing occurring in the different cells. 
However, this occurs similarly for the wild-type and variant B constructs. 
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The reason of the significant lower level of precursor protein compared to that of 
the mature protein, observed in both immunoblotting and imaging, is probably due 
to the fact that precursor proteins are processed as soon as the signal peptide 
cleavage site is exposed in the lumenal side, while protein translation is still 
occurring (Antonin, Meyer & Hartmann 2000). The full-lenght 146 amino acids 
precursor protein is therefore probably not normally present in the cells and it can 
be observed in this analysis because of the overexpression of the protein that may 
determine a saturation of the translocation/cleavage machinery, as suggested by a 
number of other groups (Cottet, Corthésy 1997, Massotte 2003, Dalton, Barton 
2014). Its presence is indeed revealed particularly in D4O7 cells due to their higher 
protein expression. Moreover, after the precursor processing, the cleaved signal 
peptide is then rapidly processed/degraded by SPP (as described in section 1.5.1.1). 
For this reason, either the precursor protein or simply the cleaved signal peptide 
cannot be easily detected during imaging analysis by probing with antibodies 
against the N-terminal tags, as they are rapidly processed and degraded, 
respectively. This further indicates that, in such conditions of protein 
overexpression, the fact that the precursor/signal sequence is differently detected 
among the transfected cells may depend on the different efficiencies of cleavage 
and degradation in place for each cell. 
The different levels observed between wild-type and variant B can still suggest a 
reduction in the efficiency of the variant B maturation. However, because of the 
considerable difference between the level of precursor and mature fractions and 
the very small difference identified between wild-type and variant B precursor, it 
appears unlikely that this inefficiency of cleavage is sufficient to significantly impair 
the trafficking and secretion of cystatin C, as indeed observed and reported in 
chapter 3, or at least not after 24 hours of analysis. 
 
Considering the different functions of the signal peptide in the protein 
translocation and maturation, the mutation in study may affect one of the steps 
involved in this process. As described in detail in section 1.5.1.2, the signal 
sequences usually share the same tripartite structure, consisting of a positively 
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charged N-terminus, a hydrophobic core and a polar C-terminal domain, also 
termed respectively n-, h- and c-region (Nilsson et al. 2015). Each of these domains 
plays a specific role in the protein maturation. The n- and h-region mediate the SRP 
recognition process and the translocation across the membrane. The 
hydrophobicity profile of the h-region has been reported to be the main criterion 
for targeting the nascent protein to the SRP-dependent co-translational pathway 
(Hatsuzawa, Tagaya & Mizushima 1997), while the n-region contributes to 
modulate the affinity of the SRP-signal peptide association (Nilsson et al. 2015). The 
basic residues in the n-region and the hydrophobic core of the signal sequence are 
also responsible for the correct orientation of the signal sequence during the 
translocation, by interacting with the translocon components (Kocik, Junne & 
Spiess 2012, Nilsson et al. 2015). The integrity of the c-region is instead crucial for 
the cleavage of the signal sequence by the SPC. Based on the (-3, -1) rule, the 
amino acid residues at -1 and -3 positions have been described to be the most 
critical to establish the site of cleavage by determining the correct interaction with 
the active site of signal peptidase. These positions are usually occupied by small 
and neutral amino acids (Nothwehr, Gordon 1990, Auclair, Bhanu & Kendall 2012). 
 
Several diseases caused by mutations within the signal sequence of secretory 
proteins have been reported, where protein function or localization were 
dramatically disrupted (Jarjanazi et al. 2008). Depending on the domain of the 
signal peptide in which the mutation occurs, different effects on protein 
maturation have been observed. For instance, mutation in the h-region of the 
signal sequence of the preproparathyroid hormone was suggested to impair the 
protein targeting or translocation of the protein. The consequent inhibition of 
protein secretion has been linked to a form of hypoparathyroidism (Arnold et al. 
1990). Whereas mutations in the c-region, and in particular involving residues at -1 
and -3 positions, were shown to mainly affect the cleavage process. For instance, 
amino acid substitution at -3 position of the signal peptide have been observed to 
cause either a failure in the cleavage, as in the case of the coagulation Factor X, or 
cleavage at an alternative site, as in the case of the anti-thrombin (Racchi et al. 
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1993). In the first case, the uncleaved precursor of factor X is retained 
intracellularly, where it is slowly degraded and the failed secretion causes a severe 
deficiency in the patients. In the case of the anti-thrombin, the cleavage occurs to a 
different site, two amino acids toward the C-terminus. Nevertheless, the resulting 
two residues shorter processed protein was reported to be normally secreted and 
to maintain its function. Indeed, no pathological condition results from this 
mutation. Another mutation at the -1 position, consisting in a Thr to Ala 
substitution, in the signal peptide of Vasopressin, has been shown to impact the 
efficiency of cleavage, generating a prevalent uncleaved and abnormally 
glycosylated product, which may accumulate intracellularly thus causing cell 
toxicity (Ito et al. 1993, Ito, Yu & Jameson 1999). This mutated vasopressin 
precursor protein has been associated with a form of Diabetes insipidus 
characterised by neuronal cell degeneration (Ito, Yu & Jameson 1999). 
 
The mutation characterizing the variant B cystatin C occurs at the -2 position, 
within the c-region of the signal sequence. It is therefore likely that targeting and 
translocation of the nascent variant B protein are not affected. However, the amino 
acid substitution in position -2 may have an effect on the orientation of the C-
terminal domain of the peptide, resulting in an unfavourable interaction between 
the cleavage site and the active site of the peptidase. A less efficient processing 
may result in the generation of protein that is uncleaved or cleaved at an 
alternative site, as suggested in earlier reports (Nguyen, Hulleman 2016, Paraoan et 
al. 2004). The resulting uncleaved or miscleaved fraction may undergo improper 
folding and accumulate intracellularly, as described for the above-mentioned 
Factor X and vasopressin proteins.  
Furthermore, as suggested for vasopressin, the abnormal uncleaved precursor 
variant B might be retained within the ER, because of the signal peptide anchored 
to the ER membrane and/or due to the status of the precursor proteins most likely 
unfolded or misfolded. Misfolded proteins are indeed generally retained in the ER 
and then targeted for degradation through the ER-associated degradation (ERAD) 
system (Ito et al. 1993, Ito, Yu & Jameson 1999). ERAD is a specific mechanism 
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responsible for removal of ER-retained misfolded and damaged proteins. It includes 
several steps consisting of the recognition and targeting of the misfolded protein to 
the dislocation-machinery located on the ER membrane and its subsequent 
translocation to the cytosol for degradation by the proteasome (Schrul et al. 2010, 
Hegde, Ploegh 2010). However, as for vasopressin, the misfolded precursor protein 
may not entirely undergo degradation, thus accumulating in the ER and eventually 
forming aggregates, which impair cell functionality (Birk et al. 2009, Ito, Yu & 
Jameson 1999). Interestingly, a study has also reported that proteins appear to be 
less stable when the signal peptide is not cleaved, thus resulting in incorrect folding 
and increased propensity to aggregate (Singh et al. 2013).  
A similar case has been also reported for the precursor form of insulin (Liu et al. 
2012) where an Ala to Asp substitution at position -1 of the signal sequence was 
indeed reported to cause an inefficient cleavage of the protein, resulting in the 
formation of two alternatively processed molecules, either uncleaved or incorrectly 
cleaved at a different cleavage site. Both forms were suggested to be misfolded 
and therefore retained in the ER and targeted to ERAD. Again, they may escape 
ERAD, accumulating within the ER and ultimately leading to generation of protein 
aggregates. In addition, this condition has been also found to interfere with the 
trafficking of other proteins, precluding their exit from the ER and activating an ER 
stress response. Interestingly, in the same study they showed that a mutation at -2 
position of the insulin precursor, consisting in an Ala to Ser substitution, therefore 
similar to cystatin C mutation, was not able to affect protein cleavage (Liu et al. 
2012). The presence of favourable residues at the -1 and -3 positions seem to be 
particularly crucial for establishing the correct interaction with the signal peptidase, 
thus permitting an effective cleavage (Auclair, Bhanu & Kendall 2012). However, 
not all the mutations compromise the protein maturation. Only a small percentage 
of the mutations identified in the signal sequence was reported to affect the 
function of the signal peptide, which results in clinical conditions (Jarjanazi et al. 
2008). Therefore, it is also possible that the mutation characterising the variant B 
protein, which does not reside in one of the critical residues of the c-region, may 
not have any significant effect on the protein processing. 
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However, in our study, the higher transfection rate and protein expression that 
characterise the D4O7 cells might have revealed a possible accumulation of the 
variant B precursor that normally may only occur over time, when the level of ER-
retained precursor proteins is sufficiently significant. If this is the case, this time-
dependent effect may occur with aging, thus being consistent with the 
progression/development of age-related diseases. As a result, even small 
difference in the cleavage might become significant in the long-term, thus causing, 
for instance, a reduction in secretion and/or an intracellular protein 
accumulation/aggregation of the uncleaved precursor. Interestingly, it has been 
recently reported that the uncleaved precursor cystatin C is highly amyloidogenic 
(Sant'Anna et al. 2016). Mature cystatin C is, per se, an aggregation-prone protein 
(Tsiolaki et al. 2015). By using validated bioinformatics programs that predict the 
aggregation propensity of proteins, Sant’Anna et al. (2016) have reported that the 
leader peptide of cystatin C contains a highly aggregation-prone sequence 
(Sant'Anna et al. 2016). As a consequence, the unprocessed precursor of cystatin C 
is even more amyloidogenic than the corresponding mature protein (Sant'Anna et 
al. 2016). Consistent with this prediction, the precursor cystatin C has been shown 
to form toxic aggregates and amyloid fibrils in vitro (Sant'Anna et al. 2016). This 
higher amyloidogenic propensity of the precursor, characterising wild-type and 
variant B equally, may be relevant in the case of an inefficient cleavage of the 
precursor, as hypothesised for the variant B. Therefore, the suggested impaired 
protein maturation may result in the intracellular retention of a highly 
amyloidogenic protein. Over time, accumulation of the precursor protein may lead 
to formation of aggregates and toxic fibrils. 
 
In conclusion, the A25T mutation might impair the cleavage of the signal peptide, 
resulting in an uncleaved fraction, which is misfolded and retained within the ER. 
This mutant precursor protein will be normally degraded by ERAD. However, if this 
fraction is not rapidly or efficiently degraded it may accumulate over time. This 
could, for instance, occur in aging and contribute to age-related diseases, where 
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decreased activity/dysfunction of the proteolytic system has been extensively 
reported (Vilchez, Saez & Dillin 2014, Hipp, Park & Hartl 2014). As the uncleaved 
precursor accumulates within the ER, it could consequently interfere with normal 
synthesis and trafficking of other proteins, inducing ER stress and leading ultimately 
to cell dysfunction. Furthermore, as the cystatin C precursor is highly 
amyloidogenic its accumulation in the ER may lead to formation of aggregates over 
time, eventually affecting cellular function and leading to cell degeneration. 
Interestingly, ER stress has been suggested to play an important role in AMD 
pathogenesis (Salminen et al. 2010). However, the variant B was recently shown to 
be unable to activate, 48-hours post-transfection, the unfolded protein response 
(UPR), which is the classical ER stress response (Nguyen, Hulleman 2016). This is 
probably due to the very small amount of proteins retained and accumulated after 
only 48-hours. 
Consistent with the hypothesis of an intracellular retention/accumulation of the 
unprocessed variant B, the precursor proteins, either wild-type or variant B, were 
sometimes observed in the IF analysis to be distributed in granules or dot-like 
structures, possibly representing protein aggregates. This may be due to the 
protein overexpression that exceeds the capacity of either the ER machinery to 
process the precursor proteins or the ERAD system to remove the excessive 
misfolded uncleaved ones. In either case, since the precursor cystatin C is highly 
amyloidogenic (Sant'Anna et al. 2016), even small amounts may lead to aggregate 
formation, as observed in IF imaging. Although in my analysis this was detected for 
both wild-type and variant B proteins, if the latter is less efficiently cleaved, variant 
B aggregates may over time accumulate and contribute to age-related disease 
conditions. 
 
Further studies are needed to confirm the inefficient processing of the variant B 
precursor. As mentioned before, analysis at longer time periods may be 
appropriate in this case, especially considering the very low levels of precursor 
protein in study. Anyway, if the lower efficiency of cleavage is confirmed, it could 
determine on one side a decrease in cystatin C secretion, thus leading to a 
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dysregulation of the proteolytic activity in the extracellular matrix, or more likely, 
the induction of ER stress due to protein aggregation, eventually leading to cell 
death. Both effects, if confirmed, could support and explain an enhanced AD and 
AMD risk in the case of the variant B. 
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5. Chapter 5 - Characterization of 
cystatin C species secreted   
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5.1. Introduction 
During analysis of secretion performed in section 3.4 the presence of two 
additional, slightly slower migrating bands, was consistently observed in the 
conditioned media of D4O7 cells transfected with variant B cystatin C, either 
untagged or tagged to FLAG or HA, after longer exposures. In this chapter, I 
describe the characterization of these bands in particular to determine whether 
these bands also represent the cystatin C protein and, if so, what causes their 
slower migration in SDS-PAGE. As an alternative cleavage site and consequent O-
glycosylation have been previously suggested to occur for the variant B cystatin C 
(Nilsson et al. 2009, Nguyen, Hulleman 2016), analysis of such a post-translational 
modification was explored. This could explain the change in molecular weight of 
the protein and may correlate variant B to disease development.  
 
5.2. Additional secreted forms of cystatin C are produced in 
RPE cells expressing variant B proteins.  
The two extra-bands were observed by Western blotting in the cultured media of 
D4O7 cells expressing the variant B cystatin C, either untagged or tagged to FLAG or 
HA, as shown in Figure 5.1 a, b and c, respectively, and by probing with either anti-
cystatin C, anti-FLAG or anti-HA antibodies, depending on the constructs. The extra-
bands were visualized only after a relatively long exposure, thus indicating that 
these species are present at very low levels compared to the bulk of the 
presumably correctly processed cystatin C. The fact that the bands were detected 
with all the constructs and with different antibodies suggests that they represent a 
form of the cystatin C protein. However, in ARPE19 cells, only one additional band 
was detected in the conditioned media for the variant B, which was of similar size 
to the intermediate band detected in D4O7 cells (Fig. 5.2). This difference is 
probably due to the different protein expression levels in the two cell tpyes, as 
discussed earlier in chapter 3 and 4, or differences in the cellular mechanisms 
leading to the formation of these alternate forms of variant B between the two cell 
lines. Only analysis in D4O7 cells was carried out in this study. 
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To further investigate whether cystatin C is the protein corresponding to these 
bands, a cystatin C pull-down was performed from the media samples in order to 
reveal if the two bands are still present. Immunoprecipitation (IP) was carried out 
for the C-terminal FLAG-tagged constructs, using the anti-FLAG beads. Figure 5.3 
shows immunoblots of media samples collected from D4O7 cells expressing wild-
type or variant B cystatin C, prior to and after the protein pull-down. In addition to 
the main band, the two minor and slower migrating bands were also visualized 
after cystatin C pull-down, probing with either anti-cystatin C or anti-FLAG 
antibodies. This further substantiates that the two bands correspond to alternative 
forms of cystatin C. 
 
Identification of the proteins in these bands was further characterised by mass 
spectrometry analysis of cystatin C pull-down samples from the conditioned media. 
Immunoprecipitates obtained from conditioned media of cells transfected with 
FLAG-tagged wild-type or variant B cystatin C or non-transfected cells (used as 
negative control), were subjected to SDS-PAGE and visualized by coomassie blue 
staining (Figure 5.4.), where it was also possible to visualize the two slightly slower 
migrating extra-bands. These bands, along with the major 13 kDa band 
corresponding to cystatin C, were isolated for all three samples (E1-E9 fractions as 
shown in figure 5.4.) and qualitatively analysed by mass spectrometry. Table 8 
shows the proteins identified for each sample using the Mascot search engine and 
subsequent analysis using the proteasome software Scaffold. For each protein 
identified in each band, the exclusive unique spectra count and the percentage of 
coverage are reported in the first and second line, respectively. The number of 
unique spectra represents the number of distinct spectra associated only with the 
protein identified. Therefore it gives indication of the proteins detected in the 
sample and a rough estimate of their amount present. However, as discussed in 
material and methods, the peptide mapping analysis utilised here does not provide 
accurate protein quantification, so it was mainly used for protein identification. The 
percentage coverage is the percentage of all the amino acids in the protein 
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sequence that were detected in each sample, which gives an indication of the 
confidence that the identification assigned to each protein is correct.  
Results show that cystatin C is the most abundant protein identified in all the 
fractions isolated from the transfected cells, E1-E3 for the wild-type and E4-E6 for 
the variant B, which correspond to the major correct sized band of cystatin C and to 
the size of the two extra-bands observed in the media sample of the variant B. As 
expected, cystatin C was found in lower abundance in the untransfected cells (E7-
E9). Surprisingly, the cystatin C protein was identified within the two additional 
bands in both wild-type and variant B samples (E1/E2 and E4/E5 respectively). 
Percentage coverage gives us a high confidence that the protein identified is 
correct. For the other proteins detected, a very small number of unique spectra 
have been found, indicating that they are present at very low amounts. Moreover, 
the percentage coverage is also very small, thus not giving a high confidence of 
their presence. As the mass of proteins expected to be found at those sized bands 
analysed is in the range of 13-20kDa, all the larger molecular weight proteins 
revealed are likely contaminants.  Furthermore, they are often present in the 
negative control. Regarding the protein within the right range, such as Protein 
IGKV2D-29 (Fragment), Calmodulin, Cofilin-1 and Peptidyl-prolyl cis-trans 
isomerase A, they are intracellular proteins that are therefore most likely 
contaminants present in small amount, as they show a very low number of unique 
spectra as well as of percentage coverage. And they are also often present in the 
untransfected control. Overall, this data indicates that the two extra bands most 
likely correspond to cystatin C proteins.  
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Figure 5.1 - Immunodetection of untagged and C-terminal tagged cystatin C constructs in 
D4O7 cells. Immunoblots of cell lysates and conditioned media collected from cells 
expressing respectively wild-type or variant B cystatin C untagged (a) or tagged to FLAG (b) 
or HA (c). Western blots were probed with anti-cystatin C antibody, which detected all the 
cystatin C constructs, anti-FLAG or anti-HA antibodies for FLAG- and HA-tagged constructs, 
respectively in figure b) and c).  
 
 
 
Figure 5.2 - Immunodetection of untagged and C-terminal tagged cystatin C constructs in 
ARPE19 cells. Immunoblots of cell lysates and conditioned media collected from cells 
expressing respectively wild-type or variant B cystatin C untagged (a) or tagged to HA (b) or 
FLAG (c). Western blots were probed with anti-cystatin C antibody, which detected all the 
cystatin C constructs, and the endogenous cystatin C. 
a) Untagged CysC constructs 
b) FLAG-tagged CysC constructs c) HA-tagged CysC constructs 
a) Untagged CysC  b) HA-tagged CysC c) FLAG-tagged CysC 
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Figure 5.3 - Immunodetection of FLAG-tagged cystatin C constructs after protein pull-
down from conditioned media of D4O7 cells. Immunoblots of conditioned media collected 
from cells expressing FLAG-tagged wild-type or variant B cystatin C or non-trasfected (NT), 
probed with anti-cystatin C or anti-FLAG antibodies. Conditioned media prior to 
immunoprecipitation was also loaded. 
 
 
Figure 5.4 - Coomassie blue staining of FLAG-tagged cystatin C after protein pull-down 
from conditioned media of D4O7 cells. Conditioned media collected from cells expressing 
FLAG-tagged wild-type or variant B cystatin C or non-transfected (NT) cells were loaded on 
gel after immunoprecipitation and visualized by coomassie blue staining, prior to mass 
spectrometry analysis. Fractions E1-E9, corresponding to the main cystatin C band and the 
two additional bands, were cut from the gel for subsequent analysis. 
 
N
T
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Table 8 - Mass spectrometry analysis. Bands were extracted from the gel in figure 5.4., 
subjected to in-gel digestion using trypsin and analysed by mass spectrometry. Proteins 
identified in each fraction (E1-E9) by using Mascott are reported in the table below, 
showing, for each of them, number of exclusive unique spectra in the first line and 
percentage coverage in the second line. 
# Identified 
Proteins 
Molecular 
Weight 
E1 E2 E3 E4 E5 E6 E7 E8 E9 
1 Cystatin C 16 kDa 22 33 20 30 31 38 8 3 0 
64% 68% 57% 68% 68% 68% 45% 19% 0 
2 Desmoplakin  332 kDa 9 1 14 4 0 0 2 0 0 
3.0% 0.24% 4.7% 1.3%   0.84%   
3 Isoform of 
P02768, Serum 
albumin  
69 kDa 5 4 4 4 3 0 2 4 4 
9.4% 7.8% 9.9% 8.1% 6.5%  3.3% 7.8% 7.8% 
4 Protein IGKV2D-
29 (Fragment)  
13 kDa 2 2 2 2 2 0 1 2 2 
17% 17% 17% 17% 17% 0.00 11% 17% 17% 
5 Calmodulin  17 kDa 3 3 4 2 4 0 0 0 0 
20% 24% 27% 10% 22%  0.00   
6 Hornerin  282 kDa 6 0 10 6 0 0 5 0 0 
4.0%  6.4% 3.8% 0.00  2.7%   
7 Cofilin-1  19 kDa 4 0 7 5 0 0 1 0 0 
34%  54% 41%   6.6%   
8 Junction 
plakoglobin  
82 kDa 3 1 1 2 0 0 2 0 0 
6.3% 1.3% 1.6% 4.0%   4.7%   
9 Desmoglein-1  114 kDa 2 0 3 2 0 0 2 0 0 
3.1%  4.7% 2.9%   3.3%   
10 Peptidyl-prolyl 
cis-trans 
isomerase A  
18 kDa 2 0 2 4 0 0 0 0 0 
12% 0.00 12% 25% 0.00  0.00   
11 Filaggrin-2  248 kDa 3 0 3 2 0 0 1 0 0 
1.4%  1.7% 0.96%   0.50%   
12 Isoform of 
P04406, 
Glyceraldehyde-
3-phosphate 
dehydrogenase 
28 kDa 1 0 2 1 0 0 1 0 3 
5.4%  12% 5.4%   5.4%  13% 
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5.3. O-glycosylation events appear to characterise an 
alternative form of variant B cystatin C 
Results obtained in the previous section indicate that the two additional bands 
detected in the secretion media represent cystatin C proteins. The two bands show 
slightly slower migration by SDS-PAGE than the usual form of cystatin C. These 
shifts in molecular mass may be due to the presence of post-translational 
modifications. Cystatin C is thought to be a non-glycosylated member of the 
cystatin family (Paraoan, Grierson 2007). However, Nilsson et al. have reported 
that the variant B undergoes an O-glycosylation event, as a result of an alternative 
cleavage of the precursor (Nilsson et al. 2009). For this reason, glycosylation 
modification was analysed in this section. 
 
Both N-linked and O-linked glycosylation were analysed. N-linked glycosylation 
occurs in the ER compartment, during the protein’s co-translational translocation, 
as soon as the acceptor site is exposed to OST in the lumen of the ER (Chavan, Yan 
& Lennarz 2005). Subsequently, the attached glycan can be further modified in the 
Golgi apparatus (Stanley 2011). O-linked glycosylation can occur only after protein 
translation, in either the ER or the cis-Golgi, on Serine or Threonine residues within 
the protein (Stanley 2011). Then, it can be also subsequently modified in the other 
Golgi compartments. For this analysis, untagged cystatin C constructs were used. 
 
Analysis of N-linked glycosylation was performed by EndoH and PNGaseF treatment 
of media samples from transfected D4O7 cells, which can cleave only N-glycans, 
added in the ER, and complex/hybrid glycans generated in the Golgi apparatus, 
respectively, as described previously. Figure 5.5 shows an immunoblot of 
conditioned media from D4O7 cells transfected with wild-type or variant B cystatin 
C or non-transfected cells, either treated or not with EndoH or PNGaseF. The two 
extra-bands are not removed after either treatment, indicating that the increased 
mass of cystatin C is not due to an N-linked glycosylation. The functionality of these 
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enzymes was confirmed earlier with the Glyco-cysC constructs as positive controls 
(section 3.5.2). 
Analysis of O-linked glycosylation was carried out by using a deglycosylation 
enzyme mix, consisting of five different glycosidases able to remove both N- and O-
linked glycans (see section 2.4.4). Figure 5.6 (a) shows an immunoblot of 
conditioned media from D4O7 cells transfected with variant B cystatin C treated or 
not with the deglycosylation mix. Both bands seem to disappear after treatment. 
However, after prolonged exposure, the intermediate band appeared to be still 
present. Because of the components present in the enzyme mix (e.g. glycerol), the 
bands were noticeably distorted. To exclude the possibility that the extra-bands are 
not visible because of the distorted migration, the enzyme mix was added to 
samples and then either incubated at 37°C or left on ice for 5-hours to allow or not 
the enzymes to act. Figure 5.6 (b) shows the immunoblot of these samples treated 
with (+) or without (-) incubation. Although the intensity and shape of the bands 
are affected by the mix, at longer exposure times it is still possible to detect the 
largest band in the treated samples without incubation. In contrast, in the 
incubated samples the slowest migrating band had disappeared. The intermediate 
band, on the contrary, seemed still to be present in both samples. A positive 
control was used to ensure that the enzyme mix worked (Figure 5.6 (c)). These 
results suggest that the shift in apparent molecular mass of at least one of the 
alternative forms of cystatin C, detected for the variant B, is likely due to an event 
of O-glycosylation. However, the intermediate band was not affected by the 
treatment, thus indicating that its different molecular weight may not be due to O-
glycosylation events.  
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Figure 5.5 - Immunodetection of untagged cystatin C in conditioned media of D4O7 cells 
subjected to N-linked deglycosylation treatment. Conditioned media collected from D4O7 
cells transfected with untagged wild-type or variant B cystatin C or non-transfected, were 
treated with EndoH or PNGaseF glycosidases and subsequently analysed by 
immunoblotting probing with anti-cystatin C antibody. Non-treated samples were also 
loaded as control. 
 
 
Figure 5.6 - Immunodetection of untagged cystatin C in conditioned media of D4O7 cells 
subjected to deglycosylation treatment. Conditioned media collected from D4O7 cells 
transfected with untagged variant B cystatin C constructs were treated with 
a) b) c) 
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Deglycosylation enzyme mix and subsequently analysed by immunoblotting with anti-
cystatin C antibody. a) Immunoblot showing two media samples treated or not with the 
deglycosylation enzyme mix. b) Immunoblot showing media samples non-treated (first 
line) and treated with the mix and either incubated (+) or not (-) for 4 hours (second and 
third line respectively), to evaluate the effect of the mix on the shape of the bands. c) 
Positive control, consisting of Glyco-cystatin C constructs treated or not with the enzyme 
mix. 
 
 
  
185 
 
5.4. Discussion 
The signal sequence of cystatin C consists of 26 amino acids located at the N-
terminus of the mature protein (Figure 5.7). Mutations within this sequence, at the 
penultimate residue, generates the variant B cystatin C, which has been found, in 
human cerebrospinal fluid, to be alternatively cleaved between the residues Ala-20 
and Val-21 of the signal peptide (Nilsson et al. 2009). This results in a six residues 
longer mature protein, which still carries the A25T mutation. Furthermore, an O-
linked glycosylation was found to be present in this alternative processed variant B 
form, which is suggested to be on Ser27 or Ser28 residues, near the traditional Gly-
26 cleavage site, or on the mutated Thr25 residue, still present in the mature form 
(Nilsson et al. 2009). Furthermore, prediction software for signal sequence, such as 
SignalP, has also confirmed the presence of a second potential cleavage site for the 
precursor Cystatin C (Nguyen, Hulleman 2016), either wild-type or variant B, with 
similar propensity compared to the conventional cleavage site at Gly-26. This 
alternative site is predicted to occur at the same Ala-20 position, reported by 
Nilsson et al. (2009) for the variant B.  
 
 
Figure 5.7 - Signal sequence of cystatin C. Amino acid sequence of the wild-type or variant 
signal peptide, residues 1 to 26, plus the first 4 amino acids of the mature protein. An 
alternative cleavage may occur at position Ala20-Val21. 
 
The presence of secreted mature proteins larger than the expected sized cystatin C, 
observed in this study, can be therefore due to the alternative cleavage that 
generates a longer processed protein and, most likely, to the presence of a post-
translational modification, such as O-glycosylation. The addition of these six amino 
acids would increase the molecular weight of the mature protein by approximately 
530 Da, while the attached glycan would result in a further increase in molecular 
weight dependent upon its structure and composition.  
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Since these alternative forms are detected in the conditioned media, it is unlikely 
that they represent the unprocessed precursor protein as it would not go through 
the secretory pathway. These processed/secreted forms are therefore more likely 
to be generated by an alternative form of protein processing. 
The aim of the work presented in this chapter was to identify the nature of the two 
bands, whether they correspond to alternative forms of cystatin C and, if this is the 
case, investigate the cause that determines these partial shifts in the size of the 
protein. The presence of alternative forms generated only in the case of the variant 
B may explain its link to diseases. 
 
Results obtained in section 5.2 strongly indicate that the two bands observed in the 
media from D4O7 cells expressing the variant B correspond to cystatin C proteins. 
They have been indeed revealed by immunoblotting using different constructs and 
probing with different antibodies, thus excluding unspecificity of the antibody used. 
Furthermore, the two bands were also detected after cystatin C pull-down, also 
probing with different antibodies, which confirms the nature of the two larger 
proteins. Finally, in agreement with immunoblotting and IP results, the extra bands 
for variant B were identified as cystatin C also by mass spectrometry analysis. 
Interestingly, cystatin C protein was detected at the size of the two extra bands 
also in the wild-type sample. This is likely due to the higher sensitivity of mass 
spectrometry, compared to coomassie staining and immunostaining, that is able to 
detect the alternative forms of cystatin C for the wild-type, even though there were 
no visible bands on the gel/blot, meaning that they are present in very small 
amount. In only one of the blots shown (figure 5.5), it was actually possible to 
detect these extra bands also for the wild-type cystatin C, even though in lower 
levels compared to the variant B, as well as for the endogenous protein.  
The peptide mapping analysis performed by mass spectrometry in this study only 
permits a qualitative characterization of the proteins. The in-gel-digestion approach 
used prior to the analysis, does not give accurate protein quantification due to 
variability in the gel cutting and protein extraction efficiency from the gel. The 
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intensity of protein bands, observed on both gels and blots, therefore provides a 
more reliable relative quantification information than mass spectrometry, thus 
indicating that the amount of these alternative forms of cystatin C is higher in the 
case of the variant B. Other proteins revealed in this analysis are most probably 
contaminants. They are present at lower level compared to cystatin C, the 
confidence of their identification is low and they are often detected in the negative 
controls. Moreover, alternative forms of cystatin C were revealed also for the wild-
type (E1 and E2), with a number of unique spectra comparable to those seen for 
variant B, despite no visible bands on the blot/gel. This further suggests that 
proteins detected with spectra counts much lower than the cystatin C in E1 and E2 
fractions, must be present at insignificant levels. 
 
The shifts in molecular mass identified by immunoblotting suggested that there 
might be a post-translational modification and/or a shift in signal sequence 
cleavage. Based on mass spectrometry results, it suggested that this phenomenon 
can also occur for the wild-type cystatin C, but at a lower frequency. The A25T 
mutation seems therefore to increase the frequency with which the alternative 
cleavage normally occurs, as observed earlier by Nguyen and Hulleman (2016). 
However, that study showed that the higher propensity to undergo cleavage at Ala-
21 in the case of the variant B occurred only under certain experimental conditions. 
These consisted of introducing modifications, by addition or substitution of amino 
acid residues, in the region close to the Gly-26 site of cleavage. In the presence of 
these modifications, all the variant B proteins produced and secreted corresponded 
to the alternative cleaved form, suggesting that these modifications exacerbated 
the effect of the variant B mutation. In our study, where no additional 
modifications were introduced, these alternative forms are only present at very 
low levels, compared to the normal sized protein. Nilsson et al (2009) have 
revealed the presence of the miscleaved variant B, carrying O-glycans, by studying 
the glycoproteome in the CSF of human donors, therefore only analysing proteins 
carrying sugar molecules. Hence, in the CSF samples analysed in their study it 
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cannot be excluded the presence, along with this alternative form, of canonically 
cleaved, non-glycosylated variant B proteins. 
 
After having identified the nature of the proteins corresponding to the two extra 
bands, the cause of their shifts in size was investigated in section 5.3. In particular, 
glycosylation events were analysed. Results indicate that no N-linked glycosylation 
occurs, consistent with the lack of N-glycosylation acceptor sites within the 
sequence of cystatin C, whereas an O-linked glycosylation appears to characterise 
the largest band present in the conditioned media, thus confirming results 
obtained by Nilsson et al. (2009). Nguyen et al. also have reported, by using O-
glycosylation prediction software, that the Variant B cystatin C has a higher 
probability to undergo O-glycosylation compared to the wild-type protein (Nguyen, 
Hulleman 2016). Therefore, the amino acid substitution at the position -2 may 
determine the conditions that facilitate the occurring of the alternative cleavage at 
Ala-21, generating a form of cystatin C that is more inclined to O-glycosylation. 
However, the intermediate band, also observed in this study, appears not to be 
affected by the deglycosylation treatment. It may therefore represent the non-
glycosylated form of the alternative cleaved cystatin C. Another possibility is the 
presence of a third alternatively cleaved form of cystatin C, at the Ala-13 residue, 
reported by Nguyen et al. (2016), resulting in a 13 residue longer protein, whose 
size is consistent with the intermediate band detected in our study (Nguyen, 
Hulleman 2016).  
In ARPE19 cells only one additional minor band was detected in the conditioned 
media by immunoblotting, also at higher molecular weight, in the case of the 
variant B, but no further characterization was carried out. However, it also 
indicates that there might be a difference in the processing of the variant B, 
resulting in an alternative form of cystatin C. 
 
The second cleavage site at Ala-21, observed by Nilsson et al. (2009) and predicted 
by the use of specific software by Nguyen et al. (2016) is supported by the 
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presence, in the signal sequence of cystatin C, of another Ala-X-Ala motif, which 
often characterises the -1 and -3 residues of a signal peptide (Auclair, Bhanu & 
Kendall 2012), as described in section 1.5.1.2. Residues at these positions, usually 
consisting of small and neutral amino acids, are critical for the signal peptidase 
interaction and therefore for specifying the site of cleavage (Nothwehr, Gordon 
1990, Auclair, Bhanu & Kendall 2012). Cleavage at the site between residues 21 and 
22 of the precursor cystatin C is therefore also predicted by the (-1,-3) rule, as 
alanine residues occupy positions 18 and 20 (figure 5.7). 
The presence of Thr instead of Ala at -2 position may have an effect on the 
orientation of the c-region of the signal peptide at the active site of the signal 
peptidase, resulting in a less favourable interaction between the usual cleavage site 
(Gly-26) and the enzyme. Conversely, it may facilitate at the same time SPC 
interaction with the alternative site at Ala-21, which has probably become more 
accessible to signal peptidase. However, the effect of the A25T mutation on the 
position of the signal sequence is probably subtle, as the conventional mature 
protein is still obtained with much higher frequency compared to the alternative 
one, even in the case of the Variant B, where it represents only a partial minor 
fraction of the total processed protein. However, the higher presence of these 
alternatively glycosylated proteins may have an effect over time if they accumulate 
in the extracellular matrix.  
 
Alteration of the cleavage position modifies the amino acid composition of the 
mature protein, resulting in additional residues at its N-terminal. This may affect 
the protein folding, which, in turn, could allow specific acceptor amino acids to be 
conformationally accessible for O-glycosylation, and ultimately influence function 
and stability of cystatin C. O-glycosylation can affect many aspects of a protein, as 
folding, function and stability (Steen et al. 1998), which could influence the 
proteolytic regulation of cystatin C in the extracellular matrix. It is therefore 
important to understand how this alternative form can affect cystatin C properties. 
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Glycosylation represents one of the main post-translational modifications, which 
has been shown to play a role in many biological processes (Steen et al. 1998). O-
glycans have been found to monitor the status of the protein folding and to ensure 
their proper sorting to specific cellular compartment. They can modulate protein 
expression, their proteolytic processing, influence their structure and solubility, and 
consequently affecting their stability and half-life (Steen et al. 1998, Bektas, 
Rubenstein 2011). For instance, some oligosaccharides have been shown to 
increase protein stability, conferring protease-resistance (Steen et al. 1998). 
Conversely, glycans have also been found to increase protein ubiquitination, thus 
promoting proteasomal degradation (Steen et al. 1998). In addition, they can also 
influence the quaternary structure, promoting protein aggregation (Steen et al. 
1998). Furthermore, by affecting the conformation and stability of a protein, O-
glycans could influence a protein biological activity (Steen et al. 1998). O-glycans 
have been described to be critical for some protein-ligand interactions, mediating 
their binding and/or the signal transduction (Steen et al. 1998, Bektas, Rubenstein 
2011). Some O-glycans, in particular, can function as sensors in certain stress 
conditions, such as cell starvation and oxidative stress, promoting cell adaptation 
and survival by regulating gene expression and activity of signalling molecules, 
enzymes, structural proteins and transcription factors (Steen et al. 1998, Bektas, 
Rubenstein 2011). Improper glycosylation of these proteins has been shown to play 
a role in human diseases (Bektas, Rubenstein 2011). Interestingly, defects in 
glycosylation have been observed in several proteins involved in AD pathogenesis 
and neuronal function (Schedin‐Weiss, Winblad & Tjernberg 2014). This indicates 
that O-glycosylation modification plays an important role in protein biogenesis. 
 
As mentioned above, the alternative processed form of cystatin C would have six 
additional amino acids at the N-terminus and an O-glycosylation likely residing in 
this region. Importantly, the N-terminal region of the mature cystatin C is critical 
for functional and regulatory mechanisms of the protein. The N-terminal segment, 
particularly the residues at positions 8-11 (Arg-Leu-Val-Gly), is essential for the 
protease inhibition function of cystatin C (Abrahamson et al. 1991). This region 
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ensures the optimal interaction with the target peptidase and is responsible for the 
initial binding to its target cathepsins (Abrahamson et al. 1991, Nycander et al. 
1998). Cystatin C inactivation and regulation also depends on the N-terminal 
regions. Its proteolytic degradation occurs through its N-terminal truncation by 
different types of proteases, as described in section 1.2.2, so that its inhibitory 
capacity is removed (Abrahamson et al. 1991, Popovič et al. 1999). Furthermore, it 
has also been found that cystatin C uptake is dependent on the integrity of the N-
terminal segment; cleavage or amino acid substitution within this region has been 
shown to affect internalization of the protein (Wallin, Abrahamson & Ekstrom 
2013). Finally, during the process of dimerization it has been found that the 
inhibitory regions of cystatin C, including the N-terminal chains, are buried within 
the dimer interface, so that its activity is inhibited (Ekiel, Abrahamson 1996) and N-
truncated forms of cystatin C have been reported to be more prone to dimerization 
and aggregation (Janowski et al. 2004). Structural integrity of the N-terminal region 
of cystatin C is therefore crucial for its correct functionality and regulation. 
The presence of additional residues and the O-glycosylation in this region may 
therefore affect cystatin C inhibitory function, its inactivation, internalization or the 
dimerization process. As a consequence, in the first two cases, there would be an 
increase or decrease of cathepsin activity resulting in an imbalance of proteolytic 
activity in the extracellular matrix. If the uptake is prevented, there would be a 
dysregulation of proteolysis both intracellularly, in the lysosome, and 
extracellularly. Proteolytic dysfunction, both inside and outside the cell, can be 
linked to AMD and AD. A similar effect would occur in case the dimerization 
mechanism is disrupted, increasing or reducing the level of active protease 
inhibitor. Increased tendency for dimer formation could lead to generation of 
protein aggregates which may affect cystatin C functionality and sequester 
functional wild-type proteins reducing inhibitory function. Presence of the 
aggregates themselves can also be disruptive for proper cell function. Interestingly, 
cystatin C has been detected in β-amyloid plaques, even though its role is still 
controversial (section 1.3.3), as it has been reported to either inhibit or contribute 
to their formation (Kaur, Levy 2012). It is possible that cystatin C has a different 
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effect on the β-amyloid plaques depending on its status, and thus contributes to 
plaque formation when present as alternative glycosylated form. If this is the case, 
the presence of these alternative forms, at higher abundance in the case of the 
variant B may explain its link to AD. Furthermore, β-amyloid peptides have been 
also described in the drusen deposits (Zhao et al. 2015, Feng, Wang 2016), 
suggesting a possible role of cystatin C also in AMD pathogenesis. 
 
O-glycans can modify protein stability, making cystatin C more resistant or 
susceptible to degradation. In the first case, the presence of this fraction may 
become significant in the long-term. That would be even more relevant in condition 
of decreased activity of the cellular proteolytic system, as occurs in aging and age-
related diseases (Vilchez, Saez & Dillin 2014, Hipp, Park & Hartl 2014). If this 
fraction is not rapidly degraded, it might result in its accumulation over time, and 
especially for the variant B where this alternative form occurs at higher frequency. 
The gradual higher presence of this alternatively processed, secreted form may 
affect the proteolytic regulation in the extracellular matrix, depending on its effect 
on the protein (as discussed above). Another possibility is that the glycosylation 
occurring on alternatively cleaved cystatin C may, for example, act as a signal to 
convey to the cell the miscleavage and so send it for degradation or could target 
the protein to a different cellular compartment.  
 
Some members of the secretory type 2 family of cystatins (e.g. cystatin E/M, F) 
have been reported to carry glycosylation and differ in function and substrate 
selectivity compared to cystatin C (Ni et al. 1998, Soh et al. 2016, Hamilton et al. 
2008). Glycosylation may therefore influence the target selectivity of the protease 
inhibitor. Furthermore, N-glycans could be responsible for targeting cystatin F to 
endosomal-lysosome pathway, likely upon internalization of secreted proteins 
(Cappello et al. 2004), thus playing a role in the protein targeting. On the contrary, 
Cystatin C was always believed not to carry any glycosylation. Nilsson et al. (2009) 
for the first time have shown that glycosylation can also occur on cystatin C, even 
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though this was observed only for the variant B protein. Interestingly, several N- 
and O-linked glycoforms of the rat homologue of cystatin C have been found to be 
produced and secreted in adult rat hippocampal derived stem/progenitor cells 
(Dahl et al. 2004). N-glycans were described to be essential for bioactivity of 
cystatin C and contribute to stimulate neurogenesis in rat hippocampus, for the 
proliferation of adult neuronal stem cells (Dahl et al. 2004). Moreover, rat 
glycosylated form of cystatin C was also shown to induce proliferation of neural 
progenitor cells derived from human brains, thus suggesting a role of glycoforms in 
human cells (Dahl et al. 2004). Several O-glycosylated forms of cystatin C have been 
also shown to be secreted in mouse primary neurons in association with exosomes, 
a mechanism that seems to be involved in both AD and AMD pathogenesis (Wang 
et al. 2009, Tong et al. 2016, Vella et al. 2008, Ghidoni et al. 2011b).  
Overall, this suggests that glycosylation may also occur for the human cystatin C 
protein, although to a minor extent, and this could affect its function, stability and 
targeting. Glycosylation appears to occur especially in the case of the variant B, 
thus suggesting a possible link of the protein with the increased risk of disease 
development. 
 
Further analysis of the mechanisms of cystatin C regulation was carried out and is 
discussed in the next chapter. 
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6. Chapter 6 - Analysis of cystatin C 
protein regulation 
  
195 
 
6.1. Introduction 
Intracellular processing and trafficking of the variant B cystatin C have been mainly 
investigated in earlier reports. Since the A25T mutation occurs in the leader 
sequence, it was expected to have an effect on these cellular mechanisms, thus 
affecting localization and secretion of the protein.  
Based on the results obtained in this study and presented in the previous chapters, 
trafficking and secretion of variant B was shown not to significantly differ from that 
of wild-type cystatin C (chapter 3). Regarding the cleavage of the signal peptide, 
results suggested a less efficient processing for the variant B precursor, generating 
an uncleaved or alternatively cleaved product (chapter 4 and 5). However, no direct 
consequences in the short-term, such as mislocalization of the precursor protein or 
substantial change in the level of secreted proteins were identified. 
The aim of the work presented in this chapter was to further investigate possible 
differences between the two forms of cystatin C that could explain the link of the 
variant B with the increased risk of developing AD and AMD conditions. For this 
purpose, several aspects of protein regulation were explored, such as degradation, 
as well as mechanisms of regulation typical of cystatin C protein, such as 
dimerization and internalization. These aspects were evaluated within the wild-
type and variant proteins. Furthermore, preliminary identification of proteins that 
may differentially interact with the two forms of cystatin C, was carried out to 
identify possible differences between wild-type and variant B. 
 
6.2. Analysis of degradation pathways 
Degradation pathways were examined to analyse the protein stability of variant B 
cystatin C, which could affect the cellular concentration of the protein and 
consequently its protease inhibition activity in the cell. 
The two main proteolytic mechanisms include the ubiquitin-proteasome system 
(UPS) and the autophagy-lysosome pathway (ALP), both essential for the 
maintenance of cell homeostasis (described in section 1.2.3.1). The UPS is mainly 
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involved in degradation of misfolded proteins, which, if not removed, can cause ER 
stress and aggregation of damaged proteins in the cytosol (Amm, Sommer & Wolf 
2014). The ALP is involved in the removal of extracellular and membrane proteins 
as well as cytosolic large protein aggregates and damaged organelles (García-
Arencibia et al. 2010, Chang et al. 2015). They are therefore both fundamental 
components of quality control to guarantee protein turnover, regulate protein 
concentration and remove toxic, damaged cellular components (Hipp, Park & Hartl 
2014, Vilchez, Saez & Dillin 2014). Impairment in both degradative systems has 
been reported to occur in aging and be involved in several degenerative conditions, 
including AMD and AD (Cheung, Ip 2011, Nedelsky, Todd & Taylor 2008, Hipp, Park 
& Hartl 2014, Vilchez, Saez & Dillin 2014). 
Cystatin C inactivation occurs by proteolytic cleavage both in the extracellular 
environment and in the intracellular lysosomal compartment by the action of 
various proteases, such as cathepsin D and L, elastase and MMP2 (Abrahamson et 
al. 1991, Lenarčič et al. 1991, Dean et al. 2007, Laurent-Matha et al. 2012). 
Removal of the intracellular cystatin C occurs in the lysosomes. However, if 
proteins are not properly folded they could be delivered, through the ERAD 
pathway, for proteosomal degradation. Variant B cystatin C has been hypothesised 
to be partially uncleaved or differently cleaved (as described in chapter 4 and 5). 
These alternative forms can result in misfolded and/or amyloidogenic proteins, 
with impaired function or stability, which could accumulate intra- and extra-
cellularly. If misfolded proteins are not removed by the proteasome system, they 
can lead to formation of large protein aggregates, which then can be removed by 
autophagy and degraded in the lysosome (Buchberger, Bukau & Sommer 2010). 
Therefore, both UPS and ALP pathways were analysed to investigate whether they 
are activated in the case of the variant B, to determine whether there is any 
impairment associated with this form of cystatin C. Analysis was carried out by 
evaluating the level of cystatin C following inhibition of either the UPS or ALP 
pathways using the inhibitors MG132 and Chloroquine (CQ), respectively. MG132 
blocks the proteolytic activity of the 26S proteasome complex (Han et al. 2009, 
Zhan et al. 2016), whereas Chloroquine (CQ) inhibits lysosomal enzyme activity by 
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altering the intra-lysosomal pH, and prevents fusion of autophagosomes and 
endosomes with lysosomes (Solomon, Lee 2009). Cystatin C constructs tagged to 
FLAG or HA at the C-terminus were used in this analysis. 
 
6.2.1. Inhibition of degradative systems affects equally wild-type 
and variant B cystatin C 
ARPE19 cells transfected with HA-tagged wild-type or variant B cystatin C 
constructs were treated over-night with MG132 or CQ. Cell lysates and conditioned 
media were then collected and analysed by immunoblotting using anti-cystatin C 
antibody, which detects transfected and endogenous cystatin C. Non-transfected 
cells were also analysed as a control. Immunoblots using anti-GAPDH antibody 
were used as loading control. 
Results obtained after MG132 treatment showed a reduction in the levels of both 
wild-type and variant B cystatin C constructs as well as of the endogenous cystatin 
C detected after higher exposure (Figure 6.1). However, no difference was 
apparent between wild-type and variant B levels after proteasome inhibition. A 
reduction of secreted proteins could be also observed in the conditioned media, 
probably as a consequence of the decreased intracellular level. Interestingly, in 
figure 6.1, the bands likely corresponding to the uncleaved precursor were 
enhanced after proteasome inhibition in both wild-type and variant B proteins.  
Results obtained after CQ treatment displayed an increase in the levels of both 
wild-type and variant B cystatin C constructs as well as of the endogenous protein 
in ARPE19 cells, as compared to the non-treated controls (Figure 6.2). Also in the 
conditioned media an increase of secreted proteins could be observed. 
The same analysis was performed in ARPE19 cells transfected with FLAG-tagged 
cystatin C constructs, shown in figure 6.3. Cell lysate and media were collected 
after over-night treatment with either MG132 or CQ and analysed by 
immunoblotting. Results obtained after proteasome inhibition showed again a 
reduction in the levels of cystatin C at a similar extent for both wild-type, variant B, 
198 
 
and endogenous cystatin C. However, results obtained after CQ treatment do not 
show the same extent of protein increase observed with HA tagged constructs. 
Overall, there is no evidence for a difference in the effect of either ALP or UPS on 
cystatin C levels between wild-type and variant B proteins. However, a general 
effect on cystatin C protein, endogenous and transfected, consisting in a decrease 
or increase, seems to occur after UPS and ALP inhibition, respectively.  
 
 
Figure 6.1 - Immunodetection of cystatin C in ARPE19 cells transfected with HA-tagged 
constructs after treatment with proteasome inhibitor MG132. Cell lysate and conditioned 
media samples collected from ARPE19 cells transfected with either wild-type or variant B 
constructs and subjected to UPS inhibition using MG132 (5µM) over-night were analysed 
by immunoblotting. Anti-cystatin C antibody was used to detect the transfected cystatin C 
constructs as well as the endogenous cystatin C visible at higher exposure. Anti-GAPDH 
antibody was used as loading control for cell lysates. Non-transfected cells were also 
analysed. 
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Figure 6.2 - Immunodetection of cystatin C in ARPE19 cells transfected with HA-tagged 
constructs after treatment with ALP-inhibitor chloroquine (CQ). Cell lysate and 
conditioned media samples collected from ARPE19 cells non-transfected and transfected 
with either wild-type or variant B constructs and subjected to ALP inhibition using CQ 
(25µM) over-night were analysed by immunoblotting. Anti-cystatin C antibody was used to 
detect the transfected cystatin C constructs as well as the endogenous cystatin C visible at 
higher exposure. Anti-GAPDH antibody was used as loading control for cell lysates. Non-
transfected cells were also analysed. 
 
 
Figure 6.3 - Immunodetection of cystatin C in ARPE19 cells transfected with FLAG-tagged 
constructs after treatment with MG132 or Chloroquine (CQ). Cell lysate and conditioned 
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media samples collected from ARPE19 cells non-transfected and transfected with either 
wild-type or variant B constructs and subjected to MG132 (5µM) or CQ (25µM) over-night 
were analysed by immunoblotting. Anti-cystatin C antibody was used to detect the 
transfected cystatin C constructs as well as the endogenous cystatin C visible at higher 
exposure. Anti-GAPDH antibody was used as loading control for cell lysates. 
 
6.2.2. Cystatin C expression increases after ALP inhibition and 
decreases after UPS inhibition 
Since no difference was identified between wild-type and variant B levels and the 
same effect was obtained for both the transfected proteins and the endogenous 
cystatin C, the level of the endogenous protein only was further analysed in non-
transfected ARPE19 cells. Immunoblotting analysis (figure 6.4 a) shows results 
obtained after CQ treatment over-night. The levels of endogenous cystatin C were 
quantified and normalised to the level of GAPDH. Quantification is reported in the 
graph in figure 6.4 b, with the level of cystatin C in the non-treated sample set to 1. 
Results showed a significant increase in cystatin C levels compared to the non-
treated control, thus confirming the observation in figure 6.2. 
The same analysis on endogenous cystatin C levels was performed on cells treated 
over-night with proteasome inhibitor MG132 (figure 6.5 a). Levels of cystatin C 
were quantified and normalised to the levels of GAPDH and results plotted in graph 
6.5 b. Results showed a significant decrease in the level of endogenous cystatin C 
compared to the non-treated control. Proteasome inhibition seems therefore to 
have a particularly important effect on cystatin C levels. Such an effect could be 
due to an indirect regulation operating at the translational or transcriptional level.  
To further investigate this aspect, the levels of mRNA expression of endogenous 
cystatin C were analysed by quantitative RT-PCR after over-night treatment with 
MG132. mRNA levels of cystatin C were normalised to levels of GAPDH and Ct 
values were measured in treated and not treated cells for comparison (figure 6.6 
a). ΔCt values were plotted using a column bar graph (figure 6.6 b). No significant 
differences between cystatin C mRNA levels in MG132-treated and non-treated 
samples were found by using two different statistical tests. 
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Figure 6.4 - Immunodetection of endogenous cystatin C in ARPE19 cells after treatment 
with Chloroquine (CQ). a) Cell lysates collected from ARPE19 cells subjected to CQ (25µM) 
treatment over-night were analysed by immunoblotting with anti-cystatin C antibody. Anti-
GAPDH antibody was used as loading control for cell lysates. b) Levels of cystatin C were 
quantified by densitometry and normalized to level of GAPDH. Level of cystatin C in non-
treated cells was set to 1. Level after treatment results 1.90 ± 0.56. Standard deviation is 
shown in the graph. One-sample t test (N=3), p=0.03 (*p<0.05) 
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Figure 6.5 - Immunodetection of endogenous cystatin C in ARPE19 cells after treatment 
with MG132. a) Cell lysates collected from ARPE19 cells subjected to MG132 (5µM) 
treatment over-night were analysed by immunoblotting with anti-cystatin C antibody. Anti-
GAPDH antibody was used as loading control for cell lysates. b) Levels of cystatin C were 
quantified by densitometry and normalized to level of GAPDH. Level of cystatin C in non-
treated cells was set to 1. Level after treatment results 0.15±0.11. Standard deviation is 
shown in the graph. One-sample t test (two-tailed, N=3), p=0.005 (** p≤0.005) 
 
 
 
Figure 6.6 - Relative quantification of cystatin C mRNA in ARPE19 cells after proteasome 
inhibition. RNA was isolated from ARPE19 cells treated and non-treated with MG132 
(5µM) over-night. cDNA was subsequently generated and analysed by qPCR. Comparative 
Ct method (ΔCt) was used for relative quantification. Data were normalized using human 
GAPDH and ΔCt values obtained in treated cells were compared to non-treated. 2^-ΔCt 
was calculated to assess whether there is a change of cystatin C mRNA expression. a) 
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Values of calculated 2^-ΔCt are reported in the table for three independent experiments. 
Paired t test (N=3), p=0.26 b) Data were plotted in bar graph with standard deviation 
shown. mRNA level of non-treated was set to 100% and level after MG132 treatment 
results 91.33% ± 8.56%. One-sample t-test (N=3), p=0.22, ns=non-significant. 
   
6.3. Analysis of cystatin C dimerization shows no difference 
between wild-type and variant B  
Protein dimerization is a mechanism that has been suggested to regulate level of 
active cystatin C in the cell, as in this conformation its activity is inhibited. This 
mechanism has been hypothesized to be involved in different cellular processes 
(described in section 1.2.2) and its impairment can lead to a proteolytic 
dysregulation and, more importantly, to protein aggregation (Janowski et al. 2001). 
Dimerization was particularly promoted in the case of the L68Q variant cystatin C 
that causes a severe form of amyloidosis (Wei et al. 1998, Rodziewicz-Motowidlo et 
al. 2006). The aim of the work presented in this section was to investigate whether 
a difference in the tendency of dimerization occurs between wild-type and variant 
B cystatin C proteins. If this is the case, a proteolytic imbalance or aggregation-
related conditions may occur affecting cell functionality. 
 
In order to analyse dimerization of intracellular cystatin C, RPE cells were co-
transfected with both the FLAG-tagged and the HA-tagged cystatin C constructs, 
either wild-type or variant B. Cell lysates where then subjected to 
immunoprecipitation by using anti-FLAG beads to pull down only the FLAG-tagged 
constructs. Subsequent immunoblotting, by probing with either anti-FLAG or anti-
HA, was performed to assess whether HA-tagged cystatin C constructs were also 
pulled down, which would indicate that they were in a dimer/multimer with the 
FLAG constructs. Levels of HA-tagged constructs were compared between wild-
type and variant B proteins to estimate a difference in their dimerization. 
In figure 6.7, immunoblotting results obtained in both ARPE19 (a) and D4O7 (b) 
cells show that HA-linked constructs are also detected in the pull-down samples 
(IP), and, taking in consideration the level of FLAG-tagged constructs isolated, their 
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level appears to be similar in both wild-type and variant B. For the D4O7 cells, non-
transfected cells were also analysed as control. Cell lysates, prior to protein pull-
down, were also displayed on the gel, showing that cells have similar levels of wild-
type and variant protein expression, for both HA and FLAG constructs used. 
However, cystatin C-HA was only detected in the IP samples at very high exposure, 
indicating that dimerization did not occur extensively.  
Analysis of dimerization was subsequently performed also for the extracellular 
cystatin C. Immunoprecipitation was carried out on the conditioned media samples 
collected from co-transfected D4O7 cells. This time, to ensure that the presence of 
the HA-constructs was not due to unspecific binding/pull-down but was actually 
due to its dimerization with the FLAG-constructs, samples from cells transfected 
with only the FLAG constructs or the HA constructs were analysed in parallel. 
In figure 6.8 immunoblotting analysis was performed on media samples subjected 
to immunoprecipitation (a), media samples prior to pull-down (b) and respective 
cell lysates (c). For each of them, samples co-transfected with both constructs or 
transfected with only one construct, are shown. Cell lysates and media samples 
prior the pull-down were used to show the level of expression of the various 
constructs. For each construct, both wild-type and variant B showed a similar level 
of expression and secretion. In the blot in figure 6.8 a, the presence of HA-tagged 
cystatin C can be observed in the pull-down samples, meaning that dimers are also 
formed in the extracellular environment. At higher exposure it is possible to see 
bands corresponding to the HA-tagged constructs also in the samples deriving from 
cells transfected only with those constructs, which should not be present in the IP 
samples. This indicates that there is a fraction of protein that is non-specifically 
pulled down during the immunoprecipitation. However, when compared to the 
level detected in the co-transfected samples, it is much lower, especially 
considering their higher levels in the media (prior to pull-down) compared to the 
one of the co-transfected sample. Therefore, the bands detected in the co-
transfected immunoprecipitated samples, using anti-HA antibody, mainly 
correspond to HA-tagged proteins that were in association with the FLAG-tagged 
cystatin C, even though they probably contain some non-specific pulled down 
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proteins. Overall, no differences were found in the level of protein dimerization for 
both intracellular and extracellular cystatin C between the wild-type and variant B 
proteins. 
 
 
Figure 6.7 - Dimerization analysis in RPE cells co-transfected with FLAG- and HA-tagged 
constructs after immunoprecipitation from cell lysates. Cell lysates collected from ARPE19 
(a) or D4O7 (b) cell line co-transfected with both FLAG- and HA-tagged constructs were 
subjected to immunoprecipitation to pull down the FLAG-tagged constructs and 
subsequently analysed by immunoblotting to assess level of HA-tagged constructs. For the 
D4O7 cells (b), cell lysate samples, prior the pull-down, were also analysed. Non-
transfected cells (NT) were used as control. Anti-FLAG and anti-HA antibodies were used to 
detect FLAG-tagged and HA-tagged constructs respectively. Level of GAPDH in the cell 
lysates was also shown. 
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Figure 6.8 - Dimerization analysis in D4O7 cells co-transfected with FLAG- and HA-tagged 
constructs after immunoprecipitation from conditioned media. a) Conditioned media 
collected from D4O7 cell line co-transfected with both FLAG- and HA-tagged constructs or 
only with FLAG or HA-tagged cystatin C were subjected to immunoprecipitation to pull 
down the FLAG-tagged constructs and subsequently analysed by immunoblotting to assess 
level of HA-tagged constructs. Media samples (b), prior to pull-down, and cell lysates (c) of 
the respective transfected cell lines were also shown. Anti-FLAG and anti-HA antibodies 
were used to detect FLAG-tagged and HA-tagged constructs respectively. Level of GAPDH 
was shown for the cell lysates. Samples from cells transfected with only one construct, 
either FLAG- or HA-tagged, were used as control. 
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6.4. Analysis of cystatin C internalization shows no 
difference between wild-type and variant B 
Cystatin C re-uptake from the extracellular matrix is a clathrin-mediated 
endocytosis mechanism essential to ensure the presence of cystatin C in the 
intracellular endosomal-lysosome compartment, where it is crucial for the 
regulation of the lysosomal cathepsin activity (Wallin, Abrahamson & Ekstrom 
2013). This mechanism has been also suggested to regulate the level of cystatin C 
both intracellularly and extracellularly (Wallin, Abrahamson & Ekstrom 2013, Wallin 
et al. 2010). Impairment of cystatin C uptake can therefore result in imbalance of 
proteolytic activity in both lysosomes and the ECM. 
Analysis of protein uptake was therefore investigated to see whether any 
difference occurs between wild-type and variant B protein. Both FLAG-tagged and 
HA-tagged constructs were used for this analysis.  
Conditioned media from RPE cells transfected with wild-type and variant B 
constructs were collected 24-hour post-transfection and used to culture non-
transfected RPE cells. After 24 hours these cells were collected and analysed for 
their internalization by immunoblotting using anti-cystatin C antibody (figure 6.9). 
A main band corresponding to the endogenous cystatin C was detected in these cell 
lysates. In D4O7 cells it is also detected a slower migrating band that corresponds 
to the exogenous cystatin C construct that has been internalized by endocytosis. 
Using either FLAG- or HA- tagged constructs, no difference was observed between 
wild-type and variant B cystatin C, indicating no modification to the internalization 
process in the case of the variant B protein. However, after 24 hours it was not 
possible to detect internalised proteins in ARPE19 cells. Probably the time is not 
sufficient to permit a substantial uptake of cystatin C in this cell line. 
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Figure 6.9 - Immunodetection of cystatin C in RPE cells for internalization analysis. D4O7 
(a) or ARPE19 (b) cells were cultured in conditioned media collected from cells transfected 
with wild-type or variant B cystatin C constructs linked to either FLAG or HA tag at the C-
terminal. Media was collected 24 hours after transfection (shown in the first four lanes of 
each blot) and cells and media from the non-transfected collected after another 24 hours. 
GAPDH levels were also detected as loading control for the cell lysates. 
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6.5. Analysis of cystatin C interacting proteins shows no 
difference between wild-type and variant B 
To further investigate possible differences between wild-type and variant B cystatin 
C proteins, analysis of the proteins interacting with cystatin C form was performed.  
D4O7 cells transfected with FLAG-tagged wild-type and variant B cystatin C were 
subjected to immunoprecipitation by using anti-FLAG beads in order to pull down 
the FLAG-tagged proteins. These samples were then analysed by mass 
spectrometry to reveal the proteins pulled-down together with cystatin C, which 
represent potential binding partners. The blot in figure 6.10 a) shows pull-down 
samples immunodetected with anti-FLAG antibody to ensure that the 
immunoprecipitation of the protein of interest was successful before proceeding 
with the mass spectrometry. Cell lysates prior the pull down were also loaded to 
ensure that the transfection worked comparably for both constructs. Subsequently, 
the pull-down samples were loaded onto a gel and detected by coomassie blue 
staining (figure 6.10 b). For each sample the entire lanes were cut from the gel and 
subjected to mass spectrometry analysis to identify the proteins pulled down 
together with the protein of interest, in order to analyse whether the variant B 
interacts with different proteins compared to the wild-type. As discussed for the 
previous mass spectrometry analysis (chapter 5), the approach as used does not 
allow a proper quantification of the proteins, so it can be used only as a qualitative 
analysis. 
Table 9 shows the proteins identified for each sample, in two independent 
experiments, where the exclusive unique spectra count is shown. Proteins selected 
and displayed in the table 9 are only those that were not present or present in a 
much lower level in the negative control compared to the FLAG-tagged constructs 
pull-down samples. The negative control was non-transfected cells also subjected 
to anti-FLAG beads precipitation, representing proteins that bind non-specifically to 
the beads. Proteins with less than five spectra counts were not considered and 
shown in the table. 
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The first four samples (highlighted in bold) listed in table 9 confirm the 
effectiveness of the analysis, as cystatin C is one the most abundant proteins 
present in the cystatin C pull-down samples compared to the negative control. The 
other three proteins listed were also expected as they are known binding proteins 
of cystatin C. Cathepsins B, L and C are targets for inhibition by cystatin C (Turk, 
Bode 1991). Their presence suggests the effective pull-down of cystatin C 
interacting proteins, thus giving credibility to the analysis. The other proteins 
identified may therefore likely represent other potential binding proteins of 
cystatin C. Furthermore, the presence of cathepsins also indicates that the cystatin 
C constructs effectively bind their normal targets and confirming that the protein 
functionality is likely not affected by the tag. More importantly, their presence also 
in the variant B protein indicates that the protein may still fulfil its activity similar as 
the wild-type cystatin C.  
Among the proteins identified, some of them are worth brief description (Table 
10). Most are chaperones and enzymes present in the ER/Golgi secretory pathway 
thus likely representing cystatin C interacting proteins. The Uniprot accession 
number for each protein identified was provided with the analysis. Information 
reported was also obtained from the Uniprot database. 
Other proteins identified correspond to structural proteins probably non-
specifically pulled down and some others proteins detected (not listed in table 9) 
have a very small spectra count that renders their presence unreliable.  Overall, no 
difference between wild-type and variant B cystatin C samples was identified. 
However, some potential intracellular binding partners for cystatin C may be of 
interest for further investigation to determine the significance of this interaction. 
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Figure 6.10 - Detection of protein pull-downs prior to mass spectrometry analysis. a) 
immunodetection of FLAG-tagged cystatin C constructs after protein pull-down from D4O7 
cell lysates expressing FLAG-tagged wild-type or variant B cystatin C. Blot was probed with 
anti-FLAG antibody. Non-transfected cells (NT) were also used as negative control. Cell 
lysates prior to immunoprecipitation were also loaded. b) Coomassie blue staining of same 
pull-down samples. Entire lanes for the three samples were cut from the gel for 
subsequent mass spectrometry analysis. 
 
Table 9 - Mass spectrometry analysis for identification of cystatin C interacting proteins. 
Entire lanes were extracted from the gel in figure, subjected to in-gel digestion using 
trypsin and analysed by mass spectrometry. Proteins were identified in each sample (WT 
cysC, VB cysC and NT), from two independent experiments, by using Mascott and reported 
in the table below, displaying number of exclusive unique spectra. 
   Exp1 Exp2 
 Identified Proteins Molecular 
Weight 
WT 
cysC 
VB 
cysC 
NT WT 
cysC 
VB 
cysC 
NT 
1 Cystatin-C 16 kDa 41 34 4 44 41 4 
2 Dipeptidyl peptidase 1 
(Cathepsin C)  
52 kDa 22 20 0 16 19 0 
3 Cathepsin B 38 kDa 11 7 0 9 10 0 
4 Cathepsin L1  38 kDa 9 6 0 8 7 0 
5 E3 ubiquitin-protein ligase 
HUWE1 482 kDa 21 18 2 8 22 5 
6 Leucyl-cystinyl aminopeptidase  117 kDa 53 34 0 49 53 0 
7 Heat shock 70 kDa protein 4L  95 kDa 17 14 0 27 23 8 
8 Heat shock 70 kDa protein 4 94 kDa 22 18 3 42 40 18 
9 Heat shock protein 105 kDa  97 kDa 18 11 3 29 22 9 
a) b) 
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10 Calnexin 68 kDa 32 32 6 30 37 8 
11 Endoplasmin  92 kDa 18 15 3 17 17 9 
12 Nodal modulator 2  139 kDa 22 24 0 19 33 1 
13 Dolichyl-
diphosphooligosaccharide-
protein glycosyltransferase 
subunit 2  
69 kDa 8 17 3 15 19 0 
14 Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit 1 
69 kDa 16 21 4 18 16 4 
15 Sequestosome-1  48 kDa 10 11 0 21 20 1 
16 Protein zer-1 homolog  88 kDa 8 15 0 20 21 0 
17 Calreticulin  48 kDa 7 8 0 11 12 7 
18 Protein ERGIC-53  58 kDa 7 4 0 12 11 0 
19 Integrin beta-1 88 kDa 9 8 0 9 11 0 
20 Procollagen-lysine,2-
oxoglutarate 5-dioxygenase 3  
85 kDa 8 11 0 9 15 0 
21 Baculoviral IAP repeat-
containing protein 6  
530 kDa 53 40 0 13 36 0 
22 Stress-70 protein, mitochondrial 74 kDa 61 61 20 85 81 42 
23 78 kDa glucose-regulated 
protein 
72 kDa 54 59 20 74 67 38 
24 Heat shock cognate 71 kDa 
protein 
71 kDa 48 48 21 68 60 38 
25 Nuclear pore membrane 
glycoprotein 210 
205 kDa 
20 23 0 16 23 0 
26 Cation-independent mannose-6-
phosphate receptor 274 kDa 
20 15 0 6 11 1 
27 Nicalin 63 kDa 7 4 0 13 9 0 
28 dCTP pyrophosphatase 1  19 kDa 7 7 0 10 11 0 
29 Laminin subunit gamma-1  178 kDa 8 4 0 7 11 0 
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Table 10 - Description of proteins identified in mass spectrometry analysis. 
Identified Proteins UniProt Code Description 
Leucyl-cystinyl 
aminopeptidase 
Q9UIQ6 Exopeptidase responsible for the degradation of 
several hormones mainly involved in maintenance 
of cardiovascular homeostasis as well as in the 
inactivation of neuronal peptides. It is not known 
if this protease is regulated by cystatin C 
E3 ubiquitin-protein 
ligase HUWE1 
Q7Z6Z7 Enzyme that mediates ubiquitination of proteins 
for their proteasomal degradation 
Protein zer-1 homolog Q7Z7L7 Subunit of the E3 ligase 
Heat shock 70 kDa 
protein 4, 4L 
P34932 and 
O95757 
Molecular chaperone involved in the protein 
folding and assembly, protein transport and 
response to unfolded proteins 
Heat shock protein 
105 kDa 
Q92598 Chaperone involved in protein folding and that 
prevents aggregation of misfolded protein under 
stress condition 
Heat shock cognate 
71 kDa protein 
P11142 Role in transcriptional regulation in inflammatory 
response and in the ERAD pathway for 
degradation of misfolded proteins 
Calnexin and 
Calreticulin 
P27824 and 
P27797 
ER chaperones that mediate the proper folding of 
N-linked glycoproteins targeted to the secretory 
pathway. Also involved in the retention of 
misfolded proteins in the ER for subsequent 
degradation 
Endoplasmin P14625 ER chaperone involved in the correct processing 
and transport of secretory proteins and in ERAD 
pathway 
Protein ERGIC-53 P49257 Mannose-binding protein for transport of 
glycoproteins from ER to the ERGIC compartment 
Dolichyl-
diphosphooligosaccha
ride-protein 
glycosyltransferase 
subunit 1, 2 
P04843 and 
P04844 
Enzyme that mediates the transfer of an 
oligosaccharide precursor to a nascent 
polypeptide chain, essential step for N-
glycosylation of proteins 
Sequestosome-1 Q13501 Involved in targeting proteins and aggregates for 
autophagy 
Baculoviral IAP 
repeat-containing 
protein 6 
Q9NR09 Anti-apoptotic protein that regulates caspases 
and promotes degradation of pro-apoptotic 
molecules 
Stress-70 protein, 
mitochondrial 
P38646 Heat shock protein present in mitochondria, ER, 
nuclei and cytosol involved in controlling cell 
proliferation and cellular aging 
78 kDa glucose-
regulated protein 
P11021 Also known as BiP, is involved in mediating the 
efficient ER translocation of proteins and their 
subsequent correct folding and assembly in the ER 
as well as in the degradation of misfolded 
proteins 
Cation-independent 
mannose-6-
phosphate receptor 
P11717 It targets glycoproteins from the TGN 
compartment to the lysosomes, as occurs for the 
lysosomal cathepsins 
214 
 
6.6. Discussion 
Cystatin C levels and activity are controlled by several mechanisms including 
degradation, dimerization and internalization (described in section 1.2.2). The aim 
of the work presented in this chapter was to investigate whether the variant B is 
differently regulated compared to the wild-type. Deregulation of any of these 
mechanisms could lead to a change of protein activity in the intracellular and/or 
extracellular compartment. This could lead to an imbalance in proteolytic activity, 
affecting several other cellular processes in which cystatin C might be involved in 
RPE, such as inflammation, apoptosis, ECM remodelling and angiogenesis.  
 
Inhibition of ALP or UPS degradative pathways was shown to affect cystatin C 
protein levels, but influencing the wild-type and variant B in the same way. 
Therefore, no difference in variant B protein stability and degradation seems to 
occur. 
Analysis in section 6.3 showed that dimerization of cystatin C occurs in RPE cells in 
both intracellular and extracellular compartments. However, it appears to involve a 
relatively small fraction of the total protein. A precise quantification of the extent 
of this process cannot be evaluated with the experimental approach used in this 
study, as only levels of HA-tagged constructs dimerizing/multimerizing with the 
FLAG-tagged constructs could be evaluated. This approach does not detect the 
fraction of FLAG-tagged cystatin C that also forms dimers with the same constructs 
as well as HA-constructs with themselves. Furthermore, this approach cannot tell 
us if the proteins detected are part of dimers, multimers or aggregates. As cystatin 
C has been reported to only form dimers in physiological conditions (Janowski et al. 
2001), we can therefore assume that this is the only species present. However, no 
difference in dimerization was identified for the variant B compared to the wild-
type. 
Analysis of cystatin C internalization showed protein uptake to occur in D4O7 cells. 
However, it was not observed with the ARPE19 cell line. This might be due to cell 
line differences and more time may be needed to allow the cystatin C uptake in 
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ARPE19 cells. However, these results indicate that the process of internalization 
occurs in RPE cells and no difference was again identified between wild-type and 
variant B.  
Results obtained from mass spectrometry in section 6.5 also showed no difference 
in the potential proteins interacting with cystatin C wild-type and variant B. The 
presence of the known target cathepsins for both forms of cystatin C suggests that 
variant B maintains its protease inhibitory activity. No additional proteins were 
found interacting with the variant B that could suggest its involvement in different 
cellular processes or its presence in other cellular compartments. In this regard, the 
lack of mitochondrial proteins further confirms that no mislocalization to the 
mitochondria occurs for variant B. Most of the proteins identified are enzymes and 
molecular chaperones mainly present in the ER/Golgi compartments implicated in 
the process of protein folding to ensure appropriate transport through the 
secretory pathway. Their presence is therefore not surprising. Interestingly, several 
proteins implicated in the glycosylation of nascent polypeptides were identified to 
interact with both wild-type and variant B, supporting the presence of cystatin C 
glycoforms described in chapter 5. Proteins involved in ERAD pathway and 
proteasomal degradation as well as autophagy were also detected. This supports 
the hypothesis of the presence of misfolded precursor or alternatively processed 
fractions, which activate these degradative pathways. In this study this occurred for 
both wild-type and variant B, possibly because of the protein over-expression 
overwhelming the system, as described previously. Proteins involved in cell 
proliferation and apoptosis are also consistent with the role of cystatin C found in 
earlier reports (as described in section 1.2.3). These potential binding candidates, 
however, need to be further investigated to confirm their interaction with cystatin 
C. 
 
Overall, results presented in this chapter indicate that no difference occurs in any 
of the investigated mechanisms of regulation between the wild-type and the 
variant B mature cystatin C, therefore excluding, most probably, their involvement 
in variant B association with diseases. Furthermore, mass spectrometry analysis did 
216 
 
not suggest any other mechanisms involving exclusively the variant B based on a 
similar set of interacting proteins. However, as this analysis is only qualitative, it 
cannot tell us whether there is a quantitative difference that could be of functional 
relevance. 
 
In the analysis of degradation (section 6.2), although no difference was found 
between wild-type and variant B proteins, significant effects on cystatin C protein 
expression were observed, consisting in a profound decrease of its level after UPS 
inhibition and, conversely, an increase after ALP inhibition. These findings were 
similar for both wild-type and variant B transfected proteins as well as for the 
endogenous protein, thus indicating a general effect on cystatin C mediated by 
both degradation pathways. 
The ALP inhibitor, chloroquine, specifically increases the pH within the lysosome 
compartment (Solomon, Lee 2009), which suppresses the lysosomal proteases 
activity, and inhibits the fusion of autophagosomes and endosomes with the 
lysosome, preventing removal of cellular debris, damaged proteins and aggregates 
engulfed in such compartments (Chen, Gombart & Chen 2011, Yoon et al. 2010). 
Previous studies have also investigated the effect of chloroquine on ARPE19 cells. 
Consistently, chloroquine caused lysosome dilation and accumulation of 
intracellular vacuoles leading to progressive accumulation of debris and 
impairment of the phagocytic activity (Chen, Gombart & Chen 2011, Yoon et al. 
2010), thus simulating the effect of impaired autophagy that occurs in the RPE in 
age-related conditions (Kaarniranta et al. 2013, Guha et al. 2014). Therefore, the 
increase of cystatin C levels, observed after ALP inhibition in this study, may be due 
to its accumulation in the autophagosomes and/or lysosomes, as it cannot be 
degraded. In particular, its presence in the endosomal-lysosome compartment, 
occurring upon internalization, reflects its physiological function in these cellular 
organelles, where it regulates cysteine-cathepsin activity and where cystatin C is 
itself degraded (Watanabe et al. 2014, Wallin, Abrahamson & Ekstrom 2013, Wallin 
et al. 2010). If the lysosomal activity is suppressed, the turnover of cystatin C would 
be therefore impaired, thus causing an increase of its level in these compartments. 
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In particular, down-regulation of aspartic-cathepsin D has been reported to occur 
due to lysosomal alkalinisation, causing impairment in photoreceptor outer 
segment (POS) degradation in RPE, during aging and AMD (Chen et al. 2009, Guha 
et al. 2014). Interestingly, cathepsin D is also known to be one of the proteases 
involved in cystatin C inactivation (Lenarčič et al. 1991). Therefore, reduced activity 
of cathepsin D after CQ treatment may determine the increased cystatin C level 
observed in this study. However, considering the low extent of internalization after 
24-hours, observed in RPE cells in this study, it seems unlikely that such increase of 
cystatin C occurs in the lysosomes, where its presence is due to re-uptake from the 
extracellular space, unless a very rapid degradation/turnover of cystatin C normally 
occurs within the lysosome, or there is a significant increase in the process of 
internalization in response to the ALP inhibition.  
The presence of cystatin C in the autophagosomes can be also due to the formation 
of cystatin C protein aggregates, as it is an aggregation-prone protein (Janowski et 
al. 2001, Tsiolaki et al. 2015) and this condition was hypothesized to particularly 
occur for the variant B (as discussed in chapter 4). Such protein aggregates, 
normally removed by the autophagy system, may accumulate in the 
autophagosomes because of the CQ-mediated ALP dysfunction, which could 
explain the increase of cystatin C protein levels. However, this second scenario is 
unlikely since it occurs not only for the over-expressed wild-type and variant B 
proteins but also for the endogenous cystatin C. Furthermore, based on the 
hypothesis, it is the precursor fraction that has been suggested to generate 
aggregates and not the mature cystatin C. 
In addition, cystatin C has been also reported to promote autophagy via inhibition 
of the AMPK-mTOR pathway with a mechanism independent of its protease 
inhibitory activity (section 1.3.2) (Tizon et al. 2010b). Activation of the autophagy 
pathway by increasing cystatin C levels has been shown to occur particularly under 
stress conditions, such as starvation and oxidative stress, and to be protective in 
several neurological disease conditions and atherosclerosis (Liu et al. 2014, Liu et 
al. 2013, Tizon et al. 2010b, Watanabe et al. 2014, Li et al. 2016), enhancing protein 
degradation and preventing apoptosis of neuronal cells. Therefore, through 
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mechanisms still unknown, possibly involving regulation of cystatin C gene 
expression, it is possible that the increase of cystatin C observed in this study after 
ALP-inhibition occurs as cellular response to activate the down-regulated ALP 
degradation system. However, since lysosomal degradation is not functional, 
accumulation of autophagosomes and debris would progressively increase. It is not 
known whether this sort of regulation occurs and whether it modulates cystatin C 
at transcriptional or translational level. These aspects therefore need further 
investigation.  
Interestingly, autophagy is particularly activated in several degenerative diseases 
characterised by lysosome dysfunction, including Alzheimer, Parkinson, Huntington 
and AMD (Cheung, Ip 2011, Kaarniranta et al. 2013, Kaarniranta et al. 2010), due to 
increased debris accumulation and protein aggregation. However, excessive 
activation of the autophagic pathway as a consequence of lysosomal dysfuntion 
has been suggested to further contribute to protein aggregation and ultimately 
lead to cell death (Wang et al. 2009, Watanabe et al. 2014, Cheung, Ip 2011).  
Finally, oxidative stress conditions and lysosome dysfunction can also lead to 
lysosomal membrane permeabilization (LMP) with consequent release of lysosomal 
enzymes (Zdolsek, Svensson 1993, Watanabe et al. 2014). In addition to the 
consequent decreased proteolytic activity, lysosomal components and debris 
released from the lysosomes may form aggregates in the cytosol and induce 
inflammation and apoptosis. Cystatin C has been also found in the cytosol upon 
LMP and consequently aggregates under oxidative stress conditions (Watanabe et 
al. 2014). This could also explain the increase of intracellular cystatin C after CQ 
treatment. 
 
Regarding the effect of inhibition of the proteasomal system on cystatin C, a very 
significant reduction in the protein level of the mature form was observed. UPS is 
mainly responsible for the removal of misfolded/damaged protein (Amm, Sommer 
& Wolf 2014). Based on the hypothesis, the variant B cystatin C may not be 
properly processed, resulting in a misfolded uncleaved or miscleaved fraction, 
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which is sent to the proteasome for degradation. Also the O-glycosylation may 
render the alternative form of cystatin C less stable and therefore susceptible to 
UPS degradation. Furthermore, in this study the protein over-expression, per se, 
may cause an accumulation of misfolded precursor proteins, which can therefore 
be sent to ERAD for degradation (as discussed in chapter 4). It was therefore 
expected that the inhibition of the proteasomal activity would cause an increase of 
the intracellular level of cystatin C, and of the variant B in particular. Surprisingly, a 
highly significant reduction of mature cystatin C levels was observed instead.  
However, the unprocessed form of cystatin C was hypothesised to be misfolded 
and therefore sent for degradation. In support of this, one of the blots (figure 6.1) 
seems to display a higher fraction of uncleaved precursor after MG132 treatment 
in both wild-type and variant B compared to the non-treated, meaning that a 
fraction of accumulated misfolded precursor might be present and sent for 
degradation, a mechanism that is disrupted after proteasome inhibition. This 
occurred for both wild-type and variant B because of the overexpression of the 
exogenous proteins, but it would likely occur only for the variant B in normal 
conditions if its cleavage is impaired, as hypothesized and discussed earlier. In 
support of this hypothesis, the identification by mass spectrometry analysis of 
several proteins involved in ERAD pathway as well as the granule-like structures 
found occasionally for the precursor protein during imaging, likely representing 
protein aggregates, also suggests the presence of accumulated misfolded proteins 
and an active involvement of UPS for their removal. The response to MG132 
treatment was not consistent, however, possibly because of the very low protein 
levels of the precursor fraction that is difficult to detect by immunoblotting. 
The reduction in the general level of mature cystatin C could be due to a 
mechanism of regulation indirectly mediated by proteasomal activity. Levels of 
cystatin C could be regulated by transcriptional or translational mechanisms 
involving factors that might, in turn, be modulated by the UPS system. At the 
transcriptional level, specific transcription factors that can be modulated by several 
stimuli, including inflammatory cytokines, hormones, growth factors, stress and 
pathogens, have been identified to regulate cystatin C gene expression (Xu et al. 
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2015). In particular, in the promoter region of cystatin C, an androgen-responsive 
element sequence, two activator protein 1 binding sites and an IRF-binding motif, 
which represent transcription factor binding sites, have been described (Xu et al. 
2015). As a result, modulation of the rate of transcription and of the processing and 
stability of mRNA can occur under certain conditions. Regulation at the level of 
cystatin C translation has not been explored. Most common mechanisms that 
control protein synthesis involve the presence of repressor proteins, which can 
bind specific sequences within mRNAs, preventing the recruitment of the ribosome 
on the initiation codon (Kozak 1992, Sonenberg, Hinnebusch 2009). This critical 
step for the initiation of translation can be also suppressed by specific secondary 
structure of the transcript or by antisense microRNA binding (Kozak 1992, 
Sonenberg, Hinnebusch 2009). As a result, mRNA translation is repressed. Another 
common mechanism involves the modulation of initiation factors or other 
translation components by phosphorylation, which can suppress protein 
translation. These and other mechanisms of regulation are reviewed elsewhere 
(Kozak 1992, Sonenberg, Hinnebusch 2009). 
Results obtained by qPCR in section 6.1 showed that the proteasome inhibition 
does not alter the level of cystatin C mRNA, thus excluding a modulation at the 
transcriptional level. An increased degradation of cystatin C is also unlikely as it 
occurs in the lysosome by proteinases, which are themselves degraded in this 
cellular compartment (Turk et al. 2012), and so are independent from the 
proteasome pathway. Therefore, it is most likely that the effect on cystatin C 
protein level is mediated by the accumulation of a protein repressor that is under 
proteasomal regulation. As a result of the proteasome inhibition, accumulation of 
this repressor and consequent suppression of cystatin C translation may therefore 
occur. 
Interestingly, reduction of serum levels of cystatin C, characterising patients 
affected by multiple myeloma, has been observed after treatment with 
bortezomib, a proteasome-inhibitor used in therapy for its anti-myeloma activity 
(Terpos et al. 2009). This further suggests a role of UPS in cystatin C regulation. 
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Impairment of the proteolytic mechanisms is observed during aging and under 
several age-related pathologic conditions such as neurodegenerative diseases, 
where accumulation and detrimental aggregation of misfolded proteins represent a 
hallmark (Hipp, Park & Hartl 2014, Vilchez, Saez & Dillin 2014, Cheung, Ip 2011). 
Dysfunction of ALP and UPS pathways in this study may simulate the conditions 
occurring in ageing and disease. Further studies are required to understand such 
mechanisms of regulation of cystatin C and how the altered higher or lower level of 
cystatin C may affect cell functionality, which could highlight a potential role of the 
protease inhibitor in the detrimental effects observed in age-related conditions, 
including the effects on the RPE in the AMD. 
In RPE, impairment of both degradative pathways has been reported to play a role 
in AMD pathogenesis (Kinnunen et al. 2012, Ferrington, Sinha & Kaarniranta 2016).  
Regarding the proteasome, a decrease in its functionality has been described to 
occur in ageing RPE, leading to accumulation of damaged oxidized and cross-linked 
proteins that can block or overwhelm the proteasomal system (Salminen et al. 
2010, Kinnunen et al. 2012). As a consequence, misfolded ubiquitinated proteins 
can accumulate intracellularly, forming aggregates and causing ER stress. This 
condition can trigger inflammatory responses, ultimately causing chronic 
inflammation and formation of drusen, which contributes toward AMD 
development (Salminen et al. 2010).  
Interestingly, a reduction of cystatin C level has been reported to occur in aging RPE 
cells (Kay et al. 2014). Therefore, based on my findings, the age-related decrease of 
cystatin C might be due to the reduced activity of the proteasome system that 
occurs in aged RPE cells. This alteration of cystatin C levels may play role in the age-
related structural and functional changes observed in RPE cells during aging as well 
as in AMD development.  
 
Autophagy also represents one of the most active mechanisms in RPE. Due to its 
function, RPE is constantly subjected to oxidative stress and therefore damaged 
proteins need to be constantly removed (Chang et al. 2015). Moreover, as 
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described in section 1.3, the RPE is also involved in phagocytosis and subsequent 
intra-lysosomal degradation of photorecepotor outer segment (POS) by the 
aspartic-cathepsin D, a mechanism fundamental for photoreceptor turnover 
(Ferrington, Sinha & Kaarniranta 2016). Also mitophagy, a form of autophagy 
responsible for removal of damaged mitochondria, is a highly active process in the 
RPE cells, considering the high metabolic activity occurring in this tissue (Thumann, 
Hoffmann & Hinton 2006). It therefore represents an essential mechanism for the 
maintenance of the RPE cell homeostasis (Chang et al. 2015, Ferrington, Sinha & 
Kaarniranta 2016). Oxidative stress has been shown to increase in ageing RPE 
causing lysosomal alkalinisation and reduced phagocytosis (Chen et al. 2009, Guha 
et al. 2014), contributing to AMD development (Jarrett, Boulton 2012). In response 
to oxidative stress, the autophagic activity also increases with age (Mitter et al. 
2014, Flores-Bellver et al. 2014). However, if lysosomal function is suppressed, the 
system is not able to degrade phagocytised POS and damaged cellular components, 
leading to progressive debris accumulation in the lysosome such as lipofuscin 
accumulation, impairment in photoreceptor degradation/renewal, activation of 
inflammatory response via cathepsin B and formation of intra- and extracellular 
deposits, such as drusen, ultimately causing RPE cell degeneration. (Ferrington, 
Sinha & Kaarniranta 2016, Kaarniranta et al. 2010, Kinnunen et al. 2012, Klettner et 
al. 2013, Kaarniranta et al. 2013). Autophagy has also been suggested to directly 
contribute to drusen formation in aged RPE (Wang et al. 2009). Therefore, altered 
levels of cystatin C, as a result of impaired ALP, has the potential to play a role in 
the proteolytic dysfunction described above during aging and AMD. 
Autophagy plays an important role also in AD, where it is implicated in the 
degradation of amyloid precursor protein (APP) and β-amyloid (Aβ). The toxic Aβ 
peptide is generated in the autophagic vacuoles, thus accumulating in AD brain 
(Cheung, Ip 2011). Impaired vacuole clearance and lysosomal activity dysfunction 
contribute to Aβ toxicity. Interestingly, this can be corrected by enhancing 
lysosomal cathepsin activity (Cheung, Ip 2011, Tizon et al. 2010b, Kaur, Levy 2012). 
Therefore, reduction of lysosomal activity may increase cystatin C levels, as 
observed after CQ treatment in this study. This would reduce cathepsin activity, 
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potentially contributing to Aβ accumulation and toxicity, as described in previous 
reports (Tizon et al. 2010b, Tizon et al. 2010a, Wang et al. 2012). This may indicate 
a role for cystatin C in promoting Aβ formation when ALP is non-functional. 
On the contrary, in other disease conditions it is the low level of cystatin C and the 
increased cathepsin activity that causes a detrimental proteolytic imbalance in the 
cell. For instance, the resulting excessive activity of cathepsins has been reported 
to degrade ECM of aneurysm walls causing rupture of cerebral aneurysms (Wu et 
al. 2016), or to promote invasion and metastasis in cancer also by ECM degradation 
(Keppler 2006, Schulte et al. 2010, Mori et al. 2016, Laurent-Matha et al. 2012, 
Wallin, Abrahamson & Ekstrom 2013). In RPE such proteolytic imbalance in the 
extracellular matrix may contribute to drusen formation, Bruch’s membrane 
disruption and abnormal neovascularization, typical of the exudative AMD. 
 
In conclusion, results indicate that cystatin C levels can be modulated by ALP and 
UPS pathways. Considering the established role of these degradative pathways and 
the involvement of cystatin C and its target cathepsins in several age-related 
diseases, including cancer, atherosclerosis and age-related degenerative disorders, 
further studies to determine the factors responsible for cystatin C regulation 
mediated by UPS and ALP could be of clinical interest in order to modulate its level 
to restore the physiological proteolytic balance within cells.  
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7. Chapter 7  - Conclusions and Future 
Work  
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Results obtained in this study showed no major difference in protein trafficking, 
stability and regulation between wild-type and variant B cystatin C.  
In particular, in contrast to the main accredited theory (Benussi et al. 2003, 
Paraoan et al. 2004), the outcomes of this study do not support a significant 
influence of the variant B mutation on protein targeting and localization as well as 
levels of protein secretion. Indeed, the variant B cystatin C was not found to divert 
from the conventional secretory pathway or interact with distinct cellular proteins, 
therefore excluding its involvement in other cellular pathways. Accordingly, this 
study provides strong evidence against the mitochondrial mislocalization of cystatin 
C being a factor contributing to AMD/AD pathogenesis. Rather, data obtained 
indicate that the EGFP tag is responsible for the protein mistrafficking observed in 
this study and most likely in previous published work (Paraoan et al. 2004). 
Regarding the secretion, only recently another study also reported no difference in 
secretion levels between the wild-type and the variant B cystatin C (Nguyen, 
Hulleman 2016), thus consistent with my findings. In addition, other mechanisms 
were investigated in this study, including protein degradation, internalization and 
dimerization, which were also found not to significantly differ between wild-type 
and variant B.  
Overall, these results indicate that the A25T mutation does not affect the targeting 
of the precursor cystatin C and, consequently, the trafficking and regulation of the 
mature protein. 
 
However, minor differences in two aspects were found between the wild-type and 
variant B cystatin C.  They consist of the presence of an uncleaved precursor, 
detected at slightly higher abundance for the variant B, and presence of an 
alternatively processed, possibly O-glycosylated form, produced and secreted at 
higher levels for variant B. The presence of both these forms may be due to a 
decreased efficiency in the signal sequence cleavage, thus indicating that the A25T 
mutation may affect the precursor processing. The existence of alternative cleaved 
and glycosylated forms is consistent with previous works (Nguyen, Hulleman 2016, 
226 
 
Nilsson et al. 2009). These events, however, were only observed for a minor 
fraction of the protein, which are unlikely to produce any significant short-term 
effects. However, they may prove to be cumulative and affect cell function in the 
long-term, consistent with the association with age-related disease. As described in 
detail previously, prolonged accumulation of either the amyloidogenic misfolded 
uncleaved fraction or the alternative processed O-glycosylated form may result in 
ER stress, cellular proteolytic imbalance and protein aggregation, which ultimately 
lead to cell degeneration. Consistent with their possible association with AMD/AD 
degenerative diseases, their accumulation could further be enhanced in aging, 
where the functionality of the cellular degradative systems is compromised. In 
support of this hypothesis, an increase of the precursor fraction was observed in 
this study to occur in response to proteasome inhibition. 
In addition, O-glycans may also be present on a small fraction of wild-type cystatin 
C. It would be therefore interesting to investigate the role of this alternative form 
and the effects the glycosylation could have on cystatin C properties, such as 
function, stability, targeting and regulation. For instance, mechanisms of 
degradation, internalization and dimerization investigated in this study, did not 
show any difference in relation to the predominant mature form of cystatin C, but 
they may be impaired for the alternative cleaved, O-glycosylated form. Depending 
on the effect of the O-glycan on the protein, it could result in a proteolytic 
imbalance intra- and extra-cellularly, as described previously. However, because in 
this study the level of this fraction was very low, it was not possible, to analyse 
these aspects in relation to this fraction.  
 
Future use of more refined approaches to variant B expression would help to 
prevent cell stress and reduced viability that overexpression approaches can 
induce, which therefore did not allow us to study long-term effects, possibly linked 
with the development of age-related diseases. This factor results to be particularly 
important considering the very low amounts of both unprocessed and differently 
processed forms identified in this study, which at these low levels compared to the 
mature form are unlikely to affect secretion, activity, regulation or cell function. To 
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overcome these limitations and further exclude effects on different cellular 
processes due to the overexpression, it would be more suitable to use cystatin C 
B/B genotyped cells, thus endogenously expressing the variant B protein, which 
would also avoid the simultaneous presence of the wild-type endogenous cystatin 
C. Given the unavailability of these cells, generation of cell lines using the 
CRISPR/Cas9-mediated genome editing technology would provide a valuable 
approach for this purpose, as it permits to introduce the variant B mutation into 
the endogenous cystatin C gene. Furthermore, in vivo studies using humanized 
mice models for wild-type and variant B cystatin C expressed under the 
endogenous cystatin C promoter for disease modelling could be also an interesting 
approach to further investigate the cellular and systemic effects of the variant B. 
 
Another aspect of this study, independent from the variant B observations, is the 
identification of a novel mechanism of regulation of cystatin C concentration and 
degradation, operated by modulation of the UPS and ALP pathways, which seem to 
act indirectly at the protein level. It would be therefore interesting to further 
elucidate these proteasome/autophagy-mediated mechanisms of regulation of 
cystatin-C and the components that are involved in these pathways. They could be 
potential targets for clinical intervention, by modulating the level of cystatin C in 
the several conditions characterised by altered level of cystatin C (see section 1.3).  
Furthermore, although the mechanism of cystatin C up-regulation observed in this 
study upon ALP inhibition is unclear, this event may also determine an increase of 
the uncleaved precursor and/or the alternatively cleaved glycosylated form of 
cystatin C, especially in the case of the variant B. Considering ALP deregulation to 
be a hallmark of age-related degenerative diseases, this event may therefore 
contribute to the increased risk of developing AMD/AD disorders in presence of the 
variant B. 
 
In conclusion, although my study did not uncover significant differences between 
wild-type and variant B, a long term dysregulation of proteolytic balance and, as a 
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consequence, impairment of cell function or viability by the presence of a higher 
proportion of the miscleaved cystatin C variant B cannot be excluded. These 
events, if confirmed, may explain the association of variant B with AMD and AD 
pathogenesis. 
However, it also has to be noted that association of variant B with both AD and 
AMD diseases is still a controversial issue. Studies reported association only in 
certain ethnic populations and under specific biological conditions (Finckh et al. 
2000, Chuo et al. 2007, Hua et al. 2012, Wang et al. 2008, Nacmias et al. 2006, 
Maruyama et al. 2001, Helisalmi et al. 2009, Roks et al. 2001). This suggests that 
genetic factors as well as the status of cellular regulatory components in age-
related conditions may play a more important role and the variant B may be, for 
unknown reasons, more susceptible to altered conditions, thus linking it to the 
disease pathogenesis. Alternatively, since AMD and AD are both complex 
multifactorial disorders, depending of several genetic and environmental factors 
(Horie-Inoue, Inoue 2014, Bettens, Sleegers & Van Broeckhoven 2013, Logue et al. 
2014), one or more of these factors could differentially affect variant B. Further 
investigation are therefore required to shed light on such mechanisms of age-
related diseases that can help us understand the possible role of cystatin C in their 
pathogenesis.  
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P.A. & van Veen, T. 2008, "rd1 Mouse retina shows an imbalance in the activity 
of cysteine protease cathepsins and their endogenous inhibitor cystatin C", 
Investigative ophthalmology & visual science, vol. 49, no. 3, pp. 1089-1096. 
Åkerblom, A., Eriksson, N., Wallentin, L., Siegbahn, A., Barratt, B.J., Becker, R.C., 
Budaj, A., Himmelmann, A., Husted, S. & Storey, R.F. 2014, "Polymorphism of 
the cystatin C gene in patients with acute coronary syndromes: Results from 
the PLATelet inhibition and patient Outcomes study", American Heart Journal, 
vol. 168, no. 1, pp. 96-102. e2. 
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K. & Walter, P. 2008, Molecular 
Biology of the Cell, 5th edn, Garland Science, New York. 
Alder, N.N., Shen, Y., Brodsky, J.L., Hendershot, L.M. & Johnson, A.E. 2005, "The 
molecular mechanisms underlying BiP-mediated gating of the Sec61 
translocon of the endoplasmic reticulum", The Journal of cell biology, vol. 168, 
no. 3, pp. 389-399. 
Amm, I., Sommer, T. & Wolf, D.H. 2014, "Protein quality control and elimination of 
protein waste: The role of the ubiquitin–proteasome system", Biochimica et 
Biophysica Acta (BBA)-Molecular Cell Research, vol. 1843, no. 1, pp. 182-196. 
Anandatheerthavarada, H.K., Biswas, G., Robin, M.-. & Avadhani, N.G. 2003, 
"Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's 
amyloid precursor protein impairs mitochondrial function in neuronal cells", 
Journal of Cell Biology, vol. 161, no. 1, pp. 41-54. 
Anandatheerthavarada, H.K. & Devi, L. 2007, "Mitochondrial translocation of 
amyloid precursor protein and its cleaved products: Relevance to 
mitochondrial dysfunction in Alzheimer's disease", Reviews in the 
neurosciences, vol. 18, no. 5, pp. 343-354. 
Andresen, M., Schmitz-Salue, R. & Jakobs, S. 2004, "Short tetracysteine tags to 
beta-tubulin demonstrate the significance of small labels for live cell imaging", 
Molecular biology of the cell, vol. 15, no. 12, pp. 5616-5622. 
230 
 
Antonin, W., Meyer, H.A. & Hartmann, E. 2000, "Interactions between Spc2p and 
other components of the endoplasmic reticulum translocation sites of the 
yeast Saccharomyces cerevisiae", The Journal of biological chemistry, vol. 275, 
no. 44, pp. 34068-34072. 
Arluison, V. & Taghbalout, A. 2015, "Cellular localization of RNA degradation and 
processing components in Escherichia coli", RNA Remodeling Proteins: 
Methods and Protocols, , pp. 87-101. 
Arnold, A., Horst, S.A., Gardella, T.J., Baba, H., Levine, M.A. & Kronenberg, H.M. 
1990, "Mutation of the signal peptide-encoding region of the 
preproparathyroid hormone gene in familial isolated hypoparathyroidism", 
The Journal of clinical investigation, vol. 86, no. 4, pp. 1084-1087. 
Ast, T., Cohen, G. & Schuldiner, M. 2013, "A network of cytosolic factors targets 
SRP-independent proteins to the endoplasmic reticulum", Cell, vol. 152, no. 5, 
pp. 1134-1145. 
Auclair, S.M., Bhanu, M.K. & Kendall, D.A. 2012, "Signal peptidase I: cleaving the 
way to mature proteins", Protein Science, vol. 21, no. 1, pp. 13-25. 
Balbín, M. & Abrahamson, M. 1991, "SstII polymorphic sites in the promoter region 
of the human cystatin C gene", Human genetics, vol. 87, no. 6, pp. 751-752. 
Balbín, M., Grubb, A. & Abrahamson, M. 1993, "An Ala/Thr variation in the coding 
region of the human cystatin C gene (CST3) detected as a SstII polymorphism", 
Human genetics, vol. 92, no. 2, pp. 206-207. 
Barlowe, C.K. & Miller, E.A. 2013, "Secretory protein biogenesis and traffic in the 
early secretory pathway", Genetics, vol. 193, no. 2, pp. 383-410. 
Barrett, A.J., Davies, M.E. & Grubb, A. 1984, "The place of human γ-trace (cystatin 
C) amongst the cysteine proteinase inhibitors", Biochemical and biophysical 
research communications, vol. 120, no. 2, pp. 631-636. 
Becker, T., Böttinger, L. & Pfanner, N. 2012, "Mitochondrial protein import: from 
transport pathways to an integrated network", Trends in biochemical sciences, 
vol. 37, no. 3, pp. 85-91. 
Bejarano, L.A. & Gonzalez, C. 1999, "Motif trap: a rapid method to clone motifs that 
can target proteins to defined subcellular localisations", Journal of cell science, 
vol. 112 ( Pt 23), no. Pt 23, pp. 4207-4211. 
Bektas, M. & Rubenstein, D.S. 2011, "The role of intracellular protein O-
glycosylation in cell adhesion and disease", Journal of biomedical research, vol. 
25, no. 4, pp. 227-236. 
231 
 
Bengtsson, E., Nilsson, J. & Jovinge, S. 2008, "Cystatin C and cathepsins in 
cardiovascular disease", Frontiers in bioscience : a journal and virtual library, 
vol. 13, pp. 5780-5786. 
Benussi, L., Ghidoni, R., Galimberti, D., Boccardi, M., Fenoglio, C., Scarpini, E., 
Frisoni, G.B. & Binetti, G. 2010, "The CST3 B haplotype is associated with 
frontotemporal lobar degeneration", European Journal Of Neurology: The 
Official Journal Of The European Federation Of Neurological Societies, vol. 17, 
no. 1, pp. 143-146. 
Benussi, L., Ghidoni, R., Steinhoff, T., Alberici, A., Villa, A., Mazzoli, F., Nicosia, F., 
Barbiero, L., Broglio, L., Feudatari, E., Signorini, S., Finckh, U., Nitsch, R.M. & 
Binetti, G. 2003, "Alzheimer disease-associated cystatin C variant undergoes 
impaired secretion", Neurobiology of disease, vol. 13, no. 1, pp. 15-21. 
Bertram, L., McQueen, M.B., Mullin, K., Blacker, D. & Tanzi, R.E. 2007, "Systematic 
meta-analyses of Alzheimer disease genetic association studies: the AlzGene 
database", Nature genetics, vol. 39, no. 1, pp. 17-23. 
Bettens, K., Sleegers, K. & Van Broeckhoven, C. 2013, "Genetic insights in 
Alzheimer's disease", The Lancet Neurology, vol. 12, no. 1, pp. 92-104. 
Bhattacharya, A., Prakash, Y. & Eissa, N.T. 2014, "Secretory function of autophagy 
in innate immune cells", Cellular microbiology, vol. 16, no. 11, pp. 1637-1645. 
Birk, J., Friberg, M.A., Prescianotto-Baschong, C., Spiess, M. & Rutishauser, J. 2009, 
"Dominant pro-vasopressin mutants that cause diabetes insipidus form 
disulfide-linked fibrillar aggregates in the endoplasmic reticulum", Journal of 
cell science, vol. 122, no. Pt 21, pp. 3994-4002. 
Bode, W., Engh, R., Musil, D., Thiele, U., Huber, R., Karshikov, A., Brzin, J., Kos, J. & 
Turk, V. 1988, "The 2.0 A X-ray crystal structure of chicken egg white cystatin 
and its possible mode of interaction with cysteine proteinases", The EMBO 
journal, vol. 7, no. 8, pp. 2593-2599. 
Bradke, F. & Dotti, C.G. 1998, "Membrane traffic in polarized neurons", Biochimica 
et Biophysica Acta (BBA)-Molecular Cell Research, vol. 1404, no. 1, pp. 245-
258. 
Braulke, T. & Bonifacino, J.S. 2009, "Sorting of lysosomal proteins", Biochimica et 
Biophysica Acta (BBA)-Molecular Cell Research, vol. 1793, no. 4, pp. 605-614. 
Brix, K. 2005, "Lysosomal proteases" in Lysosomes Springer, , pp. 50-59. 
Brodsky, J.L. & Schekman, R. 1993, "A Sec63p-BiP complex from yeast is required 
for protein translocation in a reconstituted proteoliposome", The Journal of 
cell biology, vol. 123, no. 6 Pt 1, pp. 1355-1363. 
232 
 
Brodsky, J.L., Schekman, R. & Goeckeler, J. 1995, "BiP and Sec63p are required for 
both co- and posttranslational protein translocation into the yeast 
endoplasmic reticulum", Proceedings of the National Academy of Sciences of 
the United States of America, vol. 92, no. 21, pp. 9643-9646. 
Brown, J.D., Hann, B.C., Medzihradszky, K.F., Niwa, M., Burlingame, A.L. & Walter, 
P. 1994, "Subunits of the Saccharomyces cerevisiae signal recognition particle 
required for its functional expression", The EMBO journal, vol. 13, no. 18, pp. 
4390-4400. 
Buchberger, A., Bukau, B. & Sommer, T. 2010, "Protein quality control in the cytosol 
and the endoplasmic reticulum: brothers in arms", Molecular cell, vol. 40, no. 
2, pp. 238-252. 
Butler, J.M., Sharif, U., Ali, M., McKibbin, M., Thompson, J.P., Gale, R., Yang, Y.C., 
Inglehearn, C. & Paraoan, L. 2015, "A missense variant in CST3 exerts a 
recessive effect on susceptibility to age-related macular degeneration 
resembling its association with Alzheimer’s disease", Human genetics, vol. 134, 
no. 7, pp. 705-715. 
Calero, M., Pawlik, M., Soto, C., Castaño, E.M., Sigurdsson, E.M., Kumar, A., Gallo, 
G., Frangione, B. & Levy, E. 2001, "Distinct properties of wild-type and the 
amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage 
with amyloidosis, Icelandic type", Journal of neurochemistry, vol. 77, no. 2, pp. 
628-637. 
Cappello, F., Gatti, E., Camossetto, V., David, A., Lelouard, H. & Pierre, P. 2004, 
"Cystatin F is secreted, but artificial modification of its C-terminus can induce 
its endocytic targeting", Experimental cell research, vol. 297, no. 2, pp. 607-
618. 
Chacinska, A., Koehler, C.M., Milenkovic, D., Lithgow, T. & Pfanner, N. 2009, 
"Importing Mitochondrial Proteins: Machineries and Mechanisms", Cell, vol. 
138, no. 4, pp. 628-644. 
Chang, Y., Ho, J.A., Hsu, S. & Wu, L. 2015, "Autophagic Regulation of Retinal 
Pigment Epithelium Homeostasis", Journal of Pigmentary Disorders, vol. 2015. 
Chavan, M., Yan, A. & Lennarz, W.J. 2005, "Subunits of the translocon interact with 
components of the oligosaccharyl transferase complex", The Journal of 
biological chemistry, vol. 280, no. 24, pp. 22917-22924. 
Chazotte, B. 2011, "Labeling mitochondria with MitoTracker dyes", Cold Spring 
Harbor protocols, vol. 2011, no. 8, pp. 990-992. 
Chen, H., Lukas, T.J., Du, N., Suyeoka, G. & Neufeld, A.H. 2009, "Dysfunction of the 
retinal pigment epithelium with age: increased iron decreases phagocytosis 
233 
 
and lysosomal activity", Investigative ophthalmology & visual science, vol. 50, 
no. 4, pp. 1895-1902. 
Chen, P.M., Gombart, Z.J. & Chen, J.W. 2011, "Chloroquine treatment of ARPE-19 
cells leads to lysosome dilation and intracellular lipid accumulation: possible 
implications of lysosomal dysfunction in macular degeneration", Cell & 
bioscience, vol. 1, no. 1, pp. 1. 
Chen, W., Cheng, X., Zhang, X., Zhang, Q., Sun, H., Huang, W. & Xie, Z. 2015, "The 
expression features of serum Cystatin C and homocysteine of Parkinson’s 
disease with mild cognitive dysfunction", Eur Rev Med Pharmacol Sci, vol. 19, 
no. 16, pp. 2957-2963. 
Chen, X., VanValkenburgh, C., Liang, H., Fang, H. & Green, N. 2001, "Signal 
peptidase and oligosaccharyltransferase interact in a sequential and 
dependent manner within the endoplasmic reticulum", The Journal of 
biological chemistry, vol. 276, no. 4, pp. 2411-2416. 
Cheung, Z.H. & Ip, N.Y. 2011, "Autophagy deregulation in neurodegenerative 
diseases–recent advances and future perspectives", Journal of neurochemistry, 
vol. 118, no. 3, pp. 317-325. 
Chirico, W.J., Waters, M.G. & Blobel, G. 1988, "70K heat shock related proteins 
stimulate protein translocation into microsomes", Nature, vol. 332, no. 6167, 
pp. 805-810. 
Chuo, L.J., Sheu, W.H., Pai, M.C. & Kuo, Y.M. 2007, "Genotype and plasma 
concentration of cystatin C in patients with late-onset Alzheimer disease", 
Dementia and geriatric cognitive disorders, vol. 23, no. 4, pp. 251-257. 
Cimerman, N. 2007, "Human cystatin C", Türk Biyokimya Dergisi [Turkish Journal of 
Biochemistry–Turk J Biochem], vol. 32, no. 3, pp. 95-103. 
Cimerman, N., Prebanda, M.T., Turk, B., Popovič, T., Dolenc, I. & Turk, V. 1999, 
"Interaction of cystatin C variants with papain and human cathepsins B, H and 
L", Journal of enzyme inhibition, vol. 14, no. 2, pp. 167-174. 
Conus, S. & Simon, H. 2008, "Cathepsins: key modulators of cell death and 
inflammatory responses", Biochemical pharmacology, vol. 76, no. 11, pp. 
1374-1382. 
Cottet, S. & Corthésy, B. 1997, "Cellular processing limits the heterologous 
expression of secretory component in mammalian cells", European Journal of 
Biochemistry, vol. 246, no. 1, pp. 23-31. 
234 
 
Coutinho, M.F., Prata, M.J. & Alves, S. 2012, "Mannose-6-phosphate pathway: a 
review on its role in lysosomal function and dysfunction", Molecular genetics 
and metabolism, vol. 105, no. 4, pp. 542-550. 
Craven, R.A., Egerton, M. & Stirling, C.J. 1996, "A novel Hsp70 of the yeast ER lumen 
is required for the efficient translocation of a number of protein precursors", 
The EMBO journal, vol. 15, no. 11, pp. 2640-2650. 
Crawford, F., Freeman, M., Schinka, J., Abdullah, L., Gold, M., Hartman, R., Krivian, 
K., Morris, M., Richards, D. & Duara, R. 2000, "A polymorphism in the cystatin 
C gene is a novel risk factor for late-onset Alzheimer’s disease", Neurology, vol. 
55, no. 6, pp. 763-768. 
Dahl, A., Eriksson, P., Davidsson, P., Persson, A., Ekman, R. & Westman‐Brinkmalm, 
A. 2004, "Demonstration of multiple novel glycoforms of the stem cell survival 
factor CCg", Journal of neuroscience research, vol. 77, no. 1, pp. 9-14. 
Dalton, A.C. & Barton, W.A. 2014, "Over‐expression of secreted proteins from 
mammalian cell lines", Protein Science, vol. 23, no. 5, pp. 517-525. 
Davis, A.A., Bernstein, P.S., Bok, D., Turner, J., Nachtigal, M. & Hunt, R.C. 1995, "A 
human retinal pigment epithelial cell line that retains epithelial characteristics 
after prolonged culture", Investigative ophthalmology & visual science, vol. 36, 
no. 5, pp. 955-964. 
Dean, R.A., Butler, G.S., Hamma-Kourbali, Y., Delbe, J., Brigstock, D.R., Courty, J. & 
Overall, C.M. 2007, "Identification of candidate angiogenic inhibitors 
processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic 
screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin 
regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor 
angiogenic inhibitory complexes by MMP-2 proteolysis", Molecular and 
cellular biology, vol. 27, no. 24, pp. 8454-8465. 
Deshaies, R.J., Sanders, S.L., Feldheim, D.A. & Schekman, R. 1991, "Assembly of 
yeast Sec proteins involved in translocation into the endoplasmic reticulum 
into a membrane-bound multisubunit complex", . 
Deshaies, R.J., Koch, B.D., Werner-Washburne, M., Craig, E.A. & Schekman, R. 1988, 
"A subfamily of stress proteins facilitates translocation of secretory and 
mitochondrial precursor polypeptides", Nature, vol. 332, no. 6167, pp. 800-
805. 
Devi, L. & Anandatheerthavarada, H.K. 2010, "Mitochondrial trafficking of APP and 
alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and 
Parkinson's diseases", Biochimica et Biophysica Acta - Molecular Basis of 
Disease, vol. 1802, no. 1, pp. 11-19. 
235 
 
Devi, L., Raghavendran, V., Prabhu, B.M., Avadhani, N.G. & Anandatheerthavarada, 
H.K. 2008, "Mitochondrial import and accumulation of a-synuclein impair 
complex I in human dopaminergic neuronal cultures and Parkinson disease 
brain", Journal of Biological Chemistry, vol. 283, no. 14, pp. 9089-9100. 
Dierks, T., Volkmer, J., Schlenstedt, G., Jung, C., Sandholzer, U., Zachmann, K., 
Schlotterhose, P., Neifer, K., Schmidt, B. & Zimmermann, R. 1996, "A 
microsomal ATP-binding protein involved in efficient protein transport into the 
mammalian endoplasmic reticulum", The EMBO journal, vol. 15, no. 24, pp. 
6931-6942. 
Doherty, G.J. & McMahon, H.T. 2009, "Mechanisms of endocytosis", Annual Review 
of Biochemistry, vol. 78, pp. 857-902. 
Droga-Mazovec, G., Bojic, L., Petelin, A., Ivanova, S., Romih, R., Repnik, U., Salvesen, 
G.S., Stoka, V., Turk, V. & Turk, B. 2008, "Cysteine cathepsins trigger caspase-
dependent cell death through cleavage of bid and antiapoptotic Bcl-2 
homologues", The Journal of biological chemistry, vol. 283, no. 27, pp. 19140-
19150. 
Dunn, K., Aotaki-Keen, A., Putkey, F. & Hjelmeland, L. 1996, "ARPE-19, a human 
retinal pigment epithelial cell line with differentiated properties", Experimental 
eye research, vol. 62, no. 2, pp. 155-170. 
Eckmann, J., Eckert, S.H., Leuner, K., Muller, W.E. & Eckert, G.P. 2013, 
"Mitochondria: Mitochondrial membranes in brain ageing and 
neurodegeneration", International Journal of Biochemistry and Cell Biology, 
vol. 45, no. 1, pp. 76-80. 
Ekiel, I. & Abrahamson, M. 1996, "Folding-related dimerization of human cystatin 
C", Journal of Biological Chemistry, vol. 271, no. 3, pp. 1314-1321. 
Ekström, U., Wallin, H., Lorenzo, J., Holmqvist, B., Abrahamson, M. & Avilés, F.X. 
2008, "Internalization of cystatin C in human cell lines", FEBS journal, vol. 275, 
no. 18, pp. 4571-4582. 
Eskelinen, E. & Saftig, P. 2009, "Autophagy: a lysosomal degradation pathway with 
a central role in health and disease", Biochimica et Biophysica Acta (BBA)-
Molecular Cell Research, vol. 1793, no. 4, pp. 664-673. 
Evans, E.A., Gilmore, R. & Blobel, G. 1986, "Purification of microsomal signal 
peptidase as a complex", Proceedings of the National Academy of Sciences of 
the United States of America, vol. 83, no. 3, pp. 581-585. 
Feher, J., Kovacs, I., Artico, M., Cavallotti, C., Papale, A. & Balacco Gabrieli, C. 2006, 
"Mitochondrial alterations of retinal pigment epithelium in age-related 
macular degeneration", Neurobiology of aging, vol. 27, no. 7, pp. 983-993. 
236 
 
Feng, L. & Wang, F. 2016, "Detecting A-beta Deposition and RPE Cell Senescence in 
the Retinas of SAMP8 Mice", Discovery medicine, vol. 21, no. 115, pp. 149-158. 
Ferrington, D.A., Sinha, D. & Kaarniranta, K. 2016, "Defects in retinal pigment 
epithelial cell proteolysis and the pathology associated with age-related 
macular degeneration", Progress in retinal and eye research, vol. 51, pp. 69-89. 
Finckh, U., Von Der Kammer, H., Velden, J., Michel, T., Andresen, B., Deng, A., 
Zhang, J., Müller-Thomsen, T., Zuchowski, K., Menzer, G., Mann, U., 
Papassotiropoulos, A., Heun, R., Zurdel, J., Holst, F., Benussi, L., Stoppe, G., 
Reiss, J., Miserez, A.R., Staehelin, H.B., Rebeck, G.W., Hyman, B.T., Binetti, G., 
Hock, C., Growdon, J.H. & Nitsch, R.M. 2000, "Genetic association of a cystatin 
C gene polymorphism with late-onset Alzheimer disease", Archives of 
Neurology, vol. 57, no. 11, pp. 1579-1583. 
Flanagan, J.J., Chen, J.C., Miao, Y., Shao, Y., Lin, J., Bock, P.E. & Johnson, A.E. 2003, 
"Signal recognition particle binds to ribosome-bound signal sequences with 
fluorescence-detected subnanomolar affinity that does not diminish as the 
nascent chain lengthens", The Journal of biological chemistry, vol. 278, no. 20, 
pp. 18628-18637. 
Flores-Bellver, M., Bonet-Ponce, L., Barcia, J., Garcia-Verdugo, J., Martinez-Gil, N., 
Saez-Atienzar, S., Sancho-Pelluz, J., Jordan, J., Galindo, M. & Romero, F. 2014, 
"Autophagy and mitochondrial alterations in human retinal pigment epithelial 
cells induced by ethanol: implications of 4-hydroxy-nonenal", Cell death & 
disease, vol. 5, no. 7, pp. e1328. 
Fons, R.D., Bogert, B.A. & Hegde, R.S. 2003, "Substrate-specific function of the 
translocon-associated protein complex during translocation across the ER 
membrane", The Journal of cell biology, vol. 160, no. 4, pp. 529-539. 
García-Arencibia, M., Hochfeld, W.E., Toh, P.P. & Rubinsztein, D.C. 2010, 
"Autophagy, a guardian against neurodegeneration", Seminars in cell & 
developmental biologyElsevier, , pp. 691. 
Gauthier, S., Kaur, G., Mi, W., Tizon, B. & Levy, E. 2011, "Protective mechanisms by 
cystatin C in neurodegenerative diseases", Frontiers in bioscience (Scholar 
edition), vol. 3, pp. 541-554. 
Gehrs, K.M., Anderson, D.H., Johnson, L.V. & Hageman, G.S. 2006, "Age‐related 
macular degeneration—emerging pathogenetic and therapeutic concepts", 
Annals of Medicine, vol. 38, no. 7, pp. 450-471. 
Ghidoni, R., Benussi, L., Paterlini, A., Missale, C., Usardi, A., Rossi, R., Barbiero, L., 
Spano, P. & Binetti, G. 2007, "Presenilin 2 mutations alter cystatin C trafficking 
in mouse primary neurons", Neurobiology of aging, vol. 28, no. 3, pp. 371-376. 
237 
 
Ghidoni, R., Benussi, L., Glionna, M., Desenzani, S., Albertini, V., Levy, E., Emanuele, 
E. & Binetti, G. 2010, "Plasma cystatin c and risk of developing Alzheimer's 
disease in subjects with mild cognitive impairment", Journal of Alzheimer's 
Disease, vol. 22, no. 3, pp. 985-991. 
Ghidoni, R., Benussi, L., Paterlini, A., Albertini, V., Binetti, G. & Emanuele, E. 2011a, 
"Cerebrospinal fluid biomarkers for Alzheimer's disease: The present and the 
future", Neurodegenerative Diseases, vol. 8, no. 6, pp. 413-420. 
Ghidoni, R., Paterlini, A., Albertini, V., Glionna, M., Monti, E., Schiaffonati, L., 
Benussi, L., Levy, E. & Binetti, G. 2011b, "Cystatin C is released in association 
with exosomes: A new tool of neuronal communication which is unbalanced in 
Alzheimer's disease", Neurobiology of aging, vol. 32, no. 8, pp. 1435-1442. 
Giepmans, B.N., Adams, S.R., Ellisman, M.H. & Tsien, R.Y. 2006, "The fluorescent 
toolbox for assessing protein location and function", Science (New York, N.Y.), 
vol. 312, no. 5771, pp. 217-224. 
Glenn, J.V., Mahaffy, H., Wu, K., Smith, G., Nagai, R., Simpson, D.A., Boulton, M.E. & 
Stitt, A.W. 2009, "Advanced glycation end product (AGE) accumulation on 
Bruch’s membrane: links to age-related RPE dysfunction", Investigative 
ophthalmology & visual science, vol. 50, no. 1, pp. 441-451. 
Goder, V. & Spiess, M. 2003, "Molecular mechanism of signal sequence orientation 
in the endoplasmic reticulum", The EMBO journal, vol. 22, no. 14, pp. 3645-
3653. 
Gong, X., Harrell, M., Mitchell, D., Sundin, O. & Rubin, L. 2014, "A new human 
retinal pigment epithelial cell model for interrogating the protective functions 
of xanthophylls in retinopathies (39.2)", The FASEB Journal, vol. 28, no. 1 
Supplement, pp. 39.2. 
González, C. & Bejarano, L.A. 2000, "Protein traps: using intracellular localization 
for cloning", Trends in cell biology, vol. 10, no. 4, pp. 162-165. 
Görlich, D., Prehn, S., Hartmann, E., Kalies, K. & Rapoport, T.A. 1992, "A mammalian 
homolog of SEC61p and SECYp is associated with ribosomes and nascent 
polypeptides during translocation", Cell, vol. 71, no. 3, pp. 489-503. 
Görlich, D. & Rapoport, T.A. 1993, "Protein translocation into proteoliposomes 
reconstituted from purified components of the endoplasmic reticulum 
membrane", Cell, vol. 75, no. 4, pp. 615-630. 
Grant, S.M., Shankar, S.L., Chalmers-Redman, R.M.E., Tatton, W.G., Szyf, M. & 
Cuello, A.C. 1999, "Mitochondrial abnormalities in neuroectodermal cells 
stably expressing human amyloid precursor protein (hAPP751)", Neuroreport, 
vol. 10, no. 1, pp. 41-46. 
238 
 
Gu, F., Crump, C. & Thomas, G. 2001, "Trans-Golgi network sorting", Cellular and 
Molecular Life Sciences CMLS, vol. 58, no. 8, pp. 1067-1084. 
Guha, S., Liu, J., Baltazar, G., Laties, A.M. & Mitchell, C.H. 2014, "Rescue of 
compromised lysosomes enhances degradation of photoreceptor outer 
segments and reduces lipofuscin-like autofluorescence in retinal pigmented 
epithelial cells" in Retinal Degenerative Diseases Springer, , pp. 105-111. 
Guha, S. & Padh, H. 2008, "Cathepsins: fundamental effectors of endolysosomal 
proteolysis", Indian Journal of Biochemistry and Biophysics, vol. 45, no. 2, pp. 
75. 
Halic, M., Becker, T., Pool, M.R., Spahn, C.M., Grassucci, R.A., Frank, J. & Beckmann, 
R. 2004, "Structure of the signal recognition particle interacting with the 
elongation-arrested ribosome", Nature, vol. 427, no. 6977, pp. 808-814. 
Hamilton, G., Colbert, J.D., Schuettelkopf, A.W. & Watts, C. 2008, "Cystatin F is a 
cathepsin C-directed protease inhibitor regulated by proteolysis", The EMBO 
journal, vol. 27, no. 3, pp. 499-508. 
Han, Y.H., Moon, H.J., You, B.R. & Park, W.H. 2009, "The effect of MG132, a 
proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen 
species and GSH.", Oncology reports, vol. 22, no. 1, pp. 215. 
Hatsuzawa, K., Tagaya, M. & Mizushima, S. 1997, "The hydrophobic region of signal 
peptides is a determinant for SRP recognition and protein translocation across 
the ER membrane", Journal of Biochemistry, vol. 121, no. 2, pp. 270-277. 
He, R., Shen, J., Zhao, J., Zeng, H., Li, L., Zhao, J., Liu, F. & Jia, W. 2013, "High 
cystatin C levels predict severe retinopathy in type 2 diabetes patients", 
European journal of epidemiology, vol. 28, no. 9, pp. 775. 
Hegde, R.S. & Bernstein, H.D. 2006, "The surprising complexity of signal 
sequences", Trends in biochemical sciences, vol. 31, no. 10, pp. 563-571. 
Hegde, R.S. & Ploegh, H.L. 2010, "Quality and quantity control at the endoplasmic 
reticulum", Current opinion in cell biology, vol. 22, no. 4, pp. 437-446. 
Heijne, G. 1983, "Patterns of amino acids near signal‐sequence cleavage sites", 
European journal of biochemistry, vol. 133, no. 1, pp. 17-21. 
Helisalmi, S., Vakeva, A., Hiltunen, M. & Soininen, H. 2009, "Flanking markers of 
cystatin c (CST3) gene do not show association with Alzheimer's disease", 
Dementia and geriatric cognitive disorders, vol. 27, no. 4, pp. 318-321. 
239 
 
High, S. & Dobberstein, B. 1991, "The signal sequence interacts with the 
methionine-rich domain of the 54-kD protein of signal recognition particle", 
The Journal of cell biology, vol. 113, no. 2, pp. 229-233. 
Hipp, M.S., Park, S. & Hartl, F.U. 2014, "Proteostasis impairment in protein-
misfolding and-aggregation diseases", Trends in cell biology, vol. 24, no. 9, pp. 
506-514. 
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R.L., Atwood, C.S., Johnson, 
A.B., Kress, Y., Vinters, H.V., Tabaton, M., Shimohama, S., Cash, A.D., Siedlak, 
S.L., Harris, P.L.R., Jones, P.K., Petersen, R.B., Perry, G. & Smith, M.A. 2001, 
"Mitochondrial abnormalities in Alzheimer's disease", Journal of Neuroscience, 
vol. 21, no. 9, pp. 3017-3023. 
Horie-Inoue, K. & Inoue, S. 2014, "Genomic aspects of age-related macular 
degeneration", Biochemical and biophysical research communications, vol. 
452, no. 2, pp. 263-275. 
Hu, Y., Hung, A.C., Cui, H., Dawkins, E., Bolos, M., Foa, L., Young, K.M. & Small, D.H. 
2013, "Role of cystatin C in amyloid precursor protein-induced proliferation of 
neural stem/progenitor cells", The Journal of biological chemistry, vol. 288, no. 
26, pp. 18853-18862. 
Hua, Y., Zhao, H., Lu, X., Kong, Y. & Jin, H. 2012, "Meta-analysis of the cystatin C 
(CST3) gene G73A polymorphism and susceptibility to Alzheimer's disease", 
International Journal of Neuroscience, vol. 122, no. 8, pp. 431-438. 
Huotari, J. & Helenius, A. 2011, "Endosome maturation", The EMBO journal, vol. 30, 
no. 17, pp. 3481-3500. 
Ito, M., Oiso, Y., Murase, T., Kondo, K., Saito, H., Chinzei, T., Racchi, M. & Lively, 
M.O. 1993, "Possible involvement of inefficient cleavage of preprovasopressin 
by signal peptidase as a cause for familial central diabetes insipidus", The 
Journal of clinical investigation, vol. 91, no. 6, pp. 2565-2571. 
Ito, M., Yu, R.N. & Jameson, J.L. 1999, "Mutant vasopressin precursors that cause 
autosomal dominant neurohypophyseal diabetes insipidus retain dimerization 
and impair the secretion of wild-type proteins", The Journal of biological 
chemistry, vol. 274, no. 13, pp. 9029-9037. 
Jager, R.D., Mieler, W.F. & Miller, J.W. 2008, "Age-related macular degeneration", 
New England Journal of Medicine, vol. 358, no. 24, pp. 2606-2617. 
Jaiswal, J.K., Andrews, N.W. & Simon, S.M. 2002, "Membrane proximal lysosomes 
are the major vesicles responsible for calcium-dependent exocytosis in 
nonsecretory cells", The Journal of cell biology, vol. 159, no. 4, pp. 625-635. 
240 
 
Janowski, R., Abrahamson, M., Grubb, A. & Jaskolski, M. 2004, "Domain swapping 
in N-truncated human cystatin C", Journal of Molecular Biology, vol. 341, no. 1, 
pp. 151-160. 
Janowski, R., Kozak, M., Abrahamson, M., Grubb, A. & Jaskolski, M. 2005, "3D 
domain-swapped human cystatin C with amyloidlike intermolecular ß-sheets", 
Proteins: Structure, Function and Genetics, vol. 61, no. 3, pp. 570-578. 
Janowski, R., Kozak, M., Jankowska, E., Grzonka, Z., Grubb, A., Abrahamson, M. & 
Jaskolski, M. 2001, "Human cystatin C, an amyloidogenic protein, dimerizes 
through three-dimensional domain swapping", Nature structural biology, vol. 
8, no. 4, pp. 316-320. 
Jarjanazi, H., Savas, S., Pabalan, N., Dennis, J.W. & Ozcelik, H. 2008, "Biological 
implications of SNPs in signal peptide domains of human proteins", Proteins: 
Structure, Function, and Bioinformatics, vol. 70, no. 2, pp. 394-403. 
Jarrett, S.G. & Boulton, M.E. 2012, "Consequences of oxidative stress in age-related 
macular degeneration", Molecular aspects of medicine, vol. 33, no. 4, pp. 399-
417. 
Jarrett, S.G., Lin, H., Godley, B.F. & Boulton, M.E. 2008, "Mitochondrial DNA 
damage and its potential role in retinal degeneration", Progress in retinal and 
eye research, vol. 27, no. 6, pp. 596-607. 
Johnson, N., Vilardi, F., Lang, S., Leznicki, P., Zimmermann, R. & High, S. 2012, 
"TRC40 can deliver short secretory proteins to the Sec61 translocon", Journal 
of cell science, vol. 125, no. Pt 15, pp. 3612-3620. 
Joshi, P., Benussi, L., Furlan, R., Ghidoni, R. & Verderio, C. 2015, "Extracellular 
vesicles in Alzheimer’s disease: friends or foes? Focus on aβ-vesicle 
interaction", International journal of molecular sciences, vol. 16, no. 3, pp. 
4800-4813. 
Kaarniranta, K., Salminen, A., Haapasalo, A., Soininen, H. & Hiltunen, M. 2011, 
"Age-related macular degeneration (AMD): Alzheimer's disease in the eye?", 
Journal of Alzheimer's Disease, vol. 24, no. 4, pp. 615-631. 
Kaarniranta, K., Sinha, D., Blasiak, J., Kauppinen, A., Veréb, Z., Salminen, A., 
Boulton, M.E. & Petrovski, G. 2013, "Autophagy and heterophagy 
dysregulation leads to retinal pigment epithelium dysfunction and 
development of age-related macular degeneration", Autophagy, vol. 9, no. 7, 
pp. 973-984. 
Kaarniranta, K., Hyttinen, J., Ryhanen, T., Viiri, J., Paimela, T., Toropainen, E., Sorri, 
I. & Salminen, A. 2010, "Mechanisms of protein aggregation in the retinal 
241 
 
pigment epithelial cells", Frontiers in bioscience (Elite edition), vol. 2, pp. 1374-
1384. 
Kaeser, S.A., Herzig, M.C., Coomaraswamy, J., Kilger, E., Selenica, M., Winkler, D.T., 
Staufenbiel, M., Levy, E., Grubb, A. & Jucker, M. 2007, "Cystatin C modulates 
cerebral β-amyloidosis", Nature genetics, vol. 39, no. 12, pp. 1437-1439. 
Karunadharma, P.P., Nordgaard, C.L., Olsen, T.W. & Ferrington, D.A. 2010, 
"Mitochondrial DNA damage as a potential mechanism for Age-Related 
macular Degeneration", Investigative Ophthalmology and Visual Science, vol. 
51, no. 11, pp. 5470-5479. 
Kaseda, R., Iino, N., Hosojima, M., Takeda, T., Hosaka, K., Kobayashi, A., Yamamoto, 
K., Suzuki, A., Kasai, A. & Suzuki, Y. 2007, "Megalin-mediated endocytosis of 
cystatin C in proximal tubule cells", Biochemical and biophysical research 
communications, vol. 357, no. 4, pp. 1130-1134. 
Kaur, G. & Levy, E. 2012, "Cystatin C in Alzheimer's disease", Frontiers in Molecular 
Neuroscience, , no. JULY 2012. 
Kaur, G., Mohan, P., Pawlik, M., DeRosa, S., Fajiculay, J., Che, S., Grubb, A., 
Ginsberg, S.D., Nixon, R.A. & Levy, E. 2010, "Cystatin C rescues degenerating 
neurons in a cystatin B-knockout mouse model of progressive myoclonus 
epilepsy", The American Journal Of Pathology, vol. 177, no. 5, pp. 2256-2267. 
Kay, P., Yang, Y.C., Hiscott, P., Gray, D., Maminishkis, A. & Paraoan, L. 2014, "Age-
Related Changes of Cystatin C Expression and Polarized Secretion by Retinal 
Pigment Epithelium: Potential Age-Related Macular Degeneration LinksAge-
Related Decline of Cystatin C Secretion by RPE", Investigative ophthalmology & 
visual science, vol. 55, no. 2, pp. 926-934. 
Kay, P., Yang, Y.C. & Paraoan, L. 2013, "Directional protein secretion by the retinal 
pigment epithelium: roles in retinal health and the development of age‐related 
macular degeneration", Journal of Cellular and Molecular Medicine, vol. 17, no. 
7, pp. 833-843. 
Keppler, D. 2006, "Towards novel anti-cancer strategies based on cystatin 
function", Cancer letters, vol. 235, no. 2, pp. 159-176. 
Kim, D.H. & Hwang, I. 2013, "Direct targeting of proteins from the cytosol to 
organelles: the ER versus endosymbiotic organelles", Traffic, vol. 14, no. 6, pp. 
613-621. 
Kim, R., Emi, M., Tanabe, K. & Murakami, S. 2006, "Role of the unfolded protein 
response in cell death", Apoptosis, vol. 11, no. 1, pp. 5-13. 
242 
 
Kinnunen, K., Petrovski, G., Moe, M.C., Berta, A. & Kaarniranta, K. 2012, "Molecular 
mechanisms of retinal pigment epithelium damage and development of age‐
related macular degeneration", Acta Ophthalmologica, vol. 90, no. 4, pp. 299-
309. 
Klausner, R.D., Donaldson, J.G. & Lippincott-Schwartz, J. 1992, "Brefeldin A: insights 
into the control of membrane traffic and organelle structure", J.Cell Biol, vol. 
116, no. 5, pp. 1071-1080. 
Klein, R., Knudtson, M.D., Lee, K.E. & Klein, B.E.K. 2009, "Serum cystatin C level, 
kidney disease markers, and incidence of age-related macular degeneration: 
the Beaver Dam Eye Study", Archives of Ophthalmology, vol. 127, no. 2, pp. 
193-199. 
Klettner, A., Kauppinen, A., Blasiak, J., Roider, J., Salminen, A. & Kaarniranta, K. 
2013, "Cellular and molecular mechanisms of age-related macular 
degeneration: from impaired autophagy to neovascularization", The 
international journal of biochemistry & cell biology, vol. 45, no. 7, pp. 1457-
1467. 
Kocik, L., Junne, T. & Spiess, M. 2012, "Orientation of internal signal-anchor 
sequences at the Sec61 translocon", Journal of Molecular Biology, vol. 424, no. 
5, pp. 368-378. 
Kornmann, B., Currie, E., Collins, S.R., Schuldiner, M., Nunnari, J., Weissman, J.S. & 
Walter, P. 2009, "An ER-mitochondria tethering complex revealed by a 
synthetic biology screen", Science (New York, N.Y.), vol. 325, no. 5939, pp. 477-
481. 
Kozak, M. 1992, "Regulation of translation in eukaryotic systems", Annual Review of 
Cell Biology, vol. 8, no. 1, pp. 197-225. 
Kozak, M., Jankowska, E., Janowski, R., Grzonka, Z., Grubb, A., Fernandez, M.A., 
Abrahamson, M. & Jaskolski, M. 1999, "Expression of a selenomethionyl 
derivative and preliminary crystallographic studies of human cystatin C", Acta 
Crystallographica Section D: Biological Crystallography, vol. 55, no. 11, pp. 
1939-1942. 
Lakkaraju, A.K., Thankappan, R., Mary, C., Garrison, J.L., Taunton, J. & Strub, K. 
2012, "Efficient secretion of small proteins in mammalian cells relies on Sec62-
dependent posttranslational translocation", Molecular biology of the cell, vol. 
23, no. 14, pp. 2712-2722. 
Laurent-Matha, V., Huesgen, P.F., Masson, O., Derocq, D., Prebois, C., Gary-Bobo, 
M., Lecaille, F., Rebiere, B., Meurice, G., Orear, C., Hollingsworth, R.E., 
Abrahamson, M., Lalmanach, G., Overall, C.M. & Liaudet-Coopman, E. 2012, 
"Proteolysis of cystatin C by cathepsin D in the breast cancer 
243 
 
microenvironment", FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology, vol. 26, no. 12, pp. 5172-5181. 
Lecker, S.H., Goldberg, A.L. & Mitch, W.E. 2006, "Protein degradation by the 
ubiquitin-proteasome pathway in normal and disease states", Journal of the 
American Society of Nephrology : JASN, vol. 17, no. 7, pp. 1807-1819. 
Lenarčič, B., Krašovec, M., Ritonja, A., Olafsson, I. & Turk, V. 1991, "Inactivation of 
human cystatin C and kininogen by human cathepsin D", FEBS letters, vol. 280, 
no. 2, pp. 211-215. 
Levy, E., Sastre, M., Kumar, A., Gallo, G., Piccardo, P., Ghetti, B. & Tagliavini, F. 
2001, "Codeposition of Cystatin C with Amyloid-[beta] Protein in the Brain of 
Alzheimer Disease Patients", Journal of Neuropathology & Experimental 
Neurology, vol. 60, no. 1, pp. 94-104. 
Li, W., Sultana, N., Siraj, N., Ward, L.J., Pawlik, M., Levy, E., Jovinge, S., Bengtsson, E. 
& Yuan, X. 2016, "Autophagy dysfunction and regulatory cystatin C in 
macrophage death of atherosclerosis", Journal of Cellular and Molecular 
Medicine, . 
Liang, X., Nagai, A., Terashima, M., Sheikh, A.M., Shiota, Y., Mitaki, S., Kim, S.U. & 
Yamaguchi, S. 2011, "Cystatin C induces apoptosis and tyrosine hydroxylase 
gene expression through JNK-dependent pathway in neuronal cells", 
Neuroscience letters, vol. 496, no. 2, pp. 100-105. 
Lisenbee, C.S., Karnik, S.K. & Trelease, R.N. 2003, "Overexpression and 
mislocalization of a Tail‐Anchored GFP redefines the identity of peroxisomal 
ER", Traffic, vol. 4, no. 7, pp. 491-501. 
Liu, K. & Xie, B. 2012, "Today and future of age-related macular degeneration", 
ISRN ophthalmology, vol. 2012. 
Liu, Y., Cai, H., Wang, Z., Li, J., Wang, K., Yu, Z. & Chen, G. 2013, "Induction of 
autophagy by cystatin C: a potential mechanism for prevention of cerebral 
vasospasm after experimental subarachnoid hemorrhage", European journal of 
medical research, vol. 18, no. 1, pp. 1. 
Liu, Y., Li, J., Wang, Z., Yu, Z. & Chen, G. 2014, "Attenuation of early brain injury and 
learning deficits following experimental subarachnoid hemorrhage secondary 
to cystatin C: possible involvement of the autophagy pathway", Molecular 
neurobiology, vol. 49, no. 2, pp. 1043-1054. 
Liu, G., Zhang, C., Yin, J., Li, X., Cheng, F., Li, Y., Yang, H., Uéda, K., Chan, P. & Yu, S. 
2009, "a-Synuclein is differentially expressed in mitochondria from different 
rat brain regions and dose-dependently down-regulates complex I activity", 
Neuroscience letters, vol. 454, no. 3, pp. 187-192. 
244 
 
Liu, M., Lara-Lemus, R., Shan, S.O., Wright, J., Haataja, L., Barbetti, F., Guo, H., 
Larkin, D. & Arvan, P. 2012, "Impaired cleavage of preproinsulin signal peptide 
linked to autosomal-dominant diabetes", Diabetes, vol. 61, no. 4, pp. 828-837. 
Locke, C.J., Congrove, N.R., Dismuke, W.M., Bowen, T.J., Stamer, W.D. & McKay, 
B.S. 2014, "Controlled exosome release from the retinal pigment epithelium in 
situ", Experimental eye research, vol. 129, pp. 1-4. 
Logue, M.W., Schu, M., Vardarajan, B.N., Farrell, J., Lunetta, K.L., Jun, G., Baldwin, 
C.T., DeAngelis, M.M. & Farrer, L.A. 2014, "A search for age-related macular 
degeneration risk variants in Alzheimer disease genes and pathways", 
Neurobiology of aging, vol. 35, no. 6, pp. 1510. e7-1510. e18. 
Lyko, F., Martoglio, B., Jungnickel, B., Rapoport, T.A. & Dobberstein, B. 1995, 
"Signal sequence processing in rough microsomes", Journal of Biological 
Chemistry, vol. 270, no. 34, pp. 19873-19878. 
Maetzler, W., Schmid, B., Synofzik, M., Schulte, C., Riester, K., Huber, H., 
Brockmann, K., Gasser, T., Berg, D. & Melms, A. 2010, "The CST3 BB genotype 
and low cystatin C cerebrospinal fluid levels are associated with dementia in 
Lewy body disease", Journal of Alzheimer's Disease, vol. 19, no. 3, pp. 937-942. 
Maley, F., Trimble, R.B., Tarentino, A.L. & Plummer, T.H. 1989, "Characterization of 
glycoproteins and their associated oligosaccharides through the use of 
endoglycosidases", Analytical Biochemistry, vol. 180, no. 2, pp. 195-204. 
Marques, C., Oliveira, C.S.F., Alves, S., Chaves, S., Coutinho, O., Côrte-Real, M. & 
Preto, A. 2013, "Acetate-induced apoptosis in colorectal carcinoma cells 
involves lysosomal membrane permeabilization and cathepsin D release", Cell 
death & disease, vol. 4, no. 2, pp. e507. 
Maruyama, H., Izumi, Y., Oda, M., Torii, T., Morino, H., Toji, H., Sasaki, K., Terasawa, 
H., Nakamura, S. & Kawakami, H. 2001, "Lack of an association between 
cystatin C gene polymorphisms in Japanese patients with Alzheimer's disease", 
Neurology, vol. 57, no. 2, pp. 337-339. 
Massotte, D. 2003, "G protein-coupled receptor overexpression with the 
baculovirus–insect cell system: a tool for structural and functional studies", 
Biochimica et Biophysica Acta (BBA)-Biomembranes, vol. 1610, no. 1, pp. 77-
89. 
Mathews, P.M. & Levy, E. 2016, "Cystatin C in aging and in Alzheimer’s disease", 
Ageing Research Reviews, . 
Matlack, K.E., Misselwitz, B., Plath, K. & Rapoport, T.A. 1999, "BiP acts as a 
molecular ratchet during posttranslational transport of prepro-α factor across 
the ER membrane", Cell, vol. 97, no. 5, pp. 553-564. 
245 
 
Meléndez, A. & Levine, B. 2005, "Autophagy in C. elegans", . 
Merz, G.S., Benedikz, E., Schwenk, V., Johansen, T.E., Vogel, L.K., Rushbrook, J.I. & 
Wisniewski, H.M. 1997, "Human cystatin C forms an inactive dimer during 
intracellular trafficking in transfected CHO cells", Journal of cellular physiology, 
vol. 173, no. 3, pp. 423-432. 
Meyer, H. & Hartmann, E. 1997, "The yeast SPC22/23 homolog Spc3p is essential 
for signal peptidase activity", Journal of Biological Chemistry, vol. 272, no. 20, 
pp. 13159-13164. 
Meyer, H.A., Grau, H., Kraft, R., Kostka, S., Prehn, S., Kalies, K.U. & Hartmann, E. 
2000, "Mammalian Sec61 is associated with Sec62 and Sec63", The Journal of 
biological chemistry, vol. 275, no. 19, pp. 14550-14557. 
Mi, W., Jung, S.S., Yu, H., Schmidt, S.D., Nixon, R.A., Mathews, P.M., Tagliavini, F. & 
Levy, E. 2009, "Complexes of amyloid-β and cystatin C in the human central 
nervous system", Journal of Alzheimer's Disease, vol. 18, no. 2, pp. 273-280. 
Mi, W., Pawlik, M., Sastre, M., Jung, S.S., Radvinsky, D.S., Klein, A.M., Sommer, J., 
Schmidt, S.D., Nixon, R.A. & Mathews, P.M. 2007, "Cystatin C inhibits amyloid-
β deposition in Alzheimer's disease mouse models", Nature genetics, vol. 39, 
no. 12, pp. 1440-1442. 
Misselwitz, B., Staeck, O., Matlack, K.E. & Rapoport, T.A. 1999, "Interaction of BiP 
with the J-domain of the Sec63p component of the endoplasmic reticulum 
protein translocation complex", The Journal of biological chemistry, vol. 274, 
no. 29, pp. 20110-20115. 
Mitter, S.K., Song, C., Qi, X., Mao, H., Rao, H., Akin, D., Lewin, A., Grant, M., Dunn Jr, 
W. & Ding, J. 2014, "Dysregulated autophagy in the RPE is associated with 
increased susceptibility to oxidative stress and AMD", Autophagy, vol. 10, no. 
11, pp. 1989-2005. 
Miyawaki, A., Sawano, A. & Kogure, T. 2003, "Lighting up cells: labelling proteins 
with fluorophores", Nature cell biology, vol. Suppl, pp. S1-7. 
Mollenhauer, H.H., Morré, D.J. & Rowe, L.D. 1990, "Alteration of intracellular traffic 
by monensin; mechanism, specificity and relationship to toxicity", Biochimica 
et Biophysica Acta (BBA)-Reviews on Biomembranes, vol. 1031, no. 2, pp. 225-
246. 
Monastero, R., Camarda, C., Cefalu, A.B., Caldarella, R., Camarda, L.K., Noto, D., 
Averna, M.R. & Camarda, R. 2005, "No association between the cystatin C 
gene polymorphism and Alzheimer's disease: a case-control study in an Italian 
population", Journal of Alzheimer's Disease, vol. 7, no. 4, pp. 291-295. 
246 
 
Moreira, P.I., Zhu, X., Wang, X., Lee, H., Nunomura, A., Petersen, R.B., Perry, G. & 
Smith, M.A. 2010, "Mitochondria: A therapeutic target in neurodegeneration", 
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1802, no. 
1, pp. 212-220. 
Mori, J., Tanikawa, C., Funauchi, Y., Lo, P.H.Y., Nakamura, Y. & Matsuda, K. 2016, 
"Cystatin C as a p53‐inducible apoptotic mediator that regulates cathepsin L 
activity", Cancer science, . 
Mueller-Steiner, S., Zhou, Y., Arai, H., Roberson, E.D., Sun, B., Chen, J., Wang, X., Yu, 
G., Esposito, L. & Mucke, L. 2006, "Antiamyloidogenic and neuroprotective 
functions of cathepsin B: implications for Alzheimer's disease", Neuron, vol. 51, 
no. 6, pp. 703-714. 
Nacmias, B., Bagnoli, S., Tedde, A., Cellini, E., Guarnieri, B.M., Bartoli, A., Serio, A., 
Piacentini, S. & Sorbi, S. 2006, "Cystatin C and apoe polymorphisms in Italian 
Alzheimer's disease", Neuroscience letters, vol. 392, no. 1, pp. 110-113. 
Nagai, A., Ryu, J.K., Terashima, M., Tanigawa, Y., Wakabayashi, K., McLarnon, J.G., 
Kobayashi, S., Masuda, J. & Kim, S.U. 2005, "Neuronal cell death induced by 
cystatin C in vivo and in cultured human CNS neurons is inhibited with 
cathepsin B", Brain research, vol. 1066, no. 1, pp. 120-128. 
Nedelsky, N.B., Todd, P.K. & Taylor, J.P. 2008, "Autophagy and the ubiquitin-
proteasome system: collaborators in neuroprotection", Biochimica et 
Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1782, no. 12, pp. 691-
699. 
Nejsum, L.N. & Nelson, W.J. 2009, "Epithelial cell surface polarity: the early steps", 
Frontiers in bioscience (Landmark edition), vol. 14, pp. 1088-1098. 
Ng, D.T., Brown, J.D. & Walter, P. 1996, "Signal sequences specify the targeting 
route to the endoplasmic reticulum membrane", The Journal of cell biology, 
vol. 134, no. 2, pp. 269-278. 
Nguyen, A. & Hulleman, J.D. 2016, "Evidence of alternative cystatin c signal 
sequence cleavage which is influenced by the A25T polymorphism", PloS one, 
vol. 11, no. 2, pp. e0147684. 
Ni, J., Fernandez, M.A., Danielsson, L., Chillakuru, R.A., Zhang, J., Grubb, A., Su, J., 
Gentz, R. & Abrahamson, M. 1998, "Cystatin F is a glycosylated human low 
molecular weight cysteine proteinase inhibitor", Journal of Biological 
Chemistry, vol. 273, no. 38, pp. 24797-24804. 
Nickel, W. & Wieland, F.T. 1998, "Biosynthetic protein transport through the early 
secretory pathway", Histochemistry and cell biology, vol. 109, no. 5-6, pp. 477-
486. 
247 
 
Nickel, W. 2005, "Unconventional secretory routes: direct protein export across the 
plasma membrane of mammalian cells", Traffic, vol. 6, no. 8, pp. 607-614. 
Nickel, W. & Rabouille, C. 2009, "Mechanisms of regulated unconventional protein 
secretion", Nature Reviews Molecular Cell Biology, vol. 10, no. 2, pp. 148-155. 
Nielsen, J. 2013, "Production of biopharmaceutical proteins by yeast: advances 
through metabolic engineering", Bioengineered, vol. 4, no. 4, pp. 207-211. 
Nilsson, I., Lara, P., Hessa, T., Johnson, A.E., von Heijne, G. & Karamyshev, A.L. 
2015, "The code for directing proteins for translocation across ER membrane: 
SRP cotranslationally recognizes specific features of a signal sequence", Journal 
of Molecular Biology, vol. 427, no. 6, pp. 1191-1201. 
Nilsson, J., Rüetschi, U., Halim, A., Hesse, C., Carlsohn, E., Brinkmalm, G. & Larson, 
G. 2009, "Enrichment of glycopeptides for glycan structure and attachment 
site identification", Nature methods, vol. 6, no. 11, pp. 809-811. 
Nilsson, M., Wang, X., Rodziewicz-Motowidlo, S., Janowski, R., Lindström, V., 
Önnerfjord, P., Westermark, G., Grzonka, Z., Jaskolski, M. & Grubb, A. 2004, 
"Prevention of domain swapping inhibits dimerization and amyloid fibril 
formation of cystatin C. Use of engineered disulfide bridges, antibodies, and 
carboxymethylpapain to stabilize the monomeric form of cystatin C", Journal 
of Biological Chemistry, vol. 279, no. 23, pp. 24236-24245. 
Nishio, C., Yoshida, K., Nishiyama, K., Hatanaka, H. & Yamada, M. 2000, 
"Involvement of cystatin C in oxidative stress-induced apoptosis of cultured rat 
CNS neurons", Brain research, vol. 873, no. 2, pp. 252-262. 
Nishiyama, K., Konishi, A., Nishio, C., Araki-Yoshida, K., Hatanaka, H., Kojima, M., 
Ohmiya, Y., Yamada, M. & Koshimizu, H. 2005, "Expression of cystatin C 
prevents oxidative stress-induced death in PC12 cells", Brain research bulletin, 
vol. 67, no. 1, pp. 94-99. 
Nordgaard, C.L., Karunadharma, P.P., Feng, X., Olsen, T.W. & Ferrington, D.A. 2008, 
"Mitochondrial proteomics of the retinal pigment epithelium at progressive 
stages of age-related macular degeneration", Investigative Ophthalmology and 
Visual Science, vol. 49, no. 7, pp. 2848-2855. 
Nothwehr, S.F. & Gordon, J.I. 1990, "Structural features in the NH2-terminal region 
of a model eukaryotic signal peptide influence the site of its cleavage by signal 
peptidase", The Journal of biological chemistry, vol. 265, no. 28, pp. 17202-
17208. 
Noto, D., Cefalu, A.B., Barbagallo, C.M., Pace, A., Rizzo, M., Marino, G., Caldarella, 
R., Castello, A., Pernice, V. & Notarbartolo, A. 2005, "Cystatin C levels are 
decreased in acute myocardial infarction: effect of cystatin C G73A gene 
248 
 
polymorphism on plasma levels", International journal of cardiology, vol. 101, 
no. 2, pp. 213-217. 
Nyathi, Y., Wilkinson, B.M. & Pool, M.R. 2013, "Co-translational targeting and 
translocation of proteins to the endoplasmic reticulum", Biochimica et 
Biophysica Acta (BBA)-Molecular Cell Research, vol. 1833, no. 11, pp. 2392-
2402. 
Nycander, M., Estrada, S., Mort, J.S., Abrahamson, M. & Björk, I. 1998, "Two-step 
mechanism of inhibition of cathepsin B by cystatin C due to displacement of 
the proteinase occluding loop", FEBS letters, vol. 422, no. 1, pp. 61-64. 
Obrig, T.G., Culp, W.J., McKeehan, W.L. & Hardesty, B. 1971, "The mechanism by 
which cycloheximide and related glutarimide antibiotics inhibit peptide 
synthesis on reticulocyte ribosomes", The Journal of biological chemistry, vol. 
246, no. 1, pp. 174-181. 
Ochieng, J. & Chaudhuri, G. 2010, "Cystatin superfamily", Journal of health care for 
the poor and underserved, vol. 21, no. 1 Suppl, pp. 51-70. 
Ohno-Matsui, K. 2011, "Parallel findings in age-related macular degeneration and 
Alzheimer’s disease", Progress in retinal and eye research, vol. 30, no. 4, pp. 
217-238. 
Pagano, R.E., Martin, O.C., Kang, H.C. & Haugland, R.P. 1991, "A novel fluorescent 
ceramide analogue for studying membrane traffic in animal cells: accumulation 
at the Golgi apparatus results in altered spectral properties of the sphingolipid 
precursor", J Cell Biol, vol. 113, no. 6, pp. 1267-1279. 
Panzner, S., Dreier, L., Hartmann, E., Kostka, S. & Rapoport, T.A. 1995, "Article: 
Posttranslational protein transport in yeast reconstituted with a purified 
complex of Sec proteins and Kar2p", Cell, vol. 81, pp. 561-570. 
Paraoan, L. & Grierson, I. 2007, "Focus on Molecules: Cystatin C", Experimental eye 
research, vol. 84, no. 6, pp. 1019-1020. 
Paraoan, L., Grierson, I. & Maden, B.E.H. 2003, "Fate of cystatin C lacking the leader 
sequence in RPE cells", Experimental eye research, vol. 76, no. 6, pp. 753-756. 
Paraoan, L., Grierson, I. & Maden, B.E.H. 2000, "Analysis of expressed sequence 
tags of retinal pigment epithelium: Cystatin C is an abundant transcript", 
International Journal of Biochemistry and Cell Biology, vol. 32, no. 4, pp. 417-
426. 
Paraoan, L., Hiscott, P., Gosden, C. & Grierson, I. 2010, "Cystatin C in macular and 
neuronal degenerations: Implications for mechanism(s) of age-related macular 
degeneration", Vision research, vol. 50, no. 7, pp. 737-742. 
249 
 
Paraoan, L., Ratnayaka, A., Spiller, D.G., Hiscott, P., White, M.R.H. & Grierson, I. 
2004, "Unexpected intracellular localization of the AMD-associated cystatin C 
variant", Traffic, vol. 5, no. 11, pp. 884-895. 
Paraoan, L., White, M.R.H., Spiller, D.G., Grierson, I. & Maden, B.E.H. 2001, 
"Precursor cystatin C in cultured retinal pigment epithelium cells: Evidence for 
processing through the secretory pathway", Molecular membrane biology, vol. 
18, no. 3, pp. 229-236. 
Peterson, J.H., Woolhead, C.A. & Bernstein, H.D. 2003, "Basic amino acids in a 
distinct subset of signal peptides promote interaction with the signal 
recognition particle", The Journal of biological chemistry, vol. 278, no. 46, pp. 
46155-46162. 
Pfanner, N., Craig, E.A. & Hönlinger, A. 1997, "Mitochondrial preprotein 
translocase", Annual Review of Cell and Developmental Biology, vol. 13, no. 1, 
pp. 25-51. 
Phillips, M.J. & Voeltz, G.K. 2015, "Structure and function of ER membrane contact 
sites with other organelles", Nature Reviews Molecular Cell Biology, . 
Pirttilä, T.J., Lukasiuk, K., Håkansson, K., Grubb, A., Abrahamson, M. & Pitkänen, A. 
2005, "Cystatin C modulates neurodegeneration and neurogenesis following 
status epilepticus in mouse", Neurobiology of disease, vol. 20, no. 2, pp. 241-
253. 
Plath, K., Mothes, W., Wilkinson, B.M., Stirling, C.J. & Rapoport, T.A. 1998, "Signal 
sequence recognition in posttranslational protein transport across the yeast ER 
membrane", Cell, vol. 94, no. 6, pp. 795-807. 
Ponchel, F., Toomes, C., Bransfield, K., Leong, F.T., Douglas, S.H., Field, S.L., Bell, 
S.M., Combaret, V., Puisieux, A. & Mighell, A.J. 2003, "Real-time PCR based on 
SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative 
quantification of gene rearrangements, gene amplifications and micro gene 
deletions", BMC biotechnology, vol. 3, no. 1, pp. 18. 
Pool, M.R. 2009, "A trans-membrane segment inside the ribosome exit tunnel 
triggers RAMP4 recruitment to the Sec61p translocase", The Journal of cell 
biology, vol. 185, no. 5, pp. 889-902. 
Popovič, T., Cimerman, N., Dolenc, I., Ritonja, A. & Brzin, J. 1999, "Cathepsin L is 
capable of truncating cystatin C of 11 N‐terminal amino acids", FEBS letters, 
vol. 455, no. 1-2, pp. 92-96. 
Racchi, M., Watzke, H.H., High, K.A. & Lively, M.O. 1993, "Human coagulation factor 
X deficiency caused by a mutant signal peptide that blocks cleavage by signal 
250 
 
peptidase but not targeting and translocation to the endoplasmic reticulum", 
The Journal of biological chemistry, vol. 268, no. 8, pp. 5735-5740. 
Rakoczy, P.E., Zhang, D., Robertson, T., Barnett, N.L., Papadimitriou, J., Constable, 
I.J. & Lai, C. 2002, "Progressive age-related changes similar to age-related 
macular degeneration in a transgenic mouse model", The American journal of 
pathology, vol. 161, no. 4, pp. 1515-1524. 
Rao, X., Huang, X., Zhou, Z. & Lin, X. 2013, "An improvement of the 2^(-delta delta 
CT) method for quantitative real-time polymerase chain reaction data 
analysis", Biostatistics, bioinformatics and biomathematics, vol. 3, no. 3, pp. 
71-85. 
Raposo, G. & Stoorvogel, W. 2013, "Extracellular vesicles: exosomes, microvesicles, 
and friends", The Journal of cell biology, vol. 200, no. 4, pp. 373-383. 
Ratnayaka, A., Paraoan, L., Spiller, D.G., Hiscott, P., Nelson, G., White, M.R.H. & 
Grierson, I. 2007, "A dual Golgi- and mitochondria-localised Ala25Ser precursor 
cystatin C: An additional tool for characterising intracellular mis-localisation 
leading to increased AMD susceptibility", Experimental eye research, vol. 84, 
no. 6, pp. 1135-1139. 
Repnik, U., Cesen, M.H. & Turk, B. 2013, "The endolysosomal system in cell death 
and survival", Cold Spring Harbor perspectives in biology, vol. 5, no. 1, pp. 
a008755. 
Rodriguez, A., Webster, P., Ortego, J. & Andrews, N.W. 1997, "Lysosomes behave as 
Ca2+-regulated exocytic vesicles in fibroblasts and epithelial cells", The Journal 
of cell biology, vol. 137, no. 1, pp. 93-104. 
Rodziewicz-Motowidlo, S., Wahlbom, M., Wang, X., La¸giewka, J., Janowski, R., 
Jaskólski, M., Grubb, A. & Grzonka, Z. 2006, "Checking the conformational 
stability of cystatin C and its L68Q variant by molecular dynamics studies: Why 
is the L68Q variant amyloidogenic?", Journal of structural biology, vol. 154, no. 
1, pp. 68-78. 
Roks, G., Cruts, M., Slooter, A.J., Dermaut, B., Hofman, A., Van Broeckhoven, C. & 
Van Duijn, C.M. 2001, "The cystatin C polymorphism is not associated with 
early onset Alzheimer's disease", Neurology, vol. 57, no. 2, pp. 366-367. 
Rosch, K., Naeher, D., Laird, V., Goder, V. & Spiess, M. 2000, "The topogenic 
contribution of uncharged amino acids on signal sequence orientation in the 
endoplasmic reticulum", The Journal of biological chemistry, vol. 275, no. 20, 
pp. 14916-14922. 
Rutishauser, J.a. & Spiess, M. 2002, "Endoplasmic reticulum storage diseases", 
Swiss medical weekly, vol. 132, no. 17/18, pp. 211-222. 
251 
 
Rutkowski, D.T., Ott, C.M., Polansky, J.R. & Lingappa, V.R. 2003, "Signal sequences 
initiate the pathway of maturation in the endoplasmic reticulum lumen", The 
Journal of biological chemistry, vol. 278, no. 32, pp. 30365-30372. 
Salminen, A., Kauppinen, A., Hyttinen, J., Toropainen, E. & Kaarniranta, K. 2010, 
"Endoplasmic reticulum stress in age-related macular degeneration: trigger for 
neovascularization", Mol Med, vol. 16, no. 11-12, pp. 535-542. 
Sant'Anna, R., Navarro, S., Ventura, S., Paraoan, L. & Foguel, D. 2016, "Amyloid 
properties of the leader peptide of variant B cystatin C: implications for 
Alzheimer and macular degeneration", FEBS letters, vol. 590, no. 5, pp. 644-
654. 
Sastre, M., Calero, M., Pawlik, M., Mathews, P.M., Kumar, A., Danilov, V., Schmidt, 
S.D., Nixon, R.A., Frangione, B. & Levy, E. 2004, "Binding of cystatin C to 
Alzheimer's amyloid ß inhibits in vitro amyloid fibril formation", Neurobiology 
of aging, vol. 25, no. 8, pp. 1033-1043. 
Schedin‐Weiss, S., Winblad, B. & Tjernberg, L.O. 2014, "The role of protein 
glycosylation in Alzheimer disease", FEBS Journal, vol. 281, no. 1, pp. 46-62. 
Scherer, W.F., Syverton, J.T. & Gey, G.O. 1953, "Studies on the propagation in vitro 
of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human 
malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma 
of the cervix", The Journal of experimental medicine, vol. 97, no. 5, pp. 695-
710. 
Schmidt, O., Pfanner, N. & Meisinger, C. 2010, "Mitochondrial protein import: from 
proteomics to functional mechanisms", Nature reviews Molecular cell biology, 
vol. 11, no. 9, pp. 655-667. 
Schrul, B., Kapp, K., Sinning, I. & Dobberstein, B. 2010, "Signal peptide peptidase 
(SPP) assembles with substrates and misfolded membrane proteins into 
distinct oligomeric complexes", The Biochemical journal, vol. 427, no. 3, pp. 
523-534. 
Schulte, S., Sun, J., Libby, P., MacFarlane, L., Sun, C., Lopez-Ilasaca, M., Shi, G. & 
Sukhova, G.K. 2010, "Cystatin C deficiency promotes inflammation in 
angiotensin II–induced abdominal aortic aneurisms in atherosclerotic mice", 
The American journal of pathology, vol. 177, no. 1, pp. 456-463. 
Searle, B.C. 2010, "Scaffold: a bioinformatic tool for validating MS/MS‐based 
proteomic studies", Proteomics, vol. 10, no. 6, pp. 1265-1269. 
Seibel, N.M., Eljouni, J., Nalaskowski, M.M. & Hampe, W. 2007, "Nuclear 
localization of enhanced green fluorescent protein homomultimers", 
Analytical Biochemistry, vol. 368, no. 1, pp. 95-99. 
252 
 
Shah, N., Kuntz, D.A. & Rose, D.R. 2008, "Golgi alpha-mannosidase II cleaves two 
sugars sequentially in the same catalytic site", Proceedings of the National 
Academy of Sciences of the United States of America, vol. 105, no. 28, pp. 
9570-9575. 
Shao, S. & Hegde, R.S. 2011, "A calmodulin-dependent translocation pathway for 
small secretory proteins", Cell, vol. 147, no. 7, pp. 1576-1588. 
Shaw, A.S., Peter, J.M.R. & Rose, J.K. 1988, Evidence for the Loop Model of Signal-
Sequence Insertion into the Endoplasmic Reticulum, National Academy of 
Sciences of the United States of America. 
Shlipak, M.G., Matsushita, K., Ärnlöv, J., Inker, L.A., Katz, R., Polkinghorne, K.R., 
Rothenbacher, D., Sarnak, M.J., Astor, B.C. & Coresh, J. 2013, "Cystatin C 
versus creatinine in determining risk based on kidney function", New England 
Journal of Medicine, vol. 369, no. 10, pp. 932-943. 
Singh, P., Sharma, L., Kulothungan, S.R., Adkar, B.V., Prajapati, R.S., Ali, P.S.S., 
Krishnan, B. & Varadarajan, R. 2013, "Effect of signal peptide on stability and 
folding of Escherichia coli thioredoxin", PloS one, vol. 8, no. 5, pp. e63442. 
Soh, H., Venkatesan, N., Veena, M.S., Ravichandran, S., Zinabadi, A., Basak, S.K., 
Parvatiyar, K., Srivastava, M., Liang, L.J., Gjertson, D.W., Torres, J.Z., 
Moatamed, N.A. & Srivatsan, E.S. 2016, "Cystatin E/M Suppresses Tumor Cell 
Growth through Cytoplasmic Retention of NF-kappaB", Molecular and cellular 
biology, vol. 36, no. 12, pp. 1776-1792. 
Sokol, J.P. & Schiemann, W.P. 2004, "Cystatin C antagonizes transforming growth 
factor beta signaling in normal and cancer cells", Molecular cancer research : 
MCR, vol. 2, no. 3, pp. 183-195. 
Solomon, V.R. & Lee, H. 2009, "Chloroquine and its analogs: a new promise of an 
old drug for effective and safe cancer therapies", European journal of 
pharmacology, vol. 625, no. 1, pp. 220-233. 
Sonenberg, N. & Hinnebusch, A.G. 2009, "Regulation of translation initiation in 
eukaryotes: mechanisms and biological targets", Cell, vol. 136, no. 4, pp. 731-
745. 
Stanley, P. 2011, "Golgi glycosylation", Cold Spring Harbor perspectives in biology, 
vol. 3, no. 4, pp. 10.1101/cshperspect.a005199. 
Steen, P.V.d., Rudd, P.M., Dwek, R.A. & Opdenakker, G. 1998, "Concepts and 
principles of O-linked glycosylation", Critical reviews in biochemistry and 
molecular biology, vol. 33, no. 3, pp. 151-208. 
253 
 
Stirling, C.J., Rothblatt, J., Hosobuchi, M., Deshaies, R. & Schekman, R. 1992, 
"Protein translocation mutants defective in the insertion of integral membrane 
proteins into the endoplasmic reticulum", Molecular biology of the cell, vol. 3, 
no. 2, pp. 129-142. 
Strauss, O. 2005, "The retinal pigment epithelium in visual function", Physiological 
Reviews, vol. 85, no. 3, pp. 845-881. 
Sun, B., Zhou, Y., Halabisky, B., Lo, I., Cho, S., Mueller-Steiner, S., Devidze, N., Wang, 
X., Grubb, A. & Gan, L. 2008, "Cystatin C-cathepsin B axis regulates amyloid 
beta levels and associated neuronal deficits in an animal model of Alzheimer's 
disease", Neuron, vol. 60, no. 2, pp. 247-257. 
Sundelöf, J., Sundström, J., Hansson, O., Eriksdotter-Jönhagen, M., Giedraitis, V., 
Larsson, A., Degerman-Gunnarsson, M., Ingelsson, M., Minthon, L., Blennow, 
K., Kilander, L., Basun, H. & Lannfelt, L. 2010, "Cystatin C Levels are Positively 
Correlated with both Aβ42 and Tau Levels in Cerebrospinal Fluid in Persons 
with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls", 
Journal of Alzheimer's Disease, vol. 21, no. 2, pp. 471-478. 
Sundelof, J., Arnlov, J., Ingelsson, E., Sundstrom, J., Basu, S., Zethelius, B., Larsson, 
A., Irizarry, M.C., Giedraitis, V., Ronnemaa, E., Degerman-Gunnarsson, M., 
Hyman, B.T., Basun, H., Kilander, L. & Lannfelt, L. 2008, "Serum cystatin C and 
the risk of Alzheimer disease in elderly men", Neurology, vol. 71, no. 14, pp. 
1072-1079. 
Suzuki, Y., Jin, C. & Yazawa, I. 2014, "Cystatin C triggers neuronal degeneration in a 
model of multiple system atrophy", The American journal of pathology, vol. 
184, no. 3, pp. 790-799. 
Szymańska, A., Radulska, A., Czaplewska, P., Grubb, A., Grzonka, Z. & Rodziewicz-
Motowidło, S. 2009, "Governing the monomer-dimer ratio of human cystatin c 
by single amino acid substitution in the hinge region", Acta Biochim.Pol, vol. 
56, no. 3, pp. 455-463. 
Takeyama, N., Miki, S., Hirakawa, A. & Tanaka, T. 2002, "Role of the mitochondrial 
permeability transition and cytochrome C release in hydrogen peroxide-
induced apoptosis", Experimental cell research, vol. 274, no. 1, pp. 16-24. 
Terpos, E., Katodritou, E., Tsiftsakis, E., Kastritis, E., Christoulas, D., Pouli, A., 
Michalis, E., Verrou, E., Anargyrou, K., Tsionos, K., Dimopoulos, M.A., Zervas, K. 
& Greek Myeloma Study Group 2009, "Cystatin-C is an independent prognostic 
factor for survival in multiple myeloma and is reduced by bortezomib 
administration", Haematologica, vol. 94, no. 3, pp. 372-379. 
Thumann, G., Hoffmann, S. & Hinton, D. 2006, "Cell biology of the retinal pigment 
epithelium", Retina, vol. 1, pp. 137-152. 
254 
 
Thyberg, J. & Moskalewski, S. 1999, "Role of microtubules in the organization of the 
Golgi complex", Experimental cell research, vol. 246, no. 2, pp. 263-279. 
Tizon, B., Ribe, E.M., Mi, W., Troy, C.M. & Levy, E. 2010a, "Cystatin C protects 
neuronal cells from amyloid-β-induced toxicity", Journal of Alzheimer's 
Disease, vol. 19, no. 3, pp. 885-894. 
Tizon, B., Sahoo, S., Yu, H., Gauthier, S., Kumar, A.R., Mohan, P., Figliola, M., Pawlik, 
M., Grubb, A., Uchiyama, Y., Bandyopadhyay, U., Cuervo, A.M., Nixon, R.A. & 
Levy, E. 2010b, "Induction of Autophagy by Cystatin C: A Mechanism That 
Protects Murine Primary Cortical Neurons and Neuronal Cell Lines", PLoS ONE, 
vol. 5, no. 3, pp. 1-12. 
Tong, Y., Zhou, Y., Wang, Y., Zhao, P. & Wang, Z. 2016, "Retinal Pigment Epithelium 
Cell-derived Exosomes: Possible Relevance to CNV in Wet-age Related Macular 
Degeneration", Medical hypotheses, . 
Trucco, A., Polishchuk, R.S., Martella, O., Di Pentima, A., Fusella, A., Di 
Giandomenico, D., San Pietro, E., Beznoussenko, G.V., Polishchuk, E.V. & 
Baldassarre, M. 2004, "Secretory traffic triggers the formation of tubular 
continuities across Golgi sub-compartments", Nature cell biology, vol. 6, no. 
11, pp. 1071-1081. 
Tsai, B., Ye, Y. & Rapoport, T.A. 2002, "Retro-translocation of proteins from the 
endoplasmic reticulum into the cytosol", Nature reviews Molecular cell 
biology, vol. 3, no. 4, pp. 246-255. 
Tseng, W.A., Thein, T., Kinnunen, K., Lashkari, K., Gregory, M.S., D'Amore, P.A. & 
Ksander, B.R. 2013, "NLRP3 Inflammasome Activation in Retinal Pigment 
Epithelial Cells by Lysosomal Destabilization: Implications for Age-Related 
Macular DegenerationNLRP3 Inflammasome Activity in RPE Cells", 
Investigative ophthalmology & visual science, vol. 54, no. 1, pp. 110-120. 
Tsien, R.Y. 1998, "The green fluorescent protein", Annual Review of Biochemistry, 
vol. 67, no. 1, pp. 509-544. 
Tsiolaki, P.L., Louros, N.N., Hamodrakas, S.J. & Iconomidou, V.A. 2015, "Exploring 
the ‘aggregation-prone’core of human Cystatin C: A structural study", Journal 
of structural biology, vol. 191, no. 3, pp. 272-280. 
Turk, V. & Bode, W. 1991, "The cystatins: protein inhibitors of cysteine 
proteinases", FEBS letters, vol. 285, no. 2, pp. 213-219. 
Turk, V., Stoka, V. & Turk, D. 2008, "Cystatins: biochemical and structural 
properties, and medical relevance", Front Biosci, vol. 13, no. 5, pp. 5780-5786. 
255 
 
Turk, V., Stoka, V., Vasiljeva, O., Renko, M., Sun, T., Turk, B. & Turk, D. 2012, 
"Cysteine cathepsins: from structure, function and regulation to new 
frontiers", Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, vol. 
1824, no. 1, pp. 68-88. 
Tyedmers, J., Lerner, M., Wiedmann, M., Volkmer, J. & Zimmermann, R. 2003, 
"Polypeptide-binding proteins mediate completion of co-translational protein 
translocation into the mammalian endoplasmic reticulum", EMBO reports, vol. 
4, no. 5, pp. 505-510. 
Urbizu, A., Canet‐Pons, J., Munoz‐Marmol, A.M., Aldecoa, I., Lopez, M.T., Compta, 
Y., Alvarez, R., Ispierto, L., Tolosa, E. & Ariza, A. 2015, "Cystatin C is 
differentially involved in multiple system atrophy phenotypes", 
Neuropathology and applied neurobiology, vol. 41, no. 4, pp. 507-519. 
Vella, L.J., Sharples, R.A., Nisbet, R.M., Cappai, R. & Hill, A.F. 2008, "The role of 
exosomes in the processing of proteins associated with neurodegenerative 
diseases", European Biophysics Journal, vol. 37, no. 3, pp. 323-332. 
Vilchez, D., Saez, I. & Dillin, A. 2014, "The role of protein clearance mechanisms in 
organismal ageing and age-related diseases", Nature communications, vol. 5. 
Voigt, S., Jungnickel, B., Hartmann, E. & Rapoport, T.A. 1996, "Signal sequence-
dependent function of the TRAM protein during early phases of protein 
transport across the endoplasmic reticulum membrane", The Journal of cell 
biology, vol. 134, no. 1, pp. 25-35. 
von Heijne, G. 1985, "Signal sequences: the limits of variation", Journal of 
Molecular Biology, vol. 184, no. 1, pp. 99-105. 
von Heijne, G. 1984, "Analysis of the distribution of charged residues in the N-
terminal region of signal sequences: implications for protein export in 
prokaryotic and eukaryotic cells", The EMBO journal, vol. 3, no. 10, pp. 2315-
2318. 
Wallin, H., Bjarnadottir, M., Vogel, L.K., Wassélius, J., Ekström, U. & Abrahamson, 
M. 2010, "Cystatins–Extra-and intracellular cysteine protease inhibitors: High-
level secretion and uptake of cystatin C in human neuroblastoma cells", 
Biochimie, vol. 92, no. 11, pp. 1625-1634. 
Wallin, H., Abrahamson, M. & Ekstrom, U. 2013, "Cystatin C properties crucial for 
uptake and inhibition of intracellular target enzymes", The Journal of biological 
chemistry, vol. 288, no. 23, pp. 17019-17029. 
Walter, P. & Blobel, G. 1981, "Translocation of proteins across the endoplasmic 
reticulum. II. Signal recognition protein (SRP) mediates the selective binding to 
256 
 
microsomal membranes of in-vitro-assembled polysomes synthesizing 
secretory protein", The Journal of cell biology, vol. 91, no. 2 Pt 1, pp. 551-556. 
Wang, A.L., Lukas, T.J., Yuan, M., Du, N., Tso, M.O. & Neufeld, A.H. 2009, 
"Autophagy and exosomes in the aged retinal pigment epithelium: possible 
relevance to drusen formation and age-related macular degeneration", PloS 
one, vol. 4, no. 1, pp. e4160. 
Wang, B., Xie, Y.C., Yang, Z., Peng, D., Wang, J., Zhou, S., Li, S. & Ma, X. 2008, "Lack 
of an association between Alzheimer's disease and the cystatin C (CST3) gene 
G73A polymorphism in Mainland Chinese", Dementia and geriatric cognitive 
disorders, vol. 25, no. 5, pp. 461-464. 
Wang, C., Sun, B., Zhou, Y., Grubb, A. & Gan, L. 2012, "Cathepsin B degrades 
amyloid-beta in mice expressing wild-type human amyloid precursor protein", 
The Journal of biological chemistry, vol. 287, no. 47, pp. 39834-39841. 
Wasselius, J., Håkansson, K., Abrahamson, M. & Ehinger, B. 2004, "Cystatin C in the 
anterior segment of rat and mouse eyes", Acta Ophthalmologica Scandinavica, 
vol. 82, no. 1, pp. 68-75. 
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9. APPENDIX 1: Buffer Recipes 
 
 1x TAE buffer: 
40 mM Tris (pH 7.6), 20 mM acetic acid, 1 mM EDTA 
 Resolving buffer: 
3 M Tris (pH 8.85) 
 Stacking buffer: 
0.25 M Tris (pH 6.8) 
 5X Running buffer 
0.125 M Tris, 1.25 M Glycine, 0.5% SDS 
 Transfer buffer 
0.0125 M Tris, 0.125 M Glycine, 0.05% SDS, 23.3% Ethanol 
 RIPA buffer 
50 mM Tris, 150 mM NaCl, 1mM EDTA, 1%NP-40, 0.25% Sodium-
deoxycholate, protease inhibitors  
 5X Laemmli buffer (loading buffer) 
125 mM Tris (pH 6.8), 20% Glycerol, 4% SDS, 0.625 M β-mercaptoethanol, 
bromophenol blue 
 Mitochondrial Isolation Buffer (MIB) 
20 mM Hepes-KOH, 15 mM KCl, 1.5 mM MgCl2, 250 mM Sucrose, 1 mM 
EDTA, protease inhibitors 
 
 
